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Abstract 
Urinary tract infections (UTIs), primarily caused by uropathogenic E. coli (UPEC), affect 
millions of people and account for significant morbidity and high medical costs. The key 
step in the pathogenesis of UTIs is the bacterial adhesion to urothelial cells, which is 
mediated by the virulence factor FimH located on type 1 pili. Blocking FimH and therefore 
the adhesion with FimH antagonists offers a new therapeutic approach for the prevention 
and treatment of UTIs. However, the antagonists developed so far have hardly met the 
requirements for clinical applications due to poor pharmacokinetic (PK) properties. In vivo 
studies indicated that with biphenyl α-D-mannosides as FimH antagonists, high doses were 
necessary to achieve the minimal concentrations required for anti-adhesive effects in the 
bladder. Additionally, the binding mode of an antagonist to the carbohydrate recognition 
domain of FimH can switch from an “in-docking mode” to an “out-docking mode”, 
depending on the structure of the antagonist. Further studies indicated that the existence of 
the high- and low-affinity state of FimH could complicate the binding affinity. 
To achieve oral bioavailability, to improve binding affinity, and to explore the binding 
mode, we chemically modified the biphenyl FimH antagonists with diverse strategies. To 
establish the designed compound libraries, traditional synthesis and dynamic combinatorial 
techniques were applied. The binding affinity and the thermodynamic profile of the 
antagonists were evaluated by a cell-free competitive binding assay, a competitive 
fluorescence polarization assay, a cell-based flow cytometry assay, and isothermal titration 
calorimetry (ITC). Furthermore, the PK properties were determined by in vitro and in vivo 
assays. As results, structure-activity and structure-property relationships were established 
for structurally diversified FimH antagonists. The reported strategies led to FimH 
antagonists with significantly improved PD/PK profile regarding effectiveness of the anti-
adhesive treatment.  
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1. Introduction 
 
1.1 Urinary tract infection  
Urinary tract infection (UTI), among the most prevalent infectious diseases worldwide, 
affects millions of people and accounts for significant morbidity and high medical costs 
each year.1-3 About 50% of women will experience a UTI at some points in their life and 
about 60% of them will experience recurrent infections within six months following the 
treatment of initial UTIs.4, 5 The leading cause of UTI is gram-negative uropathogenic 
Escherichia coli (UPEC), which make up to 90% of all diagnosed UTIs.6, 7 About 5-15% 
of UTIs are caused by Staphylococcus saprophyticus,8 and only a small number is caused 
by Klebsiella pneumoniae or Proteus mirabilis.3 Clinically, it is known as cystitis (a 
bladder infection) when UTI affects lower urinary tract, and it is known as pyelonephritis 
(a kidney infection) when UTI affects upper urinary tract.9 For uncomplicated lower 
urinary tract infections, the first-line treatment is a three-day treatment with trimethoprim, 
trimethoprim-sulfamethoxazole (TMP/SMX) or a fluoroquinolone (e.g. ciprofloxacin).10, 
11 For pyelonephritis, more 
aggressive treatment has to be 
applied by using longer course of 
oral/intravenous antibiotics.12 
However, recurrent infections of 
UPEC with repeated antibiotic 
exposure often lead to the 
emergence of multi-drug 
resistance, and consequently to 
treatment failure.13-15 Since the 
number of antibiotics is limited 
and the antibiotic resistance of 
UPEC is increasing,16, 17 a novel 
approach for the prevention and 
treatment of UTI is urgently 
needed. 
 
 
Figure 1.1. Infection cycle of uropathogenic E. coli (UPEC) in 
the lower urinary tract (adopted from Ref.7) 
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1.1.1 Infection cycle of UPEC 
 
The infection cycle of UPEC involves a well-defined multi-step cascade examined in 
mouse cystitis models and human UTIs (Figure 1.1).18-22 Virtually all clinical UPEC 
isolates express type 1 fimbriae (pili).23 In the initial step of infection, the pili bind to 
mannosylated glycoprotein receptors, mainly uroplakin-Ia (UPIa), on the surface of 
urinary bladder mucosa.24, 25 This adhesion prevents UPEC from being removed by the 
flow of urine and initiates the invasion of bacteria into the bladder epithelial cells.19, 26 
After entering the host cells, UPEC start replicating to form biofilm-like intracellular 
bacterial community (IBC), which can protect them from antibiotics treatment and host 
innate immune responses.18, 27 After an acute infection, UPEC can persist for many weeks 
to months in a quiescent bladder reservoir, regardless the antibiotic treatment, and re-
emerge to cause recurrent UTIs.28, 29 Eventually, UPEC detach and disperse from the IBC 
to initiate a new round of infection in other cells. Some of the dispersing UPEC can form 
filaments, invade neutrophil phagocytosis and facilitate bacteria survival.20, 21  
 
1.1.2 Uropathogenic agent – type 1 
fimbria  (pilus) 
 
Type 1 fimbriae (pili) are expressed 
by a large number of E. coli strains, 
and are found in more than 95% of 
E. coli isolates from intestinal and 
extra-intestinal infections.23, 30 Pili 
act as highly efficient adhesion tools 
for bacterial inhabiting in diverse 
environments, including biotic and 
abiotic surfaces.31-33  
 
On the surface of UPEC, type 1 pili 
are uniformly distributed, commonly 
100 to 400 per cell.34 Structurally, 
type 1 pili are 7 nm wide and several 
 
 
 
Figure 1.2. Schematic representation of type 1 pilus and 
its assembly through the chaperone-usher pathway 
(adopted from Ref.36). Pilus subunits are assembled via 
“donor strand exchange”, in which the immunoglobulin-
like fold is completed by the insertion of an anti-parallel β-
sheet of the following subunit.  
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micrometers long rod-like fibers (Figure 1.2).35, 36 The pili rods are composed of 
immunoglobulin like (Ig) FimA pilin subunits that are anchored into a chain, and the 
chain is further coiled into a helix.37, 38 FimA helix is joined to a short 3 nm thick distal 
tip fibrillum that consists of two adaptor proteins, FimF and FimG. At the tip of each 
pilus is a single mannose-specific adhesin – FimH. The pilus rod is assembled by the 
chaperone/usher pathway39-41 and in their mature form the Ig fold of each subunit is 
completed by an amino-terminal extension from a neighboring subunit in a process 
termed “donor-strand exchange” (Figure 1.2).36, 42, 43  
 
1.2 Anti-adhesive therapy 
 
More than three decades ago, Sharon and his co-workers reported the first sugar anti-
adhesive study on protecting animals against experimental infection in a UTI mouse 
model.44 They found that co-administration of methyl α-D-mannoside with type 1 
fimbriated E. coli into the urinary bladder of the mice reduced the rate of UTI by two 
thirds, while methyl α-D-glucoside, which is not a ligand of lectin FimH, was not 
effective. Since the first attachment is a crucial step in the colonization of pathogenic 
bacteria, blocking lectins with carbohydrates or analogues thereof prevents the bacterial 
adhesion to host cells and therefore offers a potential therapeutic approach for prevention 
and treatment of UTIs (Figure 1.3).34 
 
The validity of this approach has 
been further demonstrated in a 
variety of studies with different 
pathogenic bacteria and animals.32, 
45-48 Since anti-adhesive 
carbohydrate or analogues do not 
function by killing or interfering 
the growth of the pathogens, the 
bacterial strains are unlikely to 
emerge resistance to such agents.49 
Therefore, the inhibition of bacterial adhesion by FimH antagonists provides a promising 
approach to tackle the issues of the current antibiotic treatments.  
 
 
 
Figure 1.3. The illustration of anti-adhesive therapy with FimH 
antagonists (adopted from Ref. 46). In the presence of FimH 
antagonists, UPEC cannot attach to urothelial cells and are 
therefore being washed away by a bulk flow of urine. As a 
consequence, the infection cycle cannot be established. 
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1.3 The bacterial adhesin FimH 
 
The adhesin FimH (M.W. 29 
KDa), located at the tip of type 1 
pilus, consists two Ig-like domains: 
the lectin domain (residues 1-156) 
at the N-terminus, which contains 
the carbohydrate recognition 
domain (CRD), and the pilin 
domain (residues 160-279), which 
connects FimH to the pilus rod and 
regulates the switch between high- 
and low-affinity states of the lectin 
domain.50-52  
 
While the lectin domain alone is 
stable, the full-length FimH in solution is only stable in presence of FimC. The first 
structure of FimC-FimH complex was solved in 1999,50 and three years later Hung and 
his coworkers reported the first co-crystallized structure of FimC-FimH with a mannose 
ligand (Figure 1.4, PDB code 1KLF),52 which gave important insight into the binding site. 
Later, numerous structures of the FimH lectin domain alone or in complex with diverse 
mannoside ligands were published,51, 53-56 greatly facilitating the discovery of high-
affinity FimH antagonists for the treatment of UTIs.  
 
1.3.1 FimH catch bonds 
 
The term “catch bonds”, first proposed in 1988, has been defined as a stronger or longer-
lived molecular interaction under tensile mechanical forces.57 Recently, catch bonds were 
observed with two types of adhesive proteins, selectins and FimH.58, 59 Further flow 
chamber assays60-63 and atomic force microscopy (AFM) studies64 experimentally 
supported the allosteric catch bond for FimH. However, the structural mechanism of 
FimH catch bond behavior was just a putative model until recently the crystal structure of 
native full-length FimH was published.51  
 
 
 
Figure 1.4. Structure of FimHLD-FimHPD-FimC in complex 
with D-mannose (PDB code 1KLF).52 FimH (blue) is wedged 
apart by FimC (red), which provides the donor strand 
(magenta). The carbohydrate-binding site is located at the very 
tip of FimH. 
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Figure 1.5. Structure of lectin FimH integrated in the fimbrial tips (A). In the fimbrial tips the lectin 
domain of FimH is docked to the pilin domain (black) (B) and this causes conformational changes across a 
large-sheet (violet) that makes the lectin domain more compressed and the mannose-binding pocket wider, 
than it is seen in the isolated lectin domain bound to butyl mannoside (black) (C). (Picture adopted from 
Ref.51) 
 
The crystal structure elucidates that the pilin domain of FimH, which anchors the lectin to 
the fimbrial shaft, interacts with the lectin domain such that a twist in its β-sandwich fold 
is caused (Figure 1.5).51 The twisted β-sheet loosens the mannose-binding pocket of 
FimH, which is located on the opposite end of the lectin domain, thus leading to a low-
affinity state of the lectin. When tensile forces are applied, the pilin and lectin domains 
separate, and the lectin domain untwists and elongates, resulting in a tight mannose-
binding pocket therefore a high-affinity state of FimH. This mechanism, as summarized 
in Figure 1.6, has been called as “page-turning” mechanism, which forms the basis of an 
allosteric regulation in the ligand-receptor interaction under mechanical forces.51  
 
Furthermore, it has been found that the purified lectin domain is in the elongated high-
affinity conformation regardless of the presence of mannose (Figure 1.5, C). When the 
FimH lectin domain is included in the fimbrial tip, it is maintained in the compressed 
low-affinity conformation without mannose, but can switch to the elongated high-affinity 
conformation upon binding to ligand.65 However, this ligand-induced change might not 
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occur every time, and when it does occur, the change is transient because the pilin domain 
can re-dock and cause the reversion to the compressed conformation (Figure 1.5, B). In 
this case, FimH affinity and bond lifetime would remain low.51 
 
In natural environment, bacteria have 
to combat ubiquitous shear forces in 
order to successfully establish 
adhesion to their host cells. Therefore, 
catch bonds provide a way for bacteria 
to stabilize their attachment, 
particularly in the presence of flowing 
fluid.66 Based on evolutionary 
analysis, more weakly binding 
variants, such as FimH from E. coli 
F18, are evolutionarily predominant, 
suggesting that allosteric inhibition 
and corresponding catch-bond 
behavior could be beneficial for 
bacterial transmission or survival.66 
Moreover, physiological advantage of 
allosteric catch-bond adhesion could 
include resistance to soluble 
inhibitors58, 61, and rapid surface colonization.67  
 
1.3.2 Natural ligands for FimH 
 
As stated above, FimH mediates the adhesion of UPEC by interacting with the high-
mannosylated glycoprotein receptors, among which are uroplakin Ia (UPIa),25 Tamm-
Horsfall glycoprotein (THP)68 and E1- and D3-integrins.69 UPIa is a major glycoprotein 
existing on the large superficial epithelial cells in the bladder.70 Mouse UPIa4 presents 
high mannose glycans on Asn169 with a heterogeneity ranging from Man6GlcNAc2 to 
Man9GlcNAc2.24 The same high-mannose type glycans decorate E1- and D3-integrins.71 
THP is secreted in the urine as a natural inhibitor of type 1-mediated bacterial adhesion 
  
Figure 1.6. Schematic representation of FimH catch-bond 
behavior (adopted from the graphic abstract of Ref 51). A) The 
conformation of the isolated lectin domain of FimH (violet) 
exhibits a high-affinity state of FimH. B) The native interaction 
of the pilin domain and the lectin domain of FimH induces β-
sheet twisting therefore a low-affinity state of FimH. C) Shear 
force-induced untwisting in the mannose-binding domain of 
FimH enables FimH to bind mannose more strongly via catch 
bonds. 
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through its high-mannosylated Asn251 residue.72, 73  
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Figure 1.7. The structures of oligomannose-9 (1) and oligomannose-3 (2), as a part of the glycoprotein 
uroplakin Ia (UPIa) presented on urothelial cells, represent the natural ligands of FimH. 
 
Previous epitope mapping on high-mannose glycan receptors revealed high affinity of the 
FimH receptor-binding domain for oligomannose-3, a part of the high mannose glycan.74 
Thermodynamics of FimH binding were determined for oligomannose-9 and 
oligomannose-3 (1, 2 respectively, in Figure 1.7) by surface plasmon resonance (SPR) 
solution affinity measurements, which showed a higher affinity of 2 (Kd 20 nM) than 1 
(Kd 420 nM).54 The data are in accordance with the early studies carried out by Sharon 
and co-workers.75 Further studies indicated that the chitobiose unit that bridges the 
mannosides to the asparagines in the Asn-X-Ser/Thr motif of the glycoprotein receptor 
contributes significantly to the interaction with FimH.74   
1.3.3 FimH CRD  
 
Crystal structures of lectins provide important insights into the binding modes of 
interactions that mediate carbohydrate recognition.76, 77 Frequently, it has been observed 
that the lectin with a carbohydrate ligand is complexed in a well-defined network of 
hydrogen bonds, involving hydrogen-bond donors and acceptors of the ligand and the 
side chains of asparagine or glutamine residues, carboxylate groups from aspartates or 
glutamates, hydroxyl groups in serine side chains and amino groups from lysine, 
tryptophan or histidine residues of the lectin carbohydrate recognition domain (CRD). 
Water molecules can mediate the hydrogen bonding between carbohydrates and the 
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protein surface.  In some cases divalent metal ions, such as Ca2+ or Mn2+, are also 
involved in carbohydrate binding, e.g. Ca2+ stabilizes the binding site of C-type lectins 
and fix the positions of amino acids that interact with sugar ligands. Additionally, 
carbohydrate ligand can be sandwiched between aromatic amino acid side chains, leading 
to a relevant contribution of CH-π interaction and improved binding affinity.   
Since the first crystal structure of 
FimH was solved in 1999,50 numerous 
crystallographic studies on FimH CRD 
have been reported. The crystal 
structure of the FimC/FimH 
chaperone-adhesin complexed with α-
D-mannose (PDB code 1KLF, Figure 
1.4), reported by Hung and co-
workers, revealed the crucial amino 
acids for mannose recognition in great 
details.52 More recently, the reported 
structure of FimH co-crystallized with 
n-butyl α-D-mannpyranoside53 (PDB 
code 1UWF, Figure 1.8) represented the main features of FimH CRD-ligand interaction, 
and also revealed the importance of the hydrophobic interaction between the alkyl 
aglycone and the binding site. Being accommodated in a deep and negatively charged 
pocket, the mannose makes ten direct hydrogen bonds to the mannose binding site as well 
as indirect water-mediated hydrogen bonds. All hydroxyl groups on mannose, except the 
one at the anomeric position, interact extensively with FimH CRD, especially with 
residues Phe1, Asn46, Asp47, Asp54, Gln133, Asn135, and Asp140 (as shown in Figure 
1.8). Additionally, the entrance of the binding site, formed by three hydrophobic amino 
acids (Tyr48, Ile52, Tyr137), referred to as the “tyrosine gate”, can host aliphatic and 
aromatic aglycones and provide hydrophobic interactions.52, 55, 74, 78, 79 Above 
observations further lightened the way for the development of carbohydrate ligands as 
anti-adhesive therapeutics. 
 
 
 
OHO
HO
OH
O
OH
O
Asp54
O
NH2
Asn135 O
H2N
Gln133
O
O
H
H
Phe1
NH2
O
O
Asp140
O
Ile52 (sc) Solvent
OHTyr48
OHTyr137
HN
O
Asn47 N
H
O
Asn46
 
 
Figure 1.8. Schematic representation of the binding site 
of n-butyl α-D-mannpyranoside according to X-ray 
crystallography (PDB code 1UWF 47, picture provided 
by Dr. Roland C. Preston). 
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1.4 FimH antagonists 
 
As numerous crystal structures of type 1 fimbrial lectin FimH became available, a 
rational, computer-aided design of FimH antagonists for the inhibition of bacterial 
adhesion to mucosal surfaces has been largely facilitated. So far, the reported rational 
studies lead to three classes of FimH antagonists: (i) long-chain alkyl mannosides,53 (ii) 
mannosides with substituted aromatic aglycone moieties,80 and (iii) mannosides with 
extended aglycone moieties.32, 45, 47, 56, 78, 79, 81-84 
 
Since the anti-adhesion affinity of methyl α-D-mannoside (3, Figure 1.9) was identified in 
micro-53, 85-87 to millimolar80, 88 range, most drug discovery studies for FimH antagonists 
have been focusing on affinity improvement by modifying the aglycones of α-D-
mannosides. In 2005, Bouckaert and co-workers reported a series of alkyl α-D-
mannosides as potent FimH antagonists.53 Van der Waals contacts of the alkyl chain to 
the phenyl rings of the lectin’s “tyrosine gate” (Tyr48, Tyr 137 and Ile52) were found in 
the crystal structure of butyl α-D-mannoside complexed with FimH-CRD (Figure 1.8). 
Compared with the crystal structure of oligomannose-3 in complex with FimH, the butyl 
chain mimics the hydrophobic face of oligomannose-3, therefore, maintains the binding 
affinity.54 Additionally, the affinity of alkyl α-D-mannosides for FimH increases with the 
length of the alkyl aglycone; as a result, the optimal length of the alkyl chain was found 
to be seven carbon atoms. Later, the high affinity of heptyl α-D-mannoside (4, Figure 1.9) 
was also demonstrated in other studies.45, 47, 83, 86, 89-91  
 
Other than alkyl aglycones, aromatic aglycones were designed to reach the hydrophobic 
rim at the entrance of the FimH binding site. As early as 1980s, aromatic aglycone 
moieties were found to be able to enhance the affinity of the respective mannosides for 
FimH by a factor of 600 or more.80 Such findings could also be rationalized on the basis 
of the FimH crystal structures, i.e. the π-π stacking of the aromatic ring with the amino 
acid side chains of Tyr48 and Tyr137 of the binding site improves the binding affinity of 
carbohydrate ligands.56 Furthermore, a favorable effect of o-substitution on the aromatic 
ring was also observed, as introduction of a chlorine in the ortho position of the phenyl 
ring (5a o 5b, Figure 1.9) increased the affinity by a factor of 10,80 and further evidence 
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were also found with extended aromatic aglycones (6e-f and 8, Figure 1.9).45, 79, 83 
As stated above, the crystal structure of butyl α-D-mannoside with FimH shows the 
interactions of the alkyl aglycone with both Tyr48 and Tyr137 of the tyrosine gate,53 
which is termed as “in-docking mode” (Figure 1.10, Left).82 Whereas an unexpected 
docking mode was discovered upon co-crystallization of FimH with biphenyl mannoside 
6a (Figure 1.9),56 a representative of FimH antagonists with extended aromatic aglycones. 
As shown in the crystal structure of FimH with 6a (Figure 1.10, Right),56 the biphenyl 
aglycone adopts an “out-docking mode”82; that is, it interacts only with Tyr48, probably 
due to insufficient flexibility; π-π stacking of the outer aromatic ring of the biphenyl 
aglycone with Tyr48 is effected by induced fit, causing a substantial movement of Tyr48. 
In silico docking studies with biphenyl derivatives also suggested a similar “out-docking 
mode”.83 Further stabilization of the protein-ligand complex by a polar interaction 
between the ester in the meta position of mannoside and the side chain of Arg98 was also 
proposed.56 Further studies on FimH antagonists with extended aromatic moieties lead to 
a series of modified biphenyl (6b-f, Figure 1.9),32, 48, 83, 84 indolinylphenyl47 (7, Figure 
1.9) and squaric acid92, 93 (8, Figure 1.9) derivatives, showing the affinities in the low 
nanomolar range. 
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Figure 1.9. List of representatives of three classes of FimH antagonists: alkyl mannosides (3-4); 
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mannosides with aromatic aglycones (5a-b); mannosides with extended aglycones, including biphenyl 
mannosides (6a-f), indolinylphenyl mannoside (7), and squaric acid derivative (8).  
Figure 1.10. “In” and “out” docking modes of FimH antagonists. Left: crystal structure of butyl mannoside 
(PDB code: ITR7 53) bound to the FimH CRD, as a representative of “in-docking mode”. Right: crystal 
structure of biphenyl mannoside 6a bound to the FimH CRD (PDB code: 3MCY 56), as a representative of 
“out-docking mode”. 
Besides mono-valence FimH antagonists, carbohydrate-centered cluster mannosides and 
carbohydrate dendrimers were also developed and extensively studied for FimH 
inhibition. Hartmann and Imberty have summarized the recent development of 
glycodendrimers as FimH antagonists in their reviews.94, 95 Although these multi-valence 
mannosides have shown high affinities for FimH due to their cluster effects upon binding, 
their size and polarity make them unlikely exhibit drug-like properties for oral 
application.96, 97
1.5 Pharmacokinetic aspects 
The “quality” of small-molecule drug candidates, encompassing potency, selectivity and 
pharmacokinetic (PK) properties, is a key factor for successful in vivo application.96-99 
Although the development of FimH antagonists traces back to the late 1980’s, only a few 
PK studies have been reported. Recently, Ernst and co-workers published for the first 
time in vitro and in vivo PK data of a series of biphenyl α-D-mannosides, which laid a 
foundation for further lead optimization of FimH antagonists.45  
As extensively studied, a prerequisite of oral bioavailability is intestinal absorption, 
which requires an optimal balance between solubility and permeability.100, 101 In addition, 
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since the target FimH is located in the bladder, metabolic stability and fast renal 
elimination are also required. But because intestinal absorption and renal elimination are 
related to opposed properties, i.e. lipophilicity for intestinal absorption and hydrophilicity 
for renal elimination, a prodrug approach was applied.45, 83 For example, with high 
intestinal absorption, ester 6e was firstly hydrolyzed by esterases in the enterocytes and in 
the liver (“first pass”) to release the active principle, acid 6f, which underwent fast renal 
elimination and reached the target FimH in the bladder to realize the therapeutic effect 
(Figure 1.12).45  
Although the above prodrug approach has been demonstrated the effectiveness in a UTI 
mouse model, the low solubility limits the dosage of the ester pro-drugs and their further 
in vivo evaluation.45, 83 Later, further structural modifications on FimH antagonists, such 
as methyl amide-substituted biphenyl 6b84 and indolinylphenyl 747 (Figure 1.9), were 
carried out to increase oral bioavailability. Among these modified structures, the 
indolinylphenyls have shown high therapeutic potentials, resulting from optimized PK 
properties, and a substantial reduction of the dosage, i.e. a successful treatment of UTI 
with a low dosage of 1 mg/kg without any additional administration of antibiotics.47 
However, a major drawback of these indolinylphenyl antagonists is their low solubility, 
limiting their further in vivo applications.  
Figure 1.12. Schematic representation of the prodrug approach for the therapeutic application of FimH 
antagonists.45 (1-2) After orally dosing, the ester prodrug 6e was firstly hydrolyzed in the enterocytes and 
then in the liver to release the active principle 6f. (3-4) 6f underwent renal elimination, reached the target in 
the bladder and finally realized the anti-adhesive effect.  
Since low-solubility of compounds could cause other problems in drug discovery, such as 
artificially low activity values from bioassays, development challenges for formulation, 
increased development time, high-dose administration and et al,96, 102 it became an 
important PK issue for the development of FimH antagonists.45, 47, 83 Structural 
modifications (e.g. disruption of the molecular planarity103, 104) and appropriate 
formulations was considered as promising solutions.102  
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1.6 Protein-directed dynamic combinatorial chemistry 
Dynamic combinatorial chemistry (DCC), an emerging approach in drug discovery, 
produces combinatorial libraries by reversible inter-conversion of the library 
constituents.105-107 Virtually, DCC generates all possible combinations through reversible 
chemical reactions, and allows for the target-driven amplification of the active 
constituents, thus performing a self-screening process by which the active species is 
preferentially expressed (Figure 1.13). Unlike the parallel synthesis or resin-based 
combinatorial libraries, DCC approach doesn’t require the preparation of individual 
compound over synthetic steps and characterization; therefore, DCC has been recognized 
as a fast and adaptive paradigm in modern drug discovery.105  
Since the first report appeared in the late 1990s,108 the protein-directed DCC has been 
largely developed. In a protein-directed dynamic combinatorial library (DCL), the library 
population distribution is under thermodynamic control, therefore, the amplification of 
the best binder is at expense of other (nonbinding) species, generating hit structures that 
can be identified through analysis of the DCL population distribution. By this means, 
protein-directed DCC bridges the chemical synthesis and biological evaluation, meshing 
the two operations into a single process whereby the target protein directs the assembly of 
its best binder in situ. 
Because of high sensitivity to pH, temperature and chemical reagents, proteins are 
challenging templates that place restraint on the optional reversible reactions.105 
Accordingly, the DCLs must be assembled under physiological conditions, and many of 
the reversible bond formations used to generate DCL, such as S-S or C=N, are 
fundamental to biological chemistry.109, 110 Furthermore, the reversible reaction used in 
DCC should allow the potential fixation, that is the freezing of the exchange process 
either by changing the surrounding conditions (e.g. pH, temperature, solvent 
composition), or by adding quenching reagents (e.g. oxidation/reduction reagents). In this 
way, the DCLs can be easily analyzed with various analytical schemes.111 
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Figure 1.13. Schematic representation of the concepts behind DCC and virtual DCLs. (Figure adopted from 
Ref. 107) Top: a true DCL is formed through reversible exchange of initial “keys” (building blocks). A 
molecular “lock” (e.g. protein target) favors the best binder, forcing the DCL to rearrange to produce more 
of this member. Bottom: generation of a virtual DCL, the constituents of which become detectable only in 
the presence of the selector.  
So far, the most commonly used bond formation reactions in protein-directed DCC 
include imine formation,108, 112-118 hydrazone formation119-123 and disulfide bond 
formation.124, 125 Rather than attempting to review all the reported DCC cases in drug 
discovery, the present text focuses on the representative examples of the protein-directed 
DCL. As listed in Table 1 (on Page 16), the reaction conditions, analytical methods, 
advantages and drawbacks are summarized for comparison between varied reversible 
reactions. Among these examples, a striking case was reported by Campopiano, Greaney 
and co-workers, they used aniline as a nucleophilic catalyst, which allowed for 
conducting reversible hydrazone chemistry at pH 6.2 (last entry in Table 1).123 Inspired 
by their work, we designed DCLs for FimH antagonists screening (detailed in Chapter 2). 
1.7 Aims of this thesis 
The present thesis is aiming at further understanding the binding mode of FimH 
antagonists, optimization of lead structures, and development of highly active and 
bioavailable FimH antagonists.  
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The four goals of this thesis are: 1) Structure-based drug design of novel FimH 
antagonists; 2) chemical synthesis of designed structures; 3) application of dynamic 
combinatorial chemistry in lead discovery and optimization; 4) improvement of 
pharmacodynamic (PD) and pharmacokinetic (PK) properties with medicinal chemistry 
strategies, such as heterocyclic replacement and bioisostere approaches. Diverse chemical 
synthesis, i.e. traditional synthesis and in situ dynamic combinatorial approaches, were 
implemented aiming for both structural diversity and lead identification. Based on the 
results of in vitro and in vivo evaluation, structure-activity and structure-property 
relationships were established and further guided the development of FimH antagonists 
towards the final goal – “drug-likeness”. 
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Table 1. R
epresentative exam
ples of D
C
C
 in drug lead discovery (im
ine, hydrazone and disulfide form
ation as reversible reactions). 
Target protein 
Reversible 
chemistry 
Analysis method 
Advantage 
Drawback 
C
arbonic 
anhydrase (C
A
) 108,
112
Im
ine form
ation 
(N
aB
H
3 C
N
 
as 
reducing agent) 
H
PLC
-U
V
 
x Large excess of am
ine lim
ited cross-reactivity w
ith nucleophilic 
am
ino acid residues on protein surface. 
x Slow
 reduction w
ith reducing agents produces sturdy am
ines, 
w
hich are stable for analysis. 
x The im
ines taking part in the tem
plating and am
plification 
process in D
C
L are not represented in final analysis. 
x The reducing agent reduces the starting aldehyde and erodes 
the 
aldehyde 
concentration 
in 
the 
D
C
L 
and 
produces 
benzylic alcohol as side products. 
A
cetylcholine 
esterase (A
C
E) 119 
Bacillus subtilis
H
Pr kinase
120 
A
cylhydrazone 
form
ation 
at 
pH
4 
x H
PLC
-U
V
 
x Enzym
e assay 
x D
econvolution 
strategy 
x The form
ed acyl hydrazones are robust and readily am
enable to 
analysis. 
x A
 “pre-equilibrated” D
C
C
 approach w
as applied to allow
 an 
efficient equilibration of D
C
L at acidic pH
. 
x The separation of D
C
L and tem
plating processes allow
s a 
greater range of reversible reactions to be used. 
x The separation of D
C
L and tem
plating rem
oves the adaptive 
and am
plification processes of D
C
C
. 
x A
 conventional screening of a com
binatorial m
ixture library 
is required. 
N
euram
inidase
113,
114
Im
ine form
ation 
(N
H
4 B
H
3 C
N
 
as 
reducing agent) 
H
PLC
-M
S 
x The D
C
L is theoretically very large; over 40,000 com
ponents 
are possible at equilibrium
. 
x The 
transient 
com
ponents 
w
ere 
present 
at 
very 
low
 
concentration; only in the presence of target, am
plification of 
the best binders could afford detectable am
ounts of com
pound 
that could be detected by H
PLC
-M
S. 
A
 separation of the m
olecular recognition events, nam
ely 
binding of the transient im
ines to the protein and binding of 
the 
product 
am
ines 
to 
the 
protein, 
could 
bring 
false 
positive/negative results. 
H
en egg-w
hite 
lysozym
e (H
EW
L) 
D
-G
lcN
A
c-binding 
glycosidase
115 
G
lycosyltransferas
es (G
Ts) 116-118  
C
arbohydrate-
based 
im
ine 
form
ation 
(N
aB
H
3 C
N
 
as 
reducing agent) 
H
PLC
-U
V
 
The H
PLC
 analysis is aided by chrom
ophore appended to the 
carbohydrate m
oiety. 
The am
plification process required stoichiom
etric am
ounts 
of the target protein, how
ever, G
Ts are typically available in 
very sm
all am
ount. If the binding affinity of the am
ine 
products 
w
ere 
significantly 
w
eaker 
than 
the 
transient 
im
ines, 
constant 
am
plification 
of 
the 
reduced 
am
ine 
products 
could 
be 
realized 
in 
the 
presence 
of 
sub-
stoichiom
etric am
ount of target protein, e.g. G
Ts. 
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C
yclin-dependent 
kinase 2 (C
D
K
-
2) 121
H
ydrazone 
form
ation 
x X
-ray 
crystallography 
x LC
-M
S 
x O
nly very sm
all am
ount of protein is needed. 
x The protein structure influences equilibrium
 distribution of 
hydrazone in m
icrocosm
 w
ithin the crystal. 
x The total am
ount of protein in the crystals w
as too sm
all to 
cause any gross changes in the outcom
e of the reaction. 
x The crystal effect could also occur under kinetic control 
other than expected therm
odynam
ic control in D
C
L. 
C
oncanavalin A
 
(C
on A
) 124 
D
isulfide 
bond 
form
ation 
H
PLC
-U
V
 
x The D
C
L w
as isoenergetic and w
ithout significant kinetic 
disparity. 
x C
on A
 target w
as attached to sepharose beads. B
y applying 
acidic quench to the D
C
L, bound com
ponents could be w
ashed 
off the resin beads.  
x H
PLC
-resolution issues ham
pered analysis of the D
C
L 
solution at equilibrium
. 
x Q
uenching and elution show
ed the M
an dim
ers bound to the 
im
m
obilized protein. 
x The am
plification of the D
C
L by C
on A
 w
as relatively 
w
eak. 
C
alsium
 transducer 
calm
odulin 
(C
aM
) 125  
D
isulfide 
bond 
form
ation 
H
PLC
-M
S 
x D
enaturation and filtration afforded a m
ixture of all peptides 
that had bound to C
aM
 in the course of D
C
L.  
x C
entrifugation 
filtration 
step 
separated 
protein/bound 
com
ponents from
 free com
ponents in solution. 
The filtration m
em
brane affected the com
position of the 
library, com
plicating H
PLC
 analysis. 
C
arbonic 
anhydrase (C
A
) 122 
H
ydrazone 
form
ation 
ESI-FTM
S 
(electrospray 
ionization Fourier 
transform
 
m
ass 
spectrom
etry) 
x N
o denaturation of the protein. 
x N
o chrom
atography or synthesis of sub-libraries. 
x The D
C
L can be analyzed directly and fast. 
x H
igh 
requirem
ent 
of 
sam
ple 
preparation: 
nonvolatile 
buffers, 
salts, 
and 
detergents 
can 
suppress 
the 
ion 
abundance, leading to poor m
ass spectrum
 result. 
x M
S 
param
eters 
need 
to 
be 
carefully 
adjusted 
before 
m
easurem
ent. 
G
lutathione S-
transferase 
(G
ST) 123 
A
cylhydrazone 
form
ation at pH
 
6.2 
H
PLC
-U
V
 
x A
niline w
as used as a nucleophilic catalyst, w
hich allow
ed for 
conducting reversible hydrazone chem
istry at pH
6.2. 
x G
ood kinetic and therm
odynam
ic properties lead to ease of 
analysis. 
x The D
C
Ls are truly adaptive, allow
ing am
plification effects to 
be 
sim
ply 
and 
directly 
related 
to 
structures 
present 
at 
equilibrium
. 
x The building blocks of D
C
L are lim
ited to the ones w
ith 
chrom
ophores, w
hich is required for U
V
-detection at low
 
concentrations. 
x The size of the D
C
L is lim
ited by the separation capacity of 
H
PLC
. 
x Sub-libraries w
ere needed to identify the com
ponents. 
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2. Results and discussion 
 
2.1 Outline 
 
Optimization of biphenyl FimH antagonists to improve potency, aqueous solubility and 
oral bioavailability. Since the binding mode of an antagonist to the CRD of FimH can 
switch from an “in-docking mode” to an “out-docking mode”, depending on the structure 
of antagonist, different substitution patterns, such as the ortho-substituent on ring A and 
para-substituent on ring B, were introduced to explore the binding mode and therefore 
improve binding affinity. Furthermore, based on the lead structure 6d and its ester 
prodrug 6c, structural modifications were implemented to improve potency, aqueous 
solubility and oral bioavailability of biphenyl FimH antagonists. Although the prodrug 
strategy was proved to be effective in an UTI mouse model, the major drawback of the 
ester prodrugs developed until then was their low solubility, which hampered their in vivo 
application. To solve the solubility issue, different strategies were applied, including 
disruption of molecular symmetry by diverse substitution patterns and introduction of 
aromatic heterocycles. Additionally, bioisosteric replacement of the carboxylic acid 
moiety was carried out to increase the anti-adhesive efficacy, and at the same time the 
metabolically stable bioisosteres were expected to exhibit improved oral bioavailability. 
To summarize, the optimization of the lead structure 6d towards optimal anti-adhesive 
potency, aqueous solubility and oral bioavailability relies on diverse modifications 
depicted in Figure 2.1.1 and described in the following publications and manuscript: 
 
1) Introduction of methyl ester prodrug to mask the carboxylic acid moiety on ring B 
(Chapter 2.2 - Paper1). 
2) Optimization of the ortho-substituent on ring A of the biphenyl aglycone and 
introduction of flexible aglycones (Chapter 2.3 - Paper2). 
3) Bioiosteric replacement of the carboxylic acid moiety on ring B (Chapter 2.4 - 
Paper3). 
4) Introduction of aromatic heterocycles as ring B of the biaryl aglycone (Chapter 2.5 - 
Manuscript). 
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Figure 2.1.1. Modifications on biphenyl α-D-mannopyranoside lead structure 6d : 1) introduction of methyl 
ester to  mask the polar carboxylic acid substituent on ring B and therefore improve intestinal absorption; 2) 
optimization of the substitution patterns of ring A and B to study the binding mode, and to improve 
solubility by disruption of molecular symmetry; 3) replacement of ring B with aromatic heterocycles to 
improve solubility; 4) Bioisosteric replacement of the carboxylic acid moiety on ring B to improve oral 
bioavailability. 
Studies on the kinetic properties of FimH-ligand interactions. As part of the preclinical 
development process, kinetic properties of FimH antagonists were examined. With an 
amide linker the FimH antagonists were immobilized to sensor chips, and then analyzed 
with surface plasmon resonance (SPR), as described in Chapter 2.6 - Paper 4.  
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Combinatorial libraries against FimH. As another lead structure, heptyl mannoside was 
recognized as a highly potent FimH antagonist, which adopts an “in-docking mode” upon 
binding. Although numerous FimH antagonists have been developed so far, mannose is 
always an indispensable part of the structure and few modifications have been done on 
mannose ring. Additionally, in the last decade, the structures of the aglycone were mostly 
limited to the long-chain alkyls, phenyls, and biphenyls. In fact, the switch between the 
high- and low-affinity states of FimH provides a natural selection opportunity for 
discovery of diversified structures as FimH antagonists. Therefore, a combinatorial 
strategy was implemented by carrying out modifications on 2-position of mannose and on 
the aglycones. By doing so, the optimized precursor was chosen and adopted for in situ 
generation of dynamic combinatorial libraries and screening against FimH. The 
modifications on mannose and aglycones were summarized in Figure 2.1.2 and described 
in Chapter 2.7. 
Figure 2.1.2. Combinatorial strategy for lead discovery and lead optimization: combinatorial library of α-D-
mannopyranosides with 1) halogen modificaitons on the 2-position of mannose and 2) diversified aglycones 
Chapter 2.1 
33 
to optimize the structural combinations; 3) in situ generation and screening of dynamic combinatorial 
libraries against FimH protein. 
Locking the 6-hydroxyl of mannose and conformational studies. Although the 
aglycones of FimH antagonists were extensively modified, few studies on the sugar 
moiety were reported. To further extend the structural scope and to study the 
conformational factors upon FimH binding, we modified the mannose moiety by either 
stereochemically locking 6-hydroxyl group with a cyclopropane unit or introducing a 
methyl group at C-6 (Figure 2.1.3). Here I used NMR-based methods and Mosher’s 
analysis to characterize the chemical structures of 6-modified ligands and fluorescence 
polarization assay to evaluate their binding affinities, as described in Chapter 2.8.
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Figure 2.1.3. Conformational studies on modified n-heptyl mannosides. 
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2.2 Paper 1: FimH Antagonists for the Oral Treatment of Urinary Tract 
Infections: From Design and Synthesis to in Vitro and in Vivo 
Evaluation 
 
This article describes the identification of biphenyl α-D-mannopyranosides as FimH 
antagonists. The anti-adhesion efficacy of the synthesized compounds was evaluated with 
in vitro and in vivo experiments. Furthermore, an ester prodrug approach was applied for 
achieving oral bioavailability. 
 
Contribution to the project: 
Lijuan Pang synthesized compound 5, 6c and 7c. 
 
This paper was published in the Journal of Medicinal Chemistry: 
 
Klein, T.*; Abgottspon, D.*; Wittwer, M.*; Rabbani, S.*; Herold, J.*; Jiang, X.; Kleeb, 
S.; Luethi, C.; Scharenberg, M.; Bezenςon, J.; Gubler, E.; Pang, L.; Smiesko, M.; Cutting, 
B.; Schwardt, O.; Ernst, B. FimH antagonists for the oral treatment of urinary tract 
infections: from design and synthesis to in vitro and in vivo evaluation. J. Med. Chem. 
2010, 53, 8627-8641. 
 
* These authors contributed equally to the project. 
 
© 2010 American Chemical Society 
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2.3 Paper 2: FimH Antagonists: Structure-Activity and Structure-
Property Relationships for Biphenyl α-D-Mannopyranosides 
 
This article reports the optimization of biphenyl FimH antagonists with diverse structural 
modifications, notably the introduction of ortho-substituents on the phenyl ring adjacent 
to the sugar moiety, the introduction of a methylene spacer between the anomeric oxygen 
and the biphenyl moiety, and the extension of the para-substituent on the terminal phenyl 
ring. The structural design was based on the co-crystal structure of a biphenyl antagonist 
with FimH and guided by computational modeling results. Both of the designed ester 
prodrugs and their active principles (the acids) were chemically synthesized and 
evaluated for in vitro binding affinities. Furthermore, the pharmacokinetic (PK) 
properties were analyzed for the ester prodrugs. Finally, structure-activity and structure-
property relationships were established for a series of biphenyl FimH antagonists. 
 
Contribution to the project: 
Lijuan Pang performed all experiments regarding the chemical synthesis. Furthermore, 
She participated in drug design by collaborating with Dr. Adam Zalewski. She was 
responsible for writing the respective sections as well as the introduction and the 
summary of the paper. Moreover, She designed a backcover for the same issue of 
ChemMedChem, regarding this paper. 
 
This paper was published in ChemMedChem as a Very Important Paper: 
 
Pang, L. *; Kleeb, S. *; Lemme, K. *; Rabbani, S. *; Scharenberg, M.; Zalewski, A.; 
Schaedler, F.; Schwardt, O.; Ernst, B. FimH antagonists: structure-activity and structure-
property relationships for biphenyl α-D-mannopyranosides. ChemMedChem 2012, 7, 
1404-1422. 
* These authors contributed equally to the project. 
 
© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim   
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2.4    Paper 3: FimH Antagonists: Bioisosteres to Improve the in Vitro 
and in Vivo PK/PD Profile 
 
 
This article describes the lead optimization efforts for the improvement of oral 
bioavailability of biphenyl FimH antagonists. By replacing the para-carboxylate moiety 
with various bioisosteres, a series of modified antagonists were designed and synthesized. 
The in vitro and in vivo biological evaluations of the target compounds revealed the 
principles behind the improvement of PK/PD properties.   
 
Contributions to this project: 
Lijuan Pang designed the structures of the target compounds with VirtualDesignLab (a 
computational docking program). Furthermore, she synthesized all the target compounds 
and the reference compounds except 11j. She evaluated the pKa values of compounds in 
Table 3. She was also responsible for writing the synthesis sections of this paper. 
 
This paper was published in the Journal of Medicinal Chemistry: 
Kleeb, S. *; Pang, L. *; Mayer, K. *; Eris, D. *; Sigl, A. *; Preston, R.C.; Zihlmann, P.; 
Sharpe, T.; Jakob, R.P.; Abgottspon, D.; Hutter, A.S.; Scharenberg, M.; Jiang, X.; 
Navarra, G.; Rabbani, S.; Smiesko, M.; Lüdin, N.; Bezençon, J.; Schwardt, O.; Maier, T.; 
Ernst, B. FimH antagonists: Bioisosteres to improve the in vitro and in vivo PK/PD 
profile. J. Med. Chem. 2015, 58, 2221-2239. 
 
* These authors contributed equally to the project. 
 
© 2015 American Chemical Society 
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2.5      FimH Antagonists – Solubility vs. Oral Availability   
 
 
This manuscript describes the optimization of biaryl α-D-mannopyranosides, mainly 
aiming for improvement of aqueous solubility and oral bioavailability. Two major 
strategies were applied for structural modifications: 1) the rearrangement of the 
substitution patterns of the biphenyl aglycone, and 2) the introduction of aromatic 
heterocycle as terminal ring of the biaryl moiety. The chemical synthesis, binding affinity 
test and in vitro PK studies are described in details. 
 
Contribution to the project: 
Lijuan Pang participated in the structure design by computational docking, and performed 
chemical synthesis for all of the reported compounds. Additionally, she tested the binding 
affinities with the competitive fluorescence polarization assay for the chosen compounds. 
Furthermore, she was responsible for writing the entire manuscript except the 
pharmacokinetic section. 
 
This manuscript is in preparation for Journal of Medicinal Chemistry. 
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Manuscript 
 
FimH Antagonists – Solubility vs. Oral Availability 
 
Lijuan Pang,+ Simon Kleeb,+ Said Rabbani, Jacqueline Bezençon, Anja Sigl, Deniz Eris, 
Oliver Schwardt, and Beat Ernst* 
 
Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstr. 50, 
4056 Basel, Switzerland 
  
+ These authors equally contributed to this work.  
* Corresponding author, e-mail: beat.ernst@unibas.ch 
 
Keywords: Aqueous solubility, ester prodrug, FimH antagonist, oral bioavailability 
 
 
Abbreviations: Caco-2 cells, colorectal adenocarcinoma cells; CES, carboxylesterase; 
CRD, carbohydrate recognition domain; HPLC, high performance liquid 
chromatography; IC50, half maximal inhibitory concentration; LC-MS, liquid 
chromatography mass spectrometry; MAD, maximum absorbable dose; PAMPA, parallel 
artificial membrane permeability assay; P, octanol-water partition coefficient; Papp, 
apparent permeability; Pe, effective permeability; RLM, rat liver microsomes; UPEC, 
uropathogenic Escherichia coli; UTI, urinary tract infection. 
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Abstract 
Urinary tract infections (UTI) caused by uropathogenic Escherichia coli are frequent 
infectious diseases requiring antibiotic treatment. Since recurrent antibiotic exposure can 
induce antimicrobial resistance, efficient non-antibiotic prevention and treatment 
strategies are urgently needed. The first step of the pathogenesis of UTI is the bacterial 
adherence to the urothelial host cell, mediated by the mannose-binding adhesin FimH, 
which is located at the tip of bacterial pili. Biphenyl D-D-mannopyranosides with an 
electron-withdrawing carboxylate on the terminal aromatic ring of the aglycone were 
identified as potent FimH antagonists. In a preliminary study, oral availability of these 
charged FimH antagonists could be established by an ester prodrug approach, although 
for the price of a dramatically reduced solubility. In this article, the solubility problem of 
the ester prodrug is addressed by disrupting the molecular planarity and symmetry of the 
biphenyl aglycone by means of the substitution pattern and by introducing heteroatoms. 
With the parallel artificial membrane permeability assay (PAMPA) and the Caco-2 assay 
ester prodrugs with oral availability were identified. Surprisingly, those containing a 
phenyl-1H-pyrrole aglycone show high microsomal stability and therefore do not act as 
prodrugs but are renally excreted unchanged. Their potential for passive reabsorption 
leads to elevated urine concentration for up to 6 h. The best candidate, the nanomolar 
FimH antagonist 41f therefore represents a promising candidate for oral application in 
UTI treatment. 
 
Introduction 
Urinary tract infections (UTIs) – also known as acute cystitis or bladder infections – are 
among the most prevalent infectious diseases worldwide. UTIs affect millions of people 
every year and account for significant morbidity and high medical costs.[1] Complicated 
UTIs require antibiotic treatment. Since recurrent antibiotic exposure leads to the 
ubiquitous problem of antimicrobial resistance, efficient non-antibiotic prevention and 
treatment strategies are urgently needed.[2] More than 70% of UTIs are caused by 
uropathogenic Escherichia coli (UPEC).[1a,3] The first step of the infection cycle is the 
bacterial adherence to the urothelial cell surface, which prevents UPEC from being 
cleared by micturition but also triggers the invasion into the cells.[4] This initial contact is 
mediated by the bacterial adhesin FimH which is located at the tip of type 1 pili.[5] FimH 
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consists of an N-terminal carbohydrate recognition domain (CRD) and a C-terminal pilin 
domain. The CRD specifically recognizes mannosylated uroplakin Ia glycoproteins 
located on the urinary bladder mucosa, whereas the pilin domain regulates the switch 
between the low- and high-affinity states of the CRD.[6] Blocking the FimH-CRD with 
carbohydrates or mimetics thereof prevents the bacterial adherence as well as the 
subsequent infection and therefore is regarded as a potential opportunity for prevention 
and/or treatment of UTIs.[7] 
 
Over the last three decades, various mannosides and oligomannosides have been tested as 
potential antagonists for type 1 pili-mediated bacterial adhesion.[8] The crystal structure of 
FimH was first solved in 1999,[9] and since then, numerous crystallographic studies have 
been published, greatly facilitating the rational design of high-affinity ligands.[10] As 
deduced from these studies, the FimH-CRD consists of a deep, negatively charged pocket 
which accommodates the mannopyranose moiety by an extended hydrogen bond network. 
At the entrance to this cavity, the amino acids Tyr48, Tyr137, and Ile52 form a 
hydrophobic rim, the ‘tyrosine gate’, perfectly suited to host aliphatic and aromatic 
aglycones.[10a] As a consequence of these hydrophobic contacts, n-heptyl D-D-
mannopyranoside (1, Figure 1) exhibits nanomolar affinity.[10b] With aromatic aglycones, 
such as present in the antagonists 2-5, further improvements were achieved.[11] The high 
affinity of D-D-mannopyranosides with biphenyl (o 3 & 4) and indolinyl phenyl (o 5) 
aglycones could be rationalized by optimal π-π stacking interactions between the biaryl 
aglycone and the tyrosine gate.[11d,e, 11i] Depending on the aglycone, different binding 
modes have been observed. The alkyl aglycone of n-butyl D-D-mannopyranoside interacts 
with both Tyr48 and Tyr137 of the tyrosine gate.[10b] By contrast, the biphenyl aglycone 
present in antagonist 3 was shown to adopt an ‘out-docking mode’,[11f] that means, it 
interacts only with Tyr48, probably due to limited flexibility of the biphenyl moiety. 
Moreover, ortho-substituents on ring A of the biphenyl aglycone, such as the ortho-
chloro substituent in compound 4b, proved beneficial to binding because of high shape 
complementarity within the binding pocket and therefore better van der Waals 
contacts.[11j] 
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Figure 1. FimH antagonists: n-heptyl D-D-mannopyranoside (1) is used as reference compound; the squaric 
acid derivative 2, the biphenyl derivatives 3-4, and the indolinylphenyl derivative 5 exhibit nanomolar 
affinities. 
 
For numerous diseases as e.g. UTI, oral administration of therapeutics is the standard 
care, because daily therapy is required. As described in our previous publication,[11e] the 
carboxylic acid moiety in biphenyl D-D-mannoside 4b – its electron-withdrawing 
potential is essential for an enhanced π-π stacking interaction – impairs the membrane 
permeability and, as a consequence, the potential for oral absorption. Otherwise, ester 
prodrug 4a was shown to have markedly increased membrane permeability and to 
provide – upon absorption and enzyme-mediated hydrolysis – antagonist 4b, which is 
perfectly suited for rapid renal excretion. Nonetheless, low aqueous solubility (12 µg/mL) 
was identified as a major drawback of prodrug 4a, limiting the absorptive flux of the 
prodrug through the intestinal mucosa. According to the maximum absorbable dose 
(MAD) concept,[12] aqueous solubility of at least 50 µg/mL is required to achieve 
quantitative absorption of a 1 mg/kg dose of prodrug with medium permeability. 
 
Results and Discussion 
 
In the present study, the solubility issue of the ester prodrugs was addressed by two 
approaches: First, by disrupting the molecular planarity and symmetry with modified 
substitution pattern on the biphenyl moiety (Figure 2a) and second by increasing the polar 
surface area (PSA) with heterocyclic biaryl aglycones (Figure 2b).[13] For improving oral 
availability, the carboxylic acid was replaced by the bioisosteric cyano group (Figure 
2c).[14] 
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Figure 2. Modifications of the aglycone of FimH antagonists by (a) modifying the substitution pattern, (b) 
introducing heteroaryl aglycones and (c) replacing the carboxylate moiety with a bioisosteric cyano group. 
To evaluate the impact of these modifications on PK/PD properties, binding affinity to 
the FimH-CRD as well as the in vitro/in vivo pharmacokinetic properties predictive for 
oral bioavailability and metabolic stability were studied. 
Synthesis 
Biphenyl mannosides. Compounds 6a,b, 7a,b and 8a,b (Figure 2a) were synthesized 
according to a previously described procedure (for synthesis and compound 
characterization see Supporting Information).[11e] 
Synthesis of heteroaromatic building blocks (Scheme 1). Starting with the commercial 
aminophenols 9a,b, the azidophenols 10a,b were obtained via a diazotransfer reaction 
using freshly prepared triflyl azide in pyridine and copper (II) sulfate as catalyst.[15] 
Because of instability, 10a,b were used without purification in a subsequent copper (I)-
catalyzed Huisgen cycloaddition[16] with ethyl propiolate, yielding the triazolylphenols 
11a,b with high 1,4-regioselectivity (Scheme 1A). By using an Ullmann-type copper-
diamine-catalyzed N-arylation,[17] 1H-pyrazole-4-carboxylate was coupled with 4-
iodoanisole (12) in N-methyl-2-pyrrolidone (NMP) to furnish 13a. Because of the low 
reactivity of the trifluoromethyl-substituted pyrazole, the coupling reaction was carried 
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out under solvent-free condition to give 13b in quantitative yield. Demethylation of 13a,b 
with AlCl3 gave the pyrazolylphenol derivatives 14a,b. Due to the instability of 14b 
under AlCl3/nBu4NI conditions, a AlCl3/thiol combination was used to accelerate the 
reaction and to suppress byproduct formation (Scheme 1B).[18] The pyrimidinyl derivative 
17 was prepared via a nBuLi-mediated carboxylation with CO2 followed by esterification 
(Scheme 1C).[19] To synthesize the cyano-substituted pyrroles 20a,b, benzotriazol-1-
ylmethyl isocyanide (BetMIC, 18) was treated with the electron-deficient alkenes 19a,b 
under basic heterocyclization conditions (Scheme 1D).[20] 
 
Scheme 1. Reagents and conditions: a) TfN3, CuSO4, triethylamine, pyridine, 0 °C to rt, 2 h; b) ethyl 
propiolate, CuSO45H2O, sodium ascorbate, tBuOH/H2O (1:1), rt, 30 min (yield for two steps: 77% for 11a, 
48% for 11b); c) ethyl 1H-pyrazole-4-carboxylate or ethyl 3-trifluoromethyl-1H-pyrazole-4-carboxylate, 
CuI, trans-N,N’-dimethyl-1,2-cyclohexanediamine, K2CO3, NMP as solvent for 13a and solvent free for 
13b, 110 °C, 24 h (80% for 13a, quant. for 13b); d) AlCl3, cat. nBu4NI, DCE (for 14a), or 1-dodecanethiol 
without catalyst (for 14b), 0 °C to rt (60% for 14a, 26% for 14b); e) i. nBuLi, hexane, toluene, -78 °C, 1 h; 
ii. CO2 (g), -78 °C to rt, 7 h; f) conc. H2SO4 (0.8 eq), MeOH, reflux, overnight (37% for two steps); g) 
nitrile 19a,b, tBuOK, THF, 0 °C to reflux, 2 h (60% for 20a, 54% for 20b). 
 
Triazolylphenyl and pyrazolylphenyl mannosides (Schemes 2). Mannosylation of the 
phenols 11a,b and 14a,b (see Scheme 1A & B) with mannosyl fluoride 21 and BF3·Et2O 
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as promoter, yielded exclusively the D-mannosides 22a,b and 25a,b.[21] Deacetylation (o 
23a-c and 26a,b) followed by ester hydrolysis gave the test compounds 24a,b and 27a,b. 
 
 
Scheme 2. Reagents and conditions: a) BF3Et2O, DCM, mol. sieves 4 Å, 0 °C to rt, overnight (79% for 
22a, 76% for 22b, 98% for 25a, 64% for 25b); b) NaOMe, MeOH, rt, 4 h (74% for 23a, 80% for 23b); c) 
NaOEt, EtOH, rt, overnight (74% for 23c, 95% for 26a, 82% for 26b); d) 0.2 N aq. NaOH, MeOH, rt, 
overnight (30% for 24a, 90% for 24b, 70% for 27a, 79% for 27b). 
 
Pyridinylphenyl, pyrazinylphenyl, and pyrimidinylphenyl mannosides (Scheme 3). 
Mannosyl fluoride 21 was treated with 4-iodophenol or 4-bromo-2-trifluoromethylphenol 
in the presence of BF3·Et2O. The resulting iodide 28[11j] and bromide 34[11j] were 
transformed into the boronic acid pinacol esters 29[11j] and 35 under Miyaura-borylation 
conditions. In a palladium-catalyzed Miyaura-Suzuki coupling[22] of the heteroaryl 
halides 17 (see Scheme 1C) and 30a-c (commercially available) with boronic acid ester 
29, heteroarylphenyl mannosides 31a-d were obtained in good to excellent yields. 
Similarly, mannoside 36 was prepared by coupling of ester 35 and pyridinylchoride 30a. 
Deacetylation under Zemplén conditions (o 32a-d, 37) followed by saponification of the 
methyl ester yielded the sodium salts 33a-d and 38. 
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Scheme 3. Reagents and conditions: a) 4-iodophenol or 4-bromo-2-trifluoromethylphenol, BF3Et2O, 
DCM, mol. sieves 4 Å, 0 °C to rt, overnight (70% for 28, 80% for 34); b) bis(pinacolato)diborone, 
Pd(Cl2)dppfCH2Cl2, KOAc, DMF, 85 °C, overnight (80% for 29, 83% for 35); c) Pd(Cl2)dppfCH2Cl2, 
K3PO4, DMF, 85 °C, overnight (60% for 31a, 80% for 31b, 68% for 31c, 40% for 31d, 57% for 36); d) 
NaOMe, MeOH, rt, 4 h (36% for 32a, 24% for 32b, 36% for 32c, 89% for 32d, 60% for 37); e) 0.2 N aq. 
NaOH, MeOH, rt, overnight (32% for 33a, 48% for 33b, 44% for 33c, 60% for 33d, 90% for 38). 
 
Pyrrolylphenyl mannosides (Schemes 4 & 5). In a copper catalyzed N-arylation, pyrroles 
20a,b (see Scheme 1D) and 20c-f (commercial) were coupled with mannoside 39 (ortho-
Cl) to yield the pyrrolylphenyl mannosides 40a-f (Scheme 4).[18] Under similar 
conditions, mannosides 28 (without ortho-substituent) and 34 (ortho-CF3) were coupled 
with pyrrole 20f to yield 46 and 47 (Scheme 5). Because of partial deacetylation of the 
sugar moiety during N-arylation, the crude products were reacetylated to facilitate 
purification. Deacetylation of the mannose moiety (o 41a-f, 48 and 49) followed by 
saponification of the alkyl esters gave the test compounds 42-45, 50 and 51. 
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Scheme 4. Reagents and conditions: a) i. CuI, (±)-trans-1,2-diaminocyclohexane, K3PO4, 1,4-dioxane, 110 
°C, overnight; ii. Ac2O, DMAP, pyridine, rt, overnight (44% for 40a, 92% for 40b, 33% for 40c, 64% for 
40d, 99% for 40e, 77% for 40f); b) NaOMe, MeOH, rt, 4 h (65% for 41a, 38% for 41b, 83% for 41e); c) 
NaOEt, EtOH, rt, overnight (91% for 41c, 61% for 41d, 93% for 41f); d) NaOH, MeOH/H2O (1:2), rt, 12-
48 h (58% for 42, 40% for 43, 20% for 44, 57% for 45). 
 
 
Scheme 5. Reagents and conditions: a) i. CuI, (±)-trans-1,2-diaminocyclohexane, K3PO4, 1,4-dioxane, 110 
°C, overnight; ii. Ac2O, DMAP, pyridine, rt, overnight (94% for 46, 49% for 47); b) NaOEt, EtOH, rt, 
overnight (46% for 48, 85% for 49); c) NaOH, MeOH/H2O (1:2), rt, 48 h (99% for 50, 35% for 51).  
In Vitro binding affinities  
The hydrolyzed prodrugs, i.e. the free carboxylates (6-8b, 24a-b, 27a-b, 33a-d, 38, 42-45, 
50 and 51) as well as the bioisosteric cyanides (41a-b), were evaluated in a cell-free 
competitive binding assay (Table 1).[23] 
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Cell-free competitive binding assay.[23] The cell-free competitive binding assay is based 
on the competitive interaction of the compound of interest and the  biotinylated 
polyacrylamide glycopolymer TM-PAA (ManD1-3(ManD1-6)ManE1-4GlcNAcE1-
4GlcNAcE-PAA) with the isolated CRD of FimH. Complexation of the biotinylated 
glycopolymer with streptavidin coupled to horseradish peroxidase allows for 
quantification of the binding affinity of the antagonists. For every compound the assay 
was performed twice with each concentration in duplicate. To ensure comparability 
between various antagonists, the reference compound n-heptyl D-D-mannopyranoside (1) 
was tested each time in parallel. The affinities are reported relative to 1 as rIC50 in Table 
1. 
 
A comparison of the biphenyl mannoside antagonist 4b (entry 2) with the regioisomers 
6b, 7b, and 8b (entries 3-5) indicates that changing the position of the carboxylic acid on 
the terminal ring B of the biphenyl aglycone as well as modifying the substitution pattern 
on ring A substantially reduced affinity. As previously reported, the ortho-chloro 
substituent present in the antagonists 4b and 7b provides additional van der Waals 
contacts leading to binding affinity in the low nanomolar range.[11j] 
 
Table 1. Pharmacodynamic parameters of FimH antagonists. The IC50 values were determined with a cell-
free competitive binding assay.[23] The rIC50 values were calculated by dividing the IC50 of the compound of 
interest by the IC50 of reference compound 1. This leads to rIC50 values below 1.0 for derivatives with 
higher affinity than reference 1 and rIC50 above 1.0 for compounds with lower affinity than 1. 
Entry Cpd 
 
IC50  
>nM@ 
rIC50 Entry Cpd  
IC50 
>nM@ 
rIC50 
R R 
1 1[10b] O  54.9 1 12 33c 
O
N
N
COONa 
39 0.73 
2 4b[11e] 
O
COONa
Cl
 
6.7 0.09 13 33d 
O
N
N
COONa 
35 0.60 
3 6b[11e] O
COONa
Cl  
29 0.40 14 38 
O
N
COONa
CF3
 
20 0.39 
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4 7b 
O
COONa
Cl
 
12 0.19 15 41a 
O
N
Cl
CN
 
29 0.50 
5 8b 
O
COONa
Cl
 
53 0.97 16 41b 
O
N
CN
Cl
 
25 0.43 
6 24a 
O
N N
N
COONa 
16 0.30 17 42 
O
N
Cl
COONa
 
75 1.37 
7 24b 
O
N N
N
COONa
Cl
 
21 0.35 18 43 
O
N
Cl
COONa
 
23 0.41 
8 27a 
O
N
N
COONa 
111 2.02 19 44 
O
N
Cl
COONa 
25 0.45 
9 27b 
O
N
N
COONa
CF3
 
112 2.02 20 45 
O
N
COONa
Cl
 
25 0.44 
10 33a 
O
N
COONa 
16 0.30 21 50 
O
N
COONa 
65 1.18 
11 33b 
O
N
COONa 
46 0.71 22 51 
O
N
COONa
CF3
 
19 0.33 
 
All heteroaryl mannosides (entries 6-22) showed IC50 values in the nanomolar range as 
well. Nonetheless, they were weaker binders than the optimized biphenyl mannoside 4b, 
although in silico studies obtained with flexible docking (Glide software package[24]) to 
the FimH-CRD suggested a similar ‘out-docking mode’ (Figure 3). 
 
In comparison with the triazolylphenyl mannosides 24a,b (entries 6 & 7) and the 
pyrrolylphenyl mannosides 41a,b, 42-45, 50 and 51 (entries 15-22), the pyrazolylphenyl 
analogues 27a,b (entries 8 & 9) showed markedly lower affinity, even though we 
expected a similar conformation for all biaryl mannosides containing a five-membered 
aromatic heterocycle. Furthermore, a high impact of the substitution pattern on the 
binding affinity was observed for the various pyrrolylphenyl mannosides (entries 15-22). 
In agreement with previous observations,[11j,g] the ortho-chloro and the ortho-
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trifluoromethyl substituents on ring A were beneficial to affinity (50 vs. 45 & 51, entries 
20-22). The position of the electron-withdrawing carboxylic acid moiety in the 
heteroaromatic ring furthermore affected the binding affinity. In the 3-position (o 44, 
entry 19) it conferred three times higher affinity than in the 2-position (o 42, entry 17). 
In silico docking studies indeed suggest that the 2-carboxylate forces the two rings of the 
aglycone in an orthogonal orientation and therefore disrupts the S-S stacking interactions 
between the heteroaromatic ring and Tyr48 of the tyrosine gate (o 45, Figure 3B). 
Otherwise, the additional 4-methyl substituent present in 43 (entry 18) could presumably 
provide an additional hydrophobic contact (Figure 3A). 
  
Figure 3. In silico docking studies obtained with flexible docking (Glide software package[24]) to the 
FimH-CRD (PDB ID: 3MCY); top-scored binding modes of A) 43 (Table 1, entry 18) and B) 45 (entry 20).  
 
Physicochemical properties and in vitro pharmacokinetics 
For assessing the potential for intestinal absorption, lipophilicity (log P), aqueous 
solubility, and permeability through an artificial membrane (PAMPA, log Pe) as well as a 
Caco-2 cell monolayer (Papp) were determined (Table 2).[25-30] Furthermore, the esters 
were incubated with rat liver microsomes (RLM) for estimating their susceptibility to 
carboxylesterase (CES)-mediated hydrolysis.[31] Mammalian CESs are localized in the 
endoplasmatic reticulum of the liver and most other organs. Table 2 indicates the 
metabolic half lives (t1/2) as determinants of the rate of bioconversion to the respective 
acid. 
 
Table 2. Physicochemical and pharmacokinetic parameters of FimH antagonists. 
Entry Cpd 
 
log P a 
Solubility 
>Pg/mL@b 
PAMPA 
log Pe 
Caco-2 
Papp [10-6 cm/s]d 
Microsomal 
stability 
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R [cm/s]c aob boa t1/2 [min]e 
1 4a[11e] 
O
Cl
COOMe 
2.3 11.9 -4.6 5.3 ± 0.6 17.5 ± 1.3 2.1 
2 6a[11e] O
COOMe
Cl  
1.7 ± 0.1 14 ± 0 -4.7 6.1 ± 1.2 21.1 ± 1.2 22 
3 7a 
O
Cl
COOMe
 
2.7 ± 0.1 41 r 3 -4.6 r 0.2 6.7 ± 0.4 20.7 ± 2.5 84 
4 8a 
O
COOMe
Cl
 
2.7 ± 0.1 134 r 6 -4.5 r 0.1 4.5 ± 0.3 10.8 ± 0.7 13 
5 23a 
O
N N
N
COOMe  
-0.6 r 0.0 > 180 -9.4 r 0.3 n.d. n.d. 38 
6 23b 
O
N N
N
COOMe
Cl
 
0.0 r 0.0 > 150 -9.1 r 1.8 n.d. n.d. 32 
7 23c 
O
N N
N
COOEt
Cl
 
0.7 r 0.0 > 150 -10 n.d. n.d. 42 
8 26a 
O
N
N
COOEt 
0.9 r 0.0 > 180 -6.6 r 0.1 n.d. n.d. > 120 
9 26b 
O
N
N
COOEt
CF3
 
2.1r 0.0 > 180 -5.7 r 0.1 1.3 ± 0.1 12.4 ± 2.4 113 
10 32a 
O
N
COOMe 
0.2 r 0.0 > 130 -7.5 r 0.2 0.22 ± 0.05 2.3 ± 0.1 10 
11 32b 
O
N
COOMe 
1.0 r 0.0 59 r 6 -6.3 r 0.0 0.64 ± 0.06 8.3 ± 0.4 11 
12 32c 
O
N
N
COOMe 
0.1 r 0.1 > 150 -7.6 r 0.0 0.24 ± 0.01 1.8 ± 0.2 11 
13 32d 
O
N
N
COOMe 
< -1.0 95 r 6 -8.5 r 0.1 0.16 ± 0.03 0.22 ± 0.05 24 
14 37 
O
N
COOMe
CF3
 
1.3 r 0.1 > 180 -8.6 r 1.7 0.33 ± 0.04 7.2 ± 0.7 8.2 
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15 41a 
O
N
Cl
CN 
1.5r0.1 >350 -8.8r 2.0 n.d. n.d. n.d. 
16 41b 
O
N
CN
Cl
 
2.0r0.1 69 r 20 -6.3 r 0.1 n.d. n.d. n.d. 
17 41c 
O
N
Cl
COOEt
 
2.0 r 0.0 > 180 -5.2 r 0.0 n.d. n.d. > 120 
18 41d 
O
N
Cl
COOEt
 
2.7 r 0.0 34 r 4 -4.8 r 0.1 5.0 ± 0.2 35.6 ± 1.0 84 
19 41e 
O
N
Cl
COOMe 
2.1 r 0.2 > 180 -6.0 r 0.1 n.d. n.d. > 120 
20 41f 
O
N
COOEt
Cl
 
2.8 r 0.1 > 180 -4.8 r 0.1 6.4 ± 0.7 30.0 ± 2.9 > 120 
21 48 
O
N
Me
COOEt
 
2.3 r 0.0 > 180 -5.1 r 0.1 1.5 ± 0.5 17.2 ± 0.6 > 120 
22 49 
O
N
Me
COOEt
CF3
 
3.0 r 0.1 135 r 6 -5.0 r 0.2 5.0 ± 0.3 26.1 ± 1.5 > 120 
[a] Octanol-water partition coefficients (log P) were determined by a miniaturized shake flask procedure. 
The values are indicated as mean r SD of sextuplicate determinations.[25] [b] Kinetic solubility was 
measured in a 96-well format in triplicate using the µSOL Explorer solubility analyzer.[26] [c] Permeation 
through an artificial membrane (log Pe, effective permeability) was determined by PAMPA (parallel 
artificial membrane permeability assay) in quadruplicate.[27] [d] Permeation through a Caco-2 cell 
monolayer (Papp, apparent permeability) was assessed in the absorptive (aob) and secretory (boa) 
directions in triplicate.[28] [e] Microsomal stability was determined with pooled male rat liver microsomes 
(0.125 mg/mL) at pH 7.4 and 37 °C.[29] n.d., not determined. 
 
Biphenyl mannosides. As observed in our previous study,[11e] the biphenyl derivatives 4a 
and 6a (Table 2, entries 1 & 2) showed low aqueous solubility probably due to the 
symmetrical para-para substitution pattern. In order to disrupt this symmetry, the 
carboxylic acid moiety in 4a was moved from the para- to the meta-position (o 7a, 
Table 2, entry 3), leading however only to moderately improved aqueous solubility. 
Moving the chloro substituent on ring A from the ortho- to the meta-position (o 8a, 
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Table 2, entry 4) increased the dihedral angle between the aromatic rings of the bicyclic 
aglycone (Figure 4A, 60.3° for antagonist 8a vs. 39.6° for antagonist 7a, values 
calculated with MacroModel, version 9.9[30]), resulting in the disruption of the molecular 
planarity and markedly enhanced aqueous solubility. Given the elevated solubility (134 
µg/mL) and the high effective permeability (log Pe -4.5), the prodrug 8a was identified as 
the most promising biphenyl derivative for oral administration. 
 
The microsomal incubation with a low initial substrate concentration (2 µM) and a 
concentration of the microsomal protein of 0.125 mg/mL induced a fast degradation of 
prodrug 4a (t1/2 2.1 min, entry 1). The esters in the biphenyl mannosides 6a (t1/2 22 min, 
entry 2), 7a (t1/2 84 min, entry 3), and 8a (t1/2 13 min, entry 4) were less susceptible to the 
carboxylesterase (CES)-mediated metabolic turnover. The differing rates of hydrolysis 
may result from various reasons, i.e. the change in the molecular geometry and therefore 
in the accessibility of the ester by the catalytic site of the serine hydrolase CES,[31] and 
differing electron-density on the carbonyl carbon. Since the first step of the catalytic 
mechanism relies on the nucleophilic attack by the hydroxyl group of the serine 
moiety,[32] increasing electron-deficiency of the carbonyl carbon should lead to a higher 
propensity for hydrolysis. However, the calculated partial charges (G) on the carbonyl 
carbons (Figure 4A, calculated with AMSOL, Version 7.1[33]) do not correlate with the 
propensities of the corresponding esters to hydrolysis. We therefore attributed the rate 
differences of the CES-mediated hydrolysis primarily to the differing geometry of the 
aglycones, which, in case of 4a, orients the ester bond within the active site in an optimal 
position. 
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Figure 4. Dihedral angle between the aromatic rings of the bicyclic aglycones and the partial charge (G) on 
the carbonyl carbon of A) the biphenyl aglycone and B) the heteroaryl aglycone of prominent biaryl D-D-
mannopyranosides. The values were calculated with MacroModel (version 9.9) [30] and AMSOL (version 
7.1).[33] 
 
Heteroaryl mannosides. The heteroaryl mannosides (Table 2, entries 5-22) exhibited 
markedly higher aqueous solubility than biphenyl D-D-mannoside 4a. When the nitrogen 
atom is moved from the ortho- (o 32b, entry 11) to the meta-position (o 32a, entry 10) 
of the heteroaromatic moiety, the dihedral angle between the two aryl rings (Figure 4B, 
32.5° for 32b vs. 38.0° for 32a) increases, leading to a disruption of the molecular 
planarity and hence to improved solubility. Furthermore, an additional parameter leading 
to improved solubility becomes evident from the antagonists 32c and 32d. Thus, although 
32c (entry 12) has a smaller dihedral angle than 32d (entry 13) (Figure 4B, 30.9° for 32c 
vs. 36.2° for 32d) it exhibits higher solubility. One possible rational is associated with the 
desymmetrization of the aglycone, reducing compatibility for stacking and therefore 
increasing solubility. In general, most five-membered heteroaryl mannosides excel in 
high solubility, either because of the increased polarity [o triazoles 23a-c (entries 5-7) 
and pyrazoles 26a,b (entries 8 & 9)] or because of the disruption of molecular symmetry 
(o pyrroles 41a-f, 48, 49, entries 15-22). 
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As expected, increased polarity (o 23a, log P -0.6, entry 5) leads to reduced permeability 
(log Pe -9.4), i.e. poor oral absorption.[34] To enhance lipophilicity two strategies were 
followed: First, an ortho-chloro substituent was added to ring A of the biaryl aglycone 
(o 23b, entry 6) and, second, the methyl ester was replaced by an ethyl ester (o 23c, 
entry 7). However, both strategies were insufficient to substantially improve the oral 
absorption potential. For the pyrazolylphenyl derivative 26a (entry 8), although slightly 
more lipophilic than the triazolylphenyl 23c (entry 7), only low effective permeability 
(log Pe -6.6) was observed. Introduction of a trifluoromethyl substituent on the pyrazole 
moiety (o 26b, entry 9) further increased both lipophilicity and permeability but was still 
not sufficient for successful intestinal uptake. 
 
By contrast, the pyrrolylphenyl mannosides 41a-f, 48 and 49 (Table 2, entries 15-22) 
counted among the most lipophilic and the most permeable biaryl derivatives. 
Lipophilicity and permeability of antagonist 41e could be successively enhanced by 
introducing a methyl substituent in the 4-position of the pyrrole moiety (o 48, Table 2, 
entry 21) and by modifying the ortho-substituent on ring A of the biaryl aglycone (o 41f 
and 49, entries 20 & 22). For antagonists 41f and 49, effective permeability resulting 
from PAMPA (log Pe -4.8 and -5.0, respectively) suggested a high oral absorption 
potential. Moreover, the absorptive flux (apical o basal) through the Caco-2 cell 
monolayer was outstandingly high. Although the ratio Papp,boa/Papp,aob implied efflux-
carrier activity, we expected high systemic availability of 41f and 49 in vivo, notably 
because efflux transporters at human intestines are considered easily saturable when 
compounds are administered at elevated doses (e.g. > 100 mg).[35] In the case of the 
pyrrolylphenyl derivatives 41c and 41d (entries 17 & 18), introducing a 4-methyl 
substituent increased permeability as well. In turn, it made 41d the least soluble 
compound among all assessed heteroaryl mannosides. The bioisosteric replacement of the 
carboxylic moiety by a cyano group (o 41a,b, entries 15 & 16) resulted in PAMPA data 
indicating low permeability for both derivatives (log Pe -8.8 and -6.3, respectively). 
 
Lipophilicity and permeability of the biaryl mannosides with six-membered heterocycles 
(entries 10-14) could be shown to depend on number and position of the nitrogen atoms 
in the bicyclic aglycone. The pyridinylphenyl derivative 32a (entry 10) exhibited low 
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lipophilicity and permeability, whereas adding a trifluoromethyl substituent on ring A of 
the aglycone (o 37, entry 14) increased lipophilicity but did not confer higher 
permeability. By moving the pyridine nitrogen position (o 32b, entry 11), we could 
moderately increase lipophilicity and permeability. Nonetheless, antagonist 32b was still 
too hydrophilic for intestinal absorption, as suggested by PAMPA and the Caco-2 model. 
The pyrazinylphenyl mannoside 32c (entry 12) and the pyrimidinylphenyl mannoside 32d 
(entry 13) both showed low lipophilicity and low effective permeability, suggesting low 
oral availability. 
 
All heteroaryl derivatives with ester functions (Table 2, entries 5-14 and 17-22) were 
found to be less susceptible to CES-mediated bioconversion than the initial biphenyl 
mannoside 4a. Nonetheless, the experimental half-life values suggest a strong 
relationship between the molecular structure of the heteroaryl portion and the propensity 
to hydrolysis. The calculated partial charges (G) on the carbonyl carbon of prominent 
heteroaryl mannosides are shown in Figure 4B. According to these values, the electron 
distribution on the antagonists 32a-d, including six-membered heteroaromatic cycles, is 
similar to those of the biphenyl mannoside 4a. This similarity, in combination with the 
linear molecular geometry, probably explains their considerable propensity to enzyme-
mediated hydrolysis. By contrast, the analogs with a five-membered heterocycle were 
markedly less prone to CES-mediated hydrolysis, probably due to the varying molecular 
geometries and physicochemical properties affecting the substrate recognition by the 
CES.[31] 
 
Binding affinity of selected esters 
The pyrrolylphenyl esters 41e,f, 48, and 49, which were originally designed as prodrugs, 
surprisingly proved to be metabolically stable and not hydrolizable by the 
carboxylesterases. Since their lipophilicity (log P), solubility, membrane permeation (log 
Pe and Papp) fulfill the requirements for an oral uptake, the binding affinities of these 
antagonists were determined in the cell-free competitive assay (see above) as well as in a 
competitive fluorescence polarization assay (Table 3). In both assays, n-heptyl mannoside 
(1) was used as a reference compound. 
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Competitive Fluorescence Polarization Assay.[11k] For the rapid evaluation of binding 
affinity, a previously developed competitive binding assay based on fluorescence 
polarization (FP) was applied. A FimH variant consisting of the CRD linked to a His-tag 
by a thrombin cleaving site (FimH-CRD-Th-His6, expressed and purified as previously 
described)[23] was used. The antagonist of interest displaces the fluorescent-labeled 
competitor 52[11k] from the binding site, thereby reducing fluorescence polarization.[36] 
Due to the long residence time of FimH antagonists (t1/2 > 3.5 h),[37] a 24 h incubation 
time was applied before measurement of fluorescence polarization. IC50 values were 
obtained by nonlinear least-squares regression (standard four-parameter IC50 equation) 
and converted to KD using a modified Cheng-Prusoff equation.[36] The KD values 
observed for the test compounds 41e,f, 48 and 49 are summarized in Table 3. In general, 
the pyrrolylphenyl mannosides  (entries 2-5) showed higher affinity than the reference 
compound 1. The improved affinity for the ortho-substituted biaryls (Cl, 41f and CF3, 49) 
was confirmed. 
 
Table 3. Affinity of FimH antagonists to FimH-CRD-Th-His6.a The IC50 values were determined with a 
cell-free competitive binding assay.[23] The rIC50 values were calculated by dividing the IC50 of the 
compound of interest by the IC50 of reference compound 1. Dissociation constants (KD) were determined in 
a competitive fluorescence polarization assay.[36] n.d., not determined. 
 
Entry Cpd 
 
Binding Assay FP-Assay 
KD [nM] IC50 >nM@ rIC50 
1 1 O  54.9 1.0 28.3 
2 41e 
O
N
Cl
COOMe 
18.5 0.33 4.3 
3 41f 
O
N
Cl
COOEt 
25.2 0.46 7.5 
4 48 
O
N
COOEt 
24.9 0.45 24.6 
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5 49 
O
N
COOEt
CF3
 
36.9 0.72 6.0 
6 52[11k] 
O
NH
O
NH
HN
S
O
O
OHO OH
Cl
 
n.d. n.d. 1.7 
 
In vivo pharmacokinetic study. Antagonist 41f exhibiting the best in vitro PK/PD profile 
was selected for an in vivo pharmacokinetic study. It was orally applied to three mice at a 
dose of 10 mg/kg. The concentration-time profiles are shown in Figure 5. 
 
Figure 5. Urine (dashed line) and plasma (continuous line) concentration over time after an application of 10 
mg/kg of 41f. The detection limit for plasma samples was at 0.02 µg/ml, urine samples could be detected 
down to 0 µg/ml. 
 
Generally, plasma concentrations of 41f were very low, only barely exceeding the 
detection limit (0.02 µg/ml), peaking between 40 min and 1.5 h after application with a 
Cmax of only 0.04 µg/ml and subsequently dropping below the detection limit. In contrast, 
the urine concentration levels show a rapid accumulation of antagonist 41f, with a Cmax 
ranging from 10 to 16 µg/ml at 1 to 3 h post application, forming a stable concentration 
plateau, which is slightly shifted in time compared to plasma peak levels. At 8 h, 41f was 
not detectable in urine anymore. The dose appearing in urine corresponds to 
approximately 30% of the oral dose. 
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The accumulation in the urine, resulting in a relative constant plateau concentration over 
a time-period of about 3 h, is related to several important interplaying mechanisms. Both, 
PAMPA[27] and transport through a Caco-2 cell layer indicate permeability (log Papp -4.8 
cm/s, and Papp,a-b 6.4 u 10-6 cm/s, Table 3) for 41f.[38,39] However, absorption of 41f is 
slowed down by the simultaneous efflux (Papp,b-a 30 u 10-6 cm/s) by P-glycoprotein (P-
gp),[40] exceeding the uptake rate by a factor of about 5. Therefore, 41f accumulates in the 
intestinal fluids, leading to P-gp saturation and, consequently, to a prolonged, but slow 
uptake. As this effect can influence plasma and urine drug levels only for a limited time, 
further mechanisms come into play. After absorption, the compound only shortly stays in 
circulation and is rapidly excreted by glomerular filtration in the kidneys. The log P value 
of 41f (log P 2.8, Table 3) implies a high tubular reabsorption from the proximal tubuli, 
resulting in a delayed renal excretion.[38,39,41] In summary, the prolonged absorption due 
to P-gp mediated efflux combined with the delayed elimination via the kidneys due to 
reabsorption – elimination via the liver can be neglected (t1/2 >120 min in RLM, Table 3) 
– explains the observed PK profile. This PK profile could proof beneficial for UTI 
treatment, as constant high levels over an extended time would limit dosing to few or 
even only one application a day. 
 
Conclusions 
 
Starting from prodrug 4a, the present study aimed at optimizing the pharmacokinetic 
properties of the biaryl mannoside in order to achieve high oral absorption of the ester 
prodrug and rapid enzyme-mediated release of the active principle. In this regard, our first 
approach, i.e. disruption of the molecular planarity and symmetry of the biphenyl 
mannoside by modifying the substitution pattern, proved successful. Unlike compound 4a, 
the ester prodrug 8a showed solubility and membrane permeability in the range for high 
oral absorption in vivo. Moreover, hepatic esterases were shown to rapidly convert the 
ester to the polar parent compound 8b. However, shifting the substituents on the aglycone 
markedly decreased the affinity to the FimH-CRD, overriding the gain in the intestinal 
uptake potential. 
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In a second approach, the improvement of the physicochemical properties by heterocyclic 
aglycones was studied. Thereby, triazole (23a-c), pyrazole (26a,b), and six-membered 
heterocyclic moieties (32a-d and 37) proved highly beneficial to the aqueous solubility 
but in turn reduced lipophilicity and membrane permeability, which suggests, overall, 
poor oral absorption. By contrast, the pyrrolylphenyl mannosides – optimized by the 
introduction of a chloro or trifluoromethyl substituent on ring A and a methyl group on 
the terminal heterocycle (41f and 49) – exhibited permeability and aqueous solubility in 
the range for successful oral absorption. Otherwise, incubations with rat liver microsomes, 
revealing low propensity to enzyme-mediated hydrolysis, predicted erratic conversion of 
the esters to the free acids in the liver. Despite their high intestinal uptake potential, these 
esters therefore scarcely act as prodrugs facilitating the delivery of the active principles to 
the urinary bladder. Nonetheless, the introduction of a pyrrole cycle appears as a 
promising strategy for optimizing the oral absorption of biaryl mannoside analogues, 
which do not rely on an ester prodrug approach. Two competitive binding assays 
indicated high binding affinities for all the heterocyclic derivatives with either free 
carboxylate or the ester moieties.  
 
In summary, our study exemplifies the benefits of two approaches, that are rearrangement 
of the substitution pattern and introduction of aromatic heterocycles, on aqueous 
solubility of the biaryl mannosides. The high microsomal stability of the pyrrole 
derivatives indicates an action mode rather than a prodrug approach. For the esters 41f 
and 49, an optimal balance of pharmacodynamic, physicochemical and pharmacokinetic 
properties was obtained. Based on in vivo PK studies, 41f is a promising candidate to be 
tested in a UTI disease model. 
 
Experimental Section 
 
Synthesis. The synthesis of compounds 11a,b, 13a,b, 14a,b, 17, 20a,b, 22b, 23b,c, 24b, 
25a,b, 26a,b, 27a,b, 31b-d, 32b-d, 33b-d, 40a-e, 41a-e, 42-44, 47, 49, and 51, including 
compound characterization data, can be found in the Supporting Information. 
 
General Methods. NMR spectra were recorded on a Bruker Avance DMX-500 (500.1 
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MHz) spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D 
methods (COSY, HSQC, HMBC). Chemical shifts are expressed in ppm using residual 
CHCl3, CHD2OD or HDO as references. Optical rotations were measured using Perkin-
Elmer Polarimeter 341. Electron spray ionization mass spectra (ESI-MS) were obtained 
on a Waters micromass ZQ. The LC/HRMS analysis were carried out using a Agilent 
1100 LC equipped with a photodiode array detector and a Micromass QTOF I equipped 
with a 4 GHz digital-time converter. Microwave-assisted reactions were carried out with 
a CEM Discover and Explorer. Reactions were monitored by TLC using glass plates 
coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or by 
charring with a molybdate solution (a 0.02 M solution of ammonium cerium sulfate 
dihydrate and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). MPLC 
separations were carried out on a CombiFlash Companion or Rf from Teledyne Isco 
equipped with RediSep normal-phase or RP-18 reversed-phase flash columns. LC-MS 
separations were done on a Waters system equipped with sample manager 2767, pump 
2525, PDA 2525 and micromass ZQ. Size-exclusion chromatography was performed on 
Bio-Gel® P-2 Gel (45-90 mm) from Bio-Rad (Reinach, Switzerland). All compounds 
used for biological assays are at least of 98% purity based on HPLC analytical results. 
Commercially available reagents were purchased from Fluka, Aldrich, Alfa Aesar or Iris 
Biotech (Germany). Solvents were purchased from Sigma-Aldrich (Buchs, Switzerland) 
or Acros Organics (Geel, Belgium) and were dried prior to use where indicated. Methanol 
(MeOH) and ethanol (EtOH) were dried by refluxing with sodium methoxide or ethoxide 
and distilled immediately before use. Dichloromethane (DCM) was dried by filtration 
over Al2O3 (Fluka, type 5016 A basic). Molecular sieves 4Å were activated in vacuo at 
500 °C for 1 h immediately before use. 
 
General procedure A for the synthesis of mannosides 22a,b and 25a,b. To an ice-cold 
suspension of 21[21] (1.1 equiv), phenol 11a,b or 14a,b (1.0 equiv) and molecular sieves 4 
Å (600 mg) in dry DCM (5 mL), BF3Et2O (4.7 equiv) was added dropwise under argon. 
The mixture was stirred at 0 °C for 3 h, and then at rt overnight. The reaction mixture was 
filtered over Celite and the filtrate was diluted with DCM (50 mL), extracted with 0.5 N 
aq. NaOH (50 mL), water (50 mL) and brine (50 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by MPLC on silica gel 
(petrol ether/EtOAc) to yield 22a,b or 25a,b. 
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General procedure B for the coupling of mannosylated phenyls with six-membered 
heterocyclic halides. A Schlenk tube was charged with heterocyclic halide 30a-c or 17 
(1.0 eq), boronate 29 or 35 (1.1 eq), Pd(dppf)Cl2CH2Cl2 (0.03 eq), K3PO4 (1.5 eq) and a 
stirring bar. The tube was closed with a rubber septum and was evacuated and flushed 
with argon. This procedure was repeated once, then anhydrous DMF (2 mL) was added 
under a stream of argon. The mixture was degassed in an ultrasonic bath and flushed with 
argon for 5 min, and then stirred at 80-85 °C overnight. The reaction mixture was cooled 
to rt, diluted with EtOAc (50 mL), and washed with water (50 mL) and brine (50 mL). 
The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was 
purified by MPLC on silica gel (petrol ether/EtOAc) to afford heteroarylphenyls 31a-d or 
36. 
 
General procedure C for the coupling of mannosylated phenyls with substituted 
pyrrolyl halides. A Schlenk tube was charged with phenyl halide 28, 34 or 39 (1.0 eq), 
pyrrolyl halide 20a-f (1.2 eq), CuI (0.05 eq), (±)-trans-1,2-diaminocyclohexane (0.11 eq), 
K3PO4 (2.1 eq) and a stirring bar. The tube was closed with a rubber septum and was 
evacuated and flushed with argon. This procedure was repeated once, then anhydrous 1,4-
dioxane (ca. 0.5 mL, 1 M to phenyl halide) was added under a stream of argon. The 
mixture was degassed in an ultrasonic bath and flushed with argon for 5 min, and then 
stirred at 110 °C for 24 h. The reaction mixture was cooled to rt, diluted with EtOAc (50 
mL), and filtered through Celite. The filtrate was concentrated in vacuo and co-
evaporated with toluene. The residue was acetylated with pyridine/acetic 
anhydride/DMAP, concentrated and purified by MPLC on silica gel (petrol ether/EtOAc) 
to afford pyrrolylphenyls 40a-f, 46 or 47. 
 
General procedure D for deacetylation: To a solution of 22a,b, 25a,b, 31a-d, 36, 40a-
f, 46 or 47 (1.0 eq) in dry MeOH (5 mL) for producing methyl ester or in dry EtOH  (5 
mL) for producing ethyl ester, was added freshly prepared 1 M NaOMe/MeOH or 
NaOEt/EtOH (0.1 eq) under argon. The mixture was stirred at rt until the reaction was 
complete (monitored by TLC), then neutralized with Amberlyst-15 (H+) ion-exchange 
resin, filtered and concentrated in vacuo. The residue was purified by MPLC on silica gel 
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(DCM/MeOH, 10:1 to 8:1 for methyl esters or DCM/EtOH, 3:1 for ethyl esters) to afford 
23a-c, 26a-b, 32a-d, 37, 41a-f, 48 or 49. 
 
General procedure E for saponification: To a solution of 22a,b, 25a,b, 31a-d, 36, 40a-
f, 46 or 47 (1.0 eq) in MeOH (5 mL) was added 1 M NaOMe/MeOH (0.1 eq) at rt. The 
reaction mixture was stirred at rt for 4 h and concentrated. The residue was treated with 
0.5 M aq. NaOH (1 mL) for 24 h at rt. Then the pH was adjusted to 3-4 with Amberlyst-
15 (H+) and the mixture was filtered and concentrated. The crude product was 
transformed into the sodium salt by passing through a small column of Dowex 50X8 (Na+ 
form) ion-exchange resin. After concentration the residue was purified by MPLC (RP-18, 
H2O/MeOH, 1:0 to 2:1) followed by size-exclusion chromatography (P-2 gel, H2O) to 
yield 24a,b, 27a,b, 33a-d, 38, 42-45, 50 or 51 as white solids after final lyophilization 
from water. 
 
Ethyl 1-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)phenyl]-1H-1,2,3-
triazole-4-carboxylate (22a). Prepared according to general procedure A from 21 and 
11a. Yield: 341 mg (79%) as colorless oil. Rf 0.30 (petrol ether/EtOAc, 1:1); [D]D20 +76.7 
(c 0.90, MeOH); 1H NMR (500 MHz, CDCl3): G = 8.47 (s, 1H, triazole), 7.72-7.70 (m, 
2H, Ar-H), 7.29-7.27 (m, 2H, Ar-H), 5.60 (d, J = 1.7 Hz, 1H, H-1), 5.56 (dd, J = 3.0, 10.0 
Hz, 1H, H-3), 5.48 (dd, J = 1.9, 3.0 Hz, 1H, H-2), 5.40 (t, J = 10.0 Hz, 1H, H-4), 4.47 
(dd, J = 7.2, 14.2 Hz, 2H, OCH2), 4.29 (dd, J = 5.4, 12.4 Hz, 1H, H-6a), 4.11-4.07 (m, 
2H, H-5, H-6b), 2.22, 2.07, 2.06, 2.05 (4 s, 12H, 4 COCH3), 1.44 (t, J = 7.2 Hz, 3H, 
CH3); 13C NMR (126 MHz, CDCl3): G = 170.48, 170.01, 169.99, 169.69, 160.61 (5 CO), 
156.17, 140.87, 131.60, 125.52, 122.46, 117.62 (8C, Ar-C), 95.89 (C-1), 69.54 (C-5), 
69.14 (C-2), 68.66 (C-3), 65.71 (C-4), 62.03 (C-6), 61.55 (OCH2), 20.88, 20.71, 20.70 
(4C, 4 COCH3), 14.34 (CH3); ESI-MS: m/z: Calcd for C25H30N3O12 >M+H@+: 564.18, 
found: 564.20. 
 
Methyl 1-[4-(D-D-mannopyranosyloxy)phenyl]-1H-1,2,3-triazole-4-carboxylate 
(23a). Prepared according to general procedure D from 22a. Yield: 28 mg (74%) as white 
solid. Rf 0.20 (DCM/MeOH, 8:1); [D]D20 +99.8 (c 0.30, MeOH); 1H NMR (500 MHz, 
CD3OD): G = 8.94 (s, 1H, Ar-H), 7.72-7.69 (m, 2H, Ar-H), 7.25-7.23 (m, 2H, Ar-H), 5.48 
(d, J = 1.7 Hz, 1H, H-1), 3.94 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 3.85 (s, 3H, OCH3), 3.81 
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(dd, J = 3.5, 9.5 Hz, 1H, H-3), 3.70-3.60 (m, 3H, H-4, H-6), 3.48 (ddd, J = 2.4, 5.5, 9.7 
Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD): G = 162.33 (CO), 158.64, 141.14, 132.38, 
127.77, 123.47, 118.81 (8C, Ar-C), 100.26 (C-1), 75.77 (C-5), 72.34 (C-3), 71.82 (C-2), 
68.27 (C-4), 62.68 (C-6), 52.66 (OCH3); HRMS: m/z: Calcd for C16H19N3NaO8 >M+Na@+: 
404.1064, found: 404.1068. 
 
Sodium 1-[4-(D-D-mannopyranosyloxy)phenyl]-1H-1,2,3-triazole-4-carboxylate 
(24a). Prepared according to general procedure E from 22a. Yield: 5 mg (30%) as white 
solid. [D]D20 +92.0 (c 0.20, MeOH/H2O, 1:1); 1H NMR (500 MHz, D2O): G = 8.40 (s, 1H, 
Ar-H), 7.58-7.56 (m, 2H, Ar-H), 7.18-7.16 (m, 2H, Ar-H), 5.55 (d, J = 1.4 Hz, 1H, H-1), 
4.08 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 3.95 (dd, J = 3.5, 9.5 Hz, 1H, H-3), 3.73-3.57 (m, 4H, 
H-4, H-5, H-6); 13C NMR (126 MHz, D2O): G = 167.44 (CO), 156.00, 145.08, 131.02, 
125.53, 122.73, 117.65 (8C, Ar-C), 97.98 (C-1), 73.41 (C-5), 70.26, 69.72, 66.51 (C-2, C-
3, C-4), 60.60 (C-6); HRMS: m/z: Calcd for C15H17N3NaO8 >M+H@+: 390.0908, found: 
390.0905. 
 
Methyl 5-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)phenyl]-picolinate 
(31a). Prepared according to general procedure B from 29 (120 mg, 0.21 mmol) and 
methyl 5-bromopicolinate (30a, 40 mg, 0.19 mmol). Yield: 62 mg (60%) as white solid. 
Rf 0.33 (petrol ether/EtOAc, 2:3); [D]D20 +47.3 (c 0.60, MeOH); 1H NMR (500 MHz, 
CDCl3): G = 8.93 (dd, J = 0.5, 2.2 Hz, 1H, Ar-H), 8.20 (dd, J = 0.6, 8.2 Hz, 1H, Ar-H), 
7.99 (dd, J = 2.4, 8.2 Hz, 1H, Ar-H), 7.61-7.58 (m, 2H, Ar-H), 7.25-7.23 (m, 2H, Ar-H), 
5.60 (d, J = 1.8 Hz, 1H, H-1), 5.59 (dd, J = 3.6, 10.1 Hz, 1H, H-3), 5.48 (dd, J = 1.9, 3.5 
Hz, 1H, H-2), 5.41 (t, J = 10.1 Hz, 1H, H-4), 4.30 (dd, J = 5.0, 12.4 Hz, 1H, H-6a), 4.11-
4.08 (m, 2H, H-5, H-6b), 4.04 (s, 3H, OCH3), 2.23, 2.07, 2.06, 2.05 (4 s, 12H, 4 COCH3); 
13C NMR (126 MHz, CDCl3): G = 170.49, 170.01, 169.99, 169.70, 165.61 (5 CO), 156.25, 
147.93, 146.20, 138.97, 134.70, 131.35, 128.69, 125.25, 117.22 (11C, Ar-C), 95.71 (C-1), 
69.34 (C-2), 69.25 (C-5), 68.78 (C-3), 65.79 (C-4), 62.02 (C-6), 52.94 (OCH3), 20.89, 
20.71, 20.69, 20.68 (4 COCH3); ESI-MS: m/z: Calcd for C27H30NO12 >M+H@+: 560.18, 
found: 560.27. 
 
Methyl 5-[4-(D-D-mannopyranosyloxy)phenyl]-picolinate (32a). Prepared according to 
general procedure D from 31a. Yield: 15 mg (36%) as white solid. Rf 0.13 (DCM/MeOH, 
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8:1); [D]D20 +113.4 (c 0.20, MeOH); 1H NMR (500 MHz, DMSO-d6): G = 9.18 (d, J = 2.2 
Hz, 1H, Ar-H), 8.37 (dd, J = 2.2, 8.4 Hz, 1H, Ar-H), 8.20 (d, J = 8.9 Hz, 2H, Ar-H), 8.14 
(d, J = 8.4 Hz, 1H, Ar-H), 7.29 (t, J = 5.8 Hz, 2H, Ar-H), 5.55 (d, J = 1.6 Hz, 1H, H-1), 
5.15 (d, J = 4.2 Hz, 1H), 4.93 (d, J = 5.7 Hz, 1H), 4.87 (d, J = 5.6 Hz, 1H), 4.54 (t, J = 6.0 
Hz, 1H), 3.96 (s, 3H, OCH3), 3.92 (s, 1H), 3.76 (m, 1H), 3.66 (ddd, J = 1.9, 5.8, 11.6 Hz, 
1H), 3.61-3.49 (m, 2H), 3.45 (m, 1H); 13C NMR (126 MHz, DMSO-d6): G = 165.20 (CO), 
159.29, 158.04, 150.07, 137.81, 130.95, 128.57, 123.30, 119.25, 116.83 (11C, Ar-C), 
98.55 (C-1), 75.10 (C-5), 70.59, 69.94, 66.59 (C-2, C-3, C-4), 60.94 (C-6), 52.32 (OCH3); 
HRMS: m/z: Calcd for C19H21NNaO8 >M+Na@+: 414.1159, found: 414.1162. 
 
Sodium 5-[4-(D-D-mannopyranosyloxy)phenyl]-picolinate (33a). Prepared according 
to general procedure E from 31a. Yield: 3 mg (32%) as white solid. [D]D20 +99.3 (c 0.20, 
MeOH/H2O, 1:1); 1H NMR (500 MHz, D2O): G = 8.63 (s, 1H, Ar-H), 7.96 (d, J = 8.0 Hz, 
1H, Ar-H), 7.82 (d, J = 6.6 Hz, 1H, Ar-H), 7.56-7.54 (m, 2H, Ar-H), 7.13-7.11 (m, 2H, 
Ar-H), 5.54 (d, J = 1.4 Hz, 1H, H-1), 4.07 (m, 1H, H-2), 3.96 (dd, J = 3.5, 9.2 Hz, H-3), 
3.70-3.58 (m, 4H, H-4, H-5, H-6); 13C NMR (126 MHz, D2O): G = 155.75, 146.29, 
135.43, 131.05, 128.42, 123.82, 117.39 (11C, Ar-C), 97.91 (C-1), 73.33 (C-5), 70.31, 
69.80, 66.51 (C-2, C-3, C-4), 60.59 (C-6); HRMS: m/z: Calcd for C18H19NNaO8 
>M+Na@+: 400.1003, found: 400.1003. 
 
Methyl 5-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)-3-trifluoromethyl-
phenyl]-picolinate (36). A Schlenk tube was charged with 34[10j] (394 mg, 0.69 mmol), 
KOAc (203 mg, 2.07 mmol), bis(pinacolato)diborone (193 mg, 0.76 mmol) and 
Pd(dppf)Cl2CH2Cl2 (17 mg, 0.021 mmol). The tube was closed, evacuated and flushed 
with argon. Then anhydrous DMF (4 mL) was added under a stream of argon. The 
mixture was degassed in an ultrasonic bath and flushed with argon for 5 min, and then 
stirred at 85 °C overnight. The reaction mixture was cooled to rt and diluted with 
DCM/H2O (100 mL, 1:1). The organic layer was washed with H2O (50 mL) and brine (50 
mL), dried over Na2SO4 and concentrated. The residue was passed through a short silica 
gel column (petrol ether/EtOAc, 2:1) to afford crude 35 (352 mg), which was used 
directly in the next step. Compound 36 was prepared according to general procedure B 
from crude 35 (352 mg, 0.57 mmol) and methyl 5-chloropyrazine-2-carboxylate (30a, 
108 mg, 0.63 mmol). Yield: 205 mg (57%) as colorless oil. Rf 0.38 (petrol ether/EtOAc, 
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2:3); [D]D20 +64.5 (c 1.00, EtOAc); 1H NMR (500 MHz, CDCl3): G = 8.92 (d, J = 2.1 Hz, 
1H, Ar-H), 8.23 (d, J = 8.1 Hz, 1H, Ar-H), 8.00 (dd, J = 2.3, 8.1 Hz, 1H, Ar-H), 7.87 (d, J 
= 2.1 Hz, 1H, Ar-H), 7.77 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.41 (d, J = 8.7 Hz, 1H, Ar-H), 
5.72 (d, J = 1.7 Hz, 1H, H-1), 5.56 (dd, J = 3.4, 10.1 Hz, 1H, H-3), 5.50 (dd, J = 1.9, 3.4 
Hz, 1H, H-2), 5.43 (t, J = 10.1 Hz, 1H, H-4), 4.30 (dd, J = 5.1, 12.5 Hz, 1H, H-6a), 4.16-
4.02 (m, 6H, H-6b, H-5, OCH3), 2.23, 2.06 (2s, 12H, 4 COCH3); 13C NMR (126 MHz, 
CDCl3): G = 170.40, 169.94, 169.73, 169.62, 165.41 (5 CO), 153.59, 147.93, 146.98, 
137.80, 134.99, 132.06, 131.21, 126.32, 125.33, 116.15 (12C, Ar-C, CF3), 95.71 (C-1), 
70.06 (C-5), 69.10 (C-2), 68.52 (C-3), 65.48 (C-4), 61.95 (C-6), 53.03 (OCH3), 20.85, 
20.68 (4C, 4 COCH3); ESI-MS: m/z: Calcd for C28H29F3NO12 >M+H@+: 628.16, found: 
628.19. 
 
Methyl 5-[4-(D-D-mannopyranosyloxy)-3-trifluoromethyl-phenyl]-picolinate (37). 
Prepared according to general procedure D from 36. Yield: 15 mg (60%) as white solid. 
Rf 0.20 (DCM/MeOH, 8:1); [D]D20 +104.9 (c 0.40, MeOH); 1H NMR (500 MHz, 
CD3OD): G = 8.95 (dd, J = 0.7, 2.1 Hz, 1H, Ar-H), 8.25 (qd, J = 1.5, 8.2 Hz, 2H, Ar-H), 
8.06-7.92 (m, 2H, Ar-H), 7.68 (m, 1H, Ar-H), 5.72 (d, J = 1.6 Hz, 1H, H-1), 4.09 (dd, J = 
1.8, 3.4 Hz, 1H, H-2), 4.02 (s, 3H, OCH3), 3.96 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.86-3.69 
(m, 3H, H-4, H-6), 3.60 (ddd, J = 2.3, 5.7, 9.7 Hz, 1H, H-5); 13C NMR (126 MHz, 
CD3OD): G = 166.43 (CO), 156.19, 148.61, 147.34, 139.82, 136.84, 133.76, 131.17, 
126.81, 126.58, 118.09 (12C, Ar-C, CF3), 100.31 (C-1), 76.24 (C-5), 72.25 (C-3), 71.71 
(C-2), 68.11 (C-4), 62.70 (C-6), 53.28 (OCH3); HRMS: m/z: Calcd for C20H20F3NNaO8 
>M+Na@+: 482.1033, found: 482.0135. 
 
Sodium 5-[4-(D-D-mannopyranosyloxy)-3-trifluoromethyl-phenyl]-picolinate (38). 
Prepared according to general procedure E from 36. Yield: 40 mg (90%) as white solid. 
[D]D20 +71.4 (c 0.50, MeOH/H2O, 1:1); 1H NMR (500 MHz, CD3OD): G = 8.70 (s, 1H, 
Ar-H), 8.00 (s, 2H, Ar-H), 7.86-7.77 (m, 2H, Ar-H), 7.53 (m, 1H, Ar-H), 5.58 (d, J = 1.3 
Hz, 1H, H-1), 3.97 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 3.85 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 
3.73-3.59 (m, 3H, H-4, H-6), 3.49 (m, 1H, H-5); 13C NMR (126 MHz, CD3OD): G = 
172.52 (CO), 155.69, 155.16, 147.65, 137.21, 136.17, 133.48, 132.31, 132.21, 126.48, 
125.22, 118.01, 101.40 (12C, Ar-C, CF3), 100.33 (C-1), 76.15 (C-5), 72.26 (C-3), 71.75 
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(C-2), 68.12 (C-4), 62.66 (C-6); HRMS: m/z: Calcd for C19H18F3NNa2O8 >M+Na@+: 
490.0696, found: 490.0713. 
 
Ethyl 1-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)-3-chlorophenyl]-4-
methyl-1H-pyrrole-3-carboxylate (40f). Prepared according to general procedure C 
from 39 and methyl 4-methyl-1H-pyrrole-3-carboxylate (20f). Yield: 240 mg (77%) as 
colorless oil. Rf 0.34 (petrol ether/EtOAc, 3:2); [D]D20 +64.5 (c 1.00, EtOAc); 1H NMR 
(500 MHz, CDCl3): G = 7.55 (d, J = 2.5 Hz, 1H, Ar-H), 7.46 (m, 1H, Ar-H), 7.28-7.20 
(m, 2H, Ar-H), 6.76 (dd, J = 1.0, 2.4 Hz, 1H, Ar-H), 5.61 (dd, J = 3.4, 10.0 Hz, 1H, H-3), 
5.57 (d, J = 1.7 Hz, 1H, H-1), 5.54 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.41 (t, J = 10.1 Hz, 
1H, H-4), 4.33-4.26 (m, 3H, H-6b, OCH2), 4.19 (ddd, J = 2.2, 5.3, 10.1 Hz, 1H, H-5), 
4.12 (m, 1H, H-6a), 2.31 (d, J = 0.8 Hz, 3H, CH3), 2.21, 2.08, 2.05 (3 s, 12H, 4 COCH3), 
2.04 (s, 1H), 1.36 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): G = 170.41, 
169.93, 169.77, 169.73, 164.95 (5 CO), 149.71, 135.88, 125.46, 124.71, 123.48, 122.80, 
119.68, 118.99, 117.93, 117.13 (Ar-C), 96.98 (C-1), 69.92 (C-5), 69.26 (C-2), 68.71 (C-
3), 65.79 (C-4), 62.13 (C-6), 59.58 (OCH2), 21.03, 20.85, 20.70, 20.68 (4 COCH3), 14.51 
(CH3), 11.72 (CH3); ESI-MS: m/z: Calcd for C28H32ClNNaO12 >M+Na@+: 632.15, found: 
632.15. 
 
Ethyl 1-[3-chloro-4-(D-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-3-
carboxylate (41f). Prepared according to general procedure D from 40f. Yield: 55 mg 
(93%) as white solid. Rf 0.29 (DCM/MeOH, 9:1); [D]D20 +89.1 (c 0.50, MeOH); 1H NMR 
(500 MHz, CD3OD): G = 7.68 (d, J = 2.5 Hz, 1H, Ar-H), 7.58 (d, J = 2.7 Hz, 1H, Ar-H), 
7.47 (d, J = 8.9 Hz, 1H, Ar-H), 7.39 (dd, J = 2.7, 8.9 Hz, 1H, Ar-H), 6.95 (d, J = 1.0 Hz, 
1H, Ar-H), 5.58 (d, J = 1.4 Hz, 1H, H-1), 4.28 (q, J = 7.1 Hz, 2H, OCH2), 4.14 (dd, J = 
1.8, 3.2 Hz, 1H, H-2), 4.01 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.86-3.72 (m, 3H, H-4, H-6), 
3.67 (m, 1H, H-5), 2.29 (s, 3H, CH3), 1.37 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, 
CD3OD): G = 166.98 (CO), 151.75, 136.28, 126.11, 125.75, 124.16, 123.19, 120.88, 
120.51, 119.26, 117.60 (Ar-C), 101.01 (C-1), 76.04 (C-5), 72.36 (C-3), 71.78 (C-2), 
68.19 (C-4), 62.66 (C-6), 60.74 (OCH2), 14.77 (CH3), 11.96 (CH3); HRMS: m/z: Calcd 
for C20H24ClNNaO8 >M+Na@+: 464.1083, found: 464.1086. 
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Sodium 1-[3-chloro-4-(D-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-3-
carboxylate (45). Prepared according to general procedure E from 40f. Yield: 30 mg 
(57%) as white solid. 1H NMR (500 MHz, CD3OD): G = 7.69 (d, J = 2.5 Hz, 1H, Ar-H), 
7.60 (d, J = 2.6 Hz, 1H, Ar-H), 7.48 (d, J = 8.9 Hz, 1H, Ar-H), 7.42 (dd, J = 2.7, 8.9 Hz, 
1H, Ar-H), 6.97 (d, J = 1.2 Hz, 1H, Ar-H), 5.57 (d, J = 1.4 Hz, 1H, H-1), 4.13 (dd, J = 
1.8, 3.2 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.87-3.70 (m, 3H, H-4, H-6), 
3.66 (ddd, J = 2.2, 5.5, 9.6 Hz, 1H, H-5), 2.30 (s, 3H, CH3); 13C NMR (126 MHz, 
CD3OD): G = 168.95 (CO), 151.77, 136.47, 126.41, 125.80, 124.42, 123.25, 120.95, 
120.51, 119.34, 118.09 (Ar-C), 101.08 (C-1), 76.08 (C-5), 72.39 (C-3), 71.82 (C-2), 
68.23 (C-4), 62.69 (C-6), 11.92 (CH3); HRMS: m/z: Calcd for C18H20ClNNaO8 >M+H@+: 
436.0770, found: 436.0773. 
 
Ethyl 1-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)phenyl]-4-methyl-1H-
pyrrole-3-carboxylate (46). Prepared according to general procedure C from 28 and 
methyl 4-methyl-1H-pyrrole-3-carboxylate (20f). Yield: 293 mg (94%) as colorless oil. Rf 
0.47 (petrol ether/EtOAc, 3:2); [D]D20 +63.7 (c 2.20, EtOAc); 1H NMR (500 MHz, 
CDCl3): G = 7.36 (d, J = 2.4 Hz, 1H, Ar-H), 7.20 (d, J = 8.8 Hz, 1H, Ar-H), 7.15 (dd, J = 
2.5, 8.7 Hz, 1H, Ar-H), 6.91 (d, J = 1.6 Hz, 1H, Ar-H), 6.67 (d, J = 0.9 Hz, 1H, Ar-H), 
5.62 (dd, J = 3.5, 10.0 Hz, 1H, H-3), 5.57 (d, J = 1.6 Hz, 1H, H-1), 5.53 (dd, J = 1.9, 3.4 
Hz, 1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.31 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.20 
(ddd, J = 2.2, 5.2, 10.1 Hz, 1H, H-5), 4.18-4.08 (m, 3H, OCH2, H-6b), 2.21, 2.11, 2.08, 
2.07, 2.05 (5 s, 15H, 4 COCH3, CH3), 1.23 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, 
CDCl3): G = 170.52, 169.91, 169.75, 160.32 (5C, 5 CO), 150.69, 136.26, 128.55, 128.10, 
125.80, 123.86, 123.18, 120.00, 119.90, 116.17 (Ar-C), 96.86 (C-1), 69.83 (C-5), 69.32 
(C-2), 68.75 (C-3), 65.81 (C-4), 62.08 (C-6), 59.90 (OCH2), 20.85, 20.71, 20.68, 14.27, 
11.43 (6C, 4 COCH3, 2 CH3); ESI-MS: m/z: Calcd for C28H33NNaO12 >M+Na@+: 598.19, 
found: 598.16. 
 
Ethyl 1-[4-(D-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-3-carboxylate 
(48). Prepared according to general procedure D from 46. Yield: 87 mg (46%) as white 
solid. Rf 0.30 (DCM/MeOH, 8:1); [D]D20 +109.7 (c 0.80, MeOH); 1H NMR (500 MHz, 
CD3OD): G = 7.67 (d, J = 2.5 Hz, 1H, Ar-H), 7.46-7.41 (m, 2H, Ar-H), 7.27-7.22 (m, 2H, 
Ar-H), 6.95 (dd, J = 1.0, 2.4 Hz, 1H, Ar-H), 5.52 (d, J = 1.6 Hz, 1H, H-1), 4.29 (q, J = 7.1 
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Hz, 2H, OCH2), 4.04 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 3.92 (dd, J = 3.4, 9.4 Hz, 1H, H-3), 
3.84-3.70 (m, 3H, H-4, H-6), 3.62 (ddd, J = 2.4, 5.4, 9.7 Hz, 1H, H-5), 2.30 (d, J = 0.9 
Hz, 3H, CH3), 1.37 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, CD3OD): G = 167.22 
(CO), 156.53, 135.97, 126.23, 123.86, 122.85, 120.73, 118.92, 117.13 (8C, Ar-C), 100.47 
(C-1), 75.57 (C-5), 72.41 (C-3), 71.95 (C-2), 68.35 (C-4), 62.72 (C-6), 60.68 (OCH2), 
14.80, 11.98 (2 CH3); HRMS: m/z: Calcd for C20H25NNaO8 >M+Na@+: 430.1472, found: 
430.1474. 
 
Sodium 1-[4-(D-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-3-carboxylate 
(50). Prepared according to general procedure E from 46. Yield: 93 mg (99%) as white 
solid. [D]D20 +97.0 (c 0.70, MeOH/H2O, 1:2); 1H NMR (500 MHz, D2O): G = 7.51 (d, J = 
2.4 Hz, 1H, Ar-H), 7.42 (d, J = 8.9 Hz, 2H, Ar-H), 7.22 (d, J = 8.9 Hz, 2H, Ar-H), 6.93 
(s, 1H, Ar-H), 5.60 (s, 1H, H-1), 4.19 (m, 1H, H-2), 4.07 (dd, J = 3.4, 8.9 Hz, 1H, H-3), 
3.90-3.68 (m, 4H, H-4, H-5, H-6), 2.27 (s, 3H, CH3); 13C NMR (125 MHz, D2O): G = 
174.29 (CO), 153.52, 135.00, 123.89, 121.84, 121.78, 121.56, 119.09, 118.07 (10C, Ar-
C), 98.45 (C-1), 73.40 (C-5), 70.39 (C-3), 69.88 (C-2), 66.58 (C-4), 60.65 (C-6), 10.97 
(CH3); HRMS: m/z: Calcd for C18H21NNaO8 >M+Na@+: 402.1159, found: 402.1159. 
 
Cell-free competitive binding assay. 
A recombinant protein consisting of the CRD of FimH linked with a thrombin cleavage 
site to a 6His-tag (FimH-CRD-Th-6His) was expressed in E. coli strain HM125 and 
purified by affinity chromatography.[23] To determine the affinity of the various FimH 
antagonists, a competitive binding assay as described previously was applied.[23] 
Microtiter plates (F96 MaxiSorp, Nunc) were coated with 100 PL/well of a 10 Pg/mL 
solution of FimH-CRD-Th-6His in 20 mM HEPES, 150 mM NaCl, and 1 mM CaCl2, pH 
7.4 (assay buffer) overnight at 4 qC. The coating solution was discarded and the wells 
were blocked with 150 PL/well of 3% BSA in assay buffer for 2 h at 4 qC. After three 
washing steps with assay buffer (150 PL/well), a 4-fold serial dilution of the test 
compound (50 PL/well) in assay buffer containing 5% DMSO and streptavidin-
peroxidase coupled to Man-D(1-3)[Man-D(1-6)]-Man-E(1-4)-GlcNAc-E(1-4)-GlcNAcE 
polyacrylamide (TM-PAA) polymer (50 PL/well of a 0.5 Pg/mL solution) were added. 
On each individual microtiter plate, n-heptyl D-D-mannopyranoside (1) was tested in 
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parallel. The plates were incubated for 3 h at 25 qC and 350 rpm and then carefully 
washed four times with 150 PL/well assay buffer. After the addition of 100 PL/well of 
2,2’-azino-di-(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS)-substrate, the colorimetric 
reaction was allowed to develop for 4 min and then was stopped by the addition of 2% aq. 
oxalic acid before the optical density (OD) was measured at 415 nm on a microplate-
reader (Spectramax 190, Molecular Devices, Silicon Valley, CA, USA). The IC50 values 
of the compounds tested in duplicates were calculated with prism software (GraphPad 
Software, Inc., La Jolla, CA, USA). The IC50 defines the molar concentration of the test 
compound that reduces the maximal specific binding of TM-PAA polymer to FimH-CRD 
by 50%. The relative IC50 (rIC50) is the ratio of the IC50 of the test compound to the IC50 
of n-heptyl D-D-mannopyranoside (1). 
 
KD determination with fluorescence polarization assay.  
The fluorescently labeled ligand 52[11k] was used for the competitive fluorescence 
polarization assay. A serial dilution of non-labeled FimH antagonist with final 
concentrations ranging from 0-10 µM was titrated into 96-well NBSTM plates to a final 
volume of 200 µL containing a constant concentration of protein (final concentration 25 
nM) and FITC-labeled ligand 52 which was fixed at a higher concentration in competitive 
binding assays to obtain higher fluorescence intensities (final concentration 20 nM). Prior 
to measuring the fluorescence polarization, the plates were incubated on a shaker for 24 h 
at rt until the reaction reached its equilibrium. The IC50 value was determined with Prism 
(GraphPad Software Inc., La Jolla, CA, USA) by applying a standard four-parameter IC50 
function. The obtained IC50 values were converted into their corresponding KD values 
using the following derivation of the Cheng-Prusoff equation (Equation 1):[25] 
 
  
KD =
I 50
L50
KD
+
P0
K D
+1
 (1) 
where I50 and L50 are the concentrations of inhibitor and ligand at half-maximal 
inhibition, respectively, and P0 is the free concentration of protein in the absence of 
inhibitor. This variation of the Cheng-Prusoff equation is applied to competition assays 
with tight-binding inhibitors. However, the KD for antagonists, which have a higher 
affinity towards FimH than the labeled ligand could not be accurately determined with 
this equation.[25] 
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Physicochemical properties and in vitro pharmacokinetics 
 
Materials. Dimethyl sulfoxide (DMSO), 1-propanol, 1-octanol, Dulbecco’s Modified 
Eagle’s Medium (DMEM) high glucose, penicillin-streptomycin (solution stabilized, with 
10’000 units penicillin and 10 mg streptomycin/mL), L-glutamine solution (200 mM), 
magnesium chloride, ammonium acetate, and bis(4-nitrophenyl) phosphate (BNPP) were 
purchased from Sigma-Aldrich (Buchs, Switzerland). PRISMA HT universal buffer, GIT-
0 Lipid Solution, and Acceptor Sink Buffer were ordered from pIon (Woburn, MA, 
USA). MEM non-essential amino acids solution 10 mM (100X), fetal bovine serum 
(FBS), and DMEM without sodium pyruvate and phenol red were bought from Invitrogen 
(Carlsbad, CA, USA). Acetonitrile (MeCN) and methanol (MeOH) were ordered from 
Acros Organics (Geel, Belgium). Pooled male rat liver microsomes (Sprague Dawley) 
were ordered from BD Bioscience (Franklin Lakes, NJ, USA). The Caco-2 cells were 
kindly provided by Prof G. Imanidis, FHNW, Muttenz, Switzerland and originated from 
the American Type Culture Collection (Rockville, MD, USA). 
 
log P determination. The in silico prediction tool ALOGPS[42] was used to estimate the 
octanol-water partition coefficient (log P) of the compounds. Depending on these values, 
the compounds were classified into three categories: hydrophilic compounds (log P < 0), 
moderately lipophilic compounds (log P between 0 and 1) and lipophilic compounds (log 
P > 1). For each category, two different ratios (volume of 1-octanol to volume of buffer) 
were defined as experimental parameters (Table 4). 
 
Table 4. Parameters for the experimental determination of lipophilicty. 
Compound type log P ratios (1-octanol: buffer) 
hydrophilic  < 0 30:140, 40:130 
moderately lipophilic 0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
 
Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol were mixed and shaken 
vigorously for 5 min to saturate the phases. The mixture was left until separation of the 
two phases occurred, and the buffer was retrieved. Stock solutions of the test compounds 
were diluted with buffer to a concentration of 1 µM. For each compound, six 
determinations, i.e. three determinations per 1-octanol:buffer ratio, were performed in 
Chapter 2.5 
256 
different wells of a 96-well plate. The respective volumes of buffer containing analyte (1 
µM) were pipetted to the wells and covered by saturated 1-octanol according to the 
chosen volume ratio. The plate was sealed with aluminium foil, shaken (1350 rpm, 25 °C, 
2 h) on a Heidolph Titramax 1000 plate-shaker (Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany) and centrifuged (2000 rpm, 25 °C, 5 min, 5804R Eppendorf 
centrifuge, Hamburg, Germany). The aqueous phase was transferred to a 96-well plate for 
analysis by liquid chromatography-mass spectrometry (LC-MS, see below). The partition 
coefficient (log P) was calculated from the 1-octanol:buffer ratio (o:b), the initial 
concentration of the analyte in buffer (1 µM), and the concentration of the analyte in 
buffer (cB) according to Equation 2:  
log P = log 1 M  cB
c B
1
o :b
  
  ÷  (2) 
The average of the three log P values per 1-octanol:buffer ratio was calculated. If the two 
means obtained for a compound did not differ by more than 0.1 units, the results were 
accepted. 
Aqueous solubility. Solubility was determined in a 96-well format using the µSOL 
Explorer solubility analyzer (pIon, version 3.4.0.5). For each compound, measurements 
were performed in triplicate. Three wells of a deep well plate were filled with 300 µL of 
PRISMA HT universal buffer, adjusted to pH 7.4 by adding the requested amount of 
NaOH (0.5 M). Aliquots (3 µL) of a compound stock solution (40-100 mM in DMSO) 
were added and thoroughly mixed. The final sample concentration was 0.4-1.0 mM, the 
residual DMSO concentration was 1.0% (v/v). Fifteen hours after initiation of the 
experiment, the solutions were filtrated (0.2 µm 96-well filter plates) using a vacuum to 
collect manifold (Whatman Ltd., Maidstone, UK) and to remove any precipitates. Equal 
amounts of filtrate and 1-propanol were mixed and transferred to a 96-well plate for 
UV/Vis detection (190 to 500 nm, SpectraMax 190, Molecular Devices, Silicon Valley, 
CA, USA). The amount of material dissolved was calculated by comparison with the 
spectra obtained from reference samples, which were prepared by dissolving the 
compound stock solution in a 1:1 mixture of buffer and 1-propanol (final concentrations 
0.067-0.167 mM). 
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Parallel artificial membrane permeability assay (PAMPA). Effective permeability 
(log Pe) was determined in a 96-well format with PAMPA.[29] For each compound, 
measurements were performed in quadruplicate. Four wells of a deep well plate were 
filled with 650 µL of PRISMA HT universal buffer, adjusted to pH 7.4 by adding the 
requested amount of NaOH (0.5 M). Samples (150 µL) were withdrawn from each well to 
determine the blank spectra by UV/Vis-spectroscopy (190 to 500 nm, SpectraMax 190). 
The analyte dissolved in DMSO was added to the remaining buffer to yield 50 µM 
solutions. To exclude precipitation, the optical density (OD) was measured at 650 nm, 
and solutions exceeding OD 0.01 were filtrated. Afterwards, samples (150 µL) were 
withdrawn to determine the reference spectra. Further 200 µL were transferred to each 
well of the donor plate of the PAMPA sandwich (pIon, P/N 110 163). The filter 
membranes at the bottom of the acceptor plate were infused with 5 µL of GIT-0 Lipid 
Solution, and 200 µL of Acceptor Sink Buffer were filled into each acceptor well. The 
sandwich was assembled, placed in the GutBoxTM, and left undisturbed for 16 h. Then, it 
was disassembled and samples (150 µL) were withdrawn from each donor and acceptor 
well for detection of the UV/Vis spectra. Effective permeability (log Pe) was calculated 
from the compound flux deduced from the spectra, the filter area, and the initial sample 
concentration in the donor well with the aid of the PAMPA Explorer Software (pIon, 
version 3.5). 
Colorectal adenocarcinoma (Caco-2) cell permeation assay. Caco-2 cells were 
cultivated in tissue culture flasks (BD Biosciences, Franklin Lakes, NJ, USA) with 
DMEM high glucose medium, containing L-glutamine (2 mM), non-essential amino acids 
(0.1 mM), penicillin (100 U/mL), streptomycin (100 µg/mL), and fetal bovine serum 
(10%). The cells were kept at 37 °C in humidified air containing 5% CO2, and the 
medium was changed every second day. When approximately 90% confluence was 
reached, the cells were split in a 1:10 ratio and distributed to new tissue culture flasks. At 
passage numbers between 60 and 65, they were seeded at a density of 5.3 u 105 cells per 
well to Transwell 6-well plates (Corning Inc., Corning, NY, USA) with 2.5 mL of culture 
medium in the basolateral and 2 mL in the apical compartment. The medium was 
renewed on alternate days. Permeation experiments were performed between days 19 and 
21 post seeding. Previously to the experiment, the integrity of the Caco-2 monolayers was 
evaluated by measuring the transepithelial electrical resistance (TEER) with an Endohm 
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tissue resistance instrument (World Precision Instruments Inc., Sarasota, FL, USA). Only 
wells with TEER values higher than 250 Ω cm2 were used. To inhibit carboxylesterase 
activity, the Caco-2 cell monolayers were pre-incubated with bis(4-nitrophenyl) 
phosphate (BNPP, 200 µM) dissolved in transport medium (DMEM without sodium 
pyruvate and phenol red) for 40 min.[43] Experiments were performed in the apical-to-
basolateral (absorptive) and basolateral-to-apical (secretory) directions in triplicates. 
Transport medium was withdrawn from the donor compartments and replaced by the 
same volume of compound stock solution (10 mM in DMSO) to reach an initial sample 
concentration of 62.5 µM. The Transwell plate was shaken (600 rpm, 37 °C) on a 
Heidolph Titramax 1000 plate-shaker. Samples (40 µL) were withdrawn from the donor 
and acceptor compartments 30 min after initiation of the experiment and the 
concentrations were determined by LC-MS (see below). Apparent permeability (Papp) was 
calculated according to Equation 3: 
Papp =
dQ
d t
1
A  c0
(3) 
where dQ/dt is the compound flux (in mol s-1), A is the surface area of the monolayer (in 
cm2), and c0 is the initial concentration in the donor compartment (in mol cm-3).[44] After 
the experiment, TEER values were assessed again and results from wells with values 
below 250 Ω cm2 were discarded. 
Microsomal stability assay. Incubations were performed in duplicate in a 96-well format 
on an Eppendorf Thermomixer Comfort. The reaction mixture (270 µL) consisting of 
liver microsomes (0.139 µg/mL), TRIS-HCl buffer (0.1 M, pH 7.4) and MgCl2 (2 mM) 
was preheated (37 °C, 500 rpm, 10 min), and the incubation was initiated by adding 30 
µL of compound solution (20 µM in TRIS-HCl buffer). The final concentration of the 
compound was 2 µM, and the microsomal concentration was 0.125 mg/mL. At the 
beginning of the experiment (t = 0 min) and after an incubation time of 5, 10, 20, 40, and 
60 min, samples (40 µL) were transferred to 120 µL of ice-cooled MeOH and centrifuged 
(3600 rpm, 4 °C, 10 min, 5804 R Eppendorf centrifuge). Then, 80 µL of supernatant was 
transferred to a 96-well plate for analysis by LC-MS (see below). The metabolic half-life 
(t1/2) was calculated from the slope of the linear regression from the log percentage 
remaining compound versus incubation time relationship. Control experiments were 
performed in parallel by preincubating the microsomes with the specific carboxylesterase 
inhibitor BNPP (1 mM) for 5 min before addition of the compound solution.[45] 
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LC-MS measurements. Analyses were performed using an 1100/1200 Series HPLC 
System coupled to a 6410 Triple Quadrupole mass detector (Agilent Technologies, Inc., 
Santa Clara, CA, USA) equipped with electrospray ionization. The system was controlled 
with the Agilent MassHunter Workstation Data Acquisition software (version B.01.04). 
The column used was an Atlantis® T3 C18 column (2.1 u 50 mm) with a 3 µm particle 
size (Waters Corp., Milford, MA, USA). The mobile phase consisted of eluent A: H2O 
containing 0.1% formic acid (for 23a-c, 26a, 32a-d, 37, 42a-f) or 10 mM ammonium 
acetate, pH 5.0 in 95:5, H2O:MeCN (for 4a, 6-8a, 26b); and eluent B: MeCN, containing 
0.1% formic acid. The flow rate was maintained at 0.6 mL/min. The gradient was ramped 
from 95% A/5% B to 5% A/95% B over 1 min, and then hold at 5% A/95% B for 0.1 
min. The system was then brought back to 95% A/5% B, resulting in a total duration of 4 
min. MS parameters such as fragmentor voltage, collision energy, polarity were 
optimized individually for each drug, and the molecular ion was followed for each 
compound in the multiple reaction monitoring mode. The concentrations of the analytes 
were quantified by the Agilent Mass Hunter Quantitative Analysis software (version 
B.01.04). 
In vivo pharmacokinetic studies. 
Eight-week-old female C3H/HeN mice from Harlan (Venray, The Netherlands) weighing 
between 19 and 25 g were used for the PK study. Three mice were put in one cage and 
kept under specific pathogen-free conditions in the Animal House of the Department of 
Biomedicine, University Hospital of Basel. All animal experimentation guidelines 
according to the regulations of the Swiss veterinary law were followed. The animals had 
free access to chow and water ad libitum and were kept in a 12 h/12 h light/dark cycle. 
After one week of acclimatization, the mice were used for the pharmacokinetic study. 
Compound 41f was diluted in 5% DMSO in 1% Tween 80 in PBS and applied using an 
oral gavage at a dose of 10 mg/kg. Blood and urine samples (10 µL) were taken before 
the experiment (0 min) and at 6, 13, 20, 40 min, 1, 1.5, 2, 3, 4, 6, 8, and 24 h after 
administration. Samples were diluted in MeOH directly after sampling in a ratio of 1:5 to 
precipitate proteins. After centrifugation (11 min, 13000 rpm) the supernatant was 
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transferred to a 96-well plate and analyzed by LC-MS as described before. The samples at 
0 min were used to define the detection limit in plasma and urine. 
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Synthesis 
Scheme S1. Reagents and conditions: a) Pd(Cl2)dppfCH2Cl2, K3PO4, DMF, 80 °C, overnight (70%); b) 
NaOMe, MeOH, rt, 4 h (quant.); c) 0.2 N aq. NaOH, MeOH, rt, overnight (50%). 
Methyl 4’-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)-3’-chlorobiphenyl-3-
carboxylate (53). A Schlenk tube was charged with 39 (100 mg, 0.17 mmol), 52 (31 mg, 
0.17 mmol), Pd(Cl2)dppfCH2Cl2  (4 mg, 0.0051 mmol), K3PO4 (54 mg, 0.26 mmol) and a 
stirring bar. The tube was closed, evacuated and flushed with argon. This procedure was 
repeated twice, then anhydrous DMF (2 mL) was added under a stream of argon. The 
mixture was degassed in an ultrasonic bath and flushed with argon for 5 min, then stirred 
at 80 °C overnight. The reaction mixture was cooled to rt, diluted with EtOAc (20 mL), 
and washed with H2O (20 mL) and brine (20 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by MPLC on silica gel 
(petroleum ether/EtOAc) to afford 53 (70 mg, 69%) as a white solid. [D]D20 +62.8  (c 0.7, 
EtOAc); 1H NMR (500 MHz, CDCl3): G = 8.20 (s, 1H, Ar-H), 8.03 (d, J = 7.8 Hz, 1H, 
Ar-H), 7.72 (d, J = 7.9 Hz, 1H, Ar-H), 7.67 (d, J = 2.2 Hz, 1H, Ar-H), 7.51 (t, J = 7.8 Hz, 
1H, Ar-H), 7.46 (dd, J = 8.5, 2.3 Hz, 1H, Ar-H), 5.64 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 
5.61 (d, J = 1.6 Hz, 1H, H-1), 5.56 (dd, J = 3.4, 1.9 Hz, 1H, H-2), 5.41 (t, J = 10.1 Hz, 
1H, H-4), 4.30 (dd, J = 12.3, 5.3 Hz, 1H, H-6a), 4.24-4.18 (m, 1H, H-5), 4.11 (m, 1H, H-
6b), 3.96 (s, 3H, OCH3), 2.22 2.08, 2.04, 2.05 (4s, 12H, 4 OAc); 13C NMR (126 MHz, 
CDCl3): G = 170.51, 169.80 (5C, 5 CO), 150.91, 139.44, 131.18, 129.20, 129.08, 128.73, 
127.95, 126.37, 117.31 (12C, Ar-C), 96.70 (C-1), 69.82 (C-5), 69.35 (C-2), 68.79 (C-3), 
65.85 (C-4), 62.12 (C-6), 52.30 (OCH3), 20.89, 20.70 (4C, 4 COCH3); ESI-MS: m/z: 
Calcd for C28H29ClNaO12 >M+Na@+: 615.12, found: 615.17. 
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Methyl 3’-chloro-4’-(D-D-mannopyranosyloxy)biphenyl-3-carboxylate (7a). To a 
solution of 53 (28 mg, 0.05 mmol) in dry MeOH (5 mL) was added freshly prepared 1 M 
NaOH/MeOH (50 PL) under argon. The mixture was stirred at rt for 4 h, then neutralized 
with Amberlyst-15 (H+) ion-exchange resin, filtered and concentrated in vacuo. The 
residue was purified by MPLC on silica gel (DCM/MeOH, 10:1-7:1) to afford 7a (20 mg, 
quant.) as a white solid after lyophilization from H2O. [D]D20 +110.7  (c 0.3, MeOH); 1H 
NMR (500 MHz, CD3OD): G = 8.22 (s, 1H, Ar-H), 8.01 (d, J = 7.8 Hz, 1H, Ar-H), 7.85 
(d, J = 7.8 Hz, 1H, Ar-H), 7.71 (d, J = 2.2 Hz, 1H, Ar-H), 7.62-7.54 (m, 2H, Ar-H), 7.49 
(d, J = 8.6 Hz, 1H, Ar-H), 5.63 (d, J = 1.2 Hz, 1H, H-1), 4.14 (dd, J = 3.2, 1.8 Hz, 1H, H-
2), 4.03 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.96 (s, 3H, OMe), 3.86-3.71 (m, 3H, H-4, H-6b, 
H-6a), 3.68 ppm (ddd, J = 9.6, 5.4, 2.2 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD): G = 
168.38 (CO), 153.11, 141.12, 136.54, 132.38, 132.10, 130.35, 129.59, 129.42, 128.59, 
127.62, 125.40, 118.74 (Ar-C), 100.79 (C-1), 76.02 (C-5), 72.42 (C-3), 71.87 (C-2), 
68.25 (C-4), 62.69 (C-6), 52.78 (OMe); HRMS: m/z: Calcd for C20H21ClNaO8 >M+Na@+: 
447.0817, found: 447.0817. 
Sodium 3’-chloro-4’-(D-D-mannopyranosyloxy)biphenyl-3-carboxylate (7b). To a 
solution of 53 (30 mg, 0.05 mmol) in MeOH (5 mL) was added 1M NaOH/MeOH (50 
PL). The mixture was stirred at RT for 4h and concentrated. The residue was treated with 
0.5 M aq. NaOH (1 mL) for 24 h at rt. The solution was then adjusted to pH 3-4 with 
Amberlyst-15 (H+), and the mixture was filtered and concentrated. The crude product was 
transformed into the sodium salt by passing through a small column of Dowex 50X8 (Na+ 
form) ion-exchange resin. After concentration, the residue was purified by MPLC (RP-
18, H2O/MeOH, 1:0-2:1) followed by size-exclusion chromatography (P-2 gel, H2O) to 
give 7b (11 mg, 50%) as a white solid after lyophilization from H2O. [D]D20 +88.9  (c 0.3, 
MeOH); 1H NMR (500 MHz, D2O): G = 7.98 (s, 1H, Ar-H), 7.77 (d, J = 7.7 Hz, 1H, Ar-
H), 7.62, 7.53-7.37 (m, 4H, Ar-H), 7.25 (d, J = 8.6 Hz, 1H, Ar-H), 5.60 (s, 1H, H-1), 4.17 
(dd, J = 3.2, 1.8 Hz, 1H, H-2), 4.05 (dd, J = 8.7, 3.4 Hz, 1H, H-3), 3.81-3.57 (m, 4H, H-4, 
H-5, H-6); 13C NMR (126 MHz, D2O): G = 175.29 (CO), 150.10, 138.58, 137.02, 135.96, 
129.16, 128.93, 128.52, 127.95, 126.94, 126.40, 123.99, 117.85 (Ar-C), 98.60 (C-1), 
73.87 (C-5), 70.41 (C-3), 69.73 (C-2), 66.47 (C-4), 60.59 (C-6); HRMS: m/z: Calcd for 
C19H19ClNaO8 >M+H@+: 433.0661, found: 433.0661. 
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Scheme S2. Reagents and conditions: a) BF3Et2O, DCM, mol. sieves 4Å, 0 °C to rt, overnight (90%); b) 
Pd(Cl2)dppfCH2Cl2, K3PO4, DMF, 80 °C, overnight (76%); c) NaOMe, MeOH, rt, 4 h (quant.); d) 0.2 N 
aq. NaOH, MeOH, rt, overnight (61%). 
4-Bromo-3-chlorophenyl 2,3,4,6-tetra-O-acetyl-D-D-mannopyranoside (55). To an 
ice-cold suspension of 21 (200 mg, 0.57 mmol), phenol 54 (107 mg, 0.52 mmol), and 
molecular sieves (4Å, 600 mg) in dry DCM (5 mL), BF3Et2O (0.3 mL, 2.44 mmol) was 
added dropwise under argon. The mixture was stirred at 0 °C for 3 h, and then at rt 
overnight. The reaction mixture was filtered over Celite, and the filtrate was diluted with 
DCM (50 mL), extracted with 0.5 N aq. NaOH (50 mL), H2O (50 mL), and brine (50 
mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue 
was purified by MPLC on silica gel (petrol ether/EtOAc) to yield 55 (250 mg, 90%) as a 
white solid. [D]D20 +75.8  (c 0.5, EtOAc); 1H NMR (500 MHz, CDCl3): G = 7.53 (d, J = 
8.9 Hz, 1H, Ar-H), 7.29 (d, J = 2.8 Hz, 1H, Ar-H), 6.89 (dd, J = 8.9, 2.8 Hz, 1H, Ar-H), 
5.53-5.45 (m, 2H, H-3, H-1), 5.42 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 5.34 (t, J = 10.1 Hz, 1H, 
H-4), 4.27 (dd, J = 12.2, 6.0 Hz, 1H, H-6a), 4.11-4.00 (m, 2H, H-5, H-6b), 2.20, 2.06, 
2.05, 2.04 (4s, 12H, 4 COCH3); 13C NMR (126 MHz, CDCl3): G = 170.49, 169.91, 169.68 
(4 CO), 155.16, 135.17, 134.16, 118.62, 116.77, 115.84 (Ar-C), 96.05 (C-1), 69.50 (C-5), 
69.09 (C-2), 68.62 (C-3), 65.82 (C-4), 62.16 (C-6), 20.83, 20.66 (4C, 4 COCH3); ESI-
MS: m/z: Calcd for C20H22BrClNaO10 >M+Na@+: 559.00, found: 559.10. 
Methyl 4’-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)-2’-chlorobiphenyl-3-
carboxylate (56). Prepared according to the procedure for 53 from 55 (100 mg, 0.19 
mmol), 52 (33 mg, 0.19 mmol), Pd(Cl2)dppfCH2Cl2 (5 mg, 0.0057 mmol), and K3PO4 
(60 mg, 0.29 mmol). Yield: 84 mg (76%) as colorless oil. [D]D20 +76.1 (c 0.8, EtOAc); 1H 
NMR (500 MHz, CDCl3): G = 8.10-8.01 (m, 2H, Ar-H), 7.62 (m, 1H, Ar-H), 7.50 (t, J = 
7.7 Hz, 1H, Ar-H), 7.34-7.25 (m, 2H, Ar-H), 7.08 (dd, J = 8.5, 2.5 Hz, 1H, Ar-H), 5.57-
5.55 (m, 2H, H-1, H-3), 5.47 (dd, J = 3.5, 1.8 Hz, 1H, H-2), 5.38 (t, J = 10.0 Hz, 1H, H-
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4), 4.31 (dd, J = 12.7, 6.4 Hz, 1H, H-6a), 4.14-4.09 (m, 2H, H-5, H-6b), 3.93 (s, 3H, 
OCH3), 2.22, 2.07, 2.05, 2.04 (4s, 12H, 4 COCH3); 13C NMR (126 MHz, CDCl3): G = 
170.61, 170.01, 169.79 (4C, 4 CO), 155.56, 139.05, 134.49, 134.08, 133.24, 132.08, 
130.68, 130.29, 128.83, 128.27, 118.12, 115.61 (Ar-C), 96.10 (C-1), 69.52 (C-5), 69.30 
(C-2), 68.81 (C-3), 65.98 (C-4), 62.27 (C-6), 52.29 (OCH3), 20.93, 20.76 (4C, 4 COCH3); 
ESI-MS: m/z: Calcd for C28H29ClNaO12 >M+Na@+: 615.12, found: 615.14. 
Methyl 2’-chloro-4’-(D-D-mannopyranosyloxy)biphenyl-3-carboxylate (8a). Prepared 
according to the procedure for 7a from 56 (45 mg, 0.07 mmol). Yield: 32 mg (quant.) as 
white solid. [D]D20 +112.9 (c 0.7, MeOH); 1H NMR (500 MHz, CD3OD): G = 8.03 (dd, J 
= 7.4, 4.6 Hz, 2H, Ar-H), 7.65 (m, 1H, Ar-H), 7.55 (t, J = 7.7 Hz, 1H, Ar-H), 7.36-7.28 
(m, 2H, Ar-H), 7.19 (dd, J = 8.5, 2.5 Hz, 1H, Ar-H), 5.58 (d, J = 1.6 Hz, 1H, H-1), 4.06 
(dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.98-3.90 (m, 4H, H-3, OCH3), 3.87-3.72 (m, 3H, H-4, H-
6), 3.62 (ddd, J = 9.7, 5.3, 2.4 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD): G = 168.36 
(CO), 158.03, 140.83, 135.33, 134.70, 133.86, 133.10, 131.57, 131.29, 129.50, 129.48, 
119.14, 116.87 (Ar-C), 100.31 (C-1), 75.73 (C-5), 72.36 (C-3), 71.82 (C-2), 68.29 (C-4), 
62.66 (C-6), 52.77 (OCH3); HRMS: m/z: Calcd for C20H21ClNaO8 >M+Na@+: 447.0817, 
found: 447.0815. 
Sodium 2’-chloro-4’-(D-D-mannopyranosyloxy)biphenyl-3-carboxylate (8b). Prepared 
according to the procedure for 7b from 56 (25 mg, 0.04 mmol). Yield: 11 mg (61%) as 
white solid. [D]D20 +94.1 (c 0.7, MeOH/H2O, 1:1); 1H NMR (500 MHz, D2O): G = 7.95-
7.87, 7.60-7.51, 7.38-7.33 (m, 6H, Ar-H), 7.16 (dd, J = 8.6, 2.5 Hz, 1H, Ar-H), 5.63 (d, J 
= 1.6 Hz, 1H, H-1), 4.17 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 4.06 (dd, J = 9.5, 3.5 Hz, 1H, H-
3), 3.85-3.73 (m, 3H, H-4, H-6), 3.70 (m, 1H, H-5); 13C NMR (126 MHz, D2O): G = 
175.16 (CO), 155.29, 138.57, 136.31, 134.02, 132.26, 132.12, 132.08, 129.86, 128.14, 
128.03, 118.11, 115.82 (Ar-C), 98.15 (C-1), 73.47 (C-5), 70.34 (C-3), 69.79 (C-2), 66.51 
(C-4), 60.60 (C-6); ESI-MS: m/z: Calcd for C19H19ClNaO8 >M+H@+: 433.0661, found: 
433.0661. 
Ethyl 1-(4-hydroxyphenyl)-1H-1,2,3-triazole-4-carboxylate (11a). To an ice-cold 
suspension of sodium azide (429 mg, 6.60 mmol) in pyridine (8 mL), was added dropwise 
triflic anhydride (1.55 g, 0.9 mL, 5.5 mmol). The mixture was stirred at 0 °C for 2 h, then 
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this TfN3-containing solution directly was added dropwise to an ice-cold mixture of 4-
aminophenol (9a, 500 mg, 4.58 mmol), copper(II) sulfate (6 mg, 0.04 mmol), and NEt3 
(1.3 mL, 9.16 mmol) in pyridine (2 mL). The reaction mixture was stirred at 0 °C for 2 h, 
then concentrated, dissolved in EtOAc (50 mL), and extracted with H2O (50 mL) and 
brine (50 mL). The organic layer was concentrated in vacuo. The residue (crude 10a) was 
dissolved in tBuOH/water (1:1, 20 mL) and directly used in the next step. To the above 
solution containing 10a were added subsequently ethyl propiolate (0.46 mL, 4.58 mmol), 
sodium ascorbate (89 mg, 0.45 mmol) and CuSO45H2O (12 mg, 0.05 mmol) at rt. After 
stirring for 30 min, the reaction mixture was filtered over Celite, the precipitate was 
washed with water, and then dried under vacuum to yield 11a (821 mg, 77% for two 
steps) as brown solid. Rf 0.42 (petrol ether/EtOAc, 1:1); 1H NMR (500 MHz, CD3OD): G 
= 8.98 (s, 1H, Ar-H), 7.69 (d, J = 8.0 Hz, 2H, Ar-H), 6.98 (d, J = 8.0 Hz, 2H, Ar-H), 4.44 
(dd, J = 7.0, 7.1 Hz, 2H, OCH2), 1.43 (t, J = 7.0 Hz, 3H, CH3); 13C NMR (126 MHz, 
CD3OD): G = 161.97 (CO), 160.14, 141.26, 130.08, 127.56, 123.68, 117.23 (8C, Ar-C), 
62.38 (OCH2), 14.59 (CH3); ESI-MS: m/z: Calcd for C11H11N3NaO3 >M+Na@+: 256.07, 
found: 256.09. 
 
Ethyl 1-(2-chloro-4-hydroxyphenyl)-1H-1,2,3-triazole-4-carboxylate (11b). Prepared 
according to the procedure for 11a from 9b (200 mg, 1.4 mmol). Yield: 180 mg (48%). Rf 
0.52 (petrol ether/EtOAc, 1:1); 1H NMR (500 MHz, CD3OD): G = 8.90 (s, 1H, Ar-H), 
7.79 (d, J = 2.6 Hz, 1H, Ar-H), 7.55 (dd, J = 8.8, 2.6 Hz, 1H, Ar-H), 6.99 (d, J = 8.8 Hz, 
1H, Ar-H), 4.32 (q, J = 7.1 Hz, 1H, OCH2), 1.31 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 
MHz, CD3OD): G = 161.90 (CO), 127.71, 123.99, 121.92, 118.21, 101.40 (8C, Ar-C), 
62.42 (OCH2), 14.56 (CH3); ESI-MS: m/z: Calcd for C11H10ClN3NaO2 >M+Na@+: 290.03, 
found: 289.85. 
 
Ethyl 1-(4-methoxyphenyl)-1H-pyrazole-4-carboxylate (13a). To a sealable Schlenk 
tube were added CuI (16 mg, 0.082 mmol), ethyl 1H-pyrazole-4-carboxylate (230 mg, 
1.64 mmol), Cs2CO3 (2.10 mmol), and a stirring bar. The reaction vessel was closed with 
a rubber septum, evacuated and back-filled with argon. This sequence was repeated once. 
Then, 1-iodo-4-methoxybenzene (12, 461 mg, 1.97 mmol), trans-N,N’-dimethyl-1,2-
cyclohexanediamine (52 PL, 0.33 mmol) and NMP (2 mL) were added successively 
under a stream of argon. The reaction tube was sealed and stirred in a preheated oil bath 
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at 110 °C for 24 h. The reaction mixture was allowed to reach rt, diluted with EtOAc (5 
mL), filtered over Celite, and eluted with additional EtOAc (20 mL). The filtrate was 
concentrated and the resulting residue was purified by MPLC on silica gel (petrol 
ether/EtOAc, 4:1) to afford 13a (325 mg, 80%) as white solid. Rf 0.43 (petrol 
ether/EtOAc, 4:1); 1H NMR (500 MHz, CDCl3): G = 8.30, 8.07 (2 s, 2H, Ar-H), 7.60 (d, J 
= 8.8 Hz, 2H, Ar-H), 6.98 (d, J = 8.8 Hz, 2H, Ar-H), 4.33 (q, J = 7.0 Hz, 2H, OCH2), 1.37 
(t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): G = 162.93 (CO), 158.99, 141.86, 
133.08, 129.96, 121.24, 116.55, 114.65 (9C, Ar-C), 60.36 (OCH2), 55.59 (OCH3), 14.40 
(CH3); ESI-MS: m/z: Calcd for C13H15N2O3 >M+H@+: 247.11, found: 246.89. 
 
Ethyl 1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate (13b). 
Prepared according to the procedure for 13a from 1-iodo-4-methoxybenzene (12, 733 mg, 
3.13 mmol), CuI (8 mg, 0.039 mmol), ethyl 3-trifluoromethyl-1H-pyrazole-4-carboxylate 
(162 mg, 0.78 mmol), K2CO3 (226 mg, 1.64 mmol), and trans-N,N’-dimethyl-1,2-cyclo-
hexanediamine (20 PL, 0.16 mmol). Yield: 260 mg (quant.). Rf 0.45 (petrol ether/EtOAc, 
4:1); 1H NMR (500 MHz, CDCl3): G = 8.37 (s, 1H, Ar-H), 7.61 (d, J = 9.0 Hz, 2H, Ar-H), 
7.00 (d, J = 9.0 Hz, 2H, Ar-H), 4.36 (q, J = 7.1 Hz, 2H, OCH2), 1.38 (t, J = 7.1 Hz, 3H, 
CH3); 13C NMR (126 MHz, CDCl3): G = 160.83, 159.69, 132.91, 132.12, 121.70, 114.78 
(10C, CO, Ar-C), 61.08 (OCH2), 55.64 (OCH3), 14.09 (CH3); ESI-MS: m/z: Calcd for 
C14H14F3N2O3 >M+H@+: 315.10, found: 315.06. 
 
Ethyl 1-(4-hydroxyphenyl)-1H-pyrazole-4-carboxylate (14a). To a stirred ice-cold 
solution of 13a (36 mg, 0.15mmol) in DCE were added AlCl3 (200 mg, 1.5 mmol) and 
nBu4NI (550 mg, 1.5 mmol). After stirring overnight at rt, the reaction mixture was 
poured into ice-water, and extracted with DCM (20 mL). The organic layer was washed 
with satd. aq. Na2S2O3 (2 u 20 mL), dried over Na2SO4 and concentrated in vacuo. The 
residue was purified by MPLC on silica gel (petrol ether/EtOAc, 2:1) to yield 14a (20 
mg, 60%) as yellow solid. Rf 0.32 (petrol ether/EtOAc, 2:1); 1H NMR (500 MHz, 
CD3OD): G = 8.56, 8.04 (2 s, 2H, Ar-H), 7.66-7.49, 7.01-6.83 (m, 4H, Ar-H), 4.33 (q, J = 
7.1 Hz, 2H, OCH2), 1.38 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, CD3OD): G = 
164.60 (CO), 158.62, 142.53, 133.28, 131.96, 122.77, 117.40, 116.98 (9C, Ar-C), 61.57 
(OCH2), 14.69 (CH3); ESI-MS: m/z: Calcd for C12H13N2O3 >M+H@+: 233.09, found: 
232.84. 
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Ethyl 1-(4-hydroxyphenyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate (14b). To 
a solution of 13b (60 mg, 0.25 mmol) in 1-dodecanethiol (1 mL) was added AlCl3 (170 
mg, 1.27 mmol) at rt. The reaction mixture was stirred for 2 h at rt, then the reaction 
mixture was poured into ice-water and extracted with DCM (20 mL). The organic layer 
was washed with H2O (20 mL) and brine (20 mL), dried over Na2SO4 and concentrated in 
vacuo. The residue was purified by MPLC on silica gel (petrol ether/EtOAc, 2:1) to yield 
14b (15 mg, 26%, with 9% impurities, which were removed in the next step). 1H NMR 
(500 MHz, CD3OD): G = 8.75 (s, 1H, Ar-H), 7.64 (d, J = 8.9 Hz, 2H, Ar-H), 6.94 (d, J = 
8.9 Hz, 2H, Ar-H), 4.35 (dd, J = 14.3, 7.1 Hz, 2H, OCH2), 1.38 (t, J = 7.1 Hz, 3H, CH3). 
 
Methyl 5-bromopyrimidine-2-carboxylate (17). To a mixture of a of n-butyl lithium 
(1.6 M in hexanes, 1.3 mL, 2.1 mmol) and toluene (4 mL) at -78 °C was added a solution 
of 15 (0.57 g, 2.0 mmol) in toluene (2 mL). The reaction mixture was stirred for 1 h at -78 
°C. The reaction was quenched with freshly crushed dry ice. The mixture was warmed 
slowly to rt and stirred for 2 h at rt. The mixture was concentrated under reduced 
pressure, and the resulting solid was treated with acetic acid. Solid 16[S1] was collected by 
filtration, dried under vacuum, and used for the next step without further purification. To 
a solution of 16 in dry MeOH (15 mL) was added conc. H2SO4 (109 PL, 2.04 mmol). The 
reaction mixture was refluxed at 70 °C for 5 h, and then quenched with ice-water (50 
mL). After stirring for 20 min, the reaction mixture was extracted with DCM (50 mL). 
The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was 
purified by MPLC on silica gel (petrol ether/EtOAc 2:1) to afford 17 (160 mg, 37% for 
two steps) as yellow solid. Rf 0.31 (petrol ether/EtOAc, 2:1); 1H NMR (500 MHz, 
CDCl3): G = 9.00 (s, 2H, Ar-H), 4.08 (s, 3H, OCH3); 13C NMR (126 MHz, CDCl3): G = 
163.12 (CO), 158.68, 154.30, 123.50 (Ar-C), 53.79 (OCH3); ESI-MS: m/z: Calcd for 
C6H6BrN2O2 >M+H@+: 216.96, found: 216.99. 
 
3-Cyano-1H-pyrrole (20a). To a stirred solution of BetMIC (18, 200 mg, 1.26 mmol) 
and alkene 19a (83 Pl, 1.26 mmol) in THF (5 mL) at 0 °C was added tBuOK (284 mg, 
2.53 mmol). The reaction mixture was heated to reflux for 2 h, then cooled, diluted with 
water (5 mL), adjusted to pH 5 with 10% aq. HCl, and extracted with Et2O (30 mL). The 
organic layer was dried with MgSO4, filtered and concentrated. The residue was purified 
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by MPLC on silica (petrol ether/ EtOAc, 1:1) to give 20a (70 mg, 60%) as yellow solid. 
Rf 0.35 (petrol ether/EtOAc, 1:1); 1H NMR (500 MHz, CDCl3): G = 9.18-8.51 (m, 1H, 
NH), 7.33 (dt, J = 3.2, 1.8 Hz, 1H, Ar-H), 6.83 (dd, J = 4.8, 2.6 Hz, 1H, Ar-H), 6.52 (dd, 
J = 4.1, 2.7 Hz, 1H, Ar-H); 13C NMR (126 MHz, CDCl3): G 125.65, 119.19, 116.80, 
111.83, 93.34 (Ar-C, CN). The spectroscopic data were in accordance with literature 
values.[S2] 
 
3-Cyano-4-methyl-1H-pyrrole (20b). Prepared according to the procedure for 20a from 
BetMIC (18, 200 mg, 1.26 mmol) and alkene 19b (101 Pl, 1.26 mmol). Yield: 72 mg 
(54%) as yellow solid. Rf 0.64 (petrol ether/EtOAc, 1:1); 1H NMR (500 MHz, CDCl3): G 
= 8.54 (br s, 1H, NH), 7.23 (dd, J = 3.1, 2.2 Hz, 1H, Ar-H), 6.59 (td, J = 2.2, 1.0 Hz, 1H, 
Ar-H), 2.22 (d, J = 1.0 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): G = 125.22, 122.36, 
116.65, 116.51, 94.60 (Ar-C, CN), 10.37 (CH3). The spectroscopic data were in 
accordance with literature values.[S3]  
 
Ethyl 1-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)-2-chlorophenyl]-1H-
1,2,3-triazole-4-carboxylate (22b). Prepared according to general procedure A from 21 
and 11b. Yield: 170 mg (76%) as colorless oil. Rf 0.48 (petrol ether/EtOAc, 1:1); [D]D20 
+68.6 (c 0.5, EtOAc); 1H NMR (500 MHz, CDCl3): G = 8.45 (s, 1H, Ar-H), 7.87 (d, J = 
2.6 Hz, 1H, Ar-H), 7.64 (dd, J = 8.9, 2.6 Hz, 1H, Ar-H), 7.36 (d, J = 9.0 Hz, 1H, Ar-H), 
5.66-5.58 (m, 2H, H-1, H-3), 5.55 (dd, J = 3.4, 1.9 Hz, 1H, H-2), 5.41 (t, J = 10.0 Hz, 1H, 
H-4), 4.47 (q, J = 7.1 Hz, 2H, OCH2), 4.29 (dd, J = 12.2, 5.1 Hz, 1H, H-6a), 4.19-4.06 
(m, 2H, H-5, H-6b), 2.22, 2.08, 2.05, 2.04 (4 s, 12H, 4 COCH3), 1.44 (t, J = 7.1 Hz, 3H, 
CH3); 13C NMR (126 MHz, CDCl3): G = 169.76, 160.39 (5C, 5 CO), 151.98, 131.88, 
125.39, 123.22, 120.13, 117.38 (8C, Ar-C), 96.72 (C-1), 70.10 (C-5), 69.12 (C-2), 68.58 
(C-3), 65.64 (C-4), 62.02 (C-6), 61.62 (OCH2), 20.84, 20.67 (4C, 4 COCH3), 14.32 (CH3); 
ESI-MS: m/z: Calcd for C25H28ClN3NaO12 >M+Na@+: 620.13, found: 620.13. 
 
Methyl 1-[2-chloro-4-(D-D-mannopyranosyloxy)phenyl]-1H-1,2,3-triazole-4-
carboxylate (23b). Prepared according to general procedure D from 22b. Yield: 5 mg 
(80%) as white solid. Rf 0.22 (DCM/MeOH, 8:1); [D]D20 +86.2 (c 0.2, MeOH); 1H NMR 
(500 MHz, CD3OD): G = 8.99 (s, 1H, Ar-H), 7.91 (d, J = 2.6 Hz, 1H, Ar-H), 7.70 (dd, J = 
9.0, 2.7 Hz, 1H, Ar-H), 7.48 (t, J = 9.1 Hz, 1H, Ar-H), 5.56 (d, J = 1.5 Hz, 1H, H-1), 4.02 
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(dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.89 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.85 (s, 3H, OCH3), 
3.73-3.57 (m, 3H, H-4, H-6), 3.50 (ddd, J = 9.6, 5.7, 2.3 Hz, 1H, H-5); 13C NMR (126 
MHz, CD3OD): G = 162.25 (CO), 154.00, 141.30, 132.60, 127.90, 125.79, 123.90, 
121.67, 118.77, 101.40 (Ar-C), 100.83 (C-1), 76.27 (C-5), 72.37 (C-3), 71.70 (C-2), 
68.17 (C-4), 62.66 (C-6), 52.68 (OCH3); HRMS: m/z: Calcd for C16H18ClN3NaO8 
>M+Na@+: 438.0675, found: 438.0674. 
 
Ethyl 1-[2-chloro-4-(D-D-mannopyranosyloxy)phenyl]-1H-1,2,3-triazole-4-
carboxylate (23c). Prepared according to general procedure D from 22b. Yield: 64 mg 
(74%) as white solid. Rf 0.30 (DCM/MeOH, 8:1); [D]D20 +86.7 (c 0.5, MeOH); 1H NMR 
(500 MHz, CD3OD): G = 9.08 (s, 1H, Ar-H), 8.00 (d, J = 2.6 Hz, 1H, Ar-H), 7.81 (dd, J = 
9.0, 2.6 Hz, 1H, Ar-H), 7.59 (d, J = 9.0 Hz, 1H, Ar-H), 5.69 (d, J = 1.1 Hz, 1H, H-1), 
4.45 (q, J = 7.1 Hz, 2H, OCH2), 4.17 (dd, J = 3.0, 1.7 Hz, 1H, H-2), 4.03 (dd, J = 9.5, 3.4 
Hz, 1H, H-3), 3.90-3.69 (m, 3H, H-4, H-6), 3.64 (ddd, J = 9.5, 5.6, 2.2 Hz, 1H, H-5), 1.44 
(t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, CD3OD): G = 161.76 (CO), 153.86, 
141.50, 132.48, 127.68, 125.69, 123.71, 121.50, 118.70 (Ar-C), 100.75 (C-1), 76.19 (C-
5), 72.32 (C-3), 71.64 (C-2), 68.13 (C-4), 62.61, 62.46 (C-6, OCH2), 14.55 (CH3); HRMS: 
m/z: Calcd for C17H20ClN3NaO8 >M+Na@+: 452.0831, found: 452.0835. 
 
Sodium 1-[2-chloro-4-(D-D-mannopyranosyloxy)phenyl]-1H-1,2,3-triazole-4-
carboxylate (24b). Prepared according to general procedure E from 22b. Yield: 76 mg 
(90%) as white solid. [D]D20 +60.6 (c 0.3, MeOH/H2O, 1:1); 1H NMR (500 MHz, D2O): G 
= 8.48 (s, 1H, Ar-H), 7.82 (d, J = 2.0 Hz, 1H, Ar-H), 7.59 (dd, J = 8.9, 2.0 Hz, 1H, Ar-H), 
7.36 (d, J = 8.9 Hz, 1H, Ar-H), 5.65 (s, 1H, H-1), 4.18 (m, 1H, H-2), 4.03 (dd, J = 9.4, 3.4 
Hz, 1H, H-3), 3.78-3.53 (m, 4H, H-4, H-5, H-6); 13C NMR (126 MHz, D2O): G = 151.34, 
125.55, 124.46, 123.25, 120.88, 117.82, 99.99 (Ar-C), 98.52 (C-1), 73.99 (C-5), 70.36 
(C-3), 69.62 (C-2), 66.47 (C-4), 60.62 (C-6); HRMS: m/z: Calcd for C15H16ClN3NaO8 
>M+H@+: 424.0518, found: 424.0518. 
 
Ethyl 1-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)phenyl]-1H-pyrazole-4-
carboxylate (25a). Prepared according to general procedure A from 21 and 14a. Yield: 
198 mg (98%) as yellow oil. Rf 0.27 (petrol ether/EtOAc, 2:1); [D]D20 +67.5 (c 2.0, 
EtOAc); 1H NMR (500 MHz, CDCl3): G = 8.35, 8.08 (2 s, 2H, Ar-H), 7.65 (t, J = 6.1 Hz, 
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2H, Ar-H), 7.21 (d, J = 9.0 Hz, 2H, Ar-H), 5.60-5.53 (m, 2H, H-1, H-3), 5.47 (dd, J = 3.3, 
1.8 Hz, 1H, H-2), 5.39 (t, J = 10.1 Hz, 1H, H-4), 4.38-4.25 (m, 3H, H-6a, OCH2), 4.15-
4.07 (m, 2H, H-5, H-6b), 2.21, 2.07, 2.05, 2.04 (4 s, 12H, 4 COCH3), 1.38 (t, J = 7.1 Hz, 
3H, CH3); 13C NMR (126 MHz, CDCl3): G = 170.42, 169.92, 169.89, 169.66, 162.74 (5 
CO), 154.76, 142.07, 134.89, 129.92, 121.07, 117.43, 116.88 (9C, Ar-C), 95.99 (C-1), 
69.39 (C-5), 69.23 (C-2), 68.74 (C-3), 65.83 (C-4), 62.08 (C-6), 60.40 (OCH2), 20.82, 
20.65 (4C, 4 COCH3), 14.37 (CH3); ESI-MS: m/z: Calcd for C26H30N2NaO12 >M+Na@+: 
585.17, found: 585.23. 
 
Ethyl 1-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)phenyl]-3-
trifluoromethyl-1H-pyrazole-4-carboxylate (25b). Prepared according to general 
procedure A from 21 and 14b. Yield: 43 mg (64%). Rf 0.20 (petrol ether/EtOAc, 2:1); 
[D]D20 +67.0 (c 0.9, EtOAc); 1H NMR (500 MHz, CDCl3): G = 8.41 (s, 1H, Ar-H), 7.70-
7.63 (m, 2H, Ar-H), 7.26-7.20 (m, 2H, Ar-H), 5.59-5.54 (m, 2H, H-1, H-3), 5.47 (dd, J = 
3.3, 1.8 Hz, 1H, H-2), 5.39 (t, J = 10.0 Hz, 1H, H-4), 4.37 (q, J = 7.1 Hz, 2H, OCH2), 
4.29 (dd, J = 12.8, 5.8 Hz, 1H, H-6a), 4.11-4.05 (m, 2H, H-5, H-6b), 2.22, 2.06, 2.05, 
2.04 (4 s, 12H, 4 COCH3), 1.38 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): G 
= 170.45, 169.97, 169.95, 169.67, 160.68 (5 CO), 155.49, 133.95, 132.88, 121.61, 
117.52, 114.72 (9C, Ar-C), 95.96 (C-1), 69.51 (C-5), 69.20 (C-2), 68.71 (C-3), 65.79 (C-
4), 62.06 (C-6), 61.16 (OCH2), 20.85, 20.68, 20.67 (4C, 4 COCH3), 14.09 (CH3); ESI-
MS: m/z: Calcd for C27H29F3N2NaO12 >M+Na@+: 653.16, found: 653.33. 
 
Ethyl 1-[4-(D-D-mannopyranosyloxy)phenyl]-1H-pyrazole-4-carboxylate (26a). 
Prepared according to general procedure D from 25a. Yield: 30 mg (95%) as white solid. 
Rf 0.26 (DCM/MeOH, 8:1); [D]D20 +110.4 (c 0.4, MeOH); 1H NMR (500 MHz, CD3OD): 
G = 8.65 (s, 1H, Ar-H), 8.06 (s, 1H, Ar-H), 7.76-7.68 (m, 2H, Ar-H), 7.32-7.24 (m, 2H, 
Ar-H), 5.55 (d, J = 1.5 Hz, 1H, H-1), 4.34 (q, J = 7.1 Hz, 2H, OCH2), 4.06 (dd, J = 3.3, 
1.8 Hz, 1H, H-2), 3.94 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.84-3.71 (m, 3H, H-4, H-6), 3.63 
(ddd, J = 7.3, 5.9, 3.0 Hz, 1H, H-5), 1.38 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, 
CD3OD): G = 164.51 (CO), 157.34, 142.82, 135.53, 132.01, 122.35, 118.67, 117.73 (9C, 
Ar-C), 100.39 (C-1), 75.63 (C-5), 72.40 (C-3), 71.91 (C-2), 68.34 (C-4), 62.70 (C-6), 
61.62 (OCH2), 14.70 (CH3); HRMS: m/z: Calcd for C18H22N2NaO8 >M+Na@+: 417.1268, 
found: 417.1274. 
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Ethyl 1-[4-(D-D-mannopyranosyloxy)phenyl]-3-trifluoromethyl-1H-pyrazole-4-
carboxylate (26b). Prepared according to general procedure D from 25b. Yield: 12 mg 
(82%) as white solid. Rf 0.59 (DCM/MeOH, 7:1); [D]D20 +84.1 (c 0.4, MeOH); 1H NMR 
(500 MHz, CD3OD): G = 8.74 (d, J = 0.7 Hz, 1H, Ar-H), 7.71-7.63, 7.23-7.16 (m, 4H, Ar-
H), 5.45 (d, J = 1.6 Hz, 1H, H-1), 4.24 (q, J = 7.1 Hz, 2H, OCH2), 3.93 (dd, J = 3.4, 1.8 
Hz, 1H, H-2), 3.81 (dd, J = 9.4, 3.4 Hz, 1H, H-3), 3.72-3.58 (m, 3H, H-4, H-6), 3.49 
(ddd, J = 9.6, 5.4, 2.3 Hz, 1H, H-5), 1.27 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, 
CD3OD): G = 162.13 (CO), 157.93, 135.12, 134.77, 122.62, 118.71, 115.32 (9C, Ar-C), 
100.36 (C-1), 75.71 (C-5), 72.38 (C-3), 71.87 (C-2), 68.31 (C-4), 62.70 (C-6), 62.11 
(OCH2), 14.47 (CH3); HRMS: m/z: Calcd for C19H21F3N2NaO8 >M+Na@+: 485.1142, 
found: 485.1141. 
 
Sodium 1-[4-(D-D-mannopyranosyloxy)phenyl]-1H-pyrazole-4-carboxylate (27a). 
Prepared according to general procedure E from 25a. Yield: 82 mg (70%) as white solid. 
[D]D20 +118.61 (c 0.4, MeOH); 1H NMR (500 MHz, CD3OD): G = 8.61, 8.06 (2 s, 2H, Ar-
H), 7.75-7.70, 7.33-7.25 (m, 4H, Ar-H), 5.56 (d, J = 1.4 Hz, 1H, H-1), 4.06 (dd, J = 3.3, 
1.8 Hz, 1H, H-2), 3.94 (dd, J = 9.4, 3.4 Hz, 1H, H-3), 3.84-3.72 (m, 3H, H-4, H-6), 3.62 
(ddd, J = 9.6, 5.3, 2.4 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD): G = 157.32, 143.18, 
135.65, 132.19, 122.38, 118.67 (9C, Ar-C), 100.41 (C-1), 75.63 (C-5), 72.40 (C-3), 71.91 
(C-2), 68.34 (C-4), 62.70 (C-6); HRMS: m/z: Calcd for C16H18N2NaO8 >M+H@+: 
389.0955, found: 389.0956. 
 
Sodium 1-[4-(D-D-mannopyranosyloxy)phenyl]-3-trifluoromethyl-1H-pyrazole-4-
carboxylate (27b). Prepared according to general procedure E from 25b. Yield: 11 mg 
(79%) as white solid. [D]D20 +85.8 (c 0.4, MeOH); 1H NMR (500 MHz, CD3OD): G = 
8.52 (s, 1H, Ar-H), 7.69-7.60, 7.22-7.15 (m, 4H, Ar-H), 5.45 (d, J = 1.3 Hz, 1H, H-1), 
3.93 (dd, J = 3.2, 1.8 Hz, 1H, H-2), 3.81 (dd, J = 9.4, 3.4 Hz, 1H, H-3), 3.71-3.59 (m, 3H, 
H-4, H-6), 3.49 (ddd, J = 9.7, 5.3, 2.4 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD): G = 
156.18, 132.78, 121.00, 117.18 (9C, Ar-C), 98.87 (C-1), 74.15 (C-5), 70.87 (C-3), 70.38 
(C-2), 66.80 (C-4), 61.16 (C-6); HRMS: m/z: Calcd for C17H17F3N2NaO8 >M+H@+: 
457.0829, found: 457.0829. 
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Methyl 5-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)phenyl]-nicotinate 
(31b). Prepared according to general procedure B from 29 (50 mg, 0.09 mmol) and 
methyl 6-chloronicotinate (30b, 14 mg, 0.08 mmol). Yield: 40 mg (80%) as white solid. 
Rf 0.32 (petrol ether/EtOAc, 1:1); [D]D20 +82.8 (c 0.8, EtOAc); 1H NMR (500 MHz, 
CDCl3): G = 9.25 (dd, J = 0.7, 2.2 Hz, 1H, Ar-H), 8.33 (dd, J = 2.2, 8.3 Hz, 1H, Ar-H), 
8.06-8.03 (m, 2H, Ar-H), 7.77 (dd, J = 0.6, 8.4 Hz, 1H, Ar-H), 7.23-7.20 (m, 2H, Ar-H), 
5.62 (d, J = 1.7 Hz, 1H, H-1), 5.59 (dd, J = 3.6, 10.1 Hz, 1H, H-3), 5.48 (dd, J = 1.8, 3.5 
Hz, 1H, H-2), 5.40 (t, J = 10.0 Hz, 1H, H-4), 4.31 (dd, J = 4.8, 12.0 Hz, 1H, H-6a), 4.12-
4.06 (m, 2H, H-5, H-6b), 3.97 (s, 3H, OCH3), 2.22, 2.07, 2.05, 2.04 (4 s, 12H, 4 COCH3); 
13C NMR (126 MHz, CDCl3): G = 170.56, 170.01, 169.98, 169.74, 165.89 (5 CO), 160.02, 
157.03, 151.00, 137.92, 133.10, 128.88, 123.89, 119.26, 116.71 (11C, Ar-C), 95.62 (C-1), 
69.33 (C-5), 69.29 (C-2), 68.82 (C-3), 65.83 (C-4), 62.04 (C-6), 52.37 (OCH3), 20.91, 
20.73, 20.71 (4C, 4 COCH3); ESI-MS: m/z: Calcd for C27H30NO12 >M+H@+: 560.18, 
found: 560.20. 
 
Methyl 5-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)phenyl]-pyrazine-2-
carboxylate (31c). Prepared according to general procedure B from 29 (70 mg, 0.13 
mmol) and methyl 5-chloropyrazine-2-carboxylate (30c, 28 mg, 0.12 mmol). Yield: 48 
mg (68%) as white solid. Rf 0.31 (petrol ether/EtOAc, 2:3); [D]D20 +88.1 (c 1.0, EtOAc); 
1H NMR (500 MHz, CDCl3): G = 9.30 (d, J = 1.4 Hz, 1H, Ar-H), 9.09 (d, J = 1.4 Hz, 1H, 
Ar-H), 8.11-8.09, 7.27-7.25 (m, 4H, Ar-H), 5.64 (d, J = 1.7 Hz, 1H, H-1), 5.60 (dd, J = 
3.6, 10.1 Hz, 1H, H-3), 5.49 (dd, J = 1.9, 3.5 Hz, 1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 
4.30 (dd, J = 5.2, 12.4 Hz, 1H, H-6a), 4.13-4.07 (m, 5H, H-5, H-6b, OCH3), 2.23, 2.07, 
2.06, 2.04 (4 s, 12H, 4 COCH3); 13C NMR (126 MHz, CDCl3): G = 170.52, 170.01, 
169.99, 169.72, 164.60 (5 CO), 157.80, 154.42, 145.68, 140.85, 140.58, 130.03, 129.18, 
117.05 (10C, Ar-C), 95.59 (C-1), 69.45 (C-5), 69.21(C-2), 68.75 (C-3), 65.76 (C-4), 
65.76 (C-6), 53.09 (OCH3), 20.91, 20.73, 20.71 (4C, 4 COCH3); ESI-MS: m/z: Calcd for 
C26H29N2O12 >M+H@+: 561.17, found: 561.23. 
 
Methyl 5-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)phenyl]-pyrimidine-2-
carboxylate (31d). Prepared according to general procedure B from 29 (149 mg, 0.27 
mmol) and 17 (53 mg, 0.25 mmol). Yield: 54 mg (40%) as white solid. Rf 0.25 (petrol 
ether/EtOAc, 1:2); [D]D20 +91.9 (c 0.6, MeOH); 1H NMR (500 MHz, CDCl3): G = 9.02 (s, 
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2H, Ar-H), 7.54 (d, J = 8.8 Hz, 2H, Ar-H), 7.21 (d, J = 8.5 Hz, 2H, Ar-H), 5.54 (d, J = 
1.7 Hz, 1H, H-1), 5.51 (dd, J = 3.5, 10.0 Hz, 1H, H-3), 5.41 (dd, J = 1.8, 3.5 Hz, 1H, H-
2), 5.34 (t, J = 10.0 Hz, 1H, H-4), 4.22 (dd, J = 5.5, 12.8 Hz, 1H, H-6a), 4.05-3.99 (m, 
5H, H-5, H-6a, OCH3), 2.16, 2.00, 1.99, 1.98 (4 s, 12H, 4 COCH3); 13C NMR (126 MHz, 
CDCl3): G = 170.47, 170.01, 170.00, 169.68, 163.65 (5 CO), 156.91, 155.22, 154.54, 
135.13, 128.70, 127.73, 117.55 (10C, Ar-C), 95.68 (C-1), 69.44 (C-5), 69.19 (C-2), 68.72 
(C-3), 65.71 (C-4), 61.97 (C-6), 53.65 (OCH3), 29.69, 20.89, 20.71, 20.69 (4 COCH3); 
ESI-MS: m/z: Calcd for C26H29N2O12 >M+H@+: 561.17, found: 561.23. 
 
Methyl 5-[4-(D-D-mannopyranosyloxy)phenyl]-nicotinate (32b). Prepared according to 
general procedure D from 31b. Yield: 6 mg (24%) as white solid. Rf 0.40 (DCM/MeOH, 
5:1); [D]D20 +142.6 (c 0.1, MeOH); 1H NMR (500 MHz, CD3OD): G = 9.04 (dd, J = 0.7, 
2.2 Hz, 1H, Ar-H), 8.28 (dd, J = 2.2, 8.4 Hz, 1H, Ar-H), 7.96-7.93 (m, 2H, Ar-H), 7.85 
(dd, J = 0.7, 8.4 Hz, 1H, Ar-H), 7.18-7.16 (m, 2H, Ar-H), 5.49 (d, J = 1.7 Hz, 1H, H-1), 
3.93 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 3.86 (s, 3H, OCH3), 3.82 (dd, J = 3.5, 9.5 Hz, 1H, H-
3), 3.67-3.60 (m, 3H, H-4, H-6), 3.49 (ddd, J = 2.7, 5.5, 9.5 Hz, 1H, H-5); 13C NMR (126 
MHz, CD3OD): G = 151.50, 139.33, 133.28, 130.00, 125.38, 121.05, 117.96, 101.40 
(10C, Ar-C), 100.04 (C-1), 75.59 (C-5), 72.42 (C-3), 71.92 (C-2), 68.33 (C-4), 62.69 (C-
6), 52.85 (OCH3); HRMS: m/z: Calcd for C19H21NNaO8 >M+Na@+: 414.1159, found: 
414.1159. 
 
Methyl 5-[4-(D-D-mannopyranosyloxy)phenyl]-pyrazine-2-carboxylate (32c). 
Prepared according to general procedure D from 31c. Yield: 5 mg (36%) as white solid. 
Rf 0.42 (DCM/MeOH, 5:1); [D]D20 +138.4 (c 0.2, MeOH); 1H NMR (500 MHz, CD3OD): 
G = 9.14 (t, J = 1.2 Hz, 1H, Ar-H), 9.09 (t, J = 1.2 Hz, 1H, Ar-H), 8.10-8.08, 7.21-7.20 
(m, 4H, Ar), 5.51 (d, J = 1.5 Hz, 1H, H-1), 3.94 (dd, J = 1.9, 3.3 Hz, 1H, H-2), 3.92 (s, 
3H, OCH3), 3.81 (dd, J = 3.5, 9.5 Hz, 1H, H-3), 3.66-3.60 (m, 3H, H-4, H-6), 3.47 (ddd, J 
= 2.5, 5.2, 9.5 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD): G = 165.88 (CO), 160.43, 
156.27, 146.57, 142.09, 141.46, 130.40, 130.27, 118.23 (10C, Ar-C), 99.95 (C-1), 75.72 
(C-5), 72.36 (C-2), 71.85 (C-3), 68.26 (C-4), 62.66 (C-6), 53.33 (OCH3); HRMS: m/z: 
Calcd for C18H20N2NaO8 >M+Na@+: 415.1112, found: 414.1106. 
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Methyl 5-[4-(D-D-mannopyranosyloxy)phenyl]-pyrimidine-2-carboxylate (32d). 
Prepared according to general procedure D from 31d. Yield: 8 mg (89%) as white solid. 
Rf 0.40 (DCM/MeOH, 5:1); [D]D20 +134.7 (c 0.1, dioxane/H2O, 1:1); 1H NMR (500 MHz, 
DMSO-d6): G = 9.30 (s, 2H, Ar-H), 7.88 (d, J = 8.7 Hz, 2H, Ar-H), 7.28 (d, J = 8.7 Hz, 
2H, Ar-H), 5.50 (s, 1H, H-1), 5.09 (s, 1H, OH), 4.87 (s, 1H, OH), 4.80 (s, 1H, OH), 4.47 
(t, J = 5.3 Hz, 1H, OH), 3.94 (s, 3H, OCH3), 3.87 (m, 1H, H-2), 3.72 (m, 1H, H-3), 3.61 
(m, 1H, H-6a), 3.57-3.44 (m, 2H, H-4, H-6b), 3.41 (m, 1H, H-5), 3.18 (d, J = 4.9 Hz, 
1H); 13C NMR (126 MHz, DMSO-d6): G = 163.60 (CO), 157.60, 154.79, 154.20, 134.05, 
128.60, 126.22, 117.48 (10C, Ar-C), 98.68 (C-1), 75.11 (C-5), 70.61, 69.94 (C-2, C-3), 
66.65 (C-4), 60.99 (C-6), 52.76 (OCH3); HRMS: m/z: Calcd for C18H20N2NaO8 >M+Na@+: 
415.1112, found: 414.1113. 
 
Sodium 5-[4-(D-D-mannopyranosyloxy)phenyl]-nicotinate (33b). Prepared according 
to general procedure E from 31b. Yield: 10 mg (48%) as white solid. [D]D20 +138.0 (c 
0.5, MeOH/H2O, 1:1); 1H NMR (500 MHz, D2O): G = 8.66 (s, 1H, Ar-H), 7.94 (d, J = 8.0 
Hz, 1H, Ar-H), 7.46 (d, J = 8.4 Hz, 2H, Ar-H), 7.38 (d, J = 8.1 Hz, 1H, Ar-H), 6.88 (d, J 
= 8.4 Hz, 2H, Ar-H), 5.40 (s, 1H, H-1), 3.98 (m, 1H, H-2), 3.88 (dd, J = 9.6, 3.4 Hz, 1H, 
H-3), 3.67-3.54 (m, 3H, H-4, H-6), 3.50 (ddd, J = 9.8, 5.0, 2.2 Hz, 1H, H-5); 13C NMR 
(126 MHz, D2O): G = 157.78, 156.56, 149.30, 138.34, 132.14, 128.56, 120.63, 116.86 
(10C, Ar-C), 97.83 (C-1), 73.39 (C-5), 70.37 (C-3), 69.87 (C-2), 66.59 (C-4), 60.67 (C-
6); HRMS: m/z: Calcd for C18H19NNaO8 >M+H@+: 400.1003, found: 400.0993. 
 
Sodium 5-[4-(D-D-mannopyranosyloxy)phenyl]-pyrazine-2-carboxylate (33c). 
Prepared according to general procedure E from 31c. Yield: 6 mg (44%) as white solid. 
[D]D20 +90.3 (c 0.2, MeOH/H2O, 1:1); 1H NMR (500 MHz, D2O): G = 8.94, 8.89 (2 s, 2H, 
Ar-H), 7.85-7.83, 7.19-7.17 (m, 4H, Ar-H), 5.64 (d, J = 1.7 Hz, 1H, H-1), 4.17 (dd, J = 
1.8, 3.5 Hz, 1H, H-2), 4.05 (dd, J = 3.5, 9.4 Hz, H-3), 3.78-3.67 (m, 4H, H-4, H-5, H-6); 
13C NMR (126 MHz, D2O): G = 157.23, 152.73, 145.68, 143.73, 141.21, 129.32, 128.86, 
117.12 (10C, Ar-C), 97.65 (C-1), 73.38 (C-5), 69.74 (2C, C-2, C-3), 66.53 (C-4), 60.61 
(C-6); HRMS: m/z: Calcd for C17H17N2Na2O8 >M+Na@+: 423.0775, found: 423.0774. 
 
Sodium 5-[4-(D-D-mannopyranosyloxy)phenyl]-pyrimidine-2-carboxylate (33d). Pre-
pared according to general procedure E from 32d. Yield: 17 mg (60%) as white solid. 
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[D]D20 +89.5 (c 0.2, MeOH/H2O, 3:1); 1H NMR (500 MHz, D2O): G = 8.91 (bs, 2H, Ar-
H), 7.60-7.58, 7.17-7.16 (m, 4H, Ar-H), 5.55 (d, J = 1.7 Hz, 1H, H-1), 4.05 (dd, J = 1.9, 
3.5 Hz, 1H, H-2), 3.93 (dd, J = 3.5, 9.1 Hz, H-3), 3.66-3.55 (m, 4H, H-4, H-5, H-6); 13C 
NMR (126 MHz, D2O): G = 128.54, 117.60 (Ar-C), 97.85 (C-1), 73.38 (C-5), 70.30 (C-3), 
69.77 (C-2), 66.51 (C-4), 60.59 (C-6); HRMS: m/z: Calcd for C17H19N2O8 >M+H@+: 
379.1136, found: 379.1136. 
 
1-[4-(2,3,4,6-Tetra-O-acetyl-D-D-mannopyranosyloxy)-3-chlorophenyl]-1H-pyrrole-
3-carbonitrile (40a). Prepared according to general procedure C from 39 (86 mg, 0.15 
mmol) and 20a (16 mg, 0.17 mmole). Yield: 35 mg (44%) as yellow oil. Rf 0.37 (petrol 
ether/EtOAc, 2:1); [D]D20 +56.3 (c 1.7, EtOAc); 1H NMR (500 MHz, CDCl3): G = 7.45 (d, 
J = 2.6 Hz, 1H, Ar-H), 7.42 (m, 1H, Ar-H), 7.26 (d, J = 3.3 Hz, 1H, Ar-H), 7.23 (dd, J = 
8.8, 2.6 Hz, 1H, Ar-H), 6.95 (dd, J = 3.0, 2.3 Hz, 1H, Ar-H), 6.59 (dd, J = 3.0, 1.6 Hz, 
1H, Ar-H), 5.59 (dd, J = 10.1, 3.5 Hz, 1H, H-3), 5.57 (d, J = 1.8 Hz, 1H, H-1), 5.52 (dd, J 
= 3.5, 1.9 Hz, 1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.28 (dd, J = 12.3, 5.1 Hz, 1H, H-
6a), 4.16 (m, 1H, H-5), 4.10 (m, 1H, H-6b), 2.21, 2.07, 2.04, 2.04 (4 s, 12H, 4 COCH3); 
13C NMR (126 MHz, CDCl3): G = 170.40, 169.97, 169.80, 169.69 (4 CO), 150.66, 
135.03, 126.48, 125.68, 123.88, 121.21, 120.74, 117.78, 115.91, 113.73 (11C, Ar-C, CN), 
95.61 (C-1), 69.99 (C-5), 69.20 (C-2), 68.62 (C-3), 65.69 (C-4), 62.05 (C-6), 20.85, 
20.68, 20.67 (4C, 4 COCH3); ESI-MS: m/z: Calcd for C25H25ClN2NaO10 >M+Na@+: 
571.11, found: 571.18. 
 
1-[4-(2,3,4,6-Tetra-O-acetyl-D-D-mannopyranosyloxy)-3-chlorophenyl]-4-methyl-
1H-pyrrole-3-carbonitrile (40b). Prepared according to general procedure C from 39 
(50 mg, 0.09 mmol) and 20b (11 mg, 0.11 mmole). Yield: 44 mg (92%) as yellow oil. Rf 
0.29 (petrol ether/EtOAc, 2:1); [D]D20 +63.2 (c 1.0, EtOAc); 1H NMR (500 MHz, CDCl3): 
G = 7.35 (d, J = 2.6 Hz, 1H, Ar-H), 7.27 (d, J = 2.4 Hz, 1H, Ar-H), 7.20 (t, J = 8.2 Hz, 
1H, Ar-H), 7.13 (m, 1H, Ar-H), 6.69 (dd, J = 2.2, 1.1 Hz, 1H, Ar-H), 5.54 (m, 1H, H-3), 
5.49 (d, J = 1.7 Hz, 1H, H-1), 5.46 (dd, J = 3.4, 1.9 Hz, 1H, H-2), 5.34 (t, J = 10.1 Hz, 
1H, H-4), 4.22 (dd, J = 12.3, 5.2 Hz, 1H, H-6a), 4.11 (m, 1H, H-5), 4.04 (dd, J = 12.2, 3.3 
Hz, 1H, H-6b), 2.16 (d, J = 0.8 Hz, 3H, CH3), 2.14, 2.01, 1.99, 1.98 (4 s, 12H, 4 COCH3); 
13C NMR (126 MHz, CDCl3): G = 170.41, 169.97, 169.80, 169.70 (4 CO), 150.35, 
135.20, 125.73, 125.63, 124.52, 123.43, 120.26, 118.72, 117.82, 115.60 (11C, Ar-C, CN), 
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96.94 (C-1), 69.96 (C-5), 69.22 (C-2), 68.63 (C-3), 65.71 (C-4), 62.07 (C-6), 20.85, 
20.68, 20.67 (4C, 4 COCH3), 10.52 (CH3); ESI-MS: m/z: Calcd for C26H27ClN2NaO10 
>M+Na@+: 585.12, found: 585.03. 
 
Ethyl 1-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)-3-chlorophenyl]-1H-
pyrrole-2-carboxylate (40c). Prepared according to general procedure C from 39 and 
methyl 1H-pyrrole-2-carboxylate (20c). Yield: 34 mg (33%) as colorless oil. Rf 0.43 
(petrol ether/EtOAc, 3:2); [D]D20 + 61.0 (c 0.7, EtOAc); 1H NMR (500 MHz, CDCl3): G 
7.39 (d, J = 2.4 Hz, 1H, Ar-H), 7.22 (d, J = 8.8 Hz, 1H, Ar-H), 7.18 (dd, J = 8.7, 2.5 Hz, 
1H, Ar-H), 7.09 (dd, J = 3.9, 1.8 Hz, 1H, Ar-H), 6.88 (dd, J = 2.5, 1.9 Hz, 1H, Ar-H), 
6.28 (dd, J = 3.8, 2.7 Hz, 1H, Ar-H), 5.62 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 5.59 (d, J = 1.6 
Hz, 1H, H-1), 5.54 (dd, J = 3.4, 1.9 Hz, 1H, H-2), 5.41 (t, J = 10.1 Hz, 1H, H-4), 4.31 
(dd, J = 12.3, 5.2 Hz, 1H, H-6a), 4.23-4.14 (m, 3H, OCH2, H-5), 4.11 (dd, J = 12.3, 2.2 
Hz, 1H, H-6b), 2.21, 2.08, 2.07, 2.05 (4 s, 12H, 4 COCH3), 1.24 (t, J = 7.1 Hz, 3H, CH3); 
13C NMR (126 MHz, CDCl3): G = 170.51, 169.91, 169.76, 169.75, 160.31 (5 CO), 
150.88, 136.14, 129.59, 128.64, 125.88, 123.93, 123.78, 119.04, 116.18, 109.46 (C-Ar), 
96.83 (C-1), 69.85 (C-5), 69.30 (C-2), 68.73 (C-3), 65.79 (C-4), 62.07 (C-6), 60.02 
(OCH2), 20.85, 20.71, 20.67 (4C, 4 COCH3), 14.26 (CH3); ESI-MS: m/z: Calcd for 
C27H30ClNNaO12 >M+Na@+: 618.13, found: 618.18. 
 
Ethyl 1-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)-3-chlorophenyl]-4-
methyl-1H-pyrrole-2-carboxylate (40d). Prepared according to general procedure C 
from 39 and methyl 4-methyl-1H-pyrrole-2-carboxylate (20d). Yield: 67 mg (64%) as 
colorless oil. Rf 0.30 (petrol ether/EtOAc, 2:1); [D]D20 + 47.8 (c 0.7, EtOAc); 1H NMR 
(500 MHz, CDCl3): G = 7.36 (d, J = 2.4 Hz, 1H, Ar-H), 7.20 (d, J = 8.8 Hz, 1H, Ar-H), 
7.15 (dd, J = 8.7, 2.5 Hz, 1H, Ar-H), 6.91 (d, J = 1.6 Hz, 1H, Ar-H), 6.67 (d, J = 0.9 Hz, 
1H, Ar-H), 5.62 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 5.57 (d, J = 1.6 Hz, 1H, H-1), 5.53 (dd, J 
= 3.4, 1.9 Hz, 1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.31 (dd, J = 12.3, 5.3 Hz, 1H, H-
6a), 4.20 (ddd, J = 10.1, 5.2, 2.2 Hz, 1H, H-5), 4.18-4.08 (m, 3H, OCH2, H-6b), 2.21, 
2.11, 2.08, 2.07, 2.05 (5 s, 15H, 5 CH3), 1.23 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 
MHz, CDCl3): G = 170.52, 169.91, 169.75, 160.32 (5C, 5 CO), 150.69, 136.26, 128.55, 
128.10, 125.80, 123.86, 123.18, 120.00, 119.90, 116.17 (C-Ar), 96.86 (C-1), 69.83 (C-5), 
69.32 (C-2), 68.75 (C-3), 65.81 (C-4), 62.08 (C-6), 59.90 (OCH2), 20.85, 20.71, 20.68 
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(4C, 4 COCH3), 14.27, 11.43 (2 CH3); ESI-MS: m/z: Calcd for C28H32ClNNaO12 
>M+Na@+: 632.15, found: 632.16. 
 
Methyl 1-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)-3-chlorophenyl]-1H-
pyrrole-3-carboxylate (40e). Prepared according to general procedure C from 39 and 
methyl 1H-pyrrole-3-carboxylate (20e). Yield: 87 mg (99 %) as colorless oil. Rf 0.42 
(petrol ether/EtOAc, 3:2); [D]D20 + 62.5 (c 0.8, EtOAc); 1H NMR (500 MHz, CDCl3): G = 
7.60 (m, 1H, Ar-H), 7.48 (d, J = 1.4 Hz, 1H, Ar-H), 7.26 (d, J = 0.9 Hz, 2H, Ar-H), 6.95 
(m, 1H, Ar-H), 6.74 (dd, J = 3.0, 1.6 Hz, 1H, Ar-H), 5.61 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 
5.57 (d, J = 1.6 Hz, 1H, H-1), 5.54 (dd, J = 3.4, 1.9 Hz, 1H, H-2), 5.41 (t, J = 10.1 Hz, 
1H, H-4), 4.29 (dd, J = 12.3, 5.3 Hz, 1H, H-6a), 4.19 (ddd, J = 10.1, 5.2, 2.2 Hz, 1H, H-
5), 4.11 (m, 1H, H-6b), 3.84 (s, 3H, OCH3), 2.22, 2.08, 2.05 (3s, 12H, 4 COCH3); 13C 
NMR (126 MHz, CDCl3): G = 170.39, 169.92, 169.76, 169.70, 164.82 (5 CO), 150.06, 
135.81, 125.51, 124.30, 123.31, 120.62, 120.18, 118.29, 117.85, 111.92 (C-Ar), 96.93 (C-
1), 69.92 (C-5), 69.22 (C-2), 68.66 (C-3), 65.74 (C-4), 62.08 (C-6), 51.25 (OCH3), 20.83, 
20.68, 20.66 (4C, 4 COCH3); ESI-MS: m/z: Calcd for C26H28ClNNaO12 >M+Na@+: 604.12, 
found: 604.21. 
 
1-[3-Chloro-4-(D-D-mannopyranosyloxy)phenyl]-1H-pyrrole-3-carbonitrile (41a). 
Prepared according to general procedure D from 40a. Yield: 15 mg (65%) as white solid. 
Rf 0.33 (DCM/MeOH, 8:1); [D]D20 +65.8  (c 1.1, MeOH); 1H NMR (500 MHz, CD3OD): 
G = 7.86 (m, 1H, Ar-H), 7.68 (d, J = 2.6 Hz, 1H, Ar-H), 7.52 (d, J = 8.9 Hz, 1H, Ar-H), 
7.47 (dd, J = 8.9, 2.7 Hz, 1H, Ar-H), 7.28 (dd, J = 3.0, 2.3 Hz, 1H, Ar-H), 6.63 (dd, J = 
1.6, 3.0 Hz, 1H, Ar-H), 5.61 (d, J = 1.7 Hz, 1H, H-1), 4.13 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 
4.00 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.84-3.70 (m, 3H, H-4, H-6), 3.64 (ddd, J = 9.7, 5.6, 
2.3 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD): G = 152.48, 135.71, 128.46, 125.83, 
124.14, 122.82, 121.82, 119.17, 117.18, 114.15 (Ar-C, CN), 100.97 (C-1), 95.65 (Ar-C), 
76.15 (C-5), 72.38 (C-3), 71.78 (C-2), 68.20 (C-4), 62.68 (C-6); ESI-MS: m/z: Calcd for 
C17H17ClN2NaO6 >M+Na@+: 403.0667, found: 403.0669. 
 
1-[3-Chloro-4-(D-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-3-carbonitrile 
(41b). Prepared according to general procedure D from 40b. Yield: 6 mg (38%) as white 
solid. Rf 0.32 (DCM/MeOH, 8:1); [D]D20 +50.0 (c 0.3, MeOH); 1H NMR (500 MHz, 
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CD3OD): G = 7.63 (d, J = 2.4 Hz, 1H, Ar-H), 7.52 (d, J = 2.7 Hz, 1H, Ar-H), 7.37 (d, J = 
8.9 Hz, 1H, Ar-H), 7.31 (dd, J = 8.9, 2.7 Hz, 1H, Ar-H), 6.96 (dd, J = 2.3, 1.1 Hz, 1H, 
Ar-H), 5.47 (d, J = 1.7 Hz, 1H, H-1), 4.00 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 3.87 (dd, J = 
9.5, 3.4 Hz, 1H, H-3), 3.72-3.57 (m, 3H, H-4, H-6), 3.52 (ddd, J = 9.7, 5.6, 2.3 Hz, 1H, 
H-5), 2.11 (d, J = 0.9 Hz, 3H, CH3); 13C NMR (126 MHz, CD3OD): G = 152.22, 135.83, 
127.72, 125.82, 125.01, 123.71, 121.39, 120.31, 119.21, 116.77 (Ar-C, CN), 101.00 (C-
1), 96.96 (Ar-C), 76.12 (C-5), 72.38 (C-3), 71.79 (C-2), 68.21 (C-4), 62.68 (C-6), 10.44 
(CH3); ESI-MS: m/z: Calcd for C18H19ClN2NaO6 >M+Na@+: 417.0824, found: 417.0824. 
 
Ethyl 1-[3-chloro-4-(D-D-mannopyranosyloxy)phenyl]-1H-pyrrole-2-carboxylate 
(41c). Prepared according to general procedure D from 40c. Yield: 21 mg (91%) as white 
solid. Rf 0.32 (DCM/MeOH, 8:1); [D]D20 +77.6 (c 0.4, MeOH); 1H NMR (500 MHz, 
CD3OD): G = 7.32 (d, J = 8.8 Hz, 1H, Ar-H), 7.27 (d, J = 2.5 Hz, 1H, Ar-H), 7.10 (dd, J = 
8.8, 2.6 Hz, 1H, Ar-H), 6.97 (dd, J = 3.9, 1.7 Hz, 1H, Ar-H), 6.92 (m, 1H, Ar-H), 6.19 
(dd, J = 3.9, 2.7 Hz, 1H, Ar-H), 5.49 (d, J = 1.5 Hz, 1H, H-1), 4.06-3.98 (m, 3H, H-2, 
OCH2), 3.90 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.73-3.60 (m, 3H, H-4, H-6), 3.55 (ddd, J = 
9.7, 5.3, 2.4 Hz, 1H, H-5), 1.08 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, CD3OD): 
G = 162.04 (CO), 152.92, 136.88, 131.36, 129.36, 127.08, 124.87, 124.35, 120.38, 
117.82, 110.44 (Ar-C), 100.99 (C-1), 76.06 (C-5), 72.41 (C-3), 71.84 (C-2), 68.19 (C-4), 
62.66 (C-6), 61.15 (OCH2), 14.52 (CH3); HRMS: m/z: Calcd for C19H22ClNNaO8 
>M+Na@+: 450.0926, found: 450.0926. 
 
Ethyl 1-[3-chloro-4-(D-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-2-
carboxylate (41d). Prepared according to general procedure D from 40d. Yield: 14 mg 
(61%) as white solid. Rf 0.21 (DCM/MeOH, 8:1); [D]D20 +71.2 (c 0.4, MeOH); 1H NMR 
(500 MHz, CD3OD): G = 7.30 (d, J = 8.8 Hz, 1H, Ar-H), 7.23 (d, J = 2.5 Hz, 1H, Ar-H), 
7.06 (dd, J = 8.8, 2.6 Hz, 1H, Ar-H), 6.79 (d, J = 1.5 Hz, 1H, Ar-H), 6.70 (d, J = 0.9 Hz, 
1H, Ar-H), 5.48 (d, J = 1.4 Hz, 1H, H-1), 4.05-3.95 (m, 3H, H-2, OCH2), 3.89 (dd, J = 
9.5, 3.4 Hz, 1H, H-3), 3.73-3.59 (m, 3H, H-4, H-6), 3.55 (ddd, J = 9.7, 5.3, 2.4 Hz, 1H, 
H-5), 1.07 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, CD3OD): G = 162.08 (CO), 
152.74, 137.00, 129.86, 129.27, 126.98, 124.31, 124.30, 121.32, 121.14, 117.82 (Ar-C), 
101.01 (C-1), 76.04 (C-5), 72.41 (C-3), 71.85 (C-2), 68.19 (C-4), 62.65 (C-6), 61.05 
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(OCH2), 14.53, 11.47 (2 CH3); HRMS: m/z: Calcd for C20H24ClNNaO8 >M+Na@+: 
464.1083, found: 464.1083. 
 
Methyl 1-[3-chloro-4-(D-D-mannopyranosyloxy)phenyl]-1H-pyrrole-3-carboxylate 
(41e). Prepared according to general procedure D from 40e. Yield: 24 mg (83%) as white 
solid. Rf 0.27 (DCM/MeOH, 8:1); [D]D20 +82.0 (c 0.4, MeOH); 1H NMR (500 MHz, 
CD3OD): G = 7.77 (m, 1H, Ar-H), 7.63 (d, J = 2.6 Hz, 1H, Ar-H), 7.49 (d, J = 8.9 Hz, 1H, 
Ar-H), 7.43 (dd, J = 8.9, 2.7 Hz, 1H, Ar-H), 7.17 (m, 1H, Ar-H), 6.70 (dd, J = 3.0, 1.6 
Hz, 1H, Ar-H), 5.59 (d, J = 1.4 Hz, 1H, H-1), 4.14 (dd, J = 3.2, 1.8 Hz, 1H, H-2), 4.01 
(dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.89-3.70 (m, 6H, OCH3, H-4, H-6), 3.66 (ddd, J = 9.6, 
5.5, 2.2 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD): G = 167.05 (CO), 152.10, 136.30, 
125.80, 125.77, 123.74, 122.21, 121.45, 119.25, 118.82, 112.50 (Ar-C), 101.01 (C-1), 
76.11 (C-5), 72.40 (C-3), 71.80 (C-2), 68.23 (C-4), 62.69 (C-6), 51.76 (OCH3); HRMS: 
m/z: Calcd for C18H20ClNNaO8 >M+Na@+: 436.0770, found: 436.0768. 
 
Sodium 1-[3-chloro-4-(D-D-mannopyranosyloxy)phenyl]-1H-pyrrole-2-carboxylate 
(42). Prepared according to general procedure E from 40c. Yield: 14 mg (58%) as white 
solid. [D]D20 +73.8 (c 0.4, MeOH); 1H NMR (500 MHz, CD3OD): G = 7.42 (d, J = 8.8 Hz, 
1H, Ar-H), 7.39 (d, J = 2.5 Hz, 1H, Ar-H), 7.23 (dd, J = 8.8, 2.6 Hz, 1H, Ar-H), 7.02 (dd, 
J = 3.8, 1.7 Hz, 1H, Ar-H), 6.98 (m, 1H, Ar-H), 6.27 (dd, J = 3.7, 2.8 Hz, 1H, Ar-H), 5.59 
(d, J = 1.4 Hz, 1H, H-1), 4.13 (dd, J = 3.2, 1.8 Hz, 1H, H-2), 4.01 (dd, J = 9.5, 3.4 Hz, 
1H, H-3), 3.87-3.72 (m, 3H, H-4, H-6), 3.68 (ddd, J = 9.8, 5.3, 2.3 Hz, 1H, H-5); 13C 
NMR (126 MHz, CD3OD): G = 152.63, 137.37, 130.26, 129.02, 126.80, 124.31, 119.52, 
117.95, 110.01, 101.39 (Ar-C), 101.09 (C-1), 76.01 (C-5), 72.41 (C-3), 71.87 (C-2), 
68.22 (C-4), 62.67 (C-6); HRMS: m/z: Calcd for C17H18ClNNaO8 >M+Na@+: 422.0613, 
found: 422.0614. 
 
Sodium 1-[3-chloro-4-(D-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-2-
carboxylate (43). Prepared according to general procedure E from 40d. Yield: 8 mg 
(40%) as white solid. [D]D20 +74.5 (c 0.4, MeOH); 1H NMR (500 MHz, CD3OD): G = 
7.39-7.30 (m, 2H, Ar-H), 7.19 (dd, J = 8.7, 2.6 Hz, 1H, Ar-H), 6.63 (d, J = 1.6 Hz, 1H, 
Ar-H), 6.59 (d, J = 0.9 Hz, 1H, Ar-H), 5.54 (d, J = 1.5 Hz, 1H, H-1), 4.12 (dd, J = 3.3, 1.8 
Hz, 1H, H-2), 4.00 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.85-3.72 (m, 3H, H-4, H-6), 3.69 
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(ddd, J = 9.7, 5.0, 2.4 Hz, 1H, H-5), 2.09 (s, 3H, CH3); 13C NMR (126 MHz, CD3OD): G 
= 151.72, 138.57, 128.27, 126.05, 125.42, 124.18, 119.79, 117.99 (10C, Ar-C), 101.40 
(C-1), 75.89 (C-5), 72.41 (C-3), 71.91 (C-2), 68.28 (C-4), 62.62 (C-6), 11.72 (CH3); 
HRMS: m/z: Calcd for C18H20ClNNaO8 >M+H@+: 436.0770, found: 436.0774. 
 
Sodium 1-[3-chloro-4-(D-D-mannopyranosyloxy)phenyl]-1H-pyrrole-3-carboxylate 
(44). Prepared according to general procedure E from 41e. Yield: 6 mg (20%) as white 
solid. [D]D20 +92.6 (c 0.4, MeOH); 1H NMR (500 MHz, CD3OD): G = 7.74 (t, J = 1.9 Hz, 
1H, Ar-H), 7.66 (d, J = 2.6 Hz, 1H, Ar-H), 7.51 (d, J = 8.9 Hz, 1H, Ar-H), 7.46 (dd, J = 
8.9, 2.6 Hz, 1H, Ar-H), 7.17 (t, J = 2.7 Hz, 1H, Ar-H), 6.71 (dd, J = 3.0, 1.6 Hz, 1H, Ar-
H), 5.59 (d, J = 1.4 Hz, 1H, H-1), 4.13 (dd, J = 3.2, 1.8 Hz, 1H, H-2), 4.00 (dd, J = 9.5, 
3.4 Hz, 1H, H-3), 3.86-3.70 (m, 3H, H-4, H-6), 3.66 (m, 1H, H-5); 13C NMR (126 MHz, 
CD3OD): G = 152.03, 136.54, 125.81, 125.70, 123.72, 121.96, 121.43, 119.29, 112.84 
(10C, Ar-C), 101.06 (C-1), 76.11 (C-5), 72.39 (C-3), 71.82 (C-2), 68.23 (C-4), 62.69 (C-
6); HRMS: m/z: Calcd for C17H18ClNNaO8 >M+H@+: 422.0613, found: 422.0612. 
 
Ethyl 1-[4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)-3-
(trifluoromethyl)phenyl]-4-methyl-1H-pyrrole-3-carboxylate (47). Prepared according 
to general procedure C from 34 and methyl 4-methyl-1H-pyrrole-3-carboxylate (20f). 
Yield: 55 mg (49%) as colorless oil. Rf 0.48 (petrol ether/EtOAc, 3:2); [D]D20 + 60.9 (c 
1.1, EtOAc); 1H NMR (500 MHz, CDCl3): G = 7.63 (d, J = 2.6 Hz, 1H, Ar-H), 7.58 (d, J 
= 2.5 Hz, 1H, Ar-H), 7.51 (dd, J = 8.9, 2.6 Hz, 1H, Ar-H), 7.34 (d, J = 8.9 Hz, 1H, Ar-H), 
6.78 (d, J = 1.3 Hz, 1H, Ar-H), 5.65 (d, J = 1.5 Hz, 1H, H-1), 5.54 (dd, J = 10.1, 3.4 Hz, 
1H, H-3), 5.48 (dd, J = 3.3, 1.9 Hz, 1H, H-2), 5.42 (t, J = 10.1 Hz, 1H, H-4), 4.35-4.25 
(m, 3H, OCH2, H-6a), 4.13-4.04 (m, 2H, H-5, H-6b), 2.33 (d, J = 0.5 Hz, 3H, CH3), 2.22, 
2.07, 2.06, 2.05 (4 s, 12H, 4 COCH3), 1.36 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, 
CDCl3): G = 170.49, 170.01, 169.83, 169.72, 165.04 (5 CO), 151.44, 134.91, 125.23, 
124.86, 123.82, 121.65, 121.48, 121.23, 119.93, 119.89, 119.13, 117.48, 116.89 (Ar-C, 
CF3), 96.15 (C-1), 70.12 (C-5), 69.20 (C-2), 68.60 (C-3), 65.63 (C-4), 62.12 (C-6), 59.76 
(OCH2), 20.93, 20.78, 20.73 (4C, 4 COCH3), 14.60, 11.81 (2 CH3); ESI-MS: m/z: Calcd 
for C29H32F3NNaO12 >M+Na@+: 666.18, found: 666.22. 
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Ethyl 1-[4-(D-D-mannopyranosyloxy)-3-(trifluoromethyl)phenyl]-4-methyl-1H-
pyrrole-3-carboxylate (49). Prepared according to general procedure D from 47. Yield: 
17 mg (85%) as white solid. Rf 0.41 (DCM/MeOH, 8:1); [D]D20 +84.6 (c 0.4, MeOH); 1H 
NMR (500 MHz, CD3OD): G = 7.74 (dd, J = 4.9, 2.7 Hz, 3H, Ar-H), 7.64 (m, 1H, Ar-H), 
7.02 (d, J = 1.3 Hz, 1H, Ar-H), 5.64 (d, J = 1.3 Hz, 1H, H-1), 4.29 (q, J = 7.1 Hz, 2H, 
OCH2), 4.07 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.94 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.83 (dd, 
J = 12.0, 2.3 Hz, 1H, H-6a), 3.80-3.71 (m, 2H, H-4, H-6b), 3.60 (m, 1H, H-5), 2.31 (s, 
3H, CH3), 1.38 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (126 MHz, CD3OD): G = 166.97 (CO), 
135.32, 126.78, 126.29, 124.35, 120.70, 118.75, 117.82 (11C, Ar-C, CF3), 100.59 (C-1), 
76.17 (C-5), 72.22 (C-3), 71.70 (C-2), 68.11 (C-4), 62.71 (C-6), 60.76 (OCH2), 14.77, 
11.92 (2 CH3); HRMS: m/z: Calcd for C21H24F3NNaO8 >M+Na@+: 498.1346, found: 
498.1347. 
 
Sodium 1-[4-(D-D-mannopyranosyloxy)-3-(trifluoromethyl)phenyl]-4-methyl-1H-
pyrrole-3-carboxylate (51). Prepared according to general procedure E from 49. Yield: 7 
mg (35%) as white solid. [D]D20 + 96.6 (c 0.4, MeOH); 1H NMR (500 MHz, CD3OD): G = 
7.77-7.69 (m, 3H, Ar-H), 7.63 (d, J = 9.8 Hz, 1H, Ar-H), 7.01 (d, J = 1.2 Hz, 1H, Ar-H), 
5.64 (d, J = 1.2 Hz, 1H, H-1), 4.07 (dd, J = 3.2, 1.8 Hz, 1H, H-2), 3.94 (dd, J = 9.5, 3.4 
Hz, 1H, H-3), 3.88-3.70 (m, 3H, H-4, H-6), 3.61 (m, 1H, H-5), 2.31 (s, 3H, CH3); 13C 
NMR (126 MHz, CD3OD): G = 135.42, 126.76, 126.55, 124.58, 120.63, 118.77 (11C, Ar-
C, CF3), 100.62 (C-1), 76.18 (C-5), 72.23 (C-3), 71.71 (C-2), 68.13 (C-4), 62.72 (C-6), 
11.90 (CH3); HRMS: m/z: Calcd for C19H20F3NNaO8 >M+H@+: 470.1033, found: 
470.1039. 
 
HPLC data for the target compounds: 
 
System: Beckman Coulter Gold, consisting of pump 126, DAD 168 (190-400 nm) and 
auto-sampler 508. Column: Waters Atlantis T3, 3 Pm, 2.1 u 100 mm. A: H2O + 0.1% 
TFA; B: MeCN + 0.1% TFA. 
Gradient A: 0% B o 95% B (20 min); 95% B (2 min); 95% B o 5% B (3 min); 5% B o 
0% B (2 min); flow rate: 0.5 mL/min. 
Gradient B: 0% B o 70% B (20 min); 70% B (2 min); 70% B o 5% B (3 min); 5% B o 
0% B (2 min); flow rate: 0.5 mL/min. 
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Gradient C: 0% B o 50% B (20 min); 50% B (2 min); 50% B o 5% B (3 min); 5% B o 
0% B (2 min); flow rate: 0.5 mL/min. 
 
Table S1. HPLC data for the target compounds. 
Compound Formula Gradient Retention [min] Detection 
Purity 
[%] 
7a C20H21ClO8 A 17.53 298 nm 99.2 
7b C19H18ClNaO8 B 16.75 298 nm 99.8 
8a C20H21ClO8 A 17.35 294 nm 99.6 
8b C19H18ClNaO8 A 15.43 254 nm 98.8 
23a C16H19N3O8 C 9.72 272 nm 100 
23b C16H18ClN3O8 B 15.50 254 nm 97.7 
23c C17H20ClN3O8 A 15.05 254 nm 97.6 
24a C15H16N3NaO8 C 5.88 252 nm 100 
24b C15H15ClN3NaO8 A 12.58 254 nm 99.1 
26a C18H22N2O8 A 10.45 270 nm 95.0 
26b C19H21F3N2O8 A 12.98 254 nm 100 
27a C16H17N2NaO8 A 7.75 254 nm 100 
27b C17H16F3N2NaO8 A 10.15 254 nm 94.7 
32a C19H21NO8 C 12.07 312 nm 100 
32b C19H21NO8 B 15.82 328 nm 99.7 
32c C18H20N2O8 B 15.08 328 nm 100 
32d C18H20N2O8 C 9.42 308 nm 100 
33a C18H18NNaO8 C 2.37 248 nm 100 
33b C18H18NNaO8 A 12.25 270 nm 97.9 
33c C17H17N2NaO8 B 13.58 328 nm 100 
33d C17H17N2NaO8 C 7.28 248 nm 100 
37 C20H20F3NO8 A 10.70 254 nm 98.9 
38 C19H17F3NNaO8 A 8.10 257 nm 96.6 
41a C17H17ClN2O6 A 15.90 271 nm 100 
41b C18H19ClN2O6 A 16.73 271 nm 99.2 
41c C19H22ClNO8 A 12.42 254 nm 97.7 
41d C20H24ClNO8 A 13.33 254 nm 100 
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41e C18H20ClNO8 A 11.37 254 nm 98.6 
41f C20H24ClNO8 A 17.90 254 nm 99.0 
42 C17H17ClNNaO8 A 10.27 254 nm 98.1 
43 C18H19ClNNaO8 A 11.15 254 nm 98.8 
44 C17H17ClNNaO8 A 9.65 254 nm 99.8 
45 C18H19ClNNaO8 A 15.10 254 nm 98.4 
48 C20H25NO8 A 12.37 254 nm 99.7 
49 C21H24F3NO8 A 13.68 290 nm 100 
50 C18H20NNaO8 A 9.72 254 nm 100 
51 C19H19F3NNaO8 A 11.10 254 nm 98.6 
 
 
HPLC traces of the target compounds: 
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1H NMR spectra of the target compounds: 
1H NMR (500 MHz) of 7a 
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1H NMR (500 MHz) of 7b 
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1H NMR (500 MHz) of 8a 
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1H NMR (500 MHz) of 8b 
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1H NMR (500 MHz) of 23a 
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1H NMR (500 MHz) of 23b 
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1H NMR (500 MHz) of 23c 
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1H NMR (500 MHz) of 24a 
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1H NMR (500 MHz) of 24b 
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1H NMR (500 MHz) of 26a 
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1H NMR (500 MHz) of 26b 
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1H NMR (500 MHz) of 27a 
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1H NMR (500 MHz) of 27b 
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1H NMR (500 MHz) of 32a 
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1H NMR (500 MHz) of 32b 
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1H NMR (500 MHz) of 32c 
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1H NMR (500 MHz) of 32d 
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1H NMR (500 MHz) of 33a 
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1H NMR (500 MHz) of 33b 
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1H NMR (500 MHz) of 33c 
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1H NMR (500 MHz) of 33d 
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1H NMR (500 MHz) of 37 
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1H NMR (500 MHz) of 38 
 
 
 
Chapter 2.5   
 329 
1H NMR (500 MHz) of 41a 
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1H NMR (500 MHz) of 41b 
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1H NMR (500 MHz) of 41c 
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1H NMR (500 MHz) of 41d 
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1H NMR (500 MHz) of 41e 
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1H NMR (500 MHz) of 41f 
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1H NMR (500 MHz) of 42 
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1H NMR (500 MHz) of 43 
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1H NMR (500 MHz) of 44 
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1H NMR (500 MHz) of 45 
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1H NMR (500 MHz) of 48 
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1H NMR (500 MHz) of 49 
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2.6   Paper 4: Kinetic Properties of Carbohydrate – Lectin Interactions: 
FimH Antagonists 
 
 
This report describes the kinetic study on the interactions between FimH and the 
synthesized FimH antagonists. Three lead structures were chosen and immobilized on 
sensor chips via amine-coupling procedure. The kinetic properties of FimH antagonists 
were examined by surface plasmon resonance. 
 
Contributions to this project: 
Lijuan Pang synthesized the amide-chain functionalized compound 2 and the test 
compounds 8-13. 
 
This paper was published in ChemMedChem: 
 
Scharenberg, M.; Jiang, X.; Pang, L.; Navarra, G.; Rabbani, S.; Binder, F.; Schwardt, O.; 
Ernst, B.  Kinetic properties of carbohydrate – lectin interactions: FimH antagonists. 
ChemMedChem 2014, 9, 78-83. 
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2.7 Combinatorial Library Screening of FimH Antagonists: an 
Application of Protein-Directed Dynamic Strategy 
 
This chapter describes an extensive exploration on structural diversity of FimH 
antagonists. The structural modifications were carried out for both the sugar moiety and 
the aglycone. Acylhydrazone formation reaction was applied for the establishment of 
combinatorial libraries of FimH antagonists. Furthermore, the dynamic combinatorial 
libraries were in situ generated and screened against both the native full-length FimH and 
its lectin domain. 
As a result, thiophene derivatives 42/43c with an acylhydrazone linkage were 
demonstrated to be highly effective candidates for further in vitro and in vivo studies. 
 
Contributions to this project: 
Lijuan Pang designed the structural modifications and synthesized all the reported 
compounds except compound 13a. She also designed and performed the dynamic 
combinatorial experiments for in situ generation and screening of FimH antagonists. 
Furthermore, she tested the binding affinity of all the target compounds with a 
competitive fluorescence polarization assay.  
 
Keywords: Urinary tract infections, uropathogenic Escherichia coli, native full-length 
FimH, FimH antagonists, lead discovery, lead optimization, dynamic combinatorial 
chemistry, dynamic combinatorial library, fluorescence polarization assay, isothermal 
titration calorimetry. 
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2.7.1 Introduction 
 
Urinary tract infections (UTIs) are among the most prevalent infectious diseases affecting 
millions of people each year.1, 2 The leading cause of UTI is uropathogenic Escherichia 
coli (UPEC), which make up 70-95% of diagnosed cases.3 UTIs are treated with 
antibiotics,4, 5 however, recurrent infections of UPEC followed by repeated antibiotic 
exposure often lead to the emergence of antimicrobial resistance, and consequently to 
treatment failure.6, 7  
 
UPEC express filamentous surface organelles, called type 1 pili (fimbriae), which act as 
highly efficient adhesion tools for UPEC inhabiting in host cells.8 At the tips of these pili, 
a bacterial lectin, FimH, is located. FimH binds to oligomannoside containing 
glycoproteins, mainly uroplakin-Ia (UPIa), and thus mediates UPEC adhesion to the 
urinary bladder mucosa.9 This adhesion prevents the clearance of E. coli by the flow of 
urine and facilitates UPEC invasion.10, 11 Blocking FimH with carbohydrates or 
glycomimetics inhibits UPEC adhesion and therefore prevents bacterial infection.12 The 
anti-adhesive agent doesn’t act by killing or preventing growth of bacteria, thus unlikely 
causing bacterial resistance. FimH antagonist therefore offers a great therapeutic potential 
in prevention and/or treatment of UTI. 
 
The development of FimH antagonists as anti-adhesive agents started more than two 
decades ago when Sharon and co-workers reported their pioneering work.13, 14 They 
explored various mono- and oligomannosides as potential antagonists for type 1 pili-
mediated bacterial adhesion and observed interactions in the micro- to millimolar range. 
In 1999, the first crystal structure of FimH was solved,15 since then numerous 
crystallographic studies have been published, greatly facilitating the discovery of high-
affinity FimH antagonists.16-18 So far, the reported FimH antagonists lead to two major 
classes of structures (Figure 2.7.1), including the long-chain alkyl mannosides (1)17 and 
the mannosides with extended aromatic aglycones (2-5).19-22 
 
Based on the reported crystal structures, the high affinity can be rationalized17, 20: First, 
the hydroxyl groups on mannose interact extensively with the binding pocket by forming 
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direct and indirect hydrogen bonds; second, the aliphatic or aromatic aglycones can be 
hosted in the “tyrosine gate” (Tyr48, Tyr137, and Ile 52) through hydrophobic 
interactions. Co-crystallization of n-butyl D-D-mannoside17 (Figure 2.7.2A) and biphenyl 
mannoside 320 (Figure 2.7.2B) suggested two docking modes23: One is the “in-docking 
mode”, that is the aliphatic aglycone inserts into the tyrosine gate and interact with both 
tyrosines (Tyr48 and Tyr137); the other is the “out-docking mode”, that is the biphenyl 
aglycone interacts only with Tyr48, and the S-S stacking of the outer aromatic ring of the 
biphenyl aglycone with Tyr48 is effected by induced fit. Whereas the optimized 
structures with extended aromatic aglycones showed nanomolar affinities toward the 
lectin domain of FimH, the reported in vitro screening assays were complicated by the 
high- and low-affinity states of FimH.24 More recently, a crystal structure of native full-
length FimH, reported by Le Trong and co-workers, elucidated that the pilin domain 
stabilizes the lectin domain in the low-affinity state, whereas the isolated lectin domain 
adopts the high-affinity state.25 These findings explained a loss of affinity of the 
developed FimH antagonists toward full-length FimH, when compared to the lectin 
domain alone.  
 
 
 
Figure 2.7.1. FimH antagonists: n-heptyl D-D-mannoside (1)17 used as reference compound; the squaric 
acid derivative 219, biphenyl derivatives 3-420, 21, and indolinylphenyl mannoside 522 exhibit nanomolar 
affinities. 
 
To further explore the structural scope and to improve binding affinities of FimH 
antagonists, we synthesized a series of modified D-D-mannosides with aliphatic or 
aromatic aglycones. Moreover, we investigated in situ generation and screening of 
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dynamic combinatorial libraries of FimH antagonists to boost the in vitro screening and 
lead optimization process. 
 
 
Figure 2.7.2. Crystal structure of A) n-butyl D-D-mannoside (PDB ID: 1UWF)17 and B) biphenyl 3 (PDB 
ID: 3MCY)20 bound to the FimH CRD. Pictures were generated with PyMOL26: the red ball represents 
water molecule; yellow dashed line represents hydrogen bonds in the ligand site. 
 
2.7.2 In Silico Docking and Structural Design 
 
In most of the reported FimH antagonists, the sugar ring is a conservative structure – 
mannose. According to the crystal structures, all of the hydroxyls on mannose are 
involved in the hydrogen-bonding network. Hence modifications on mannose ring could 
break the ligand-protein interactions and decrease the binding affinity. However, from a 
thermodynamic point of view the hydroxyl group increases desolvation penalty and 
unfavorable binding enthalpy as well. Compared to hydroxyl, halogen atoms are less 
polar, exhibiting low desolvation penalty.27 In silico docking studies with 2-halogen 
substituents on mannose showed that 2-F could form possible polar C-F bond-protein 
interaction in the binding pocket (Figure 2.7.3A).28 Moreover, 2-Cl and 2-Br could 
displace the water molecule and interact with the carbonyl of Phe1 by forming a halogen 
bond (Figure 2.7.3B, 2-Cl).  
 
Further in silico docking studies with various aglycone structures suggested either an “in-
docking mode” or an “out-docking mode” with the aliphatic or aromatic ring systems. 
Whereas the aromatic aglcones are more rigid than the aliphatic aglycones therefore 
could decrease the entropic penalty upon binding, with the aliphatic rings we could 
further explore the binding pocket and the two binding modes.  Different substitution 
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patterns were introduced through a hydrazone linkage in order to detect the optimal 
orientations of the aglycones (Figure 2.7.3C, para-substitution; Figure 2.7.3D, meta-
substitution). 
 
 
Figure 2.7.3. In silico docking studies obtained with flexible docking (VirtualDesignLab28) to the same 
FimH CRD structure; top-scored binding mode of A) heptyl 2-fluoro-D-D-mannopyranoside (13a), B) 
heptyl 2-chloro-D-D-mannopyranoside (13b), C) representative of the para-substituted acylhydrazone 
aglycone (32a), D) representative of the meta-substituted acylhydrazone aglycone (36). 
 
Starting from n-heptyl D-D-mannoside (1), we explored the modifications on both sugar 
ring and the aglycone moiety (Figure 2.7.4):  
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1) To investigate the modifications on mannose ring, we replaced the 2-hydroxyl 
with halogen substituents − F, Cl and Br − to enable either a polar interaction or 
halogen bonding. 
2) To expand the structural diversity of the aglycone and further study the binding 
modes, we introduced a series of aglycones with either aliphatic chain, or aliphatic 
/aromatic ring system.  
3) To facilitate the in vitro screening and lead optimization process, acylhydrazone 
linkages were applied, evaluated and optimized with in situ generation and 
screening of DCLs.29, 30 
 
Dynamic combinatorial library 
screening
OHO
HO
O
OH
OH Replacement of 2-OH with halogens: F, Cl, Br
R
R
R R R
R R R
R = N
N
H
Ar
O
Modificaitons on aglycone with aliphatic or aromatic ring systems
1)
2)
3)
 
Figure 2.7.4. Modifications to the sugar moiety and the aglycone of FimH antagonists by 1) replacement of 
2-OH on mannose with halogen atoms, 2) modifications on aglycone with both aliphatic and aromatic ring 
systems, 3) DCL screening of acylhyrazones. 
 
2.7.3 Chemical Synthesis 
 
2.7.3.1 Replacement of 2-OH with halogens (Scheme 2.7.1) 
 
The benzylidene protecting derivative 7 was prepared from D-D-glucose derivative 6 in 
the presence of camphorsulfonic acid and benzaldehyde dimethyl acetal in acetonitrile.31 
In a regioselective benzylation of 7, mannoside 8 with free 2-OH was obtained.32 
Triflation of the 2-OH of 8 followed by nucleophilic substitutions with ammonium or 
lithium halides gave the 2-halogen substituted compounds 9a-c.33 Compared to the 
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substitution with fluoride, the substitution with chloride and bromide proceeded more 
slowly and the reaction was not complete even after two days. Due to the same polarity of 
the triflate intermediate and the chloride/bromide products, crude 9b-c were used directly 
in the next step. Removal of benzylidene and benzyl protection yielded mannosides 10a-
c, which were acetylated under acetic anhydride/sulfuric acid condition to give acetates 
11a-c. Selective deacetylation of the anomeric hydroxyls, followed by 
trichloroacetimidation, and then mannosylation afforded the heptyl mannoside derivatives 
12a-c. Final deacetylation using Zemplén conditions gave the test compounds 13a-c. 
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Scheme 2.7.1. Reagents and conditions: a) PhCH(OMe)2, camphorsulfonic acid, CH3CN, 50°C, overnight 
(81%); b) i. nBu2SnO, toluene, reflux, 3h; ii. BnBr, CsF, DMF, rt, overnight (50%); c) i. Tf2O, pyridine, 
DCM, -20°C, 2h; ii. TBAF, THF, 50°C, overnight for 9a (50%); LiCl, NMP, rt, 2 days for 9b; TBAB, 
DMF, 60°C, 2 days for 9c; d) i. 80% AcOH/H2O, 60°C; ii. 10% Pd/C, H2 (g), MeOH/EtOAc/DCM (3:1:1), 
rt, 1h, 10a-c (90-94%); e) conc. H2SO4, Ac2O, rt, 3h, 11a-c (98% to quant.); f) i. NH4OAc, DMF, rt, 
overnight; ii. NaH, trichloroacetonitrile, DCM, rt, 2h; iii. n-heptanol, TMSOTf, DCM, 0°C to rt, 6h, 12a-c 
(70-80%); g) NaOMe, MeOH, rt, 4h, 13a-c (67-70%). 
 
2.7.3.2 Modifications with aliphatic aglycones (Scheme 2.7.2-3) 
 
Mannosylation of alcohols 15a-c, with mannosyl fluoride 23 as donor and BF3Et2O as 
promoter, yielded D-mannosides 16a-c stereo specifically. Deacetylation of 16a-c 
followed by selective protection with 2-methoxypropene and catalytic amount of p-
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toluenesulfonic acid formed 2,3:4,6-di-O-isopropylidene mannosides 17a-c. Reduction of 
the methyl ester moiety of 17a-b in the presence of diisobutylaluminium hydride afforded 
the aldehydes 18a-b, whereas the ester 17c was reduced to alcohol 20 due to high 
reactivity. Under Swern Oxidation condition alcohol 20 was converted to aldehyde 21 in 
good yield. Deprotection of isopropylidene followed by hydrazone formation under acidic 
conditions yielded the test compounds 19a-b and 22.  
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Scheme 2.7.2. Reagents and conditions: a) BF3·Et2O, hydroxycarboxylate 15a-c, DCM, 0°C to rt, 
overnight (83% for 16a, 78% for 16b, 63% for 16c); b) i. NaOMe, MeOH, rt, 4h; ii. 2,2-dimethyl 
propanone, TsOH, DMF, rt, overnight (62% for 17a, 81% for 17b, 78% for 17c); c) DIBAL-H, DCM, -
78°C (70% for 18a, 71% for 18b, 85% for 20); d) i. 80% AcOH/H2O, 60°C, 1h; ii. benzohydrazide, AcOH, 
acetonitrile/H2O (3:7), rt, overnight (87% for 19a, 92% for 19b, 50% for 22); e) (COCl)2, DMSO, TEA, 
DCM, -78°C to rt (89%). 
 
As described above, similar synthetic route was applied to introduce the 4- and 6-
membered ring systems (Scheme 2.7.3). Mannosylation of alcohols 24a-c with mannosyl 
fluoride 14 could afford the expected mannosides, however, low yields (< 25%) due to 
partially deacetylation of 14 hampered the scale-up of the reactions. Therefore, we 
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changed the mannosylation donor to perbenzoylated mannosyl bromide 23, which gave 
acceptable yields for the synthesis of 25a-c. After a series of protecting and functional 
group manipulations, the test compounds 28a-c were obtained in good to excellent yields.  
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Scheme 2.7.3. Reagents and conditions: a) hydroxycycloalkane carboxylate 24a-c, HgBr2, Hg(CN)2, DCM, 
rt, overnight (69% for 25a, 85% for 25b, 75% for 25c); b) i. NaOMe, MeOH, rt, 4h; ii. 2,2-dimethyl 
propanone, TsOH, DMF, rt, overnight (86% for 26a, 61% for 26b, 60% for 26c); c) DIBAL-H, DCM, -
78°C (74% for 27a, 54% for 27b, 98% for 27c); d) i. 80% AcOH/H2O, 60°C, 1h; ii. benzohydrazide, 
AcOH, acetonitrile/H2O (3:7), rt, 2h (quant. for 28a-c). 
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Scheme 2.7.4. Reagents and conditions: a) BF3·Et2O, DCM, 4-hydroxybenzaldehyde 29a-b or 3-
hydroxybenzaldehyde 33, 0°C to rt, overnight (82% for 30a, 72% for 30b, 95% for 34); b) NaOMe, MeOH, 
rt, 4h (quant.); c) benzohydrazide, AcOH, acetonitrile/H2O (3:7), rt, 2h (quant.). 
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2.7.3.3 Modifications with aromatic aglycones (Scheme 2.7.4-5) 
 
Hydroxylbenzaldehydes 29a-b and 33 were mannosylated with donor 14 to yield the 
benzyl mannosides 30a-b and 34 (Scheme 2.7.4). Subsequent deacetylation yielded the 
aldehydes 31a-b and 34. In the hydrazone formation reactions test compounds 32a-b and 
36 were synthesized. To synthesize the 2-F and 2-Cl aryl mannosides, peracetylated 
mannose 11a-b were firstly treated with HBr to prepare the bromide donors, which were 
mannosylated with hydroxyl benzaldehydes 29a and 33 in the presence of Ag2O to yield 
37a-b and 39a-b (Scheme 2.7.5). Deacetylation with sodium methoxide yielded the 
aldehydes 38a-b and 40a-b respectively for dynamic combinatorial screening. 
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Scheme 2.7.5. Reagents and conditions: a) i. HBr (30% in AcOH), Ac2O, AcOH, RT, overnight; ii. 29a or 
33, Ag2O, acetonitrile, 38°C, 1h (46% for 37a, 40% for 37b, 38% for 39a, 39% for 39b); g) NaOMe, 
MeOH, rt, 4h (96% for 38a, 14% for 38b, 73% for 40a, 64% for 40b). 
 
2.7.4 Biological Evaluation 
 
2.7.4.1 Isothermal titration calorimetry (ITC) with 2-halogenated mannosides.  
 
Table 2.7.1. Thermodynamic parameters of the interaction of selected FimH-antagonists with FimH-CRD-
Th-His6. 
Entry Compd 
O
X
OH
HO
HO
O  
X = 
KD 
>nM@ 
'G 
>KJ/mol@ 
'H 
>KJ/mol@ 
- T'S 
>KJ/mol@ 
Desolvation 
Penalty ('H) 
>KJ/mol@ 
1 1 OH 28 -43.1 -47.1 3.9 36.38 
2 13a F 637 -35.4 -28.2 -7.1 1.87 
3 13b Cl 1452 -33.3 -24.1 -9.3 6.90 
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4 13c Br 2142 -32.4 -21.7 -10.7 9.27 
 
To test our hypothesis regarding halogen replacement at 2-position of mannose and 
desolvation, we performed ITC experiments with compounds 1 and 13a-c (Table 2.7.1). 
ITC allows the simultaneous determination of the change in enthalpy (∆H) and the 
dissociation constant (KD) for ligand-protein binding.34, 35 The measured thermodynamic 
parameters showed that 2-halogenated heptyl mannosides (13a-c) have lower binding 
affinities than the reference compound (1), and the ranking of enthalpic term indicated 
that there is no halogen bonding with 2-Cl or 2-Br. According to previous study published 
by Cabani and coworkers, the desolvation penalty of polar groups is enthalpic driven.27 
Subtracting the desolvation penalties described in Cabani’s report showed that all 
halogen-substituents interacted comparably with FimH, again indicating no halogen 
bonding at the 2-position. 
 
2.7.4.2 Competitive fluorescence polarization assay.  
 
For a rapid evaluation of binding affinity of the modified aglycones (19a-b, 22, 28a-c, 
32a-b, 36), we used a competitive binding assay based on fluorescence polarization (FP) 
as descried in Chapter 2.4. In the FP-assay, the antagonist of interest displaces a 
fluorescent-labeled competitor from the binding site, thereby reducing fluorescence 
polarization.36 Before the measurement of fluorescence polarization, a 24 h incubation 
time was applied in the presence of the lectin domain of FimH due to the long residence 
time of FimH antagonists (t1/2 > 3.5 h),37 whereas a 3 h incubation time was used in the 
presence of the native full-length FimH due to a shorter half-life (in millisecond range).38 
These assays were performed twice for every compound with each concentration in 
duplicate. IC50 values were obtained by nonlinear least-squares regression (standard four-
parameter IC50 equation) and converted to KD using a modified Cheng-Prusoff equation.36 
The KD values observed for the test compounds 1, 19a-b, 22, 28a-c, 32a-b and 36 are 
summarized in Table 2.7.2.  
 
A comparison of the affinities between compounds 19a-b, 22 and 28a-c clearly indicates 
that both the orientation and the size of the aglycones are important factors upon binding. 
More linear structures 19a and 28a showed better affinities than the folded structures 19b 
and 28b. With the same orientation, the optimal size of the aliphatic aglycone is six-
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membered ring system (o28b), which gave eight-fold higher affinity than four-
membered ring (o28a). Furthermore, affinity improvement with aromatic aglycones 
(o32a-b) clearly indicates an optimal size and rigidity of the aglycone moieties. 
However, an affinity loss was observed with meta-substituted phenyl (36) indicating an 
unfavorable orientation. Combined the optimal size and orientation, the elongated 
aromatic aglycones with para-substituted hydrazone moiety (o32a-b) showed highest 
affinities. Additionally, an electron-withdrawing fluoro-substituent at ortho-position 
slightly increased affinity probably because of the decreased electron density of the 
phenyl ring and enhanced S-S interaction with Tyr48. To further optimize the 
acylhydrazone moiety, 32a-b were chosen as the lead structures for in situ dynamic 
combinatorial screening. 
 
Table 2.7.2. Binding affinity of FimH antagonists determined by fluorescence polarization assay.36 
Entry Compd 
O
OH
OH
HO
HO
OR  
R= 
Against the 
lectin domain of 
FimH 
KD >nM@ 
Against the full-
length FimH 
KD >μM@ 
1 1 O  28.4 2.3 
2 19a O HC N
H
N
OMe  
652.3 n.d. 
3 19b O HC N
H
N
OMe  
3548.7 n.d. 
4 22 O HC N
H
N
O  
1479.1 n.d. 
5 28a 
O
N
N
H
O
 
853.0 n.d. 
6 28b 
O
N
N
H
O
 
106.3 n.d. 
7 28c 
O
N
N
H
O
 
236.6 n.d. 
8 32a 
O
N
N
H
O
 
17.7 n.d. 
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9 32b 
O
N
N
H
O
F
 
11.7r0.1 0.29r0.01 
10 36 O N
H
N
O  
97.5 n.d. 
11 42a O
F
N
N
H
O NH
 
12.3r0.4 0.41r0.03 
12 42b O
F
N
N
H
O
O
 
9.0r3.5 0.14r0.01 
13 42c O
F
N
N
H
O
S
 
6.0r0.9 0.13r0.01 
14 42d 
O
F
N
N
H
O
tBu 
31.2r1.2 0.58r0.07 
15 50a 
O
N
N
H
O
N
Me
 
n.d. 0.47r.0.04 
16 50b 
O
N
N
H
O
S
N
Me
 
n.d. 0.36r0.05 
17 50c 
O
N
N
H
O
N
 
n.d. 0.35r0.01 
18 50d 
O
N
N
H
O
Me  
n.d. 0.40r0.15 
19 50e 
O
N
N
H
O
Cl  
n.d. 0.64r0.07 
20 50f 
O
N
N
H
O
OMe 
n.d. 0.40r0.01 
21 50g 
O
N
N
H
O
NH  
n.d. 0.42r0.02 
22 50h 
O
N
N
H
O
S
Cl
 
n.d. 0.68r0.04 
23 43c 
O
N
N
H
O
S
 
n.d. 0.21r0.02  
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2.7.5  Dynamic Combinatorial Screening 
 
To further optimize the lead structures and to explore the binding pocket of FimH, we 
applied the synthesized aldehydes (31a-b, 35, 38a-b and 40a-b) to generate DCLs.29 The 
equilibrium between aldehydes, hydrazides and acylhydrazones was established through 
the formation of acylhydrazone linkages. The reversible reaction was accelerated by 
aniline, a nucleophilic catalyst, which allows the reaction to reach equilibrium in 24 h 
under neutral conditions.30 Adaptive DCLs were synthesized in the presence of full-
length FimH or its lectin domain. The protein-template DCLs were incubated at room 
temperature for at least 48 h before HPLC analysis. Raising the pH with aqueous NaOH 
stopped the reversible reaction, at the same time, denatured the protein FimH. Compared 
with other denaturing methods, such as urea or acidic conditions, NaOH provided an 
optimal condition for quenching the reaction and releasing up to 80% of the bond ligands. 
Using a centrifuge filter, the denatured protein was filtered off and the filtrate was ready 
for HPLC analysis. Sub-libraries or individual products were synthesized for the HPLC 
assignment. Peak changes were calculated by subtracting the peak percentages of the 
blank DCL composition. Synthesizing the DCLs in the presence of bovine serum albumin 
(BSA) as control experiments produced no measurable amplification, indicating FimH 
proteins as being responsible for the component amplifications. 
 
Initial DCL experiments using aldehyde 32b and five hydrazides 41a-e were carried out 
in the presence of either native full-length FimH or its lectin domain (Scheme 2.7.6). The 
equilibration was complete in 48 h in the presence of full-length FimH. However, with 
the lectin domain of FimH the distribution of DCL-1 components were shifting after more 
than 72 h incubation time, which could be explained by the long residence time of FimH 
ligands to the lectin domain alone. To verify that the amplifications were not due to a 
kinetic selection, the lectin-domain of FimH was added to a pre-equilibrated DCL and 
similar equilibrium was achieved after 96 h. After 72 h, clear amplifications could be 
observed for both FimH targets: in each case the same acylhydrazone (42c) was selected 
as the best binder, which was amplified to ~30% of its concentration in the blank DCL, at 
the expense of nearly 30% of 42d in the DCL of full-length FimH (Scheme 2.7.6). To 
confirm the DCL-1 composition reflecting the affinity ranking, 42a-d were individually 
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synthesized, and their binding affinities towards both full-length FimH and its lectin 
domain were evaluated with a competitive fluorescence polarization assay (Entry 11-14, 
Table 2.7.2). Because the lectin domain of FimH represents the high-affinity state of 
FimH, the KD values towards the lectin domain are higher compared to the native full-
length protein. For both FimH targets, the DCL-1 amplified hydrazone 42c as the most 
active (KD: 6.0r0.9 nM vs. lectin domain of FimH, 0.13r0.01 PM vs. full-length FimH), 
and hydrazone 42d as the least active (KD: 31.2r1.2 nM vs. lectin domain of FimH, 
0.58r0.07 PM vs. full-length FimH) among the library members.  
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Scheme 2.7.6. FimH-templated DCL-1. DCL conditions: the native full-length FimH or the lectin domain 
of FimH, aldehyde 31b, acylhydrazides 41a-e (25 μM each), and aniline (10 mM) in Na-phosphate buffer 
(50mM, pH 7.0) containing <3% DMSO for 96h. 
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Scheme 2.7.7. FimH-templated DCL-2. DCL conditions: the native full-length FimH (25 μM), aldehydes 
31a, 35, 38a-b, 40a-b and acylhydrazides 41a-e (25 μM each), and aniline (10 mM) in Na-phosphate buffer 
(50mM, pH 7.0) containing <3% DMSO for 48h. 
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Scheme 2.7.8. FimH-templated DCL-3. DCL conditions: the native full-length FimH, aldehyde 31a, 
acylhydrazides 49a-h, 41c (25 μM each), and aniline (10 mM) in Na-phosphate buffer (50mM, pH 7.0) 
containing <3% DMSO for 48h. 
Further DCL experiments were investigated to study the modifications on mannose and 
substitution patterns on the aromatic aglycones. The full-length FimH-directed DCL-2 
was synthesized in the presence of aldehydes 31a, 35, 38a-b (2-F) and 40a-b (2-Cl) and 
five hydrazides 41a-e (Scheme 2.7.7). Three components marked by asterisks (32a, 43b 
and 43c) were clearly amplified, indicating the mannose with 2-OH and the para-
substituted benzaldehyde (31a) as an optimal precursor and 43c as the best binder among 
the DCL-2 components.  
Subsequently, a lead optimization DCL was synthesized with aldehyde 31a and nine 
hydrazides (41c and 49a-h) in the presence of full-length FimH (Scheme 2.7.8, DCL-3). 
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As a result, thiophene hydrazide 41c was the most positively selected fragment, 
indicating 43c as the optimized structure. Further control experiment involved BSA 
showed no clear amplification of any DCL members, indicating the positive selection 
coming from the template protein – FimH. Competitive fluorescence polarization assay 
was then performed to establish whether the amplified ligand in the FimH-directed lead-
optimization DCL indeed has high affinity toward full-length FimH (Entry 15-23, Table 
2.7.2). In the FP-assay, thiophene 43c showed the lowest KD value (0.21r0.02 PM), 
correlating with the DCL screening results. 
Figure 2.7.5. In silico docking studies obtained with flexible docking (VirtualDesignLab28) to the same 
FimH CRD structure; top-scored binding mode of A) 42c and B) 28b. 
To gain a molecular insight into the affinity difference between the hydrazones we carried 
out further in silico docking studies with VirtualDesignLab.28 An “out-docking mode” 
was revealed for thiophenes 42/43c, and a strong S-S stacking of the acylhydrazone 
linkage with Tyr48 was observed (Figure 2.7.5A). As previously reported,39 an ortho-
substitution on the phenyl moiety adjacent to the anomeric center could interact with the 
empty space of the protein surface, which explained the affinity improvement of the 
substituted ligand 42c (ortho-F, KD: 0.13r0.01 PM vs. full-length FimH) comparing to 
43c (ortho-H, KD: 0.21r0.02 PM vs. full-length FimH). With the aliphatic ring system, 
neither the acylhydrazone nor the outer phenyl ring of 28b could form S-S interaction 
with the tyrosine gate, and the binding was between the “in” and “out” docking mode due 
to an unfavorable shape of the cyclohexane moiety (Figure 2.7.5B). 
2.7.6 Conclusion 
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In this study, we have investigated a series of structurally diversified D-D-mannosides, 
aiming at exploring the binding pocket of FimH and optimizing the lead structures as 
FimH antagonists. In this regard, we firstly modified the mannose ring by replacement of 
the 2-OH with halogen atoms in order to achieve the possible polar interaction (2-F) and 
halogen bonding (2-Cl, Br). Subsequent ITC measurements of the thermodynamic 
parameters indicated unfavorable enthalpy contributions for all the halogen-replaced 
antagonists therefore confirmed mannose ring as a conservative structure for antagonizing 
FimH. Further modifications on the aglycone, i.e. introduction of the aliphatic or aromatic 
aglycones with various lengths, sizes, rigidity, and orientations, were implemented. 
Binding affinities were evaluated with a competitive fluorescence polarization assay, 
which allowed a rapid screening for the synthesized antagonists. A comparison of the 
affinities revealed the importance of the size and orientation of the aglycone, and the best 
combination was observed with the para-substituted aromatic moieties (32a-b).  
Introduction of the acylhydrazone linkages to the aglycone moieties enabled in situ 
generation and screening of DCLs, further extended the structural scope of FimH 
antagonists. The reversible formation of acylhydrazones was demonstrated to be 
compatible with the protein target FimH, and the adaptive DCLs allowed amplification 
effects directly related to the structures presented at equilibrium. The difference between 
half-lives of the antagonists toward the lectin domain and the full-length FimH resulted in 
varied reaction rates to reach the equilibrium in DCLs. Denaturing conditions were 
optimized to ensure the release of the high-affinity antagonists. To optimize the structures 
for antagonizing full-length FimH, three DCLs were applied, and 43 acylhydrazones were 
screened. As indicated in all the DCLs, the thiophene fragment (41c) was selected to form 
the best binders (42/43c). The high affinity of ligands 42/43c was further confirmed by 
the pharmacodynamic evaluation with a FP-assay, and supported by in silico docking 
results. 
In summary, our study explored the structural diversity of D-D-mannosides as FimH 
antagonists in a broad range and further confirmed the optimal substitution patterns on 
mannose and the aglycone moiety. An application of acylhydrazone DCC demonstrated 
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and thus offered a powerful tool for structural modifications of FimH antagonist and other 
lectin-targeting ligands. The optimized ligands, thiophene derivatives 42/43c, represent 
promising candidates for future in vitro and in vivo studies. 
 
2.7.7 Experimental Section 
 
General methods: NMR spectra were recorded on a Bruker Avance DMX-500 (500.1 
MHz) spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D 
methods (COSY, HSQC, HMBC). Chemical shifts are expressed in ppm using residual 
CHCl3, CHD2OD or HDO as references. Optical rotations were measured using Perkin-
Elmer Polarimeter 341. Electron spray ionization mass spectra (ESI-MS) were obtained 
on a Waters micromass ZQ. The LC/HRMS analysis were carried out using a Agilent 
1100 LC equipped with a photodiode array detector and a Micromass QTOF I equipped 
with a 4 GHz digital-time converter. Microwave-assisted reactions were carried out with 
a CEM Discover and Explorer. Reactions were monitored by TLC using glass plates 
coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or by 
charring with a molybdate solution (a 0.02 M solution of ammonium cerium sulfate 
dihydrate and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). MPLC 
separations were carried out on a CombiFlash Companion or Rf from Teledyne Isco 
equipped with RediSep normal-phase or RP-18 reversed-phase flash columns. LC-MS 
separations were done on a Waters system equipped with sample manager 2767, pump 
2525, PDA 2525 and micromass ZQ. Size-exclusion chromatography was performed on 
Bio-Gel® P-2 Gel (45-90 mm) from Bio-Rad (Reinach, Switzerland). All compounds 
used for biological assays are at least of 98% purity based on HPLC analytical results. 
Commercially available reagents were purchased from Fluka, Aldrich, Alfa Aesar or Iris 
Biotech (Germany). Solvents were purchased from Sigma-Aldrich (Buchs, Switzerland) 
or Acros Organics (Geel, Belgium) and were dried prior to use where indicated. Methanol 
(MeOH) and ethanol (EtOH) were dried by refluxing with sodium methoxide and 
distilled immediately before use. Dichloromethane (DCM) was dried by filtration over 
Al2O3 (Fluka, type 5016 A basic). Molecular sieves 4Å were activated in vacuo at 500°C 
for 1 h immediately before use. 
 
General procedure A for the preparation of mannosides 12a-c: To a solution of 11a-c 
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(1.0 equiv) in DMF (2 mL), NH4OAc (2.0 equiv) was added. The mixture was stirred at 
RT overnight. The reaction mixture was extracted with EtOAc (10 mL) and washed with 
water (10 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The 
residue was dissolved with DCM (2 mL), and added with 60% NaH in mineral oil (0.15 
equiv) and trichloroacetonitrile (10 equiv) at RT. The reaction mixture was stirred at RT 
for 1.5h. The mixture was concentrated and dried in vacuo to give the crude 
trichloroacetimidate donor. To a suspension of the crude trichloroacetimidate, n-heptanol 
(2 equiv), and molecular sieves (4 Å, 600 mg) in dry DCM (5 mL), TMSOTf (0.15 equiv) 
was added dropwise under argon. The mixture was stirred at RT for 5h, then filtered over 
Celite and concentrated. The residue was purified by MPLC on silica gel (PE/EtOAc) to 
yield 12a-c. 
 
General procedure B for deacetylation: To a solution of 12a-c, (1.0 equiv) in dry 
MeOH (5 mL) was added freshly prepared 1M NaOMe/MeOH (0.1 equiv) under argon. 
The mixture was stirred at RT until the reaction was complete (monitored by TLC), then 
neutralized with Amberlyst-15 (H+) ion-exchange resin, filtered and concentrated in 
vacuo. The residue was purified by MPLC on silica gel (DCM/MeOH 10:1-8:1) to 
affored 13a-c. 
 
General procedure C for the synthesis of 16a-c, 30a-b, 34. To an ice-cold suspension 
of 14 (200 mg, 0.57 mmol, 1.0 equiv), alcohol 15a-c or phenol 29a-b, 33 (0.52 mmol, 1.0 
equiv), and molecular sieves (4Å, 600 mg) in dry DCM (5 mL), BF3Et2O (0.3 mL, 2.44 
mmol, 4.7 equiv) was added dropwise under argon. The mixture was stirred at 0°C for 3h, 
and then at RT overnight. The reaction mixture was filtered through Celite, and then the 
filtrate was diluted with DCM (50 mL), extracted with 0.5 N aq. NaOH (50 mL), water 
(50 mL) and brine (50 mL). The organic layer was dried over Na2SO4 and concentrated in 
vacuo. The residue was purified by MPLC on silica gel (petroleum ether/EtOAc) to yield 
16a-c, 30a-b and 34. 
 
General procedure D for the synthesis of 17a-c and 26a-c. 16a-c or 25a-c was firstly 
deacetylated according to general procedure B and concentrated to afford the deacetylated 
mannosides. To a solution of the deacetylated mannoside (1.0 equiv) in 2,2-
dimethylpropanone/DMF (2:1), TsOH (0.01 equiv) was added at RT. The mixture was 
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stirred at RT overnight, diluted with EtOAc (20 mL), and washed with water (20 mL). 
The organic layer was dried over Na2SO4 and concentrated. The residue was purified by 
MPLC on silica gel (PE/EtOAc 4:1) to give 17a-c and 26a-c as colorless oil. 
 
General procedure E for DIBAL-H reduction: To a solution of 17a-c or 26a-c (0.2 
mmol, 1 equiv) in dry DCM (5 mL) at -78 °C, DIBAL-H (1M in DCM, 0.22 mL, 0.22 
mmol) was added dropwise. The reaction mixture was stirred at -78 °C for 1h, and then 
quenched with a saturated solution of potassium sodium tartrate (10 mL). The mixture 
was extracted with DCM (15 mL). The organic layer was dried over Na2SO4 and 
concentrated. The residue was purified by MPLC on silica gel (PE/EtOAc 4:1) to give 
18a-b, 20 and 27a-c. 
 
General procedure F for preparation of hydrazones 19a-b, 22, 28a-c: A solution of 
18a-b, 21, 27a-c in 80% AcOH/H2O was stirred at 60 °C for 1h. The reaction mixture 
was concentrated in vacuo to give the crude aldehyde. To a solution of aldehyde (0.02 
mmol, 1 equiv) in a mixture of acetonitrile/H2O (3:7, 2 mL), benzohydrazide (3 mg, 
0.022 mmol, 1.1 equiv) was added. The reaction mixture was stirred at RT overnight. The 
mixture was concentrated and the residue was purified by MPLC (RP-18, H2O/MeOH 1:0 
– 1:1) to give 19a-b, 22, 28a-c as white solids after final lyophilization from H2O. 
 
General procedure G for preparation of mannosides 25a-c: To a suspension of 23 (1.0 
equiv), alcohol 24a-c (1.0-1.5 equiv) and molecular sieves (4Å, 1.2 g) in dry DCM, 
HgBr2 (1.3 equiv) and Hg(CN)2 (1.3 equiv)  was added under argon. The reaction mixture 
was stirred at RT overnight. The reaction mixture was filtered through Celite and 
concentrated in vacuo. The residue was purified by MPLC on silica gel (petroleum 
ether/EtOAc) to yield 25a-c. 
 
General procedure H for preparation of mannosides 37a-b and 39a-b: To a solution 
of 11a-b (0.30 mmol, 1 equiv) in acetic acid (1.5 mL), hydrobromic acid solution (33 wt. 
% in acetic acid, 0.5 mL) was added at RT. The reaction mixture was stirred at RT 
overnight. The reaction mixture was poured into ice-water (20 mL), extracted with DCM 
(20 mL). The organic phase was washed with saturated NaHCO3 aqueous solution (20 
mL), dried with Na2SO4, and concentrated in vacuo to give the bromide intermediate. To 
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a solution of the bromide intermediate in acetonitrile (5 mL), phenol (0.36 mmol, 1.2 
equiv) and freshly prepared Ag2O (0.45 mmol, 1.5 equiv) were added. Then the mixture 
was stirred at 38 °C for 1h. The reaction mixture was filtered through Celite and 
concentrated. The residue was purified by MPLC (PE/EtOAc 1:1) to give 37a-b and 39a-
b. 
 
General procedure I for the preparation of hydrazones 32a-b, 36, 42a-d and 50a-h: 
To a mixture of the aldehyde 31a-b or 35 (5 mg, 1 equiv.) and the corresponding 
hydrazide (1 equiv.) in ethanol, a few drops of glacial acetic acid was added at RT. The 
mixture was stirred at RT overnight, and then concentrated. The residue was purified by 
MPLC (MeOH/H2O 1:2) to give 32a-b and 36. Compound 42a-d and 50a-h were 
purified directly by preparative HPLC-MS (HPLC conditions: Column: SunFireTM 5 P 
prepC18 19u150 mm, flow rate = 15 mL  min-1, gradient H2O / MeCN (0.1% formic 
acid) from 95% to 5% over 20 min). 
 
Methyl 4,6-O-benzylidene-D-D-glucopyranoside (7). Prepared according to the similar 
procedure as described in literature. 1H NMR (500 MHz, CDCl3): G 7.49 (d, J = 5.6 Hz, 
2H, Ph), 7.37 (d, J = 4.7 Hz, 3H, Ph), 5.53 (s, 1H, PhCHO2), 4.79 (d, J = 2.9 Hz, 1H, H-
1), 4.29 (dd, J = 9.8, 4.3 Hz, 1H, H-6a), 3.93 (t, J = 9.2 Hz, 1H, H-3), 3.86 - 3.77 (m, 2H, 
H-5 and H-6b), 3.74 (t, J = 10.2 Hz, 1H, H-4), 3.63 (t, J = 7.5 Hz, 1H, H-2), 3.53 - 3.43 
(m, 4H, H-4, -OCH3), 2.77 (s, 1H, OH), 2.31 (d, J = 9.4 Hz, 1H, OH). The proton NMR 
was consistent with literature data.31 
 
Methyl 3-O-benzyl-4,6-O-benzylidene-D-D-glucopyranoside (8). Prepared according to 
the similar procedure as described in literature. 1H NMR (500 MHz, CDCl3): G 7.49 (d, J 
= 5.8 Hz, 2H, Ph), 7.42 - 7.28 (m, 8H, Ph), 5.51 (s, 1H, PhCHO2), 4.78 (d, J = 12.2 Hz, 
1H, PhCHH), 4.70 (d, J = 12.2 Hz, 1H, PhCHH), 4.61 (d, J = 3.3 Hz, 1H, H-1), 4.26 (dd, 
J = 10.1, 4.8 Hz, 1H, H-6a), 4.15 (t, J = 9.3 Hz, 1H, H-3), 3.81 (td, J = 9.9, 4.8 Hz, 1H, 
H-5), 3.70 (t, J = 10.3 Hz, 1H, H-6b), 3.54 - 3.44 (m, 2H, H-2, H-4), 3.37 (s, 3H, OCH3). 
The proton NMR was consistent with literature data.32 
 
Methyl 2-deoxy-2-fluoro-3-O-benzyl-4,6-O-benzylidene-D-D-mannopyranoside (9a). 
A solution of α-D-glucopyranoside 8 (800 mg, 2.15 mmol) in CH2Cl2 (10 mL) and 
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pyridine (0.9 mL, 10.8 mmol) was cooled to −20 °C, treated with Tf2O (0.43 mL, 
2.60 mmol), stirred for 15 min at −20 °C for 2 h. A solution of the residue in CH2Cl2 was 
washed with sat. NaHCO3 aq. solution (10 mL). The organic layer was dried over Na2SO4 
and concentrated in vacuo. The triflate residue was then treated with TBAF (1M solution 
in THF, 10 mL), stirred at 50 °C for 48 h, cooled to room temperature, concentrated and 
purified by MPLC (petrol ether (PE)/EtOAc 3:1) to yield 9a (540 mg, 50%) as a colorless 
oil. 1H NMR (500 MHz, CDCl3): G 7.49 (dt, J = 4.5, 2.5 Hz, 2H, Ar), 7.43 - 7.26 (m, 8H, 
Ar), 5.63 (s, 1H, PhCHO2), 4.86 (dd, J = 7.0, 5.3 Hz, 2H, PhCHH, H-1), 4.74 (dt, 2JH,F = 
48.8, J = 2.2 Hz, 1H, H-2), 4.76 (d, J = 12.2, PhCHH), 4.33 - 4.26 (m, 1H, H-6a), 4.15 - 
4.08 (m, 1H, H-6b), 3.92 (ddd, 3JH,F = 27.8, J = 10.0, 2.7 Hz, 1H, H-3), 3.88 - 3.77 (m, 
2H, H-5, H-6b), 3.39 (s, 3H, OCH3). The proton NMR was consistent with literature 
data.33 
 
Methyl 2-deoxy-2-chloro-D-D-mannopyranoside (10b): According to the similar 
procedure for the preparation of 9a, 9b was prepared by treatment of the triflate 
intermediate (478 mg, 0.95 mmol) with LiCl (201 mg, 4.75 mmol) in N-methyl-2-
pyrrolidone (2 mL) at RT overnight. The reaction mixture was then diluted with EtOAc 
(20 mL), and washed with water (20 mL) and brine (20 mL). The organic layer was dried 
over Na2SO4, concentrated and purified by MPLC (PE/EtOAc 8:1) to give crude 9b (393 
mg). The crude 9b was treated with 80% AcOH in water (5 mL) at 60°C for 1h, and then 
concentrated in vacuo. The residue was dissolved in a mixed solvent of 
MeOH/EtOAc/DCM (3:1:1), added with 10% Pd/C (60 mg), and stirred under hydrogen 
atmosphere at RT for 1h. The reaction mixture was filtered and concentrated. The residue 
was purified by MPLC (DCM/MeOH 9:1) to yield 10b (60 mg, 32% over two steps) as 
colorless oil. [D]D = +80.22 (c = 1.5, MeOH); 1H NMR (500 MHz, MeOD): G 4.85 (s, 1H, 
H-1), 4.22 (d, J = 2.0 Hz, 1H, H-2), 3.99 (dd, J = 9.1, 3.3 Hz, 1H, H-3), 3.87 (d, J = 11.8 
Hz, 1H, H-6a), 3.71 (dd, J = 11.8, 6.1 Hz, 1H, H-6b), 3.66 (t, J = 9.5 Hz, 1H, H-4), 3.60 - 
3.53 (m, 1H, H-5), 3.42 (s, 3H); 13C NMR (126 MHz, MeOD): G 102.43(C-1), 75.22 (C-
5), 71.00 (C-3), 68.30 (C-4), 63.00 (C-2), 62.84 (C-6), 55.58 (OCH3); ESI-MS: m/z: calcd 
for C7H13ClNaO5 [M+Na]+: 235.03, found: 234.76. 
 
Methyl 2-deoxy-2-bromo-D-D-mannopyranoside (10c): According to the similar 
procedure for the preparation of 9a, 9c was prepared by treatment of the triflate 
Chapter 2.7   
 379 
intermediate (540 mg, 1.07 mmol) with nBu4NBr (700 mg, 2.14 mmol) in DMF (5 mL) at 
60°C for 48h. The reaction mixture was then diluted with EtOAc (50 mL), and washed 
with water (50 mL) and brine (50 mL). The organic layer was dried over Na2SO4, 
concentrated and purified by MPLC (PE/EtOAc 5:1) to give the crude 9c (280 mg). The 
crude product 9c was treated with 80% AcOH in water (5 mL) at 60°C for 1h, and then 
concentrated in vacuo. The residue was dissolved in a mixed solvent of 
MeOH/EtOAc/DCM (3:1:1), added with 10% Pd/C (150 mg), and stirred under hydrogen 
atmosphere at RT for 1h. The reaction mixture was filtered and concentrated. The residue 
was purified by MPLC (DCM/MeOH 10:1) to yield 10b (150 mg, 55% over two steps) as 
colorless oil. [D]D = + 53.47 (c = 0.8, EtOAc); 1H NMR (500 MHz, MeOD): G 4.96 (s, 
1H), 4.31 (dd, J = 3.8, 1.3 Hz, 1H, H-2), 3.87 (dd, J = 11.8, 2.3 Hz, 1H, H-6a), 3.82 (dd, J 
= 9.0, 3.9 Hz, 1H, H-3), 3.71 (dd, J = 11.8, 6.1 Hz, 1H, H-6b), 3.66 (t, J = 9.4 Hz, 1H, H-
4), 3.62 - 3.57 (m, 1H, H-5), 3.42 (s, 3H, CH3); 13C NMR (126 MHz, MeOD): G 102.65 
(C-1), 75.35 (C-5), 70.44 (C-3), 69.12 (C-4), 62.88 (C-6), 56.37 (C-6), 55.60 (C-2); ESI-
MS: m/z: calcd for C7H13BrNaO5 [M+Na]+: 278.98, found 278.79. 
 
2-Deoxy-2-fluoro-1,3,4,6-tetra-O-acetyl-D-D-mannopyranoside (11a): 9a (350 mg, 
0.93 mmol) was treated with 80% AcOH in water (5 mL) at 60°C for 1h, and then 
concentrated in vacuo. The residue was dissolved in a mixed solvent of 
MeOH/EtOAc/DCM (3:1:1), added with 10% Pd/C, and stirred under hydrogen 
atmosphere at RT for 1h. The reaction mixture was filtered and concentrated to afford 
crude 10a. The crude product 10a was mixed with acetic anhydride (2 mL) and conc. 
H2SO4 (63 Pl, 1.19 mmol). The reaction mixture was stirred at RT overnight, and then 
diluted with DCM (20 mL). After being washed with sat. NaHCO3 aq. solution (20 mL) 
and brine (50 mL), the organic layer was dried over Na2SO4 and concentrated in vacuo. 
The residue was purified by MPLC (PE/EtOAc 2:1) to yield 11a (276 mg, 84%) as 
colorless oil. [D]D = + 53.17 (c = 0.9, EtOAc); 1H NMR (500 MHz, CDCl3): G 6.27 (dd, 
3JH,F = 6.5 Hz, J = 2.1 Hz, 1H, H-1), 5.41 (t, J = 10.1 Hz, 1H, H-4), 5.26 (ddd, 3JH,F = 
27.9 Hz, J = 10.2, 2.6 Hz, 1H, H-3), 4.75 (dt, 2JH,F = 48.7 Hz, J = 2.4 Hz, 1H, H-2), 4.27 
(dd, J = 12.5, 4.5 Hz, 1H, H-6a), 4.11 (dd, J = 12.4, 2.4 Hz, 1H, H-6b), 4.05 (ddd, J = 
10.1, 4.4, 2.3 Hz, 1H, H-5), 2.17, 2.11, 2.09, 2.05 (4s, 12H, 4 COOCH3); 13C NMR (126 
MHz, CDCl3) G: 170.72, 170.24, 169.30, 168.04 (4 CO), 90.15 (JC,F = 31.07 Hz, C-1), 
85.93 (JC,F = 182.09 Hz, H-2), 70.75 (C-5), 69.50 (JC,F = 17.0 Hz, C-3), 65.17 (C-4), 
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61.75 (C-6), 20.84, 20.71, 20.70, 20.59 (4C, COOCH3). ESI-MS: m/z: calcd for 
C14H19FNaO9 [M+Na]+: 373.09, found: 372.98. 
 
2-Deoxy-2-chloro-1,3,4,6-tetra-O-acetyl-D-D-mannopyranoside (11b): 10b (20 mg, 
0.09 mmol) was mixed with acetic anhydride (0.25 mL) and conc. H2SO4 (7.5 Pl, 0.14 
mmol). The reaction mixture was stirred at RT overnight, and then diluted with DCM (10 
mL). After being washed with sat. NaHCO3 aq. solution (10 mL) and brine (10 mL), the 
organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified 
by MPLC (PE/EtOAc 2:1) to yield 11b (34 mg, 99%) as colorless oil. [D]D = + 27.51 (c = 
1.7, EtOAc); 1H NMR (500 MHz, CDCl3): G 6.24 (s, 1H, H-1), 5.48 (t, J = 9.9 Hz, 1H, H-
4), 5.36 (dd, J = 9.8, 3.1 Hz, 1H, H-3), 4.40 (s, 1H, H-2), 4.25 (dd, J = 12.4, 4.3 Hz, 1H, 
H-6a), 4.14 (d, J = 12.7 Hz, 1H, H-6b), 4.09 (d, J = 10.0 Hz, 1H, H-5), 2.18, 2.11, 2.10, 
2.07 (4 s, 12H, 4 COOCH3); 13C NMR (126 MHz, CDCl3): G 170.68, 170.12, 169.27, 
168.10 (4 CO), 92.91 (C-1), 71.19 (C-5), 69.24 (C-3), 64.91 (C-4), 61.88 (C-6), 56.36 (C-
2), 20.87, 20.71, 20.69, 20.61 (4 COOCH3). ESI-MS: m/z: calcd for C14H19ClNaO9 
[M+Na]+: 389.06, found: 388.97. 
 
2-Deoxy-2-bromo-1,3,4,6-tetra-O-acetyl-D-D-mannopyranoside (11c): Prepared 
according to the similar procedure of 11b from 10c (100mg, 0.39 mmol). Yield: 136 mg 
(85%). [D]D = + 20.13 (c = 0.9, EtOAc); 1H NMR (500 MHz, CDCl3): G 6.32 (d, J = 1.7 
Hz, 1H, H-1), 5.49 (t, J = 9.9 Hz, 1H, H-4), 5.20 (dd, J = 9.7, 4.0 Hz, 1H, H-3), 4.44 (dd, 
J = 4.0, 1.7 Hz, 1H, H-2), 4.24 (dd, J = 12.4, 4.6 Hz, 1H, H-6a), 4.16 (dd, J = 12.4, 2.4 
Hz, 1H, H-6b), 4.10 (ddd, J = 10.0, 4.5, 2.6 Hz, 1H, H-5), 2.17, 2.11, 2.11, 2.07 (4 s, 
12H, 4 COOCH3); 13C NMR (126 MHz, CDCl3): G 170.70, 170.07, 169.28, 168.12 (4 
CO), 93.19 (C-1), 71.33 (C-5), 68.82 (C-3), 65.63 (C-4), 61.89 (C-6), 47.82 (C-2), 20.88, 
20.77, 20.71, 20.62 (4 COOCH3). ESI-MS: m/z: calcd for C14H19BrNaO9 [M+Na]+: 
433.01, found: 432.91. 
 
Heptyl 2-deoxy-2-fluoro-3,4,6-tetra-O-acetyl-D-D-mannopyranoside (12a): Prepared 
according to general procedure A from 11a (176 mg, 0.57 mmol). Yield: 122 mg (60%) 
as colorless oil. 1H NMR (500 MHz, CDCl3): G 5.31 (t, J = 10.0 Hz, 1H, H-4), 5.25 (ddd, 
J = 28.0, 10.0, 2.5 Hz, 1H, H-3), 4.98 (dd, J = 7.0, 1.5 Hz, 1H, H-1), 4.73 (dt, J = 50.0, 
2.5 Hz, 1H, H-2), 4.27 (dd, J = 12.0, 5.0, 1H, H-6a), 4.12 (dd, J = 12.0, 2.0 Hz, 1H, H-
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6b), 3.97 (ddd, J = 9.5, 4.5, 2.0 Hz, 1H, H-5), 3.71 (dt, J = 9.5, 6.5 Hz, 1H, H-
OCH2C6H13), 3.47 (dt, J = 9.5, 6.5 Hz, 1H, H-OCH2C6H13), 2.10, 2.09, 2.04 (3s, 3 
COCH3), 1.58 (m, 2H), 1.31 (m, 8H), 0.87 (m, 3H, CH3); 13C NMR (126 MHz, CDCl3): 
G 170.75, 170.17, 169.53 (3 COCH3), 97.12 (d, J = 28.63 Hz, C-1), 87.05 (d, J = 178.25 
Hz, C-2), 69.99 (d, J = 16.5 Hz, C-3), 68.67 (OCH2C6H13), 68.41 (C-5), 65.91 (C-4), 
62.18 (C-6), 32.79, 31.71, 28.98, 25.99, 22.58, 14.06 (OCH2C6H13), 20.78, 20.74, 20.65 
(3C, COCH3); HR-MS: m/z: calcd for C19H31FNaO8 [M+Na]+: 429.1901, found: 
429.1905. 
 
Heptyl 2-deoxy-2-chloro-3,4,6-tetra-O-acetyl-D-D-mannopyranoside (12b): Prepared 
according to general procedure A from 11b (60 mg, 0.28mmol). Yield: 42 mg (35%) as 
colorless oil. [D]D = +35.0 (c = 1.3, EtOAc); 1H NMR (500 MHz, CDCl3): G 5.43 - 5.34 
(m, 2H, H-3, H-4), 4.96 (s, 1H, H-1), 4.38 (s, 1H, H-2), 4.25 (dd, J = 12.2, 4.9 Hz, 1H, H-
6a), 4.14 (d, J = 12.1 Hz, 1H, H-6b), 3.99 (s, 1H, H-5), 3.68 (dd, J = 16.3, 6.9 Hz, 1H, -
OCH- of heptyl), 3.48 (dd, J = 16.1, 6.7 Hz, 1H, -OCH- of heptyl), 2.10, 2.09, 2.05 (3 s, 
9H, 3COOCH3), 1.67 - 1.55 (m, 2H, CH2), 1.30 (d, J = 12.6 Hz, 8H, 4 CH2), 0.89 (d, J = 
6.9 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): G 170.72, 170.07, 169.50 (3 CO), 99.72 
(C-1), 69.77 (C-3), 68.88 (CH2), 68.83 (C-5), 65.60 (C-4), 62.34 (C-6), 57.70 (C-2), 
31.74, 29.28, 29.00, 26.03, 22.60 (5C, CH2), 20.79, 20.73, 20.67 (4C, CO), 14.07 (CH3); 
ESI-MS: m/z: calcd for C19H31ClNaO8 [M+Na]+: 445.16, found: 445.12. 
 
Heptyl 2-deoxy-2-bromo-3,4,6-tetra-O-acetyl-D-D-mannopyranoside (12c): Prepared 
according to general procedure A from 11c (207 mg, 0.52 mmol). Yield: 60 mg (26%) as 
colorless oil. [D]D = + 38.2 (c = 0.4, EtOAc); 1H NMR (500 MHz, CDCl3): G 5.40 (t, J = 
9.9 Hz, 1H, H-4), 5.23 (dd, J = 9.7, 4.0 Hz, 1H, H-3), 5.06 (s, 1H, H-1), 4.44 (dd, J = 4.0, 
1.3 Hz, 1H, H-2), 4.24 (dd, J = 12.2, 5.0 Hz, 1H, H-6a), 4.14 (dd, J = 12.2, 2.4 Hz, 1H, 
H-6b), 4.00 (ddd, J = 10.0, 4.9, 2.4 Hz, 1H, H-5), 3.68 (dt, J = 9.6, 6.8 Hz, 1H, -OCH-), 
3.47 (dt, J = 9.6, 6.6 Hz, 1H, -OCH-), 2.11, 2.09, 2.05 (3 s, 9H, 3 COOCH3), 1.60 (dd, J = 
14.1, 6.9 Hz, 2H, CH2), 1.37 - 1.27 (m, 8H, 4 CH2), 0.89 (t, J = 6.9 Hz, 3H, CH3); 13C 
NMR (126 MHz, CDCl3): G 170.72, 170.01, 169.50 (3 CO), 99.95 (J = 9.43 Hz, C-1), 
69.34 (C-3), 68.98 (C-5), 68.87 (OCH2), 66.28 (C-4), 62.34 (C-6), 49.71 (C-2), 31.74, 
29.31, 29.01, 26.04, 22.60 (5C, 5 CH2), 20.83, 20.74, 20.67 (3 CH3 of OAc), 14.07 (CH3); 
ESI-MS: m/z: calcd for C19H31BrNaO8 [M+Na]+: 489.11, found: 489.04. 
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Heptyl 2-deoxy-2-fluoro-D-D-mannopyranoside (13a): Prepared according to general 
prodedure B from 12a (134 mg, 0.33 mmol). Yield: 71 mg (77%). [D]D = + 75.4 (c = 0.4, 
DCM); 1H NMR (500 MHz, CDCl3): G 4.93 (dd, J = 7.5, 1.5 Hz, 1H, H-1), 4.66 (d, J = 
50.0 Hz, 1H, H-2), 3.92 – 3.82 (m, 4H, H-6a, H-6b, H-4, H-3), 3.68 (dt, J = 9.5, 6.5 Hz, 
1H, H-OCH2C6H13), 3.59 (m, 1H, H-5), 3.41 (dt, J = 9.5, 6.5 Hz, 1H, H-OCH2C6H13), 
4.21, 3.03, 2.10 (3, 4, 6-OH), 1.56 (m, 2H), 1.27 (m, 8H), 0.88 (t, J = 7.0 Hz, 3H, CH3); 
13C NMR (126 MHz, CDCl3): G 97.41 (d, J = 29.13 Hz, C-1), 89.71 (d, J = 172.63 Hz, C-
2), 71.91 (C-5), 70.82 (d, J = 17.5 Hz, C-3), 68.22 (OCH2C6H13), 67.66 (C-4), 61.73 (C-
6), 31.73, 29.30, 29.02, 25.98, 22.59, 14.06 (OCH2C6H13); HR-MS: m/z: calcd for 
C19H31FNaO8 [M+Na]+: 303.1584, found: 303.1585. 
 
Heptyl 2-deoxy-2-chloro-D-D-mannopyranoside (13b): Prepared according to general 
prodedure B from 12b (30 mg, 0.07 mmol). Yiled: 14 mg (67%) as a white solid. [D]D = 
+ 60.9 (c = 0.6, MeOH); 1H NMR (500 MHz, MeOD): G 4.94 (s, 1H, H-1), 4.22 (s, 1H, 
H-2), 4.02 (dd, J = 8.9, 2.9 Hz, 1H, H-3), 3.85 (d, J = 11.7 Hz, 1H, H-6a), 3.77 (dd, J = 
15.8, 6.9 Hz, 1H, -OCH- of heptyl), 3.74 - 3.63 (m, 2H, H-4, H-6b), 3.63 - 3.56 (m, 1H, 
H-5), 3.47 (dd, J = 15.6, 6.5 Hz, 1H, -OCH- of heptyl), 1.62 (d, J = 6.7 Hz, 2H, CH2), 
1.45 - 1.28 (m, 8H, 4 CH2), 0.93 (t, J = 6.3 Hz, 3H, CH3); 13C NMR (126 MHz, MeOD): 
G 101.31 (C-1), 75.33 (C-5), 71.09 (C-3), 69.10 (CH2), 68.35 (C-4), 63.24 (C-6), 62.86 
(C-2), 32.99, 30.62, 30.25, 27.30, 23.70 (5 CH2), 14.44 (CH3); ESI-MS: m/z: calcd for 
C13H25ClNaO5 [M+Na]+: 319.13, found: 318.86. 
 
Heptyl 2-deoxy-2-bromo-D-D-mannopyranoside (13c): Prepared according to general 
prodedure B from 12c (60 mg, 0.13 mmol). Yiled: 26 mg (60 %) as a white solid. [D]D = 
+67.5 (c = 0.8, MeOH); 1H NMR (500 MHz, MeOD): G 5.05 (s, 1H, H-1), 4.31 (dd, J = 
3.8, 1.3 Hz, 1H, H-2), 3.88 - 3.82 (m, 2H, H-3, H-6a), 3.76 (dt, J = 9.5, 6.7 Hz, 1H, -
OCH-), 3.73 - 3.60 (m, 3H, H-4, H-5, H-6b), 3.47 (dt, J = 9.5, 6.4 Hz, 1H, -OCH-), 1.67 - 
1.58 (m, 2H, CH2), 1.44 - 1.30 (m, 8H, 4 CH4), 0.93 (t, J = 7.0 Hz, 3H, CH3); 13C NMR 
(126 MHz, MeOD): G 101.54 (C-1), 75.46 (C-5), 70.53 (C-3), 69.18 (C-4), 69.15 (OCH2), 
62.90 (C-6), 56.66 (C-2), 33.00, 30.66, 30.25, 27.30, 23.70 (5 CH2), 14.45 (CH3); ESI-
MS: m/z: calcd for C13H25BrNaO5 [M+Na]+:  363.08, found: 362.94. 
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(R)-Methyl 2-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)propanoate (16a): 
Prepared according to general procedure C from 14 and methyl D-(+) lactate 15a. Yield: 
187 mg (83%) as yellow oil. [D]D = +68.8 (c = 1.4, EtOAc); 1H NMR (500 MHz, CDCl3): 
G 5.42 - 5.34 (m, 2H, H-2, H-3), 5.28 (t, J = 10.0 Hz, 1H, H-4), 4.97 (s, 1H, H-1), 4.35 (d, 
J = 7.0 Hz, 1H, -CH(CH3)-), 4.27 (dd, J = 12.2, 5.5 Hz, 1H, H-6b), 4.17 - 4.09 (m, 1H, H-
6a), 4.00 (ddd, J = 9.9, 5.4, 2.4 Hz, 1H, H-5), 2.15, 2.10, 2.05, 2.00 (4s, 12H, 4 OAc), 
1.48 (d, J = 7.0 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): G 172.17, 170.73, 169.97, 
169.91, 169.85 (5 C=O), 96.96 (C-1), 71.19 (-CH(CH3)-), 69.50 (C-5), 69.22 (C-2), 68.95 
(C-3), 66.41 (C-4), 62.65 (C-6), 52.40 (COOCH3), 21.00, 20.83 (4 OAc), 18.56 (CH3); 
ESI-MS: m/z: calcd for C18H26NaO12 [M+Na]+: 457.13, found: 457.15. 
 
(S)-Methyl 2-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)propanoate (16b): 
Prepared according to general procedure C from 14 and methyl L-(-) lactate 15b.  Yield: 
165 mg (73%) as colorless oil. [D]D = +24.9 (c = 2.8, EtOAc); 1H NMR (500 MHz, 
CDCl3): G 5.39 (dd, J = 10.1, 3.4 Hz, 1H, H-3), 5.32 (t, J = 10.0 Hz, 1H, H-4), 5.27 (dd, J 
= 3.4, 1.8 Hz, 1H, H-2), 4.90 (d, J = 1.6 Hz, 1H, H-1), 4.31 (ddd, J = 9.9, 4.3, 2.1 Hz, 1H, 
H-5), 4.26 (dd, J = 12.3, 4.3 Hz, 1H, H-6b), 4.16 (q, J = 6.8 Hz, 1H, -CH(Me)COOMe), 
4.01 (dd, J = 12.3, 2.1 Hz, 1H, H-6a), 3.74 (s, 3H, COOCH3), 2.16, 2.10, 2.05, 2.00 (4s, 
12H), 1.44 (d, J = 6.8 Hz, 3H, CH3); 13C NMR (126MHz, CDCl3): G 172.58, 170.76, 
170.12, 169.91, 169.84 (5C, 4 OAc, COOMe), 98.41 (C-1), 74.81 (-CH(Me)COOMe), 
69.84 (C-2), 69.20 (C-5), 69.08 (C-3), 65.93 (C-4), 62.20 (C-6), 52.23 (COOCH3), 20.95, 
20.82, 20.76 (4C, 4 OAc), 18.34 (CH3); ESI-MS: m/z: calcd for C18H26NaO12 [M+Na]+: 
457.13, found: 457.15. 
 
Methyl 1-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)cyclopropanecarboxylate 
(16c): Prepared according to general procedure C from 14 and methyl 1-
hydroxycyclopropanecarboxylate 15c.  [D]D = +33.4 (c = 0.7, EtOAc); 1H NMR (500 
MHz, CDCl3): G 5.37-5.32 (m, 2H, H-2, H-3), 5.26 (t, J = 9.9 Hz, 1H, H-4), 5.10 (d, J = 
1.7 Hz, 1H, H-1), 4.24 (dd, J = 12.2, 5.9 Hz, 1H, H-6b), 4.15 - 4.04 (m, 2H, H-5, H-6a), 
3.74 (s, 3H, COOCH3), 2.15, 2.10, 2.04, 2.00 (4s, 12H, 4 OAc), 1.49 (ddd, J = 10.8, 7.9, 
4.7 Hz, 1H, H-cyclopropyl), 1.40 (ddd, J = 10.4, 7.9, 4.9 Hz, 1H, H-cyclopropyl), 1.32 - 
1.27 (m, 1H, H-cyclopropyl), 1.19 (ddd, J = 10.8, 8.0, 4.9 Hz, 1H, H-cyclopropyl); 13C 
NMR (126 MHz, CDCl3): G 172.83, 170.72, 170.06, 170.00, 169.89 (5 C=O), 98.90 (C-
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1), 69.90 (C-2), 69.36 (C-5), 68.84 (C-3), 66.35 (C-4), 62.77 (C-6), 52.63 (COOCH3), 
21.04, 20.84 (4 OAc), 16.27, 15.60 (C-cyclopropyl); ESI-MS: m/z: calcd for C19H26NaO12 
[M+Na]+: 469.13, found: 469.11.  
 
(R)-Methyl 2-(2,3:4,6-bis-O-methylethylidene-D-D-mannopyranosyloxy)propanoate 
(17a): Prepared according to general procedure D from 16a (200 mg, 0.46 mmol). Yield: 
99 mg (62%) as colorless oil. [D]D = +15.3 (c = 1.5, EtOAc); 1H NMR (500 MHz, 
CDCl3): G 5.15 (s, 1H, H-1), 4.38 (q, J = 7.0 Hz, 1H, -CH(CH3)-), 4.29 (d, J = 5.6 Hz, 
1H, H-2), 4.17 (dd, J = 8.0, 5.6 Hz, 1H, H-3), 3.87 (dd, J = 10.8, 5.6 Hz, 1H, H-6b), 3.79 
- 3.71 (m, 5H, H-4, H-6a, COOCH3), 3.62 - 3.53 (m, 1H, H-5), 1.55, 1.52, (2s, 2 CH3), 
1,43 (d, J = 7.0 Hz, 6H, 2 CH3), 1.36 (s, 3H, CH3); 13C NMR (126 MHz, CDCl3): G 
172.85 (C=O), 109.63, 100.13, 99.88, 96.99 (C-1), 75.97 (C-2), 74.75 (C-3), 72.81 (C-4), 
70.30 (-CH(CH3)-), 62.11(C-5), 62.04 (C-6), 52.26 (COOCH3), 29.15, 28.30, 26.29, 
18.88, 18.84 (5 CH3); ESI-MS: m/z: calcd for C16H26NaO8 [M+Na]+: 369.15, found: 
369.04. 
 
(S)-Methyl 2-(2,3:4,6-bis-O-methylethylidene-D-D-mannopyranosyloxy)propanoate 
(17b): Prepared according to general procedure D from 16b (160 mg, 0.37 mmol). Yield: 
103 mg (81%) as yellow oil. [D]D = -25.3 (c = 1.3, EtOAc); 1H NMR (500 MHz, CDCl3): 
G 5.08 (s, 1H, H-1), 4.25 - 4.09 (m, 4H), 3.78 - 3.63 (m, 7H), 1.54 (s, 3H), 1.50 (s, 3H), 
1.45 - 1.39 (m, 6H), 1.35 (s, 3H); 13C NMR (126 MHz, CDCl3): G 173.14 (C=O), 109.50, 
99.74, 98.63 (C-1), 76.27 (C-2), 75.06 (C-3), 73.63 (C-4), 72.55 (-CH(CH3)-), 62.18 (C-
5), 61.94 (C-6), 52.23 (COOCH3), 29.14, 28.26, 26.23, 18.96, 18.19 (5 CH3); ESI-MS: 
m/z: calcd for C16H26NaO8 [M+Na]+: 369.15, found: 368.80. 
 
Methyl 1-(2,3:4,6-bis-O-methylethylidene-D-D-
mannopyranosyloxy)cyclopropanecarboxylate (17c): Prepared according to general 
procedure D from 16c (175 mg, 0.39 mmol). Yield: 96 mg (68 %) as colorless oil. [D]D = 
+61.1 (c = 1.4, EtOAc); 1H NMR (500 MHz, CDCl3): G 5.27 (s, 1H, H-1), 4.30 (d, J = 5.6 
Hz, 1H, H-2), 4.15 (dd, J = 7.6, 5.7 Hz, 1H, H-3), 3.80 (dd, J = 10.0, 5.0 Hz, 1H, H-6b), 
3.74 (s, 3H, COOCH3), 3.73 - 3.61 (m, 3H, H-4, H-5, H-6a), 1.55 (s, 3H, CH3), 1.51 (s, 
3H, CH3), 1.45 - 1.35 (m, 8H, 2H from cyclopropyl and 2 CH3), 1.33 - 1.28 (m, 1H, 
cyclopropyl), 1.19 - 1.14 (m, 1H, cyclopropyl); 13C NMR (126 MHz, CDCl3): G 173.21 
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(C=O), 109.51, 99.78, 99.08 (C-1), 76.32 (C-2), 74.90 (C-3), 72.62 (C-4), 62.40 (C-5), 
62.04 (C-6), 60.10, 52.50 (COOCH3), 29.14, 28.27, 26.30, 18.90, 16.78, 15.01 (2 -CH2- 
and 4 CH3); ESI-MS: m/z: calcd for C17H26NaO8 [M+Na]+: 381.15, found: 381.09.  
 
(R)-2-(D-D-Mannopyranosyloxy)propanal (deprotected 18a): Prepared according to 
general procedure E and F from 17a (84 mg). Yield: 28 mg (49% for two steps) as white 
solid.  [D]D = +90.4 (c = 0.7, MeOH); 1H NMR (500 MHz, CDCl3): G 5.08 (d, J = 1.4 Hz, 
1H, H-1), 4.96 (d, J = 4.3 Hz, 1H, -CH(CH3)-), 4.00 (dd, J = 3.3, 1.7 Hz, 1H, H-2), 3.91 
(d, J = 10.0 Hz, 1H, H-6b), 3.84 (dd, J = 9.6, 3.4 Hz, 1H, H-3), 3.83-3.73 (m, 3H, H-4, H-
5, H-6a), 3.66 (t, J = 9.6 Hz, 1H, -CH(OH)2-), 1.25 (d, J = 6.5 Hz, 3H, CH3); 13C NMR 
(126 MHz, CDCl3): G 100.67 (C-1), 91.38 (-CH(CH3)-), 76.65 (C-5), 73.08 (C-4), 70.40 
(C-3), 70.13 (C-2), 66.84 (-CH(OH)2-), 60.99 (C-6), 15.41 (CH3); ESI-MS: m/z: calcd for 
C9H16NaO7 [M+Na]+: 259.08, found: 258.91. 
 
(S)-2-(2,3:4,6-Bis-O-methylethylidene-D-D-mannopyranosyloxy)propanal (18b): 
Prepared according to general procedure E from 17b (70 mg). Yield: 45 mg (71%) as 
colorless oil.  [D]D = -9.4 (c = 1.1, EtOAc); 1H NMR (500 MHz, CDCl3): G 9.60 (d, J = 
1.7 Hz, 1H, CHO), 5.13 (s, 1H, C-1), 4.25 (d, J = 5.8 Hz, 1H), 4.20 (dd, J = 7.6, 5.9 Hz, 
1H), 4.04 (qd, J = 6.9, 1.7 Hz, 1H), 3.83 - 3.77 (m, 1H), 3.77 - 3.71 (m, 1H), 3.71 - 3.62 
(m, 2H), 1.54, 1.50, 1.42, 1.36 (4s, 12H, 4 CH3), 1.31 (d, J = 6.9 Hz, 3H, CH3); 13C NMR 
(126 MHz, CDCl3): G 201.33 (CHO), 109.66, 100.12, 99.87, 97.91 (C-1), 78.80, 76.16, 
74.93, 72.51, 62.25, 61.76, 29.12, 28.22, 26.20, 18.88, 14.84; ESI-MS: m/z: calcd for 
C15H24NaO7 [M+Na]+: 339.14, found: 339.02. 
 
(1-(2,3:4,6-Bis-O-methylethylidene-D-D-mannopyranosyloxy)cyclopropyl) 
methanol (20): Prepared according to general procedure E from 17c (72 mg, 0.2 mmol). 
Yield: 56 mg (85%) as a white solid. [D]D = +13.0 (c = 0.5, EtOAc); 1H NMR (500 MHz, 
CDCl3): G 5.21 (d, J = 0.4 Hz, 1H, H-1), 4.15 (t, J = 6.4 Hz, 1H, H-3), 4.03 (dd, J = 5.7, 
1.0 Hz, 1H, H-2), 3.90 (dd, J = 8.3, 6.3 Hz, 2H, H-6a, -CHOH), 3.82 - 3.70 (m, 3H, H-4, 
H-5, H-6b), 3.34 (dd, J = 12.6, 8.5 Hz, 1H, -CHOH), 2.94 (d, J = 6.7 Hz, 1H, -OH), 1.53, 
1.51, 1.42, 1.33 (4 s, 12H, 4 CH3), 1.00 (dd, J = 11.0, 5.4 Hz, 1H), 0.91 - 0.81 (m, 1H), 
0.75 (ddd, J = 10.1, 6.7, 5.7 Hz, 1H), 0.67 (ddd, J = 10.1, 6.4, 5.1 Hz, 1H) (4 H on 
cyclopropyl); 13C NMR (126 MHz, CDCl3): G 109.72, 100.13, 99.88, 98.28 (C-1), 76.68 
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(C-2), 75.01 (C-3), 72.53 (C-5), 67.91 (-CH2OH), 65.26, 62.65 (C-4), 61.90 (C-6), 29.12, 
28.19, 26.21, 18.89 (4 CH3), 13.14, 10.04 (2C on cyclopropyl); ESI-MS: m/z: calcd for 
C16H26NaO7 [M+Na]+: 353.16, found: 353.12. 
 
1-(2,3:4,6-Bis-O-methylethylidene-D-D-
mannopyranosyloxy)cyclopropanecarbaldehyde (21): To a solution of oxalyl chloride 
(10 PL, 0.12 mmol) in CH2Cl2 (1 mL) cooled at −78 °C was added dropwise a solution 
of DMSO (7.6 PL, 0.11 mmol) in CH2Cl2 (0.5 mL). After 5 min, a solution of 20 (32 
mg, 0.10 mmol) in CH2Cl2 (0.5 mL) was added. The reaction mixture was then stirred 
for 15 min at −78 C and triethylamine (67 PL, 0.49 mmol) was added. After 10 min at 
−78 C, the mixture was allowed to warm to RT and diluted with CH2Cl2 (20 mL). The 
organic layer was successively washed with a saturated aqueous solution of NH4Cl (10 
mL) and brine (10 mL). The combined organic extracts were dried over Na2SO4, and 
concentrated in vacuo. The residue was purified by MPLC on silica gel (PE/EtOAc 2:1) 
to give 21 (29 mg, 94%) as yellow oil. [D]D = +44.3 (c = 0.5, EtOAc); 1H NMR (500 
MHz, CDCl3): G 9.36 (s, 1H, CHO), 5.15 (s, 1H, H-1), 4.23 (d, J = 5.8 Hz, 1H, H-2), 4.17 
(t, J = 6.5 Hz, 1H, H-3), 3.88 - 3.81 (m, 1H, H-6a), 3.73 (tt, J = 19.8, 7.7 Hz, 3H, H-4, H-
5, H-6b), 1.58 -1.28 (m, 16H, 4 CH3, 2 CH2); 13C NMR (126 MHz, CDCl3): G 199.56 
(CO), 109.54, 99.73, 99.03 (C-1), 76.09 (C-2), 74.81 (C-3), 72.37 (C-5), 67.71 (C-4), 
62.49 (C-6), 61.72, 29.00, 28.09, 26.10, 18.76, 17.88, 14.53; ESI-MS: m/z: calcd for 
C16H24NaO7 [M+Na]+: 351.14, found: 351.09. 
 
(R,E)-N'-(2-(D-D-Mannopyranosyloxy)propylidene)benzohydrazide (19a): Prepared 
according to general procedure F from 18a (5 mg, 0.02 mmol). Yield: 4.8 mg (87%). [D]D 
= +158.7 (c = 0.2, MeOH); 1H NMR (500 MHz, MeOD): G 7.90 (d, J = 7.4 Hz, 2H, H-
Ar), 7.70 (d, J = 6.0 Hz, 1H, H-Ar), 7.61 (t, J = 7.4 Hz, 1H, H-Ar), 7.52 (t, J = 7.6 Hz, 
2H, H-Ar), 4.98 (s, 1H, H-1), 4.53 - 4.43 (m, 1H, -CH(CH3)-), 3.91 - 3.80 (m, 2H, H-2, 
H-6b), 3.77 - 3.69 (m, 2H, H-3, H-6a), 3.67-3.60 (m, 2H, H-4, H-5), 1.42 (d, J = 6.5 Hz, 
3H, CH3); 13C NMR (126 MHz, MeOD): G 154.72 (CHO), 133.32, 129.73, 128.72 (6C, 
Ar), 101.10 (C-1), 75.31 (C-5), 75.12 (-CH(CH3)-), 72.47 (C-2), 72.34 (C-3), 68.58 (C-4), 
62.96 (C-6), 18.55 (CH3); ESI-MS: m/z: calcd for C16H22N2NaO7 [M+Na]+: 377.13, 
found 377.02. 
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(S,E)-N'-(2-(D-D-Mannopyranosyloxy)propylidene)benzohydrazide (19b): Prepared 
according to general procedure F from 18b (5 mg, 0.02 mmol). Yield: 5.2 mg (90%). [D]D 
= +32.9 (c = 0.4, MeOH); 1H NMR (500 MHz, D2O): G 7.76 (d, J = 7.4 Hz, 2H, Ar), 7.64 
- 7.54 (m, 2H, Ar, CHO), 7.49 (dd, J = 16.0, 8.2 Hz, 2H, Ar), 4.90 (s, 1H, H-1), 4.51 (p, J 
= 6.5 Hz, 1H, CH(CH3)CHO), 3.91 (dd, J = 3.2, 1.7 Hz, 1H, H-2), 3.90 - 3.83 (m, 1H, H-
6a), 3.79 (dd, J = 9.3, 3.4 Hz, 1H, H-3), 3.71 (dd, J = 12.1, 6.1 Hz, 1H, H-6b), 3.68 - 3.55 
(m, 2H, H-5, H-4), 1.38 (d, J = 6.7 Hz, 3H, CH3); 13C NMR (126 MHz, D2O): G 153.53 
(CHO), 132.86, 128.91, 127.54 (6C, Ar), 97.76 (C-1), 73.19 (C-5), 71.13 
(CH(CH3)CHO), 70.41 (C-3), 70.03 (C-2), 66.80 (C-4), 61.00 (C-6), 18.17 (CH3); ESI-
MS: m/z: calcd for C16H22N2NaO7 [M+Na]+:377.13, found 377.04. 
 
(E)-N'-((1-D-D-Mannopyranosyloxycyclopropyl)methylene)benzohydrazide (22): 
Prepared according to general procedure F from 21 (25 mg, 0.07 mmol). Yield: 3 mg 
(11%). [D]D = +70.8 (c = 0.2, MeOH); 1H NMR (500 MHz, CDCl3): G 7.70 (dd, J = 28.9, 
6.7 Hz, 5H), 7.63 - 7.53 (m, 2H), 7.48 (dt, J = 12.5, 7.7 Hz, 4H), 5.12 (d, J = 1.5 Hz, 1H, 
H-1), 4.05 - 3.99 (m, 1H, H-2), 3.81 (d, J = 9.9 Hz, 1H, H, H-4), 3.78 - 3.65 (m, 3H, H-3, 
H-5, H-6a), 3.60 (dd, J = 12.7, 6.5 Hz, 1H, H-6b), 1.60 - 1.49 (m, 1H), 1.34 - 1.17 (m, 
2H), 1.17 - 1.05 (m, 1H); 13C NMR (126 MHz, D2O): G 167.29 (CO), 156.01, 132.68, 
132.21, 128.88, 128.82, 127.44, 126.98 (C-Ar), 100.74 (C-1), 73.50 (C-5), 70.23 (C-3), 
70.18 (C-2), 66.69 (C-4), 61.44 (=C(COOMe)O-), 60.95 (C-6), 15.21, 12.98 (2 CH2) 
;ESI-MS: m/z: calcd for C17H22N2NaO7 [M+Na]+: 389.13, found: 389.00. 
 
(1S,3S)-Methyl 3-(2,3,4,6-tetra-O-benzoyl-D-D-
mannopyranosyloxy)cyclobutanecarboxylate (25a): Prepared according to general 
procedure G from 23 (337 mg, 0.51 mmol) and cyclobutanecarboxylate 24a  (100 mg, 
0.77 mmol). Yield: 250 mg (69%) as colorless oil. [D]D = + 37.9 (c = 1.0, EtOAc); 1H 
NMR (500 MHz, CDCl3): G 8.15 - 8.07 (m, 2H, Ar), 8.08 - 8.03 (m, 2H, Ar), 8.01 - 7.94 
(m, 2H, Ar), 7.88 - 7.80 (m, 2H, Ar), 7.58 (dd, J = 16.5, 7.6 Hz, 2H, Ar), 7.50 (t, J = 7.4 
Hz, 1H, Ar), 7.45 - 7.32 (m, 7H, Ar), 7.26 (t, J = 7.8 Hz, 2H, Ar), 6.13 (t, J = 9.8 Hz, 1H, 
H-4), 5.93 (dd, J = 10.1, 3.3 Hz, 1H, H-3), 5.67 (dd, J = 3.0, 1.9 Hz, 1H, H-2), 5.12 (d, J 
= 1.5 Hz, 1H, H-1), 4.67 (dd, J = 13.8, 4.0 Hz, 1H, H-6a), 4.54 - 4.45 (m, 2H, H-6b, H-5), 
4.23 (t, J = 7.1 Hz, 1H, OCH(CH2)2), 2.74 - 2.55 (m, 3H, cyclobutyl), 2.47 (ddd, J = 18.1, 
13.7, 5.2 Hz, 2H, cyclobutyl); 13C NMR (126 MHz, CDCl3): G 174.46, 170.69, 170.12, 
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169.95, 169.83 (5 CO), 96.77 (C-1), 69.75 (C-2), 69.02 (C-3), 69.00 (C-5), 68.39 
(OCH(CH2)2), 66.31 (C-4), 62.60 (C-6), 52.05 (COOCH3), 34.72, 33.83, 29.33 (3 C-
cyclobutyl); ESI-MS: m/z: calcd for C40H36NaO12 [M+Na]+: 731.21, found: 731.27. 
 
(1S,4S)-Ethyl 4-(2,3,4,6-tetra-O-benzoyl-D-D-
mannopyranosyloxy)cyclohexanecarboxylate (25b): Prepared according to general 
procedure G from 23 (400 mg, 0.61 mmol) and cyclohexanecarboxylate 24b (157 mg, 
0.91 mmol). Yield: 354 mg (78%). [D]D = -35.8 (c = 1.9, EtOAc); 1H NMR (500 MHz, 
CDCl3): G 8.08 (ddd, J = 12.2, 8.2, 1.2 Hz, 4H, Ar), 7.98 (dd, J = 8.3, 1.1 Hz, 2H, Ar), 
7.84 (dd, J = 8.3, 1.2 Hz, 2H, Ar), 7.64 - 7.23 (m, 12H, Ar), 6.09 (dd, J = 12.5, 7.5 Hz, 
1H, H-4), 5.93 (dd, J = 10.1, 3.3 Hz, 1H, H-3), 5.66 (dd, J = 3.2, 1.8 Hz, 1H, H-2), 5.21 
(d, J = 1.7 Hz, 1H, H-1), 4.67 (dt, J = 3.7, 3.1 Hz, 1H, H-6a), 4.54 - 4.45 (m, 2H, H-5, H-
6b), 4.23 - 4.14 (m, 2H, COOCH2CH3), 3.95 - 3.86 (m, 1H, OCH(CH2)2), 2.46 - 1.60 (m, 
9H, cyclohexyl), 1.30 (t, J = 7.1 Hz, 3H, COOCH2CH3); 13C NMR (126 MHz, CDCl3): G 
174.98, 166.18, 165.58, 165.53, 165.48 (5CO), 133.45, 133.15, 133.06, 129.88, 129.86, 
129.74, 129.42, 129.16, 129.00, 128.59, 128.44, 128.43, 128.31 (Ar), 96.32 (C-1), 74.13 
(OCH(CH2)2), 71.18 (C-2), 70.12 (C-3), 69.13 (C-5), 67.12 (C-4), 63.05 (C-6), 60.38 
(CO2CH2CH3), 41.20 (CH(CH2)2(CO2)), 30.51, 28.64, 24.26, 24.04 (4C on cyclohexyl), 
14.30 (CO2CH2CH3); ESI-MS: m/z: calcd for C43H42NaO12 [M+Na]+: 773.26, found: 
773.45. 
 
(1R,4R)-Ethyl 4-(2,3,4,6-tetra-O-benzoyl-D-D-
mannopyranosyloxy)cyclohexanecarboxylate (25c): Prepared according to general 
procedure G from 23 (382 mg, 0.58 mmol) and cyclohexanecarboxylate 25c (100 mg, 
0.58 mmol). Yield: 328 mg (75%). [D]D = -33.3 (c = 1.0, EtOAc); 1H NMR (500 MHz, 
CDCl3): G 8.07 (ddd, J = 10.6, 8.2, 1.1 Hz, 4H, Ar), 7.97 (dd, J = 8.3, 1.1 Hz, 2H, Ar), 
7.83 (dd, J = 8.3, 1.1 Hz, 2H, Ar), 7.64 - 7.20 (m, 14H, Ar), 6.05 (t, J = 10.0 Hz, 1H, H-
4), 5.92 (dd, J = 10.1, 3.3 Hz, 1H, H-3), 5.64 (dd, J = 3.2, 1.8 Hz, 1H, H-2), 5.25 (d, J = 
1.7 Hz, 1H, H-1), 4.72 - 4.63 (m, 1H, H-6a), 4.56 - 4.43 (m, 2H, H-5, H-6b), 4.13 (q, J = 
7.1 Hz, 2H, COOCH2CH3), 3.71 (td, J = 10.1, 5.0 Hz, 1H, OCH(CH2)2), 2.28 (ddd, J = 
14.8, 7.4, 3.6 Hz, 1H, CH(CH2)2(CHO)), 2.23 - 1.37 (m, 10H, cyclohexyl), 1.26 (t, J = 
7.1 Hz, 3H, COOCH2CH3); 13C NMR (126 MHz, CDCl3): G 175.42, 166.31, 165.69 
(5CO), 133.62, 133.59, 133.32, 133.26, 130.00, 129.98, 129.88, 129.84, 129.51, 129.26, 
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129.13, 128.74, 128.61, 128.59, 128.45 (Ar), 96.24 (C-1), 76.69 (OCH(CH2)2), 71.26 (C-
2), 70.23 (C-3), 69.17 (C-5), 67.32 (C-4), 63.27 (C-6), 60.47 (CO2CH2CH3), 42.30 
(CH(CH2)2(CO2)), 32.48, 30.80, 27.17, 27.04 (4C on cyclohexyl), 14.38 (CO2CH2CH3); 
ESI-MS: m/z: calcd for C43H42NaO12 [M+Na]+: 773.26, found: 773.45. 
 
(1S,3S)-Methyl 3-(2,3:4,6-bis-O-methylethylidene-D-D-
mannopyranosyloxy)cyclobutanecarboxylate (26a): Prepared according to general 
procedure D from 25a (290 mg, 0. 41 mmol). Yield: 132 mg (86%). [D]D = + 15.2 (c = 
1.1, EtOAc); 1H NMR (500 MHz, CDCl3): G 5.02 (s, 1H, H-1, H-1), 4.15 (d, J = 3.0 Hz, 
2H, H-2, H-3), 4.12 - 4.03 (m, 1H, H-cyclobutyl), 3.82 (dd, J = 10.7, 5.6 Hz, 1H, H-6a), 
3.77 - 3.65 (m, 5H, H-4, H-5, COOCH3), 3.59 (td, J = 10.2, 5.6 Hz, 1H, H-6b), 2.72 - 
2.59 (m, 1H, H-cyclobutyl), 2.59 - 2.45 (m, 2H, H-cyclobutyl), 2.36 - 2.21 (m, 2H, H-
cyclobutyl), 1.54, 1.51, 1.43, 1.35 (4 s, 12H, 4 CH3); 13C NMR (126 MHz, CDCl3): G 
174.57 (CO), 109.43, 99.68, 96.87 (C-1), 76.05 (C-2), 74.85 (C-3), 72.68 (C-5), 67.33 (C-
cyclobutyl), 61.92 (C-4), 61.63 (C-6), 51.91 (COOCH3), 35.06, 33.51, 29.40 (3 C-
cyclobutyl), 29.05, 28.17, 26.12, 18.77 (4 CH3); ESI-MS: m/z: calcd for C18H28NaO8 
[M+Na]+: 395.17, found: 395.03. 
 
(1S,4S)-Methyl 4-(2,3:4,6-bis-O-methylethylidene-D-D-
mannopyranosyloxy)cyclohexanecarboxylate (26b): Prepared according to general 
procedure D from 25b (438 mg, 0. 58 mmol). Yield: 140 mg (60%). [D]D = + 14.4 (c = 
1.7, EtOAc); 1H NMR (500 MHz, CDCl3): G 5.11 (s, 1H, H-1), 4.21 - 4.09 (m, 2H, H-2, 
H-3), 3.87 – 3.79 (m, 2H, H-6a, OCH(CH2)2), 3.77 - 3.69 (m, 2H, H-4, H-5), 3.67 (s, 3H, 
COOCH3), 3.60 (td, J = 10.2, 5.6 Hz, 1H, H-6b), 2.41 - 2.31 (m, 1H, CH(CH2)2(CO2)), 
1.93 - 1.44 (m, 14H, cyclohexyl, 2CH3), 1.42 (s, 3H, CH3), 1.35 (s, 3H, CH3); 13C NMR 
(126 MHz, CDCl3): G 175.77 (CO), 109.37 (C(O)2(CH3)2), 99.69(C(O)2(CH3)2), 95.70 
(C-1), 76.60 (C-3), 74.88 (C-2), 72.89 (C-4), 71.01 (OCH(CH2)2), 62.08 (C-5), 61.43 (C-
6), 51.61 (COOCH3), 41.57(CH(CH2)2(CO2)), 30.68 (1C on cyclohexyl), 29.06 (CH3), 
28.24 (CH3), 27.88 (1C on cyclohexyl), 26.23 (CH3), 23.94, 23.60 (2C on cyclohexyl), 
18.79 (CH3); ESI-MS: m/z: calcd for C20H32NaO8 [M+Na]+: 423.20, found: 423.19. 
 
(1R,4R)-Methyl 4-(2,3:4,6-bis-O-methylethylidene-D-D-
mannopyranosyloxy)cyclohexanecarboxylate (26c): Prepared according to general 
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procedure D from 25c (300 mg, 0.40 mmol). Yield: 89 mg (56%). [D]D = + 37.0 (c = 1.7, 
EtOAc); 1H NMR (500 MHz, CDCl3): G 5.15 (s, 1H, H-1), 4.17 - 4.08 (m, 2H, H-2, H-3), 
3.85 (dt, J = 7.6, 3.8 Hz, 1H, H-6a), 3.77 – 3.70 (m, 2H, H-4, H-5), 3.66 (s, 3H, 
COOCH3), 3.64 - 3.53 (m, 2H, H-6b, OCH(CH2)2), 2.31 - 2.22 (m, 1H, CH(CH2)2(CO2)), 
2.10 – 1.94 (m, 4H, cyclohexyl), 1.58 - 1.20 (m, 16H, 4CH3, 4H on cyclohexyl); 13C 
NMR (126 MHz, CDCl3): G 175.78 (CO), 109.38 (C(O)2(CH3)2), 99.70 (C(O)2(CH3)2), 
95.85 (C-1), 76.54 (C-3), 74.89 (C-2), 74.56 (OCH(CH2)2), 72.86 (C-4), 62.07 (C-5), 
61.43 (C-6), 51.63 (COOCH3), 42.09 (CH(CH2)2(CO2)), 32.39 , 30.34 (2C on 
cyclohexyl), 29.08 (CH3), 28.21 (CH3), 27.09, 26.85 (2C on cyclohexyl), 26.18 (CH3), 
18.79 (CH3); ESI-MS: m/z: calcd for C20H32NaO8 [M+Na]+: 423.20, found: 423.31. 
 
(1S,3S)-3-(2,3:4,6-Bis-O-methylethylidene-D-D-
mannopyranosyloxy)cyclobutanecarbaldehyde (27a): Prepared according to general 
procedure E from 26a (132 mg, 0.35 mmol). Yield: 90 mg (74%). [D]D = + 63.9 (c = 0.7, 
DCM/MeOH 2:1); 1H NMR (500 MHz, CDCl3): G 9.68 (d, J = 2.4 Hz, 1H, -CHO), 5.03 
(s, 1H, H-1), 4.21 (t, J = 7.5 Hz, 1H, H-cyclobutyl), 4.16 - 4.10 (m, 2H, H-2, H-3), 3.83 
(dd, J = 10.8, 5.7 Hz, 1H, H-6a), 3.79 - 3.68 (m, 2H, H-4, H-5), 3.63 - 3.52 (m, 1H, H-
6b), 2.82 - 2.70 (m, 1H, H-cyclobutyl), 2.47 (dtd, J = 9.9, 7.5, 2.7 Hz, 2H, H-cyclobutyl), 
2.24 (tdd, J = 11.6, 6.8, 4.9 Hz, 2H, H-cyclobutyl), 1.54, 1.51, 1.43, 1.35 (4 s, 12H, 4 
CH3); 13C NMR (126 MHz, CDCl3): G 173.14 (C=O), 109.50, 99.74, 98.63 (C-1), 76.27 
(C-2), 75.06 (C-3), 73.63 (C-5), 72.55 (C-cyclobutyl), 62.18 (C-4), 61.94 (C-6), 52.23 
(COOCH3), 29.14, 28.26, 26.23 (C-cyclobutyl), 18.96, 18.19 (4 CH3); ESI-MS: m/z: 
calcd for C17H26NaO7 [M+Na]+: 365.16, found: 364.96. 
 
(1S,4S)-4-(2,3:4,6-Bis-O-methylethylidene-D-D- 
mannopyranosyloxy)cyclohexanecarbaldehyde (27b): Prepared according to general 
procedure E from 26b (140 mg, 0.35 mmol). Yield: 70 mg (54%). [D]D = + 16.0 (c = 3.5, 
EtOAc); 1H NMR (500 MHz, CDCl3): G 9.66 (s, 1H, CHO), 5.14 (s, 1H, C-1), 4.22 – 4.11 
(m, 2H, H-2, H-3), 3.92 – 3.81 (m, 2H, H-6a, OCH(CH2)2), 3.80 - 3.72 (m, 2H, H-4, H-
5), 3.61 (td, J = 10.3, 5.6 Hz, 1H, H-6b), 2.35 -2.26 (m, 1H, CH(CH2)2(CHO)), 1.93 - 
1.51 (m, 14H, 2CH3, 8H on cyclohexyl), 1.45 (s, 3H, CH3), 1.38 (s, 3H, CH3); 13C NMR 
(126 MHz, CDCl3): G 204.29 (CHO), 109.40 (C(O)2(CH3)2), 99.71 (C(O)2(CH3)2), 95.70 
(C-1), 76.55 (C-3), 74.87 (C-2), 72.84 (C-4), 71.45 (OCH(CH2)2), 62.06 (C-5), 61.48 (C-
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6), 48.31 (CH(CH2)2(CHO)), 30.44 (C on cyclohexyl), 29.05 (CH3), 28.22 (CH3), 27.71 
(C on cyclohexyl), 26.21 (CH3), 21.32, 20.99 (2C on cyclohexyl), 18.78 (CH3); ESI-MS: 
m/z: calcd for C19H30NaO7 [M+Na]+: 393.19, found: 393.08. 
 
(1R,4R)-4-(2,3:4,6-Bis-O-methylethylidene-D-D-
mannopyranosyloxy)cyclohexanecarbaldehyde (27c): Prepared according to general 
procedure E from 26c (70 mg, 0.18 mmol). Yield: 64 mg (98%). [D]D = + 22.8 (c = 2.3, 
EtOAc); 1H NMR (500 MHz, CDCl3): G 9.61 (d, J = 1.1 Hz, 1H, CHO), 5.13 (s, 1H, H-
1), 4.14 - 4.09 (m, 2H, H-2, H-3), 3.83 (dd, J = 10.8, 5.6 Hz, 1H, H-6a), 3.75 - 3.67 (m, 
2H, H-4, H-6b), 3.64 - 3.52 (m, 2H, H-5, OCH(CH2)2), 2.24 - 2.15 (m, 1H, 
CH(CH2)2(CHO)), 2.07 - 1.94 (m, 4H, cyclohexyl), 1.52, 1.49 (2s, 6H, 2CH3), 1.44 - 1.28 
(m, 10H, 2CH3 and cyclohexyl); 13C NMR (126 MHz, CDCl3): G 203.74 (CHO), 109.37 
(C(O)2(CH3)2), 99.68 (C(O)2(CH3)2), 95.90 (C-1), 76.51 (C-3), 74.86 (C-2), 74.38 (C-4), 
72.81 (OCH(CH2)2), 62.03 (C-5), 61.47 (C-6), 48.89 (CH(CH2)2(CHO)), 31.84, 29.75(2C 
on cyclohexyl), 29.06, 28.20, 26.17 (3CH3), 23.77, 23.52 (2C on cyclohexyl), 18.77 
(CH3); ESI-MS: m/z: calcd for C19H30NaO7 [M+Na]+: 393.19, found: 393.22. 
 
(E)-N'-((1S,3S)-3-(D-D-Mannopyranosyloxycyclobutyl)methylene)benzohydrazide 
(28a): Prepared according to general procedure F from 27a (25 mg, 0.09 mmol). Yield: 
10 mg (28%). [D]D = + 28.3 (c = 0.6, MeOH); 1H NMR (500 MHz, D2O): G 7.72 (d, J = 
7.6 Hz, 2H), 7.69 - 7.64 (m, 1H), 7.56 (dt, J = 15.1, 7.4 Hz, 1H), 7.47 (dd, J = 16.8, 8.8 
Hz, 2H), 4.84 (s, 1H), 4.22 (t, J = 7.4 Hz, 1H), 3.85 (s, 1H), 3.83 - 3.78 (m, 1H), 3.71 
(ddd, J = 17.5, 10.5, 4.4 Hz, 2H), 3.65 - 3.56 (m, 2H), 2.80 - 2.70 (m, 1H), 2.52 (dt, J = 
11.4, 6.8 Hz, 2H), 2.17 - 2.02 (m, 2H); 13C NMR (126 MHz, D2O): G 158.05 (CO), 
132.64, 132.20, 128.85, 128.81, 127.43, 126.97 (C-Ar), 98.81 (C-1), 73.05 (C-5), 70.46 
(C-3), 70.08 (C-2), 68.33 (-CH(CH2)2-), 66.71 (C-4), 60.86 (C-6), 34.67, 33.53, 27.88 (3 
CH2); ESI-MS: m/z: calcd for C18H24N2NaO7 [M+Na]+: 403.15, found: 403.10. 
 
(E)-N'-((1S,4S)-4-(D-D-Mannopyranosyloxycyclohexyl)methylene)benzohydrazide 
(28b): Prepared according to general procedure F from 27b (18 mg, 0.05 mmol). Yield: 7 
mg (37%). [D]D = + 41.1 (c = 1.6, MeOH); 1H NMR (500 MHz, MeOD): G 7.89 (d, J = 
7.4 Hz, 2H, Ar), 7.61 (dd, J = 17.3, 6.6 Hz, 2H, Ar, CH=N), 7.51 (t, J = 7.6 Hz, 2H, Ar), 
4.91 (d, J = 1.2 Hz, 1H, H-1), 3.98 (s, 1H, OCH(CH2)2), 3.85 (d, J = 11.2 Hz, 1H, H-6a), 
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3.82 (dd, J = 3.2, 1.7 Hz, 1H, H-2), 3.79 - 3.70 (m, 2H, H-5, H-6b), 3.68 - 3.61 (m, 2H, 
H-3, H-4), 2.45 (dd, J = 9.8, 4.3 Hz, 1H, CH(CH2)2(CH=N)), 2.02 - 1.51 (m, 8H, 
cyclohexyl); 13C NMR (126 MHz, MeOD): G 166.88 (CONH), 158.48, 134.32 (CH=N), 
133.17, 129.71, 128.66 (C-Ar), 99.70 (C-1), 74.92 (C-3), 72.78 (C-2), 72.71 (C-5), 72.24 
(OCH(CH2)2), 68.79 (C-4), 63.01 (C-6), 40.99 (CH(CH2)2(CH=N)), 31.39, 28.96, 25.93, 
25.53 (4 CH2); ESI-MS: m/z: calcd for C20H28N2NaO7 [M+Na]+: 431.18, found: 431.17.  
 
(E)-N'-((1R,4R)-4-(D-D-Mannopyranosyloxycyclohexyl)methylene)benzohydrazide 
(28c): Prepared according to general procedure F from 27c (15 mg, 0.04 mmol). Yield: 11 
mg (68%). [D]D = + 193.1 (c = 0.3, MeOH); 1H NMR (500 MHz, MeOD): G 7.91 - 7.85 
(m, 2H, Ar), 7.63 – 7.56 (m, 2H, Ar, CH=N), 7.51 (t, J = 7.6 Hz, 2H, Ar), 4.96 (d, J = 1.4 
Hz, 1H, H-1), 3.88 - 3.83 (m, 1H, H-6a), 3.77 (dd, J = 3.3, 1.7 Hz, 1H, H-2), 3.76 - 3.59 
(m, 5H, H-3,4,5,6b, and OCH(CH2)2), 2.40 - 2.30 (m, 1H, CH(CH2)2(CH=N)), 2.22 - 1.29 
(m, 8H, cyclohexyl); 13C NMR (126 MHz, MeOD): G 166.87 (CONH), 158.08, 134.28, 
133.19 (CH=N), 129.71, 128.65 (5C-Ar), 99.61 (C-1), 75.96 (C-3), 74.80 (C-2), 72.72 
(C-5), 72.60 (OCH(CH2)2), 68.80 (C-4), 63.04 (C-6), 41.42 (CH(CH2)2(CH=N)), 33.55, 
31.70, 29.35, 29.08 (4 CH2); ESI-MS: m/z: calcd for C20H28N2NaO7 [M+Na]+: 431.18, 
found: 431.11. 
 
4-(2,3,4,6-Tetra-O-acetyl-D-D-mannopyranosyloxy)benzaldehyde (30a): Prepared 
according to general procedure C from 14 (100mg, 0.28 mmol) and 4-
hydroxybenzaldehyde (29a) (38 mg, 0.31 mmol). Yield: 106 mg (82%). [D]D = + 82.5 (c 
= 1.94, EtOAc); 1H NMR (500 MHz, CDCl3): G 9.93 (s, 1H, CHO), 8.08 - 7.71 (m, 2H, 
H-Ar), 7.27 - 7.17 (m, 2H, H-Ar), 5.64 (d, J = 1.7 Hz, 1H, H-1), 5.56 (dd, J = 10.0, 3.5 
Hz, 1H, H-3), 5.46 (dd, J = 3.5, 1.9 Hz, 1H, H-2), 5.38 (t, J = 10.0 Hz, 1H, H-4), 4.28 
(dd, J = 12.2, 5.3 Hz, 1H, H-6b), 4.09 - 4.01 (m, 2H, H-5, H-6a), 2.22, 2.06, 2.05, 2.02 
(4s, 12H, 4OAc); 13C NMR (126 MHz, CDCl3): G 190.78 (CHO), 170.52, 170.03, 169.76, 
160.26 (4COOCH3), 131.95, 131.83, 116.75 (C-Ar), 95.60 (C-1), 69.73 (C-5), 69.21(C-
2), 68.75 (C-3), 65.84 (C-4), 62.10 (C-6), 20.93, 20.76 (4 OAc); ESI-MS: m/z: calcd for 
C21H24NaO11 [M+Na]+: 475.12, found: 475.16. 
 
3-Fluoro-4-(2,3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)benzaldehyde (30b): 
Prepared according to general procedure C from 14 (200 mg, 0.57 mmol) and 3-fluoro-4-
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hydroxybenzaldehyde (29b) (88 mg, 0.63 mmol). Yield: 193 mg (72%). [D]D = + 147.9 (c 
= 0.6, EtOAc); 1H NMR (500 MHz, CDCl3): G 9.90 (s, 1H, -CHO), 7.65 (t, J = 10.3 Hz, 
2H, H-Ph), 7.36 (t, J = 7.8 Hz, 1H, H-Ph), 5.64 (s, 1H, H-1), 5.57 (d, J = 10.1 Hz, H-3), 
5.52 (s, 1H, H-2), 5.39 (t, J = 10.0 Hz, 1H, H-4), 4.28 (dd, J = 12.0, 5.0 Hz, 1H, H-6a), 
4.17 - 4.03 (m, 2H, H-5, H-6b), 2.22, 2.07, 2.05, 2.02 (4s, 12H, 4 COOCH3); 13C NMR 
(126 MHz, CDCl3): G189.67 (CHO), 170.39, 169.90, 169.75, 169.68 (4 CO from 
COOCH3), 153.16 (d, JF-C = 252.0 Hz), 148.42 (d, JF-C = 11.3 Hz), 132.45 (d, JF-C = 5.1 
Hz), 127.27 (d, JF-C = 3.3 Hz), 117.76, 116.76 (d, JF-C = 18.9 Hz) (6C-Ph), 96.74 (C-1), 
70.01 (C-5), 69.04 (C-2), 68.50 (C-3), 65.68 (C-4), 61.98 (C-6), 20.83, 20.67, 20.66, 
20.63 (4 COOCH3); ESI-MS: m/z: calcd for C21H23FNaO11 [M+Na]+: 493.11, found: 
493.12. 
 
4-(D-D-Mannopyranosyloxy)benzaldehyde (31a): Prepared according to general 
procedure B from 30a (106mg, 0.23 mmol). Yield: 50 mg (75%).  [D]D = + 41.1 (c = 1.6, 
MeOH); 1H NMR (500 MHz, MeOD): G 9.89 (s, 1H, CHO), 7.95 - 7.84 (m, 2H, Ar), 7.35 
- 7.26 (m, 2H, Ar), 5.66 (d, J = 1.7 Hz, 1H, H-1), 4.05 (dd, J = 3.4, 1.9 Hz, 1H, H-2), 3.93 
(dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.80 – 3.70 (m, 3H, H-4, H-6a, H-6b), 3.55 (ddd, J = 9.8, 
5.4, 2.5 Hz, 1H, H-5); 13C NMR (126 MHz, MeOD): G 192.92 (CO), 162.92, 132.94, 
132.55, 117.89 (Ar), 99.89 (C-1), 75.89 (C-5), 72.32 (C-2), 71.72 (C-3), 68.22 (C-4), 
62.64 (C-6); ESI-MS: m/z: calcd for C13H16NaO7 [M+Na]+: 307.08, found: 306.84. 
 
3-Fluoro-4-(D-D-mannopyranosyloxy)benzaldehyde (31b): Prepared according to 
general procedure B from 30b (100mg, 0.21 mmol). Yield: 62 mg (96%). [D]D = + 144.0 
(c = 0.6, MeOH); 1H NMR (500 MHz, DMSO-d6): G 9.89 (d, J = 1.8 Hz, 1H, CHO), 7.83 
- 7.68 (m, 2H, H-Ar), 7.59 (t, J = 8.3 Hz, 1H, H-Ar), 5.63 (d, J = 1.6 Hz, 1H, H-1), 5.19 
(d, J = 4.5 Hz, 1H, OH-2), 4.91 (d, J = 5.8 Hz, 1H, OH-4), 4.87 (d, J = 5.9 Hz, 1H, OH-
3), 4.48 (t, J = 6.0 Hz, 1H, OH-6), 3.90 (t, J = 4.8 Hz, 1H, H-2), 3.70 (ddd, J = 9.1, 5.7, 
3.4 Hz, 1H, H-3), 3.60 (ddd, J = 12.4, 6.2, 2.3 Hz, 1H, H-6b), 3.52 (td, J = 9.5, 5.8 Hz, 
1H, H-4), 3.46 (dt, J = 11.9, 6.1 Hz, 1H, H-6a), 3.40 - 3.34 (m, 1H, H-5, overlap with 
DMSO); 13C NMR (126 MHz, DMSO-d6): 190.97 (CO), 152.12 (JC,F = 247.1 Hz), 149.0 
(JC,F = 10.8 Hz), 130.78 (JC,F = 5.1 Hz), 127.72 (JC,F = 2.9 Hz), 117.82, 115.76 (JC,F = 
18.7 Hz), 99.35 (C-1), 75.68 (C-5), 70.46 (C-3), 69.66 (C-2), 66.37 (C-4), 60.87 (C-6); 
ESI-MS: m/z: calcd for C13H15FNaO7 [M+Na]+: 325.07, found: 324.93. 
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(E)-N'-(4-(D-D-Mannopyranosyloxy)benzylidene)benzohydrazide (32a): Prepared 
according to general procedure I from 31a (100 mg, 0.22 mmol). Yield: 67 mg (75%). 
[D]D = + 128.2 (c = 0.3, MeOH); 1H NMR (500 MHz, DMSO-d6): G 11.76 (s, 1H, -
CH=N-), 8.42 (s, 1H, -CONH-), 7.92 (d, J = 7.5 Hz, 2H, H-Ar), 7.68 (d, J = 8.5 Hz, 2H, 
H-Ar), 7.60 (t, J = 7.2 Hz, 1H, H-Ar), 7.54 (t, J = 7.5 Hz, 2H, H-Ar), 7.18 (d, J = 8.5 Hz, 
2H, H-Ar), 5.47 (s, 1H, H-1), 5.06 (d, J = 4.2 Hz, 1H, OH-2), 4.84 (d, J = 5.7 Hz, 1H, 
OH-4), 4.77 (d, J = 5.9 Hz, 1H, OH-3), 4.46 (t, J = 5.9 Hz, 1H, OH-6), 3.85 (s, 1H, H-2), 
3.70 (t, J = 9.0 Hz, 1H, H-3), 3.66 - 3.58 (m, 1H, H-6a), 3.56 - 3.44 (m, 2H, H-4, H-6b), 
3.43 - 3.36 (m, 1H, H-5, overlap with DMSO); 13C NMR (126 MHz, DMSO-d6): G 
162.95 (CO), 157.85 (C-Ar), 147.47 (-CH=N-), 133.51, 131.64, 128.55, 128.43, 128.06, 
127.54, 116.89 (C-Ar), 98.64 (C-1), 75.09 (C-5), 70.61 (C-3), 69.95 (C-2), 66.64 (C-4), 
60.98 (C-6); ESI-MS: m/z: calcd for C20H22N2NaO7 [M+Na]+: 425.13, found: 425.10. 
 
(E)-N'-(3-Fluoro-4-(D-D-mannopyranosyloxy)benzylidene)benzohydrazide (32b): 
Prepared according to general procedure I from 31b (5 mg, 0.017 mmol). Yield: 5 mg 
(71%). [D]D = + 100.1 (c = 0.2, MeOH); 1H NMR (500 MHz, MeOD): G 8.29 (s, 1H, -
CH=N-), 7.99 - 7.92 (m, 2H, H-Ar), 7.80 (dd, J = 12.0, 1.8 Hz, 1H, H-Ar), 7.62 (d, J = 
7.4 Hz, 1H, H-Ar), 7.59 – 7.50 (m, 3H, H-Ar), 7.47 (t, J = 8.3 Hz, 1H, H-Ar), 5.60 (d, J = 
1.4 Hz, 1H, H-1), 4.10 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.95 (dd, J = 9.4, 3.4 Hz, 1H, H-3), 
3.85 – 3.71 (m, 3H, H-4, H-6a, H-6b), 3.66 (ddd, J = 9.7, 5.4, 2.3 Hz, 1H, H-5); 13C NMR 
(126 MHz, MeOD): G 167.12 (CO), 155.58 (C-Ar), 149.06 (-CH=N-), 134.14, 133.38, 
129.78, 128.76, 126.20, 119.46, 115.46 (JC,F = 20.13 Hz), 101.18 (C-1), 76.06 (C-5), 
72.30 (C-3), 71.76 (C-2), 68.18 (C-4), 62.65 (C-6); ESI-MS: m/z: calcd for C20H22FN2O7 
[M+H]+: 421.14, found: 421.13. 
 
3-(2,3,4,6-Tetra-O-acetyl-D-D-mannopyranosyloxy)benzaldehyde (34): Prepared 
according to general procedure C from 14 (200mg, 0.57 mmol) and 3-
hydroxybenzaldehyde (33) (77 mg, 0.63 mmol). Yield: 245 mg (95%).  [D]D = + 35.70 (c 
= 0.7, EtOAc); 1H NMR (500 MHz, CDCl3): G 9.98 (s, 1H, H-CHO), 7.64 (dd, J = 2.4, 
1.4 Hz, 1H, H-Ar), 7.60 (dt, J = 7.5, 1.1 Hz, 1H, H-Ar), 7.50 (t, J = 7.8 Hz, 1H, H-Ar), 
7.36 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H, H-Ar), 5.59 (d, J = 1.7 Hz, 1H, H-1), 5.56 (dd, J = 
10.0, 3.5 Hz, 1H, H-3), 5.46 (dd, J = 3.5, 1.9 Hz, 1H, H-2), 5.37 (t, J = 10.1 Hz, 1H, H-4), 
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4.32 - 4.24 (dd, J = 6.1, 12.5 Hz, 1H, H-6b), 4.10 – 4.05 (m, 2H, H-5, H-6a), 2.21, 2.06, 
2.05, 2.01 (4s, 12H, 4 OAc); 13C NMR (126 MHz, CDCl3): G 191.55 (CHO), 170.66, 
170.12, 170.08, 169.84 (4 COOCH3), 156.32, 138.17, 130.52, 125.16, 123.17, 116.31 (C-
Ar), 96.00 (C-1), 69.57 (C-5), 69.38 (C-2), 68.87 (C-3), 66.05 (C-4), 62.30 (C-6), 20.99, 
20.82, 20.74 (4C, 4 OAc); ESI-MS: m/z: calcd for C21H24NaO11 [M+Na]+: 475.12, found: 
475.13. 
 
3-(D-D-Mannopyranosyloxy)benzaldehyde (35): Prepared according to general 
procedure B from 34 (160 mg, 0.35 mmol). Yield: 103 mg (quant.). [D]D = + 131.9 (c = 
0.3, MeOH); 1H NMR (500 MHz, DMSO-d6): G 9.98 (s, 1H, CHO), 7.65 – 7.50 (m, 3H 
H-Ar), 7.42 (ddd, J = 7.9, 2.5, 1.4 Hz, 1H, H-Ar), 5.49 (d, J = 1.7 Hz, 1H, H-1), 5.08 (s, 
1H, OH-2), 4.87 (s, 1H, OH-4), 4.82 (s, 1H, OH-3), 4.47 (s, 1H, OH-6), 3.86 (dd, J = 3.2, 
1.9 Hz, 1H, H-2), 3.70 (dd, J = 9.2, 3.2 Hz, 1H, H-3), 3.62 - 3.43 (m, 3H, H-4, H-6a, H-
6b), 3.43 – 3.36 (m, 1H, H-5, overlap with DMSO); 13C NMR (126 MHz, DMSO-d6): G 
192.88 (CO), 156.77, 137.58, 130.37, 123.24, 123.12, 116.63 (C-Ar), 98.80 (C-1), 75.14 
(C-5), 70.61 (C-3), 69.90 (C-2), 66.60 (C-4), 60.91 (C-6); ESI-MS: m/z: calcd for 
C13H16NaO7 [M+Na]+: 307.08, found: 306.91. 
 
(E)-N'-(3-(D-D-Mannopyranosyloxy)benzylidene)benzohydrazide (36): Prepared 
according to general procedure F from 35 (26 mg, 0.06 mmol). Yield: 19 mg (53%). [D]D 
= + 110.8 (c = 0.3, MeOH); 1H NMR (500 MHz, MeOD): G 8.33 (s, 1H, -CH=N-), 8.00 - 
7.90 (m, 2H, H-Ar), 7.70 (s, 1H, H-Ar), 7.62 (t, J = 7.4 Hz, 1H, H-Ar), 7.54 (t, J = 7.6 
Hz, 2H, H-Ar), 7.45 (d, J = 7.6 Hz, 1H, H-Ar), 7.37 (t, J = 7.9 Hz, 1H, H-Ar), 7.20 (dd, J 
= 8.1, 1.7 Hz, 1H, H-Ar), 5.61 (d, J = 1.4 Hz, 1H, H-1), 4.06 (dd, J = 3.3, 1.8 Hz, 1H, H-
2), 3.96 (dd, J = 9.4, 3.4 Hz, 1H, H-3), 3.85 - 3.70 (m, 3H, H-4, H-6a, H-6b), 3.65 (ddd, J 
= 9.6, 5.4, 2.4 Hz, 1H, H-5); 13C NMR (126 MHz, MeOD): G 167.11 (C=O), 158.23 (C-
Ar), 150.35 (-N=CH-), 137.00, 134.10, 133.35, 130.94, 129.74, 128.76, 123.44, 120.38, 
115.97 (C-Ar), 100.06 (C-1), 75.55 (C-5), 72.40 (C-3), 71.93 (C-2), 68.42 (C-4), 62.76 
(C-6); ESI-MS: m/z: calcd for C20H22N2NaO7 [M+Na]+: 425.13, found: 425.03.  
 
4-(2-Deoxy-2-fluoro-3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)benzaldehyde 
(37a): Prepared according to general procedure H from 11a (106 mg, 0.30 mmol). Yield: 
57 mg (46%).  [D]D = +137.82 (c = 0.9, EtOAc); 1H NMR (500 MHz, CDCl3): G 9.94 (s, 
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1H, -CHO), 7.99 - 7.78 (m, 2H, Ar), 7.36 - 7.14 (m, 2H, Ar), 5.81 (dd, J = 6.6, 1.8 Hz, 
1H, H-1), 5.53 - 5.40 (m, 2H, H-3, H-4), 5.00 (dt, J = 48.8, 2.1 Hz, 1H, H-2), 4.26 (dd, J 
= 12.4, 5.0 Hz, 1H, H-6a), 4.09 (dd, J = 12.4, 2.3 Hz, 1H, H-6b), 4.04 (ddd, J = 9.5, 5.0, 
2.2 Hz, 1H, H-5), 2.15, 2.06, 2.02 (3 s, 9H, 3 COOCH3); 13C NMR (126 MHz, CDCl3): G 
190.63 (CHO), 170.51, 170.19, 169.42 (3 COOCH3), 159.96, 131.91, 131.88, 116.60 (C-
Ar), 95.06 (d, J = 30.7 Hz, C-1), 86.35 (d, J = 180.9 Hz, C-2), 69.67 (C-5), 69.53 (d, J = 
16.8 Hz, C-3), 65.35 (C-4), 61.68 (C-6), 20.75, 20.63, 20.60 (3 COOCH3); ESI-MS: m/z: 
calcd for C19H21FNaO9 [M+Na]+: 435.11, found: 435.04. 
 
4-(2-Deoxy-2-chloro-3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)benzaldehyde 
(37b): Prepared according to general procedure H from 11b (110 mg, 0.30 mmol). Yield: 
42 mg (36%). [D]D = +143.47 (c = 1.0 , EtOAc); 1H NMR (500 MHz, CDCl3): G 9.94 (s, 
1H, -CHO), 7.91 - 7.85 (m, 2H, Ar), 7.26 - 7.21 (m, 2H, Ar), 5.77 (d, J = 1.5 Hz, 1H, H-
1), 5.57 (dd, J = 9.8, 3.9 Hz, 1H, H-3), 5.49 (t, J = 9.9 Hz, 1H, H-4), 4.64 (dd, J = 3.8, 1.6 
Hz, 1H, H-2), 4.23 (dd, J = 12.4, 5.1 Hz, 1H, H-6a), 4.10 (dd, J = 12.4, 2.3 Hz, 1H, H-
6b), 4.04 (ddd, J = 9.9, 5.1, 2.2 Hz, 1H, H-5), 2.14, 2.07,  2.03 (3s, 9H, 3 COOCH3); 13C 
NMR (126 MHz, CDCl3): G 190.66 (CHO), 170.51, 170.13, 169.41 (3 COOCH3), 160.08, 
131.91, 116.60 (C-Ar), 97.73 (C-1), 70.06 (C-5), 69.31 (C-3), 65.02 (C-4), 61.80 (C-6), 
56.89 (C-2), 20.76, 20.63 (3C, 3 COOCH3); ESI-MS: m/z: calcd for C19H21ClNaO9 
[M+Na]+: 451.08, found: 451.10.  
 
4-(2-Deoxy-2-fluoro-D-D-mannopyranosyloxy)benzaldehyde (38a): Prepared 
according to general procedure B from 37a (18 mg, 0.04 mmol). Yield: 12 mg (96%). 
[D]D = +111.0 (c = 1.0 , MeOH); 1H NMR (500 MHz, MeOD): G 9.90 (s, 1H), 7.97 - 7.85 
(m, 2H), 7.37 - 7.27 (m, 2H), 5.90 (dd, J = 6.9, 1.9 Hz, 1H, H-1), 4.87 (dt, 49.1, 2.4 Hz, 
1H, H-2), 3.99 (ddd, J = 30.8, 9.6, 2.7 Hz, 1H, H-3), 3.83 - 3.69 (m, 3H, H-4, H-6a, H-
6b), 3.63 - 3.56 (m, 1H, H-5); 13C NMR (126 MHz, MeOD): G 192.88 (CHO), 162.42, 
132.92, 132.88, 118.01 (C-Ar), 97.06 (d, J = 31.3 Hz, C-1), 90.61 (d, J = 175.6 Hz, C-2), 
76.01 (C-5), 71.45 (d, J = 17.5 Hz, C-3), 68.22 (C-4), 62.33 (C-6); ESI-MS: m/z: calcd 
for C13H15FNaO6 [M+Na]+: 309.07, found: 308.93.  
 
4-(2-Deoxy-2-chloro-D-D-mannopyranosyloxy)benzaldehyde (38b): Prepared 
according to general procedure B from 37b (31 mg, 0.07 mmol). Yield: 3 mg (14%). [D]D 
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= +169.5 (c = 0.2 , MeOH);  1H NMR (500 MHz, MeOD): G 9.81 (s, 1H, CHO), 7.86 - 
7.80 (m, 2H, Ar), 7.27 - 7.20 (m, 2H, Ar), 5.79 (d, J = 1.5 Hz, 1H, H-1), 4.41 (dd, J = 3.8, 
1.6 Hz, 1H, H-2), 4.15 (dd, J = 9.2, 3.8 Hz, 1H, H-3), 3.76 - 3.67 (m, 2H, H-4, H-6a), 
3.63 (dd, J = 12.1, 5.5 Hz, 1H, H-6b), 3.53 (ddd, J = 9.7, 5.5, 2.4 Hz, 1H, H-5); 13C NMR 
(126 MHz, MeOD): G 192.88 (CO), 162.51, 132.93, 132.83, 117.96 (C-Ar), 99.69 (C-1), 
76.55 (C-5), 70.76 (C-3), 67.86 (C-4), 62.43 (C-6), 62.36 (C-2); ESI-MS: m/z: calcd for 
C13H15ClNaO6 [M+Na]+: 325.04, found: 324.93.  
 
3-(2-Deoxy-2-fluoro-3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)benzaldehyde 
(39a): Prepared according to general procedure H from 11a (106 mg, 0.30 mmol). Yield: 
47 mg (38%). [D]D = +91.9 (c = 0.8, EtOAc); 1H NMR (500 MHz, CDCl3): G 10.00 (s, 
1H, CHO), 7.67 - 7.58 (m, 2H, Ar), 7.51 (t, J = 7.8 Hz, 1H, Ar), 7.40 - 7.34 (m, 1H, Ar), 
5.76 (dd, 3JH,F = 6.6 Hz, J =1.9 Hz, 1H, H-1), 5.53 - 5.38 (m, 2H, H-3, H-4), 4.99 (dt, 
2JH,F = 48.9 Hz, J = 2.1 Hz, 1H, H-2), 4.27 (dd, J = 12.7, 5.7 Hz, 1H, H-6a), 4.11 - 4.04 
(m, 2H, H-5, H-6b), 2.15, 2.06, 2.02 (3 s, 9H, 3COOCH3); 13C NMR (126 MHz, CDCl3): 
G 191.34 (CHO), 170.59, 170.20, 169.45 (3CO(O)), 156.01, 138.09, 130.48, 125.15, 
122.80, 116.26 (6C, Ar), 95.44 (C-1, 2JC,F = 48.9 Hz), 86.45 (C-2, 1JC,F = 180.9 Hz), 
69.61 (C-3, 3JC,F = 16.8 Hz), 69.49 (C-5), 65.50 (C-4), 61.84 (C-6), 20.76, 20.61 (3C, 
CH3); ESI-MS: m/z: calcd for C19H21FNaO9 [M+Na]+: 435.11, found: 435.04. 
 
3-(2-Deoxy-2-chloro-3,4,6-tetra-O-acetyl-D-D-mannopyranosyloxy)benzaldehyde 
(39b): Prepared according to general procedure H from 11b (110 mg, 0.30 mmol). Yield: 
50 mg (39%). [D]D = +68.02 (c = 1.0 , EtOAc); 1H NMR (500 MHz, CDCl3): G 9.99 (s, 
1H, CHO), 7.64 (dd, J = 2.4, 1.4 Hz, 1H, Ar), 7.61 (dt, J = 7.5, 1.1 Hz, 1H, Ar), 7.51 (t, J 
= 7.9 Hz, 1H, Ar), 7.37 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H, Ar), 5.73 (d, J = 1.5 Hz, 1H, H-1), 
5.58 (dd, J = 9.8, 3.9 Hz, 1H, H-3), 5.48 (t, J = 9.9 Hz, 1H, H-4), 4.64 (dd, J = 3.8, 1.6 
Hz, 1H, H-2), 4.24 (dd, J = 12.5, 5.6 Hz, 1H, H-6a), 4.13 - 4.06 (m, 2H, H-6b, H-5), 2.14, 
2.07, 2.02 (3s, 9H, 3 COOCH3); 13C NMR (126 MHz, CDCl3): G 191.38 (CHO), 170.58, 
170.12, 169.43 (3 COOCH3), 156.10, 138.07, 130.45, 125.07, 122.83, 116.28 (C-Ar), 
98.10 (C-1), 69.87 (C-5), 69.39 (C-3), 65.17 (C-4), 61.96 (C-6), 57.02 (C-2), 20.77, 
20.63, 20.60 (3C, 3 COOCH3); ESI-MS: m/z: calcd for C19H21ClNaO9 [M+Na]+: 451.08, 
found: 451.12. 
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3-(2-Deoxy-2-fluoro-D-D-mannopyranosyloxy)benzaldehyde (40a): Prepared 
according to general procedure B from 39a (16 mg, 0.04 mmol). Yield: 8 mg (73%). [D]D 
= +119.3 (c = 0.7, MeOH); 1H NMR (500 MHz, MeOD): G 9.98 (s, 1H, CHO), 7.70 (s, 
1H), 7.63 (d, J = 7.5 Hz, 1H, H-Ar), 7.55 (t, J = 7.8 Hz, 1H, H-Ar), 7.47 (dd, J = 8.1, 1.6 
Hz, 1H, H-Ar), 5.83 (d, J = 5.7 Hz, 1H, H-1), 4.98 – 4.75 (m, 1H, H-2), 4.00 (ddd, J = 
30.9, 9.6, 2.6 Hz, 1H, H-3), 3.86 – 3.67 (m, 3H, H-4, H-6a, H-6b), 3.69 - 3.58 (m, 1H, H-
5); 13C NMR (126 MHz, MeOD): G 193.75 (CO), 158.10, 139.56, 131.52, 125.32, 124.35, 
117.83 (C-Ar), 97.47 (J = 31.0 Hz, C-1), 90.76 (J = 175.4 Hz, C-2), 75.83 (C-5), 71.51 (J 
= 17.5 Hz, C-4), 68.24 (J = 20.6 Hz, C-6); ESI-MS: m/z: calcd for C13H15FNaO6 
[M+Na]+: 309.07, found: 308.93. 
 
3-(2-Deoxy-2-chloro-D-D-mannopyranosyloxy)benzaldehyde (40b): Prepared 
according to general procedure B from 39b (16 mg, 0.04 mmol). Yield: 7 mg (64%). [D]D 
= +111.2 (c = 0.6, MeOH); 1H NMR (500 MHz, MeOD): G 9.98 (s, 1H), 7.69 (dd, J = 2.4, 
1.4 Hz, 1H, Ar), 7.63 (dt, J = 7.5, 1.2 Hz, 1H, Ar), 7.55 (t, J = 7.8 Hz, 1H, Ar), 7.46 (ddd, 
J = 8.2, 2.6, 1.1 Hz, 1H, Ar), 5.81 (d, J = 1.5 Hz, 1H, H-1), 4.50 (dd, J = 3.8, 1.6 Hz, 1H, 
H-2), 4.25 (dd, J = 9.2, 3.8 Hz, 1H, H-3), 3.85 - 3.77 (m, 2H, H-4, H-6a), 3.72 (dd, J = 
12.0, 5.6 Hz, 1H, H-6b), 3.70 - 3.64 (m, 1H, H-5); 13C NMR (126 MHz, MeOD): G 
193.74 (CHO), 158.21, 139.56, 131.51, 125.22, 124.30, 117.83 (C-Ar), 100.10 (C-1), 
76.40 (C-5), 70.82 (C-3), 67.96 (C-4), 62.54 (C-6), 62.47 (C-2); ESI-MS: m/z: calcd for 
C13H15ClNaO6 [M+Na]+: 325.04, found: 324.81. 
 
Hydrazones 42a-d: Prepared according to general procedure I from 31b (5 mg, 0.017 
mmol, 1 equiv.) and the corresponding hydrazide (1 equiv.). Compounds 42a-d were 
purified with preparative HPLC-MS, and the yields were calculated after lyophilization. 
 
42a: Yield: 5 mg (71%). 1H NMR (500 MHz, MeOD): G 8.29 (s, 1H, -CH=N-), 8.01 - 
7.91 (m, 2H, H-Ar), 7.80 (dd, J = 12.0, 1.8 Hz, 1H, H-Ar), 7.63 (t, J = 7.4 Hz, 1H, H-Ar), 
3.59 – 3.51 (m, 3H, H-Ar), 7.47 (t, J = 8.3 Hz, 1H, H-Ar), 5.60 (d, J = 1.5 Hz, 1H, H-1), 
4.10 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 3.95 (dd, J = 9.4, 3.4 Hz, 1H, H-3), 3.87 – 3.70 (m, 
3H, H-4, H-6a, H-6b), 3.66 (ddd, J = 9.7, 5.4, 2.4 Hz, 1H, H-5), 3.36 – 3.33 (m, 2H, -
CH2-); ESI-MS: m/z: calcd for C23H25FN3O7 [M+H]+: 474.17, found: 474.06. 
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42b: Yield: 4 mg (67%). 1H NMR (500 MHz, MeOD): G 8.29 (s, 1H, -CH=N-), 7.83 – 
7.74 (m, 2H, H-Ar), 7.57 – 7.43 (m, 2H, H-Ar), 7.33 (d, J = 3.4 Hz, 1H, H-Ar) 6.68 (s, 
1H, H-Ar), 5.59 (s, 1H, H-1), 4.10 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 3.95 (dd, J = 9.4, 3.5 
Hz, 1H, H-3), 3.85 – 3.71 (m, 3H, H-4, H-6a, H-6b), 3.70 – 3.63 (m, 1H, H-5); ESI-MS: 
m/z: calcd for C18H20FN2O8 [M+H]+: 411.12, found: 410.99. 
 
42c: Yield: 5 mg (62%). 1H NMR (500 MHz, MeOD): G 8.32 - 7.41 (m, 6H, -CH=N-, H-
Ar), 7.23 (dd, J = 11.1, 6.8 Hz, 1H, H-Ar), 5.60 (s, 1H, H-1), 4.12 - 4.08 (m, 1H, H-2), 
3.95 (dd, J = 9.4, 3.4 Hz, 1H, H-3), 3.90 - 3.72 (m, 3H, H-4, H-6a, H-6b), 3.71 – 3.61 (m, 
1H, H-5); ESI-MS: m/z: calcd for C18H20FN2O7S [M+H]+: 427.10, found: 426.99. 
 
42d: Yield: 2 mg (30%). 1H NMR (500 MHz, MeOD): G 8.29 (s, 1H, -CH=N-), 7.96 – 
7.77 (m, 3H, H-Ar), 7.60 (d, J = 8.5 Hz, 2H, H-Ar), 7.56 - 7.43 (m, 2H, H-Ar), 5.60 (s, 
1H, H-1), 4.10 (dd, J = 3.2, 1.7 Hz, 1H, H-2), 3.95 (dd, J = 9.4, 3.4 Hz, 1H, H-3), 3.86 - 
3.70 (m, 3H, H-4, H-6a, H-6b), 3.70 - 3.62 (m, 1H, H-5), 1.39 (s, 9H, H-tBu); ESI-MS: 
m/z: calcd for C24H30FN2O7 [M+H]+: 477.20, found: 477.09. 
 
Hydrazones 43c and 50a-h: Prepared according to general procedure I from 31a (2 mg, 
1 equiv.) and the corresponding hydrazide (1 equiv.). Compounds 43c and 50a-h were 
purified with preparative HPLC-MS. Yield: 50-60%. 
 
43c: 1H NMR (500 MHz, MeOD): G 7.94 - 7.71 (m, 5H, -CH=N-, H-Ar), 7.29 - 7.17 (m, 
3H, H-Ar), 5.59 (s, 1H, H-1), 4.04 (s, 1H, H-2), 3.93 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.84 - 
3.70 (m, 3H, H-4, H-6a, H-6b), 3.65 – 3.54 (m, 1H, H-5); ESI-MS: m/z: calcd for 
C18H21N2O7S [M+H]+: 409.11, found: 409.04. 
 
50a: 1H NMR (500 MHz, MeOD): G 8.21 (s, 1H, -CH=N-), 7.78 (d, J = 8.7 Hz, 2H, H-
Ph), 7.20 (d, J = 8.8 Hz, 2H, H-Ph), 6.95 (d, J = 2.3 Hz, 2H, H-Pyrrole), 6.22 - 6.10 (m, 
1H, H-Pyrrole), 5.57 (d, J = 1.7 Hz, 1H, H-1), 4.04 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 3.98 (s, 
3H, CH3), 3.93 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.83 - 3.70 (m, 3H, H-4, H-6a, H-6b), 3.64 
- 3.57 (m, 1H, H-5); ESI-MS: m/z: calcd for C19H24N3O7 [M+H]+: 406.16, found: 406.09. 
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50b: 1H NMR (500 MHz, MeOD): G 8.37 (s, 1H, -CH=N-), 8.24 (s, 1H, H-thiazole), 7.83 
(d, J = 8.8 Hz, 2H, H-Ph), 7.22 (d, J = 8.8 Hz, 2H, H-Ph), 5.59 (d, J = 1.6 Hz, 1H, H-1), 
4.04 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 3.93 (dd, J = 9.5, 3.5 Hz, 1H, H-3), 3.83 - 3.70 (m, 
3H, H-4, H-6a, H-6b), 3.59 (ddd, J = 9.8, 5.2, 2.6 Hz, 1H, H-5), 2.80 (s, 3H, CH3); ESI-
MS: m/z: calcd for C18H22N3O7S [M+H]+: 424.12, found: 424.08. 
 
50c: 1H NMR (500 MHz, MeOD): G 9.10 (s, 1H, -CH=N-), 8.77 (dd, J = 4.9, 1.5 Hz, 1H, 
H-Py), 8.38 (dt, J = 8.0, 1.9 Hz, 1H, H-Py), 8.33 (s, 1H, H-Py), 7.83 (d, J = 8.8 Hz, 2H, 
H-Ph), 7.63 (dd, J = 7.9, 4.9 Hz, 1H, H-Py), 7.23 (d, J = 8.8 Hz, 2H, H-Ph), 5.59 (d, J = 
1.5 Hz, 1H, H-1), 4.05 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.93 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 
3.83 - 3.70 (m, 3H, H-4, H-6a, H-6b), 3.59 (ddd, J = 9.7, 5.2, 2.5 Hz, 1H, H-5); ESI-MS: 
m/z: calcd for C19H22N3O7 [M+H]+: 404.15, found: 404.11. 
 
50d: 1H NMR (500 MHz, MeOD): G 8.30 (s, 1H, -CH=N-), 7.83 (dd, J = 15.5, 8.4 Hz, 
4H, H-Ar), 7.36 (d, J = 8.1 Hz, 2H, H-Ar), 7.21 (d, J = 8.7 Hz, 2H, H-Ar), 5.58 (d, J = 
1.4 Hz, 1H, H-1), 4.04 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.93 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 
3.84 - 3.70 (m, 3H, H-4, H-6a, H-6b), 3.60 (ddd, J = 9.7, 5.2, 2.5 Hz, 1H, H-5), 2.45 (s, 
3H, CH3); ESI-MS: m/z: calcd for C22H24N3O7 [M+H]+: 442.16, found: 442.14. 
 
50e: 1H NMR (500 MHz, MeOD): G 8.31 (s, 1H, -CH=N-), 7.94 (d, J = 8.5 Hz, 2H, H-
Ar), 7.82 (d, J = 8.7 Hz, 2H, H-Ar), 7.56 (d, J = 8.5 Hz, 2H, H-Ar), 7.22 (d, J = 8.7 Hz, 
2H, H-Ar), 5.59 (d, J = 1.3 Hz, 1H, H-1), 4.04 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.93 (dd, J 
= 9.5, 3.4 Hz, 1H, H-3), 3.83 - 3.70 (m, 3H, H-4, H-6a, H-6b), 3.59 (ddd, J = 9.7, 5.2, 2.5 
Hz, 1H, H-5); ESI-MS: m/z: calcd for C20H22ClN2O7 [M+H]+: 437.11, found: 437.15. 
 
50f: 1H NMR (500 MHz, MeOD): G 8.30 (s, 1H, -CH=N-), 7.94 (d, J = 8.8 Hz, 2H, H-
Ar), 7.81 (d, J = 8.7 Hz, 2H, H-Ar), 7.21 (d, J = 8.7 Hz, 2H, H-Ar), 7.07 (d, J = 8.9 Hz, 
2H, H-Ar), 5.58 (d, J = 1.3 Hz, 1H, H-1), 4.04 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.93 (dd, J 
= 9.5, 3.4 Hz, 1H, H-3), 3.90 (s, 3H, CH3), 3.83 - 3.71 (m, 3H, H-4, H-6a, H-6b), 3.60 
(ddd, J = 9.7, 5.2, 2.5 Hz, 1H, H-5); ESI-MS: m/z: calcd for C21H25N2O8 [M+H]+: 433.16, 
found: 433.11. 
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50g: 1H NMR (500 MHz, MeOD): G 8.23 (s, 2H, H-Ar), 8.07 (s, 1H, -CH=N-), 7.80 (d, J 
= 6.5 Hz, 2H, H-Ar), 7.48 (d, J = 7.7 Hz, 1H, H-Ar), 7.31 - 7.16 (m, 4H, H-Ar), 5.58 (d, J 
= 1.6 Hz, 1H, H-1), 4.05 (dd, J = 3.4, 1.8 Hz, 1H, H-2), 3.94 (dd, J = 9.5, 3.4 Hz, 1H, H-
3), 3.85 - 3.71 (m, 3H, H-4, H-6a, H-6b), 3.61 (ddd, J = 9.8, 5.2, 2.6 Hz, 1H, H-5); ESI-
MS: m/z: calcd for C22H24N3O7 [M+H]+: 442.16, found: 442.14. 
 
50h: 1H NMR (500 MHz, MeOD): G 8.33 (s, 1H, -CH=N-), 8.06 - 7.94 (m, 2H, H-Ar), 
7.84 (d, J = 8.5 Hz, 2H, H-Ar), 7.61 (dd, J = 6.0, 3.2 Hz, 2H, H-Ar), 7.24 (d, J = 8.6 Hz, 
2H, H-Ar), 5.60 (s, 1H, H-1), 4.05 (s, 1H, H-2), 3.93 (dd, J = 9.5, 3.2 Hz, 1H, H-3), 3.85 - 
3.69 (m, 3H, H-4, H-6a, H-6b), 3.64 – 3.55 (m, 1H, H-5); ESI-MS: m/z: calcd for 
C22H21ClN2NaO7S [M+Na]+: 515.07, found: 515.06. 
 
Isothermal Titration Calorimetry (ITC). All thermodynamic experiments were 
performed with the FimH-CRD-Th-His6 protein using a VP-ITC instrument from 
MicroCal, Inc. (GE Healthcare, Northampton, MA, USA) with a sample cell volume of 
1.4523 mL. The measurements were performed with 2.5 or 5% DMSO at 25 °C, a stirring 
speed of 307 rpm, and 10 µcal s-1 reference power. The protein samples were dialyzed in 
assay buffer prior to all experiments. Compounds 1 and 13a-c were measured in a direct 
fashion by titration of ligand (120-2000 µM) into protein (10-55 µM) with injections of 
3-6 µL at intervals of 10 min to ensure non-overlapping peaks. The quantity c = Mt(0) 
KD–1, where Mt(0) is the initial macromolecule concentration, is of importance in titration 
microcalorimetry. The c-values of the direct titrations were below 1000 and thus within 
the reliable range. Baseline correction and peak integration was achieved with the Origin 
7 software  (OriginLab, Northampton, MA, USA). An initial 2 µL-injection was excluded 
from data analysis. Baseline subtraction and curve fitting with the three variables N 
(concentration correction factor), KD (dissociation constant), and ∆H° (change in 
enthalpy) was performed with the SEDPHAT software version 10.40 (National Institute 
of Health). A binary complex model was employed. The thermodynamic parameters were 
calculated with the following equation (Equation 1)35: 
 
  (1) 
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where ∆G°, ∆H°, and ∆S° are the changes in free energy, enthalpy, and entropy of 
binding, respectively, T is the absolute temperature, and R is the universal gas constant 
(8.314 J mol-1 K-1).  
KD Determination of FimH Antagonists. The fluorescently previously reported labeled 
ligand was used for the competitive fluorescence polarization assay. A serial dilution of 
non-labeled FimH antagonist with final concentrations ranging from 0-10 µM was titrated 
into 96-well NBSTM plates to a final volume of 200 µL containing a constant 
concentration of protein (final concentration: 25 nM for the lectin domain of FimH; 250 
nM for the native full-length FimH) and FITC-labeled ligand which was fixed at a higher 
concentration in competitive binding assays to obtain higher fluorescence intensities 
(final concentration: 20 nM when tested against the lectin domain of FimH; 25 nM when 
tested against the native full-length FimH). Prior to measuring the fluorescence 
polarization, the plates were incubated for 24 h (in the presence of the lectin domain) or 3 
h (in the presence of the full-length FimH) at RT until the reaction reached its 
equilibrium. The IC50 value was determined with Prism (GraphPad Software Inc., La 
Jolla, CA, USA) by applying a standard four-parameter IC50 function. The obtained IC50 
values were converted into their corresponding KD values using the following derivation 
of the Cheng-Prusoff equation (Equation 2)36: 
 
  
KD =
I 50
L50
KD
+
P0
K D
+1
 (2) 
where I50 and L50 are the concentrations of inhibitor and ligand at half-maximal 
inhibition, respectively, and P0 is the free concentration of protein in the absence of 
inhibitor. This variation of the Cheng-Prusoff equation is applied to competition assays 
with tight-binding inhibitors.36 
 
FimH-templated DCLs. The aldehyde (1.26 PL each if more than one aldehyde, 10 mM, 
DMSO), hydrazides (1.26 PL each, 10 mM, DMSO), and aniline (5 PL, 1M, DMSO) 
were added to the protein solution (500 PL, 25-30 PM in sodium phosphate buffer 50 
mM, pH 7.0). For native full-length FimH, the lectin domain of FimH, and the BSA 
control, the protein concentrations are 25.0 PM, 30.5 PM and 0.44 mg  mL-1, 
respectively. The amount of DMSO should be adjusted to less than 3%. To establish a 
blank DCL composition, same buffer solution was used to set up the reaction accordingly. 
The DCL was allowed to stand at room temperature, and was monitored periodically by 
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HPLC. At the set-up time points, the pH of the reaction was raised to 13 by adding NaOH 
(10 PL, 10M, aqueous) to 100 PL reaction system, and the denatured protein was 
removed by ultrafiltration using 5,000 MWCO filter (Spin-X). HPLC analysis was 
performed and the traces were compared with the blank composition (HPLC conditions: 
column, Atlantis T3 3 Pm, C18, 21u150 mm; flow rate, 0.5 mL min-1; wavelength, 310 
nm; temperature, 30 qC; gradient H2O/MeCN (0.01% TFA) from 95% to 55% over 53 
min). All of the experiments were performed in triplicate.  
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2.8 Synthesis and Evaluation of 6-Modified Mannosides as FimH 
Antagonists 
This chapter describes structural modifications on n-heptyl mannoside by either 
stereochemically locking 6-hydroxyl group with a cyclopropane unit or introducing a 6-
methyl, aiming at exploring possible interactions within the binding pocket and 
expanding the structural scope of FimH ligands. The chemical structures of the 
synthesized ligands were characterized by NMR and Mosher’s analysis. The binding 
affinity of the synthesized ligands was evaluated by fluorescence polarization (FP) assay. 
As a result, the direction of 6-hydroxyl indeed affects ligand-FimH protein interaction. 
Furthermore, the cyclopropane derivatives provide new scaffolds for other receptors that 
bind to 1C4 conformational mannosides. 
Contribution to the project: 
Lijuan Pang synthesized and characterized all the reported compounds. 
Keywords 
Uropathogenic Escherichia coli, urinary tract infection, bacterial adhesin FimH, FimH 
antagonists, n-heptyl mannoside, NMR, Mosher’s analysis, fluorescence polarization 
assay 
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2.8.1 Introduction 
Urinary tract infections (UTIs), among the most prevalent infectious diseases, are 
primarily caused by gram-negative uropathogenic Escherichia coli (UPEC).1 Most UPEC 
isolates express type 1 pili, where bacterial lectin FimH is located.2 The carbohydrate 
recognition domain (CRD) of FimH binds to mannose-containing receptors on human 
bladder epithelial cells and thus mediates UPEC adherence and invasion.3 FimH-CRD 
consists of amino acids with hydrophilic side chains therefore can establish extensive 
hydrogen-bond network with the hydroxyl groups of D-mannose.4 In addition, at the 
entrance of the binding pocket, three hydrophobic amino acids (Tyr48, Ile52, and Tyr137) 
form the so called “tyrosine gate”, which can accommodate aliphatic or aromatic 
aglycones.5, 6 Based on the crystal structures, numerous FimH antagonists have been 
developed for the prevention and treatment of UTIs.7 
So far, the reported FimH antagonists can be categorized into two major classes: long-
chain alkyl mannosides6 and mannosides with extended aromatic aglycones8-12 (Figure 
2.8.1). Although the aglycones of FimH antagonists were extensively modified, few 
studies on the sugar moiety were reported.10 n-Heptyl mannoside (1), commonly used 
reference in bioassays, was chosen as a model compound in this study. To further extend 
the structural scope, we modified the mannose by either stereochemically locking 6-
hydroxyl group with a cyclopropane unit or introducing a methyl group at C-6 (Figure 
2.8.2). Here we used NMR-based methods and Mosher’s analysis13 to characterize the 
chemical structures of 6-modified ligands and fluorescence polarization assay14 to 
evaluate their binding affinities. 
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Figure 2.8.1. FimH antagonists: n-heptyl D-D-mannoside (1)6; the squaric acid derivative (2)9, biphenyl 
derivatives (3-4)10, 11, and indolinylphenyl mannoside (5)12. 
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Figure 2.8.2. Structure design of 6-modified n-heptyl mannoside (1). 
2.8.2 Chemical Synthesis 
2.8.2.1 Synthesis of cyclopropane derivatives 6 and 7 (Scheme 2.8.1) 
Our starting point of synthesis was n-heptyl mannoside (1) that was efficiently protected 
with tert-butyldimethylsilyl (TBDMS) at 6-position followed by global benzylation to 
yield 10. TBDMS deprotection under acidic condition gave 11. Swern oxidation of 6-
hydroxyl afforded aldehyde intermediate, which was subsequently transformed into enol 
acetate 12 in the presence of acetic anhydride and potassium carbonate.15 The structure of 
(Z)-configured 12 was characterized by 2D-NMR and NOESY experiments. In a 
Simmons-Smith-Furukawa reaction16, olefin 12 was transformed into C-5 cyclopropane 
derivatives. The resulting diastereoisomers were separated after deacetylation under 
Zemplén conditions to afford 13 and 14. Conformational analysis by 1H NMR and 2D-
NMR experiments revealed that in contrast to n-heptyl mannoside (1), the cyclopropanes 
13 and 14 did not adopt the common 4C1 but a 1C4 chair conformation (Figure 2.8.3). 
Hydrogenolysis afforded the cyclopropanated mannosides 6 and 7. 
2.8.2.2. Synthesis of 6-methyl derivatives 8 and 9 (Scheme 2.8.2) 
Previously synthesized compound 11 was subjected to a Swern oxidation reaction 
followed by carbonyl addition in the presence of methyl lithium. The 6-methylated 15
and 16 were obtained in a ratio of 1:1 and could be separated by careful chromatography. 
Hydrogenolysis afforded the modified mannosides 8 and 9 in good yields. The absolute 
configuration of the newly generated 6-carbinol was deduced by Mosher’s analysis.13 
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Scheme 2.8.1. Reagents and conditions: a) TBDMSCl, triethylamine, DMAP, DMF, 0qC to rt, overnight; 
b) BnBr, NaH, TBAI, THF, 0qC to rt, overnight (60% for two steps); c) H2SO4, MeOH, rt, overnight (90%);
d) i. oxalyl chloride, DMSO, triethylamine, DCM, -78qC to rt, 4h; ii. K2CO3, Ac2O, acetonitrile, reflux, 
overnight (80%); e) ZnEt2, CH2I2, 1,2-dichloroethane, 50qC, overnight (40%); f) NaOMe, MeOH, rt, 1h 
(74% for 13, 43% for 14); g) Pd/C, H2 (g), MeOH/DCM/EtOAc (3:1:1), rt, 1h (85% for 6, 83% for 7). 
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Figure 2.8.3. Coupling constants determined by 1H NMR and 2D-COSY in D2O. 
2.8.2.3 Synthesis of 6-methyl derivatives 8 and 9 (Scheme 2.8.2) 
Previously synthesized compound 11 was subjected to a Swern oxidation reaction 
followed by carbonyl addition in the presence of methyl lithium. The 6-methylated 15
and 16 were obtained in a ratio of 1:1 and could be separated by careful chromatography. 
Hydrogenolysis afforded the modified mannosides 8 and 9 in good yields. The absolute 
configuration of the newly generated 6-carbinol was deduced by Mosher’s analysis.13 
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Scheme 2.8.3. Reagents and conditions: S-(+)- or R-(-)-MTPA-Cl, pyridine, DCM, rt, overnight (40%).
2.8.3 Structural Characterization - Mosher’s Analysis 
R- and S-Mosher esters (17 and 18) were synthesized from 15 and S-(+)-/R-(-)-MTPA 
chloride (Scheme 2.8.3), respectively.13 The phenyl substituent in each of the MTPA 
esters imposes a magnetic shielding effect on protons residing above/below the phenyl 
ring, resulting in a more upper field chemical shift for the affected protons in the NMR 
spectrum. 1H NMR spectral data of the diastereomeric esters (17 and 18) were 
comparatively analyzed, and the chemical shifts were listed in Table 2.8.1. ∆GSR values 
(defined, by convention, to be GS - GR) were calculated. By observing a positive ∆GSR of 5-
proton versus a negative value of 6-methyl, we can deduce that 5-proton is shielded in R-
ester (17) and 6-methyl is shielded in S-ester (18), therefore the absolute configuration of 
C-6 in 15 is S. Thus the absolute configuration of C-6 in 16 is R. 
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Table 2.8.1. ∆G (=GS - GR) data for the R- and S-MTPA Mosher esters (17 and 18).13 
G R-ester (17) G S-ester (18) ∆GSR (=GS - GR)
(ppm) (ppm) ppm Hz (500 MHz) 
6-Me 1.47 1.34 -0.13 -65 
H-6 5.61 5.70 +0.09 45 
H-5 3.55 3.59 +0.04 20 
H-4 3.76 3.86 +0.10 50 
H-3 3.87 3.91 +0.04 20 
H-2 3.71 3.76 +0.05 25 
H-1 4.85 4.86 +0.01 5 
2.8.4 Biological Evaluation 
To evaluate the binding affinity of modified n-heptyl mannosides (6-9), we used a 
competitive binding assay based on fluorescence polarization (FP) as descried in Chapter 
2.4. In a FP-assay, the test compound displaces a fluorescent-labeled competitor from the 
binding site, thereby reducing fluorescence polarization. Before the measurement of 
fluorescence polarization, a 24 h incubation time was applied in the presence of FimH-
CRD. The assay was performed twice for each compound with each concentration in 
duplicate. IC50 values were obtained by nonlinear least-squares regression (standard four-
parameter IC50 equation) and converted to KD using a modified Cheng-Prusoff equation. 
The KD values observed for the test compounds are summarized in Table 2.8.2.
Table 2.8.2. Affinity of synthesized antagonists to FimH-CRD-Th-His6. Dissociation constants (Kd) were 
determined in a competitive fluorescence polarization assay.  
Entry Cpd Structure Kd >PM@ 
1 1
O
OH
OH
HO
HO
O
0.028 
2 6
O O
OH
OH
OH
OH > 30 
3 7 O O
OH
OH
OH
HO ---a
4 8
O
OH
OH
HO
HO
O
Me 7.5 
5 9
O
OH
OH
HO
HO
O
Me 2.6 
a. The binding affinity was not detectable.
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In general, the modified compounds (6-9) have shown lower affinity than n-heptyl 
mannoside (1) toward FimH-CRD. More than 1000-fold affinity decrease was observed 
with 6 and 7 due to conformational change of the sugar ring. The affinity difference 
between 8 and 9 shows that the direction of 6-hydroxyl group affects the binding affinity, 
and the decreased affinity indicates that the methyl group might be too bulky to fit into 
the binding pocket. 
2.8.5 Conclusion 
The modified heptyl mannosides 6-9 have shown different binding affinities, indicating 
that the direction of 6-hydroxyl indeed affects the ligand-protein interaction.  However, 6-
methyl is too bulky to maintain the high affinity; a fine tune of 6-substituent could be 
beneficial for further development of FimH antagonists. NMR analysis of derivatives 6 
and 7 revealed the structural details of the stereochemically locked mannosides. Locking 
6-hydroxyl of D-mannoses with cyclopropane unit provide new scaffolds for other protein 
targets that bind to 1C4 conformational mannosides.17 
2.8.6 Experimental Section 
General methods. NMR spectra were recorded on a Bruker Avance DMX-500 (500.1 
MHz) spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D 
methods (COSY, HSQC, HMBC). Chemical shifts are expressed in ppm using residual 
CHCl3, CHD2OD or HDO as references. Optical rotations were measured using Perkin-
Elmer Polarimeter 341. Electron spray ionization mass spectra (ESI-MS) were obtained 
on a Waters micromass ZQ. Reactions were monitored by TLC using glass plates coated 
with silica gel 60 F254 (Merck) and visualized by using UV light and/or by charring with a 
molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and 
ammonium molybdate tetrahydrate in aqueous 10% H2SO4). MPLC separations were 
carried out on a CombiFlash Companion or Rf from Teledyne Isco equipped with 
RediSep normal-phase or RP-18 reversed-phase flash columns. Commercially available 
reagents were purchased from Fluka, Aldrich, or Alfa Aesar. Solvents were purchased 
from Sigma-Aldrich (Buchs, Switzerland) or Acros Organics (Geel, Belgium) and were 
dried prior to use where indicated. Methanol (MeOH) was dried by refluxing with sodium 
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methoxide and distilled immediately before use. Dichloromethane (DCM) and 
acetonitrile were dried by filtration over Al2O3 (Fluka, type 5016 A basic). Molecular 
sieves 4Å were activated in vacuo at 500°C for 1 h immediately before use. 
Compound 10:  TBDMSCl (0.91g, 6.04 mmol), triethylamine (2.5 mL, 17.6 mmol), and 
DMAP (31 mg, 0.25 mmol) were added to a solution of n-heptyl mannoside (1)6 (1.4 g, 
5.03 mmol) in DMF (5 mL) cooled at 0 °C. The mixture was stirred at 0°C for 1h, and 
then at rt overnight. The reaction mixture was diluted with EtOAc (50 mL), filtered over 
celite, and then the filtrate was extracted with water (50 mL) and brine (50 mL). The 
organic layer was dried over Na2SO4, filtered and concentrated in vacuo to give the crude 
intermediate, which was then used directly. To a solution of the intermediate in dry THF 
(10 mL) at 0°C, NaH (60%, 0.8 g, 20 mmol), BnBr (1.6 mL, 13.3 mmol) and 
tetrabutylammonium iodide (61 mg, 0.17 mmol) were added. The reaction mixture was 
then stirred at 0°C to rt overnight. The reaction was diluted with EtOAc (50 mL), 
extracted with water (50 mL u 3). The organic layer was dried over Na2SO4, filtered and 
concentrated. The residue was purified by MPLC on silica gel (petrol ether (PE)/EtOAc 
10:1) to afford compound 10 (1.9 g, 60% for two steps) as colorless oil. Rf = 0.61 
(PE/EtOAc, 10:1); [D]D20 +22.9 (c 2.0, EtOAc); 1H NMR (500 MHz, CDCl3): G 7.37 - 
7.20 (m, 15H, H-Ar), 4.86 (d, J = 10.9 Hz, 1H, CHPh), 4.74 (d, J = 1.3 Hz, 1H, H-1), 
4.68 (d, J = 12.4 Hz, 1H, CHPh), 4.64 - 4.53 (m, 4H, 4 CHPh), 3.88 - 3.82 (m, 2H, H-3, 
H-4), 3.82 - 3.74 (m, 2H, H-6a, H-6b), 3.69 (s, 1H, H-2), 3.61 – 3.50 (m, 2H, H-5, OCH-
heptyl), 3.25 (dt, J = 9.6, 6.6 Hz, 1H, OCH-heptyl), 1.48 - 1.39 (m, 2H, CH2-heptyl), 1.28 
- 1.13 (m, 8H, 4 CH2-heptyl), 0.88 - 0.79 (m, 12H, CH3-heptyl, tBu), 0.01 (d, J = 5.6 Hz, 
6H, 2 SiCH3); 13C NMR (126 MHz, CDCl3): G 138.77, 138.71, 138.61, 128.34, 128.31, 
128.24, 128.02, 127.67, 127.65, 127.57, 127.47, 127.43 (C-Ar), 97.49 (C-1), 80.39 (C-3), 
75.29 (C-2), 75.12 (CH2Ph), 75.08 (C-4), 73.22 (C-5), 72.49, 72.18 (2 CH2Ph), 67.35 
(OCH2), 62.89 (C-6), 31.78, 29.43, 29.10, 26.11, 25.94 (5 CH2), 22.61, 18.31, 14.09, -
5.12, -5.27 (6 CH3); ESI-MS: m/z: calcd for C40H58NaO6Si >M + Na@+: 685.39, found: 
685.46. 
Compound 11: To a solution of 10 (0.85 g, 1.3 mmol) in MeOH (7 mL) at rt was added 
1N H2SO4 in MeOH (130 PL, 0.13 mmol). The reaction mixture was stirred at rt 
overnight and then concentrated. The residue was purified by MPLC on silica gel 
(PE/EtOAc 4:1) to afford compound 11 (0.64 g, 90%) as colorless oil. Rf = 0.42 
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(PE/EtOAc, 4:1); [D]D20 +16.5 (c 0.4, EtOAc); 1H NMR (500 MHz, CDCl3): G 7.42 - 7.26 
(m, 15H, H-Ar), 4.94 (d, J = 10.9 Hz, 1H, CHPh), 4.81 – 4.76 (m, 2H, 2 CHPh), 4.74 - 
4.61 (m, 4H, H-1, 3 CHPh), 4.01 - 3.90 (m, 2H, H-3, H-4), 3.89 - 3.68 (m, 3H, H-2, H-6a, 
H-6b), 3.70 - 3.53 (m, 2H, H-5, OCH-heptyl), 3.32 (dt, J = 9.6, 6.6 Hz, 1H, OCH-heptyl), 
1.54 - 1.44 (m, 2H, CH2-heptyl), 1.35-1.18 (m, 8H, 4 CH2-heptyl), 0.91 - 0.82 (m, 3H, 
CH3); 13C NMR (126 MHz, CDCl3): G 138.53, 138.41, 138.37, 128.43, 128.37, 128.11, 
127.81, 127.75, 127.67, 127.62, 127.57 (C-Ar), 98.19 (C-1), 80.32 (C-3), 75.27 (C-4), 
75.04 (2C, C-2, CH2Ph), 72.92, 72.27(2 CH2Ph), 72.08 (C-5), 67.73 (OCH2), 62.49 (C-6), 
31.75, 29.40, 29.07, 26.06, 22.62 (5 CH2), 14.09 (CH3); ESI-MS: m/z: calcd for 
C34H44NaO6 >M + Na@+: 571.30, found: 571.38. 
Compound 12: To a solution of oxalyl chloride (37 PL, 0.43 mmol) in DCM (1 mL) at -
78°C, a solution of DMSO (28 PL, 0.40 mmol) in DCM (0.5 mL) was added. After 5 
min, a solution of 11 (196 mg, 0.36 mmol) in DCM (1 mL) was added to the reaction 
mixture. After 15 min, triethylamine (0.25 mL, 1.8 mmol) was added at -78°C. The 
reaction mixture was stirred at -78°C for another 10 min, and then allowed to warm up to 
rt. The reaction mixture was diluted with DCM (10 mL), extracted with sat.NH4Cl (10 
mL) and brine (10 mL). The organic layer was concentrated, azeotroped with tolune (5 
mL u 3), and then dried in vacuo for 3h. The residue was dissolved with dry acetonitrile 
(5 mL), mixed with K2CO3 (100 mg, 0.72 mmol) and Ac2O (70 PL, 0.72 mmol) at rt. And 
then the reaction mixture was stirred at 80°C overnight. The reaction mixture was then 
filtered through celite, concentrated and purified by MPLC on silica gel (PE/EtOAc, 6:1) 
to afford the enol ether 12 (119 mg, 57%) as colorless oil. Rf = 0.42 (PE/EtOAc, 6:1); 
[D]D20 -19.3 (c 1.0, EtOAc); 1H NMR (500 MHz, CDCl3): G 7.37 - 7.26 (m, 15H, H-Ar), 
7.02 (d, J = 0.7 Hz, 1H, H-6), 4.97 (d, J = 4.4 Hz, 1H, H-1), 4.79 - 4.56 (m, 6H, 6 CHPh), 
4.18 (d, J = 7.2 Hz, 1H, H-4), 3.94 - 3.88 (m, 2H, H-3, OCH-heptyl), 3.86 - 3.81 (m, 1H, 
H-2), 3.50 (dt, J = 9.3, 6.7 Hz, 1H, OCH-heptyl), 2.16 (s, 3H, OAc), 1.61 - 1.55 (m, 2H, 
CH2-heptyl), 1.34 - 1.20 (m, 8H, 4 CH2-heptyl), 0.88 (t, J = 6.9 Hz, 3H, CH3); 13C NMR 
(126 MHz, CDCl3): G 167.47 (CO), 138.41, 138.36, 137.85, 135.71, 128.41, 128.33, 
127.85, 127.72, 127.70, 127.62, 122.75 (C-Ar), 100.77 (C-1), 78.14 (C-3), 75.88 (C-2), 
74.41 (C-4), 73.33, 72.95, 72.52 (3 CH2Ph), 69.25 (OCH2), 31.79, 29.45, 29.08, 26.04, 
22.61 (5 CH2), 20.68 (COCH3), 14.09 (CH3); ESI-MS: m/z: calcd for C36H44NaO7 >M + 
Na@+: 611.30, found: 611.16. 
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Compound 13 and 14:  A two-neck flash was charged with 12 (650 mg, 1.1 mmol), 
CH2I2 (0.89 mL, 11.1 mmol), 4Å sieves (1.3 g), dry 1,2-dichloroethane (11 mL) and a 
stirring bar. The reaction mixture was stirred at 50°C under argon atmosphere for 2h. 
Then the reaction mixture was cooled with ice-bath, and added with ZnEt2 (1M in 
Hexane, 5.5 mL, 5.5 mmol) dropwise. After 5 min at rt, the reaction mixture was stirred 
at 50°C overnight. The reaction mixture was cooled to rt, diluted with DCM (50 mL), 
extracted with sat.NaHCO3 (50 mL u 3). The organic layer was dried over Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by MPLC on silica gel (PE/ 
EtOAc, 8:1) to give the acetate intermediates (265 mg, isomer ratio 2:1, 40%). The 
isomers were dissolved in MeOH (2 mL) and added with freshly prepared 0.5 M 
NaOMe/MeOH (0.1 equiv) under argon. The mixture was stirred at rt for 1h, and then 
neutralized with Amberlyst-15 (H+) ion-exchange resin, filtered and concentrated in 
vacuo. The residue was purified by MPLC (PE/EtOAc 4:1) to give the products as 
colorless oil.  
Compound 13: Yield: 127 mg, 73%. Rf = 0.33 (PE/EtOAc, 4:1); [D]D20 +15.2 (c 1.0, 
EtOAc); 1H NMR (500 MHz, CDCl3): G 7.40 - 7.22 (m, 13H, H-Ar), 7.21 - 7.15 (m, 2H, 
H-Ar), 4.90 (d, J = 4.6 Hz, 1H, H-1), 4.79 (d, J = 12.1 Hz, 1H, CHPh), 4.74 (d, J = 12.1 
Hz, 1H, CHPh), 4.72-4.60 (m, 3H, 3 CHPh), 4.50 (d, J = 11.7 Hz, 1H, CHPh), 3.91 (dd, J 
= 6.8, 3.0 Hz, 1H, H-3), 3.80 (dd, J = 4.4, 3.2 Hz, 1H, H-2), 3.74 (dt, J = 9.3, 6.7 Hz, 1H, 
OCH-heptyl), 3.60 (s, 1H, H-4), 3.39 (dt, J = 9.4, 6.7 Hz, 1H, OCH-heptyl), 3.34 (dt, J = 
7.4, 3.9 Hz, 1H, H-6), 2.02 (d, J = 4.7 Hz, 1H, OH), 1.59 - 1.50 (m, 2H, CH2-heptyl), 
1.29 (td, J = 12.5, 5.9 Hz, 8H, 4 CH2-heptyl), 1.04 (t, J = 7.3 Hz, 1H, H-7a), 0.88 (t, J = 
6.9 Hz, 3H, CH3), 0.69 (dd, J = 7.4, 4.2 Hz, 1H, H-7b); 13C NMR (126 MHz, CDCl3): G 
138.58, 138.30, 128.39, 128.35, 127.88, 127.66, 127.63, 127.60 (C-Ar), 100.42 (C-1), 
78.25 (C-3), 76.36 (C-2), 75.89 (C-4), 73.44, 72.91(3 CH2Ph), 69.18 (OCH2), 57.02 (C-
5), 50.29 (C-6), 31.81, 29.55, 29.15, 26.04, 22.63 (5 CH2), 16.43 (C-7), 14.12 (CH3); ESI-
MS: m/z: calcd for C35H44NaO6 >M + Na@+: 583.30, found: 583.34.  
Compound 14: Yield: 35 mg, 43%. Rf = 0.33 (PE/EtOAc, 4:1); [D]D20 +20.7 (c 1.3, 
EtOAc); 1H NMR (500 MHz, CDCl3): G 7.40 - 7.24 (m, 13H, H-Ar), 7.21 - 7.17 (m, 2H, 
H-Ar), 4.80 – 4.74 (m, 3H, H-1, 2 CHPh), 4.67 (s, 2H, 2 CHPh), 4.65 -4.59 (m, 1H, 
CHPh), 4.47 (d, J = 11.7 Hz, 1H, CHPh), 3.87 (dd, J = 6.3, 3.0 Hz, 1H, H-3), 3.79 - 3.61 
(m, 3H, H-2, H-4, OCH-heptyl), 3.50 - 3.43 (m, 1H, H-6), 3.37 (dt, J = 9.4, 6.9 Hz, 1H, 
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OCH-heptyl), 2.96 (d, J = 2.6 Hz, 1H, OH), 1.56 – 1.45 (m, 2H, CH2-heptyl), 1.34 - 1.20 
(m, 8H, 4 CH2-heptyl), 0.93 (t, J = 7.2 Hz, 1H, H-7a), 0.88 (t, J = 7.0 Hz, 3H, CH3), 0.83 
(dd, J = 7.3, 4.3 Hz, 1H, H-7b); 13C NMR (126 MHz, CDCl3): G 138.43, 138.35, 138.12, 
128.39, 128.38, 128.36, 127.97, 127.79, 127.74, 127.69, 127.66, 127.49 (C-Ar), 101.14 
(C-1), 78.02 (C-3), 76.39 (C-4), 76.10 (C-2), 73.48, 73.19, 73.06 (3 CH2Ph), 70.12 
(OCH2), 59.43 (C-5), 49.81 (C-6), 31.72, 29.59, 28.98, 25.88, 22.59 (5 CH2), 18.16 (C-7), 
14.07 (CH3); ESI-MS: m/z: calcd for C35H44NaO6 >M + Na@+: 583.30, found: 583.34. 
Compound 6 and 7: To a solution of 13 or 14 (10 mg, 0.017 mmol, 1.0 eq.) in a mixture 
of MeOH/DCM/EtOAc (3:1:1, 0.5 mL) Pd/C (10 wt.% on activated carbon, 10 mg) was 
added under argon atmosphere. The argon was exchange by a hydrogen atmosphere and 
the reaction mixture was stirred at rt for 1h. The reaction mixture was filtered through 
celite and concentrated. The residue was purified by MPLC on silica gel (DCM/MeOH 
8:1) to afford 6 or 7 as colorless oil.  
Compound 6: Rf = 0.26 (DCM/MeOH, 8:1); [D]D20 +68.4 (c 0.1, MeOH); 1H NMR (500 
MHz, D2O): G 4.75 (d, J = 7.1 Hz, 1H, H-1), 3.98 (t, J = 3.4 Hz, 1H, H-3), 3.82 – 3.76 
(dd, J = 16.7, 7.1 Hz, 1H, OCH-heptyl); 3.72 (dd, J = 6.9, 3.2 Hz, 1H, H-2), 3.55 (dd, J = 
16.7, 7.1 Hz, 1H, OCH-heptyl), 3.41 (dd, J = 7.5, 4.5 Hz, 1H, H-6), 3.27 (d, J = 4.2 Hz, 
1H, H-4), 1.61 - 1.48 (m, 2H, CH2), 1.32-1.14 (m, 8H, 4 CH2), 0.96 (t, J = 7.8 Hz, 1H, H-
7a), 0.79 (t, J = 7.0 Hz, 3H, CH3), 0.73 (dd, J = 7.6, 4.5 Hz, 1H, H-7b); 13C NMR (126 
MHz, D2O): G 99.88 (C-1), 71.79 (C-4), 70.97 (C-3), 70.28 (OCH2), 68.30 (C-2), 58.99 
(C-5), 51.26 (C-6), 31.00, 28.61, 28.19, 25.02, 21.95 (5 CH2), 13.64 (C-7), 13.36 (CH3); 
ESI-MS: m/z: calcd for C14H26NaO6 >M + Na@+: 313.1622, found: 313.1622. 
Compound 7: Rf = 0.35 (DCM/MeOH, 8:1); [D]D20 +93.8 (c 0.1, MeOH); 1H NMR (500 
MHz, D2O): G 4.75 (d, J = 7.3 Hz, 1H, H-1), 4.00 (t, J = 3.8 Hz, 1H, H-3), 3.85 - 3.73 (m, 
2H, H-2, OCH-heptyl), 3.56 (dt, J = 10.7, 6.9 Hz, 1H, OCH-heptyl), 3.44 (dd, J = 7.4, 4.8 
Hz, 1H, H-6), 3.28 (d, J = 4.3 Hz, 1H, H-4), 1.61 – 1.48 (m, 2H, CH2), 1.34 – 1.14 (m, 
8H, 4 CH2), 1.03 (t, J = 7.1 Hz, 1H, H-7a), 0.90 - 0.84 (m, 1H, H-7b), 0.80 (t, J = 6.7 Hz, 
3H, CH3); 13C NMR (126 MHz, D2O): G 100.54 (C-1), 72.09 (C-4), 71.46 (C-3), 70.51 
(OCH2), 68.59 (C-2), 59.52 (C-5), 49.81 (C-6), 31.02, 28.69, 28.18, 25.03, 21.95 (5 CH2), 
17.30 (C-7), 13.36 (CH3); ESI-MS: m/z: calcd for C14H26NaO6 >M + Na@+: 313.1622, 
found: 313.1622. 
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Compound 15 and 16: To a solution of oxalyl chloride (37 PL, 0.43 mmol) in DCM (1 
mL) at -78°C, a solution of DMSO (28 PL, 0.40 mmol) in DCM (0.5 mL) was added. 
After 5 min, a solution of 11 (200 mg, 0.36 mmol) in DCM (1 mL) was added to the 
reaction mixture. After 15 min, triethylamine (0.26 mL, 1.8 mmol) was added at -78°C. 
The reaction mixture was stirred at -78°C for another 10 min, and then allowed to warm 
up to rt. The reaction mixture was diluted with DCM (10 mL), extracted with sat.NH4Cl 
(10 mL) and brine (10 mL). The organic layer was concentrated, azeotroped with tolune 
(5 mL u 3), and then dried in vacuo for 3h. To a solution of the residue in dry THF (2 mL) 
at -78°C was added MeLi (1.6 M in diethyl ether, 0.36 mL, 0.36 mmol). The reaction 
mixture was stirred at -78°C to rt for 6h. The reaction mixture was quenched with ice 
water (10 mL), and then extracted with DCM (10 mL u 2). The organic layer was dried 
over Na2SO4, filtered and concentrated in vacuo. The residue was purified by MPLC on 
silica gel (PE/EtOAc 4:1) to give compound 15 and 16 (1:1, 40 mg, 40%) as colorless oil. 
Compound 15: Rf = 0.40 (PE/EtOAc 4:1); [D]D20 +19.2 (c 0.9, EtOAc); 1H NMR (500 
MHz, CDCl3): G 7.38 - 7.26 (m, 15H, H-Ar), 4.95 (d, J = 10.7 Hz, 1H, CHPh), 4.82 (d, J 
= 1.4 Hz, 1H, H-1), 4.79 (d, J = 12.2 Hz, 1H, CHPh), 4.70 (d, J = 4.1 Hz, 1H, CHPh), 
4.68 (d, J = 5.8 Hz, 1H, CHPh), 4.66 (d, J = 1.8 Hz, 2H, CHPh), 4.09 (t, J = 9.5 Hz, 2H, 
H-4, H-6), 3.90 (dd, J = 9.4, 3.0 Hz, 1H, H-3), 3.78 - 3.76 (m, 1H, H-2), 3.58 (dt, J = 9.5, 
6.8 Hz, 1H, OCH-heptyl), 3.40 (dd, J = 9.7, 1.0 Hz, 1H, H-5), 3.32 (dt, J = 9.6, 6.4 Hz, 
1H, OCH-heptyl), 1.54 - 1.47 (m, 2H, CH2), 1.29 (dd, J = 15.3, 6.9 Hz, 11H, 4 CH2, CH3-
6), 0.88 (t, J = 6.8 Hz, 3H, CH3-heptyl); 13C NMR (126 MHz, CDCl3): G 138.61, 138.55, 
138.46, 128.42, 128.40, 128.36, 128.14, 127.76, 127.70, 127.67, 127.63, 127.62, 127.54 
(C-Ar), 98.22 (C-1), 80.45 (C-3), 75.33 (CH2Ph), 75.14 (C-2), 75.09 (C-4), 74.37 (C-5), 
72.86, 72.25 (2 CH2Ph), 67.60 (OCH2), 65.62 (C-6), 31.76, 29.41, 29.08, 26.16, 22.63 (5 
CH2), 20.33 (CH3-6), 14.10 (CH3-heptyl); ESI-MS: m/z: calcd for C35H46NaO6 >M + 
Na@+: 585.32, found: 585.36. 
Compound 16: Rf = 0.45 (PE/EtOAc 4:1); [D]D20 +29.2 (c 0.8, EtOAc); 1H NMR (500 
MHz, CDCl3): G 7.40 - 7.25 (m, 15H, H-Ar), 4.99 (d, J = 10.9 Hz, 1H, CHPh), 4.79 (d, J 
= 1.6 Hz, 1H, H-1), 4.75 (d, J = 12.4 Hz, 1H, CHPh), 4.71 – 4.59 (m, 4H, CHPh), 4.04 (s, 
1H, H-6), 3.97 - 3.89 (m, 2H, H-3, H-4), 3.77 (s, 1H, H-2), 3.62 (dt, J = 9.5, 6.8 Hz, 1H, 
OCH-heptyl), 3.54 (dd, J = 8.5, 5.1 Hz, 1H, H-5), 3.31 (dt, J = 9.5, 6.5 Hz, 1H, OCH-
heptyl), 2.83 (d, J = 3.5 Hz, 1H, OH), 1.56 - 1.48 (m, 2H, CH2), 1.33 – 1.23 (m, 8H, 4 
CH2), 1.21 (d, J = 6.3 Hz, 3H, CH3-6), 0.88 (t, J = 6.2 Hz, 3H, CH3-heptyl); 13C NMR 
Chapter 2.8 
419 
(126 MHz, CDCl3): G 138.38, 138.32, 138.00, 128.50, 128.42, 128.37, 128.14, 127.87, 
127.73, 127.66 (C-Ar), 97.88 (C-1), 80.61 (C-4), 74.98 (C-3), 74.91 (C-2), 73.71 
(CH2Ph), 72.76 (C-5), 72.03 (2 CH2Ph), 68.82 (C-6), 67.63 (OCH2), 31.78, 29.40, 29.10, 
26.12, 22.63 (5 CH2), 18.16 (CH3-6), 14.11(CH3-heptyl); ESI-MS: m/z: calcd for 
C35H46NaO6 >M + Na@+: 585.32, found: 585.36. 
Compound 8 and 9: To a solution of 15 or 16 (7 mg, 0.012 mmol) in a mixture of 
MeOH/DCM/EtOAc (3:1:1, 0.5 mL) Pd/C (10 wt.% on activated carbon, 7 mg) was 
added under argon atmosphere. The argon was exchange by a hydrogen atmosphere and 
the reaction mixture was stirred at rt for 1h. The reaction mixture was filtered through 
celite and concentrated. The residue was purified by MPLC on silica gel (DCM/MeOH 
8:1) to afford 8 or 9 as colorless oil. 
Compound 8: Yield: 3 mg, 83%; Rf = 0.40 (DCM/MeOH 8:1); [D]D20 +77.3 (c 0.8, 
MeOH); 1H NMR (500 MHz, MeOD): G 4.79 (s, 1H, H-1), 4.13 (q, J = 6.4 Hz, 1H, H-5), 
3.87 - 3.75 (m, 2H, H-2, H-4), 3.70 (t, J = 8.2 Hz, 2H, H-3, OCH-heptyl), 3.44 (dd, J = 
15.5, 6.5 Hz, 1H, OCH-heptyl), 3.30 (1H, H-6), 1.61 (s, 2H, CH2), 1.45 – 1.32 (m, 8H, 4 
CH2), 1.29 (d, J = 6.6 Hz, 3H, CH3-6), 0.93 (t, J = 6.3 Hz, 3H, CH3-heptyl); 13C NMR
(126 MHz, MeOD): G 101.70 (C-1), 76.09 (C-6), 72.99 (C-3), 72.37 (C-2), 68.60 (C-4), 
68.41 (OCH2), 65.99 (C-5), 32.98, 30.62, 30.24, 27.41, 23.70 (5 CH2), 20.37 (CH3-6), 
14.42 (CH3-heptyl); ESI-MS: m/z: calcd for C14H28NaO6 >M + Na@+: 315.1778, found: 
315.1779. 
Compound 9: Yield: 3.2 mg, 88%; Rf = 0.42 (DCM/MeOH 8:1); [D]D20 +80.8 (c 0.86, 
MeOH); 1H NMR (500 MHz, MeOD): G 4.74 (d, J = 1.2 Hz, 1H, H-1), 4.07 - 4.02 (m, 
1H, H-5), 3.79 (dd, J = 3.1, 1.6 Hz, 1H, H-2), 3.76 (dt, J = 9.5, 6.7 Hz, 1H, OCH-heptyl), 
3.70 (dd, J = 9.3, 3.3 Hz, 1H, H-3), 3.65 (t, J = 9.4 Hz, 1H, H-4), 3.47 (dd, J = 9.4, 4.3 
Hz, 1H, H-6), 3.41 (dt, J = 9.6, 6.3 Hz, 1H, OCH-heptyl), 1.66 - 1.57 (m, 2H, CH2), 1.45 
- 1.30 (m, 8H, 4 CH2), 1.27 (d, J = 6.4 Hz, 3H, CH3-6), 0.93 (t, J = 6.9 Hz, 3H, CH3-
heptyl); 13C NMR (126 MHz, MeOD): G 101.52 (C-1), 75.89 (C-6), 72.80 (C-3), 72.15 
(C-2), 70.87 (C-4), 69.37 (C-5), 68.48 (OCH2), 33.02, 30.62, 30.28, 27.38, 23.70 (5 CH2), 
17.99 (CH3-6), 14.43 (CH3-heptyl); ESI-MS: m/z: calcd for C14H28NaO6 >M + Na@+: 
315.1778, found: 315.1779. 
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Compound 17 and 18: To a solution of 15 (19 mg, 0.03 mmol) in dry DCM (1 mL) was 
added S-(+)- MTPA chloride or R-(-)-MTPA chloride (17 mg, 0.06 mmol) and pyridine 
(8 PL, 0.10 mmol) at rt. The reaction mixture was stirred at rt for 2h. The reaction 
mixture was then diluted with ethyl ether (10 mL) and extracted with water (10 mL u 2). 
The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue 
was purified by MPLC on silica gel (PE/EtOAc 4:1) to give compound 17 or 18 (10 mg, 
40%) as colorless oil. 
Compound 17: Rf = 0.66 (PE/EtOAc 4:1); [D]D20 +44.4 (c 1.0, EtOAc); 1H NMR (500 
MHz, CDCl3): G 7.61 (d, J = 7.2 Hz, 2H, H-Ar), 7.38 - 7.21 (m, 18H, H-Ar), 5.65 - 5.57 
(m, 1H, H-6), 4.85 (d, J = 1.5 Hz, 1H, H-1), 4.78 (d, J = 10.2 Hz, 1H, CHPh), 4.68 (d, J = 
12.1 Hz, 1H, CHPh), 4.62 (d, J = 2.4 Hz, 2H, CHPh), 4.58 (d, J = 12.1 Hz, 1H, CHPh), 
4.28 (d, J = 10.2 Hz, 1H, CHPh), 3.87 (dd, J = 9.2, 3.0 Hz, 1H, H-3), 3.76 (t, J = 9.5 Hz, 
1H, H-4), 3.73 - 3.70 (m, 1H, H-2), 3.59 – 3.51 (m, 2H, H-5, OCH-heptyl), 3.48 (s, 3H, 
OCH3), 3.32 (dt, J = 9.6, 6.5 Hz, 1H, OCH-heptyl), 1.51 – 1.44 (m, 4H, CH2, CH3-6), 
1.34 – 1.19 (m, 8H, 4 CH2), 0.88 (t, J = 6.8 Hz, 3H, CH3-heptyl); 13C NMR (126 MHz, 
CDCl3): G 166.54 (CO), 138.60, 138.55, 138.35, 131.97, 129.67, 128.61, 128.57, 128.51, 
128.34, 127.94, 127.85, 127.75, 127.64, 127.59 (C-Ar), 97.87 (C-1), 80.66 (C-3), 75.35 
(CHPh), 75.28 (C-2), 74.84 (C-4), 73.21 (C-5), 72.80, 72.11 (2 CHPh), 71.15 (C-6), 
67.82 (OCH-heptyl), 55.67 (OCH3), 31.88, 29.58, 29.22, 26.30, 22.76 (5 CH2), 16.45 
(CH3-6), 14.23 (CH3-heptyl); ESI-MS: m/z: calcd for C45H53F3NaO8 >M + Na@+: 801.36, 
found: 801.46. 
Compound 18: Rf = 0.66 (PE/EtOAc 4:1); [D]D20 -16.0 (c 0.6, EtOAc); 1H NMR (500 
MHz, CDCl3): G 7.60 - 7.53 (m, 2H, H-Ar), 7.40 - 7.26 (m, 18H, H-Ar), 5.75 - 5.67 (m, 
1H, H-6), 4.88 (d, J = 10.0 Hz, 1H, CHPh), 4.86 (d, J = 1.6 Hz, 1H, H-1), 4.72 (d, J = 
11.9 Hz, 1H, CHPh), 4.67 (s, 1H, CHPh), 4.62 (d, J = 12.0 Hz, 1H, CHPh), 4.44 (d, J = 
10.0 Hz, 1H, CHPh), 3.91 (dd, J = 9.2, 2.9 Hz, 1H, H-3), 3.86 (t, J = 9.4 Hz, 1H, H-4), 
3.78 - 3.74 (m, 1H, H-2), 3.59 - 3.52 (m, 2H, H-5, OCH-heptyl), 3.47 (s, 3H, OCH3), 3.32 
(dt, J = 9.6, 6.5 Hz, 1H, OCH-heptyl), 1.52 - 1.44 (m, 2H, CH2), 1.34 (d, J = 6.6 Hz, 3H, 
CH3-6), 1.31 – 1.20 (m, 8H, 4 CH2), 0.87 (t, J = 6.9 Hz, 3H, CH3-heptyl); 13C NMR (126 
MHz, CDCl3): G 166.54 (CO), 138.41, 138.34, 138.24, 131.81, 129.50, 128.48, 128.45, 
128.42, 128.37, 128.30, 127.81, 127.79, 127.72, 127.65 (C-Ar), 97.83 (C-1), 80.62 (C-3), 
75.36 (CHPh), 75.23 (C-2), 74.82 (C-4), 73.14 (C-5), 73.00, 72.07 (2 CHPh), 70.31 (C-
6), 67.72 (OCH-heptyl), 55.74 (OCH3), 31.73, 29.42, 29.07, 26.15, 22.62 (5 CH2), 16.46 
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(CH3-6), 14.08 (CH3-heptyl); ESI-MS: m/z: calcd for C45H53F3NaO8 >M + Na@+: 801.36, 
found: 801.52. 
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3. Summary and Outlook
The goal of the present thesis was to optimize the lead structures of carbohydrate 
mimetics, to develop highly potent, orally available FimH antagonists for the treatment of 
urinary tract infections. For this purpose, various structural modifications were 
performed, being guided by computational modeling and biological evaluation results. 
Diverse strategies were implemented in order to improve the binding affinity, to explore 
the binding mode, and to optimize the pharmacokinetic (PK) properties of FimH 
antagonists (Figure 3.1). The structures of the synthesized compounds were designed 
based on crystal structures of the ligand-protein complexes and in silico docking studies. 
Divergent synthetic procedures were carried out and optimized. Both traditional synthetic 
strategies and dynamic combinatorial techniques were applied for establishing the 
designed compound libraries.  
Starting from highly potent biphenyl D-D-mannopyranoside with a para-carboxylate on 
the terminal aromatic ring of the aglycone, an ester prodrug approach was successfully 
applied for masking the polar carboxylate and, hence, for increasing the membrane 
permeability.1 However, the aqueous solubility of the initially developed antagonists was 
in the low Pg/mL range, which hampered their oral application and complicated their in 
vivo evaluation. To solve the solubility problem, we firstly introduced different 
substitution patterns to the aglycone moiety in order to decrease the crystal packing 
energy by disruption of the molecular planarity and symmetry. Further modifications 
included introduction of heterocyclic aryl aglycones, and bioisosteric replacement of the 
carboxylic ester moiety to improve both PD and PK properties. All above approaches 
indeed increased the solubility and PD/PK properties of a series of biaryl FimH 
antagonists, according to in vitro results. In vivo evaluation of the selected candidates will 
be performed in a further step. 
While the optimized PK profile is a prerequisite for achieving oral bioavailability, the 
binding affinity plays another crucial role for a successful treatment. As previously 
reported, the binding mode of an antagonist to the CRD of FimH can switch from an “in-
docking mode” to an “out-docking mode”, depending on the structure of the antagonist.2 
Moreover, the “catch bond” behavior of FimH, that is the lectin domain of FimH is 
stabilized in a low-affinity state by the pili domain and the isolated lectin domain adopts a 
Chapter 3 
425 
high-affinity state, further complicated the binding affinity of FimH antagonists.3, 4 To 
study the binding mode, to optimize the potency, and to explore the CRD of FimH, we 
investigated the structure-activity relationships (SARs) for diversified compound 
libraries. By introducing ortho substituents on ring A (Figure 3.1), we demonstrated the 
correlation between vdW volumes of the substituents and the enthalpy term, which 
indicated the importance of shape complementarity.5 With a series of bioisosteric 
replacement of the para-carboxylic ester on ring B, a four- to five-fold improvement of 
affinity was achieved, resulting from reduced desolvation penalty and improved fit in the 
binding pocket.6 In situ generation and screening of dynamic combinatorial libraries 
(DCLs) further boosted the lead optimization process toward the native full-length FimH, 
and provided a rapid and efficient platform of the ligand screening. 
OHO
OH
OH
HO
O
COOH
A
B
Lead optimization
Bioisosteric replacement
Diverse 
substitution 
patterns
Heteroaromaic aglyconeModificaitons on mannose
Dynamic 
combinatorial 
libraries
Figure 3.1. Lead optimization strategies for the development of FimH antagonists. 
In summary, our studies established structural-activity and structure-property 
relationships for a series of structurally diversified D-D-mannosides. Balancing between 
the PD and PK properties to make a best compromise is critical for lead optimization of 
FimH antagonists. Further in vitro and in vivo pharmacokinetic studies provided 
insightful understanding of the anti-adhesive efficiency of biaryl FimH antagonists. The 
thorough lead optimization studies will further support the development of biaryl D-D-
Chapter 3 
426 
mannosides towards a marketed drug for the prevention and treatment of urinary tract 
infections. 
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